

Final Version of 2009 AJCC Melanoma Staging and Class

Journal of Clinical Oncology

27, 6199-6206

DOI: 10.1200/jco.2009.23.4799

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | ecancermedalscience. Ecancermedalscience, 2013, 7, 315. | 0.6 | 3 |
| 2 | Surgical excision margins for primary cutaneous melanoma. The Cochrane Library, 2009, , CD004835. | 1.5 | 119 |
| 3 | Use of Anti-phosphohistone H3 Immunohistochemistry to Determine Mitotic Rate in Thin Melanoma. American Journal of Dermatopathology, 2010, 32, 650-654. | 0.3 | 62 |
| 4 | Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Research, 2010, 20, 501-506. | 0.6 | 9 |
| 5 | Genetic determinants of disease progression and survival in melanoma. Melanoma Research, 2010, 20, e8-e9. | 0.6 | 0 |
| 6 | Sarcoidosis Induced by Interferon- γ in Melanoma Patients. Journal of Immunotherapy, 2010, 33, 834-839. | 1.2 | 39 |
| 7 | P26b Outcome of sentinel node negative patients with primary cutaneous melanoma-prognostic factors and survival probabilities. Melanoma Research, 2010, 20, e54-e55. | 0.6 | 6 |
| 8 | P28 Treatment of lentigo maligna with imiquimod: a follow up of 61 patients. Melanoma Research, 2010, 20, e55. | 0.6 | 0 |
| 9 | Cutaneous melanoma in the elderly: epidemiology and management. Aging Health, 2010, 6, 383-392. | 0.3 | 0 |
| 10 | Advances and short comings in the early diagnosis of melanoma. Melanoma Research, 2010, 20, 450-458. | 0.6 | 15 |
| 11 | 2010 TNM Staging System for Cutaneous Melanoma and Beyond. Annals of Surgical Oncology, 2010, 17, 1475-1477. | 0.7 | 111 |
| 12 | Predicting Survival Outcome of Localized Melanoma: An Electronic Prediction Tool Based on the AJCC Melanoma Database. Annals of Surgical Oncology, 2010, 17, 2006-2014. | 0.7 | 106 |
| 13 | The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma. Annals of Surgical Oncology, 2010, 17, 2992-2999. | 0.7 | 9 |
| 14 | Detection of Melanoma Nodal Metastases; Differences in Detection Between Elderly and Younger Patients Do Not Affect Survival. Annals of Surgical Oncology, 2010, 17, 3008-3014. | 0.7 | 12 |
| 15 | Multimarker Reverse Transcriptase-Polymerase Chain Reaction Assay in Lymphatic Drainage and Sentinel Node Tumor Burden. Annals of Surgical Oncology, 2010, 17, 3314-3323. | 0.7 | 8 |
| 16 | The Prognostic Significance of Nonsentinel Lymph Node Metastasis in Melanoma. Annals of Surgical Oncology, 2010, 17, 3330-3335. | 0.7 | 33 |
| 17 | Premalignant epithelial disorders of the vulva: squamous vulvar intraepithelial neoplasia, vulvar Paget's disease and melanoma in situ. Acta Obstetrica Et Gynecologica Scandinavica, 2010, 89, 741-748. | 1.3 | 45 |
| 23 | Surveillance after surgical treatment of melanoma: Futility of routine chest radiography. Surgery, 2010, 148, 711-717. | 1.0 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 24 | Dermatopathology of skin cancer in solid organ transplant recipients. <i>Transplantation Reviews</i> , 2010, 24, 172-189. | 1.2 | 33 |
| 25 | Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients. <i>BMC Cancer</i> , 2010, 10, 63. | 1.1 | 35 |
| 26 | The persistent anchor of lymph node removal in patients with melanoma. <i>Cancer</i> , 2010, 116, 1150-1152. | 2.0 | 0 |
| 27 | Characteristics of the coexistence of melanoma and renal cell carcinoma. <i>Cancer</i> , 2010, 116, 5716-5724. | 2.0 | 22 |
| 28 | Sentinel node biopsy in melanoma: Technical considerations of the procedure as performed at the John Wayne Cancer Institute. <i>Journal of Surgical Oncology</i> , 2010, 101, 669-676. | 0.8 | 65 |
| 29 | The role of spectrophotometry in the diagnosis of melanoma. <i>BMC Dermatology</i> , 2010, 10, 5. | 2.1 | 13 |
| 30 | Cutaneous metastases from internal malignancies. <i>Dermatologic Therapy</i> , 2010, 23, 567-580. | 0.8 | 55 |
| 31 | Prognostic models for melanoma. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 68-75. | 0.7 | 4 |
| 32 | New research advances for treating metastatic melanoma. <i>International Journal of Dermatology</i> , 2010, 49, 712-714. | 0.5 | 0 |
| 33 | Is GP-led follow-up feasible?. <i>British Journal of Cancer</i> , 2010, 102, 1445-1446. | 2.9 | 5 |
| 34 | Tattoo pigment mimicking metastatic malignant melanoma in an axillary sentinel lymph node. <i>BMJ Case Reports</i> , 2010, 2010, bcr0120102607-bcr0120102607. | 0.2 | 0 |
| 35 | Surgery of Primary Melanomas. <i>Cancers</i> , 2010, 2, 824-841. | 1.7 | 16 |
| 36 | Prognostic Significance of Melanoma Differentiation and Trans-Differentiation. <i>Cancers</i> , 2010, 2, 989-999. | 1.7 | 11 |
| 37 | Methyl Sulfone Induces Loss of Metastatic Properties and Reemergence of Normal Phenotypes in a Metastatic Cloudman S-91 (M3) Murine Melanoma Cell Line. <i>PLoS ONE</i> , 2010, 5, e11788. | 1.1 | 31 |
| 38 | Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review. <i>Core Evidence</i> , 2010, 5, 39. | 4.7 | 9 |
| 39 | Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, E46; author reply E47. | 3.3 | 4 |
| 40 | Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases. <i>Journal of Clinical Oncology</i> , 2010, 28, 2452-2459. | 0.8 | 374 |
| 41 | Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. <i>Clinical Chemistry</i> , 2010, 56, 1148-1157. | 1.5 | 70 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 42 | From Melanocyte to Metastatic Malignant Melanoma. <i>Dermatology Research and Practice</i> , 2010, 2010, 1-8. | 0.3 | 96 |
| 43 | Mucosal Melanomas: A Case-Based Review of the Literature. <i>Oncologist</i> , 2010, 15, 772-781. | 1.9 | 101 |
| 44 | Advances in systemic treatment of melanoma. <i>Annals of Oncology</i> , 2010, 21, vii339-vii344. | 0.6 | 44 |
| 45 | PLX4032: does it keep its promise for metastatic melanoma treatment?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1439-1449. | 1.9 | 24 |
| 46 | Some of the 2009 American Joint Committee on Cancer Melanoma Staging and Classification Is Not Evidence Based. <i>Journal of Clinical Oncology</i> , 2010, 28, e479-e479. | 0.8 | 1 |
| 47 | Reply to J.M. Thomas et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e480-e481. | 0.8 | 1 |
| 48 | Melanoma MicroRNA Signature Predicts Post-Recurrence Survival. <i>Clinical Cancer Research</i> , 2010, 16, 1577-1586. | 3.2 | 204 |
| 49 | Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2514-2516. | 0.3 | 10 |
| 50 | The biology behind prognostic factors of cutaneous melanoma. <i>Current Opinion in Oncology</i> , 2010, 22, 163-168. | 1.1 | 37 |
| 51 | No Role for Melanoma Treatment in the Association between Melanoma and Amyotrophic Lateral Sclerosis or Parkinson's Disease. <i>Neuroepidemiology</i> , 2010, 35, 303-304. | 1.1 | 5 |
| 52 | Contrast-Enhanced Ultrasound: A Filter Role in AJCC Stage I/II Melanoma Patients. <i>Oncology</i> , 2010, 79, 370-375. | 0.9 | 16 |
| 53 | P27 New therapeutic strategies for stage III melanoma. <i>Melanoma Research</i> , 2010, 20, e55. | 0.6 | 0 |
| 54 | Melanoma Staging. <i>Journal of the Dermatology Nurses' Association</i> , 2010, 2, 254-259. | 0.1 | 4 |
| 55 | Case 30-2010. <i>New England Journal of Medicine</i> , 2010, 363, 1352-1360. | 13.9 | 0 |
| 56 | Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients. <i>Cancer Biology and Therapy</i> , 2010, 10, 1081-1087. | 1.5 | 117 |
| 57 | S100A13 is a new angiogenic marker in human melanoma. <i>Modern Pathology</i> , 2010, 23, 804-813. | 2.9 | 61 |
| 59 | High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study. <i>Journal of Translational Medicine</i> , 2010, 8, 115. | 1.8 | 31 |
| 60 | Initial Evaluation, Diagnosis, Staging, Treatment, and Follow-up of Patients with Primary Cutaneous Malignant Melanoma. Consensus Statement of the Network of Catalan and Balearic Melanoma Centers. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 129-142. | 0.2 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 61 | Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function. <i>Cancer Research</i> , 2010, 70, 5213-5219. | 0.4 | 659 |
| 62 | CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients. <i>European Journal of Surgical Oncology</i> , 2010, 36, 1211-1214. | 0.5 | 30 |
| 63 | Implications of the 2009 American Joint Committee on Cancer Melanoma Staging and Classification on Dermatologists and Their Patients. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 142-147. | 1.6 | 13 |
| 64 | Office Management of Melanoma Patients. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 232-237. | 1.6 | 5 |
| 65 | New Therapeutic Options in the Medical Management of Advanced Melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 249-257. | 1.6 | 14 |
| 66 | Sentinel Node Biopsy for Melanoma: An Update After Two Decades of Experience. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 238-248. | 1.6 | 31 |
| 67 | Valoraci3n inicial, diagn3stico, estadificaci3n, tratamiento y seguimiento de los pacientes con melanoma maligno primario de la piel. Documento de consenso de la Xarxa de Centres de Melanoma de Catalunya i Balears. <i>Actas Dermo-sifiliogr3ficas</i> , 2010, 101, 129-142. | 0.2 | 21 |
| 68 | Risk factors associated with local and in-transit recurrence of cutaneous melanoma. <i>American Journal of Surgery</i> , 2010, 200, 770-775. | 0.9 | 46 |
| 69 | Alpha 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 575-586. | 1.5 | 18 |
| 70 | Quantitative measurement of circulating lymphoid-specific helicase (<i>HELLS</i>) gene transcript: a potential serum biomarker for melanoma metastasis. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 845-848. | 1.5 | 13 |
| 71 | Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 897-919. | 1.5 | 46 |
| 72 | Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2695-2706. | 0.9 | 32 |
| 73 | Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1383-1394. | 1.5 | 7 |
| 74 | Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects. <i>Oncologist</i> , 2011, 16, 5-24. | 1.9 | 472 |
| 75 | Prognostic biomarkers in ovarian cancer. <i>Cancer Biomarkers</i> , 2011, 8, 231-251. | 0.8 | 34 |
| 76 | Regional Treatment Strategies for In-Transit Melanoma Metastasis. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 79-103. | 0.6 | 30 |
| 77 | Melanoma Pathology: Important Issues for Clinicians Involved in the Multidisciplinary Care of Melanoma Patients. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 19-37. | 0.6 | 19 |
| 78 | The Dermis as a Portal for Dendritic Cell-Targeted Immunotherapy of Cutaneous Melanoma. <i>Current Topics in Microbiology and Immunology</i> , 2011, 351, 181-220. | 0.7 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 79 | Metastasectomy for Stage IV Melanoma: For Whom and How Much?. Surgical Oncology Clinics of North America, 2011, 20, 133-144. | 0.6 | 28 |
| 80 | Advanced Stages of Melanoma: Role of Structural Imaging. PET Clinics, 2011, 6, 37-54. | 1.5 | 0 |
| 81 | Sentinel Lymph Node Biopsy for Melanoma: Critical Assessment at its Twentieth Anniversary. Surgical Oncology Clinics of North America, 2011, 20, 57-78. | 0.6 | 21 |
| 82 | Circulating Serologic and Molecular Biomarkers in Malignant Melanoma. Mayo Clinic Proceedings, 2011, 86, 981-990. | 1.4 | 85 |
| 83 | Recurrence of Melanoma. PET Clinics, 2011, 6, 55-70. | 1.5 | 2 |
| 84 | European ancestry and polymorphisms in DNA repair genes modify the risk of melanoma: A case-control study in a high UV index region in Brazil. Journal of Dermatological Science, 2011, 64, 59-66. | 1.0 | 32 |
| 85 | What Does Ulceration of a Melanoma Mean for Prognosis?. Advances in Surgery, 2011, 45, 225-236. | 0.6 | 6 |
| 86 | Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsy-FDG-PET/CT. PET Clinics, 2011, 6, 9-25. | 1.5 | 6 |
| 87 | Primary Cutaneous Melanoma: Prognostic Factors Not Included in the Classification of the American Joint Committee on Cancer. Actas Dermo-sifiligráficas, 2011, 102, 255-263. | 0.2 | 5 |
| 88 | Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2011, 64, 1284-1290. | 0.5 | 18 |
| 89 | Primary malignant melanoma of the vagina with repeated local recurrences and brain metastasis. Journal of the Chinese Medical Association, 2011, 74, 376-379. | 0.6 | 12 |
| 90 | Regulation of pathological lymphangiogenesis requires factors distinct from those governing physiological lymphangiogenesis. Journal of Dermatological Science, 2011, 61, 85-93. | 1.0 | 15 |
| 91 | The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. Journal of Dermatological Science, 2011, 61, 187-193. | 1.0 | 185 |
| 92 | Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: An immunohistochemical study and analysis of prognostic value. Journal of Dermatological Science, 2011, 62, 116-123. | 1.0 | 41 |
| 93 | Role of Chemokines in Melanoma Progression. Actas Dermo-sifiligráficas, 2011, 102, 498-504. | 0.2 | 4 |
| 94 | Sentinel Node Biopsy in Melanoma: An Update. Actas Dermo-sifiligráficas, 2011, 102, 749-753. | 0.2 | 0 |
| 95 | Descriptive Analysis of Cutaneous Recurrence Patterns in Patients with Melanoma. Actas Dermo-sifiligráficas, 2011, 102, 791-796. | 0.2 | 4 |
| 96 | Ipilimumab: A Novel Treatment for Metastatic Melanoma. Annals of Pharmacotherapy, 2011, 45, 510-519. | 0.9 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 97 | Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. <i>Modern Pathology</i> , 2011, 24, 487-494. | 2.9 | 51 |
| 98 | Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance?. <i>Molecular Oncology</i> , 2011, 5, 137-149. | 2.1 | 49 |
| 99 | Immunologic functions as prognostic indicators in melanoma. <i>Molecular Oncology</i> , 2011, 5, 183-189. | 2.1 | 22 |
| 100 | Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. <i>Molecular Oncology</i> , 2011, 5, 124-136. | 2.1 | 135 |
| 101 | Quality Assurance Parameters and Predictors of Outcome for Ilioinguinal and Inguinal Dissection in a Contemporary Melanoma Patient Population. <i>Annals of Surgical Oncology</i> , 2011, 18, 2521-2528. | 0.7 | 46 |
| 102 | Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance. <i>Molecular Pharmaceutics</i> , 2011, 8, 2039-2049. | 2.3 | 109 |
| 103 | Fotemustine for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2891-2904. | 0.9 | 24 |
| 104 | In vivo photoacoustic microscopy of human cutaneous microvasculature and a nevus. <i>Journal of Biomedical Optics</i> , 2011, 16, 1. | 1.4 | 107 |
| 105 | Sentinel-Lymph-Node Biopsy for Cutaneous Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 1738-1745. | 13.9 | 127 |
| 106 | Copy Number Gains in 11q13 and 8q34 Are Highly Linked to Prognosis in Cutaneous Malignant Melanoma. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 352-358. | 1.2 | 70 |
| 107 | Features Associated with Survival in Metastatic Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines. <i>Cancer Biotherapy and Radiopharmaceutics</i> , 2011, 26, 407-415. | 0.7 | 20 |
| 108 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2517-2526. | 13.9 | 4,074 |
| 109 | The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1395-1407. | 1.4 | 8 |
| 110 | Staging and Prognosis of Cutaneous Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 1-17. | 0.6 | 148 |
| 115 | Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. <i>Clinical Radiology</i> , 2011, 66, 224-236. | 0.5 | 66 |
| 116 | Technique and outcomes of isolated limb infusion for locally advanced malignant melanoma – A radiological perspective. <i>Clinical Radiology</i> , 2011, 66, 1175-1180. | 0.5 | 3 |
| 117 | Current and future adjuvant immunotherapies for melanoma: Blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach. <i>Cancer Treatment Reviews</i> , 2011, 37, 133-142. | 3.4 | 9 |
| 118 | Methods of detection of circulating melanoma cells: A comparative overview. <i>Cancer Treatment Reviews</i> , 2011, 37, 284-290. | 3.4 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 119 | A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up. <i>European Journal of Cancer</i> , 2011, 47, 1977-1989. | 1.3 | 56 |
| 120 | New drugs in melanoma: It's a whole new world. <i>European Journal of Cancer</i> , 2011, 47, 2150-2157. | 1.3 | 168 |
| 121 | The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection. <i>European Journal of Surgical Oncology</i> , 2011, 37, 225-232. | 0.5 | 17 |
| 122 | Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2011, 37, 681-687. | 0.5 | 27 |
| 123 | Maximizing the clinical usefulness of a nomogram to select patients candidate to sentinel node biopsy for cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2011, 37, 675-680. | 0.5 | 23 |
| 124 | Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 1152-1160. | 0.6 | 37 |
| 125 | Guidelines of care for the management of primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 1032-1047. | 0.6 | 417 |
| 126 | Subungual Malignant Melanoma. <i>Journal of Hand Surgery</i> , 2011, 36, 704-707. | 0.7 | 25 |
| 127 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516. | 13.9 | 6,976 |
| 128 | Therapy for metastatic melanoma: an overview and update. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 725-737. | 1.1 | 55 |
| 129 | Modelling melanoma in mice. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 1158-1176. | 1.5 | 42 |
| 130 | Histopathologische Befundung maligner Melanome in Übereinstimmung mit der AJCC-Klassifikation 2009: Literaturübersicht und Empfehlungen zum praktischen Vorgehen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 690-700. | 0.4 | 6 |
| 131 | Diagnosis of Melanoma. <i>PET Clinics</i> , 2011, 6, 1-8. | 1.5 | 8 |
| 132 | 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. <i>Lancet, The</i> , 2011, 378, 1635-1642. | 6.3 | 182 |
| 133 | BRAF V600E Mutated Gene Variant as a Circulating Molecular Marker in Metastatic Melanoma Patients. , 2011, , . | | 1 |
| 134 | Differential Scanning Calorimetry, as a New Method to Monitor Human Plasma in Melanoma Patients with Regional Lymph Node or Distal Metastases. , 2011, , . | | 6 |
| 135 | Adaptation to ER Stress as a Mechanism of Resistance of Melanoma to Treatment. , 2011, , . | | 0 |
| 136 | New Molecular Targets for the Systemic Therapy of Melanoma. , 0, , . | | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 137 | The Roles of S100 Proteins and RAGE in Melanoma. , 0, , . | | 1 |
| 138 | Adjuvant peginterferon alfa-2b therapy in stage III melanoma. Expert Review of Dermatology, 2011, 6, 567-575. | 0.3 | 0 |
| 139 | Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM. Annals of the Royal College of Surgeons of England, 2011, 93, 514-522. | 0.3 | 8 |
| 140 | Melanoma cutÃ¢neo: estudo prospectivo de 42 casos. Anais Brasileiros De Dermatologia, 2011, 86, 1233-1235. | 0.5 | 1 |
| 141 | Surgical Management of Malignant Melanoma of Gastrointestinal Tract. , 2011, , . | | 1 |
| 142 | Promising Experimental Therapies for Metastatic Melanoma. , 2011, , . | | 0 |
| 143 | Cutaneous Metastases from Malignant Melanoma: Clinical Features and New Therapeutic Perspectives. , 2011, , . | | 2 |
| 144 | Current Insight Into the Metastatic Process and Melanoma Cell Dissemination. , 0, , . | | 0 |
| 145 | Challenging Problems in the Surgical Management of Melanoma. , 2011, , . | | 0 |
| 146 | Melanoma During Pregnancy. , 2011, , . | | 1 |
| 147 | Non-Invasive Determination of Breslow Index. , 0, , . | | 0 |
| 148 | Melanoma cutÃ¢neo: estudo epidemiolÃ³gico de 30 anos em cidade do sul do Brasil, de 1980-2009. Anais Brasileiros De Dermatologia, 2011, 86, 932-941. | 0.5 | 25 |
| 149 | Common Genetic Variants of MUTYH are not Associated with Cutaneous Malignant Melanoma: Application of Molecular Screening by Means of High-Resolution Melting Technique in a Pilot Case-Control Study. International Journal of Biological Markers, 2011, 26, 37-42. | 0.7 | 5 |
| 150 | Malignant Melanoma in the Elderly: Different Regional Disease and Poorer Prognosis. Journal of Cancer, 2011, 2, 538-543. | 1.2 | 105 |
| 151 | Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. OncoTargets and Therapy, 2011, 4, 137. | 1.0 | 46 |
| 152 | Serum Proteomic Profiling Reveals Potential Biomarkers for Cutaneous Malignant Melanoma. International Journal of Biological Markers, 2011, 26, 82-87. | 0.7 | 14 |
| 153 | Proteomics in Melanoma Biomarker Discovery: Great Potential, Many Obstacles. International Journal of Proteomics, 2011, 2011, 1-8. | 2.0 | 26 |
| 154 | Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma. International Journal of Proteomics, 2011, 2011, 1-9. | 2.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 155 | Proteomics-Based Disease Biomarkers. <i>International Journal of Proteomics</i> , 2011, 2011, 1-2. | 2.0 | 3 |
| 156 | Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. <i>Clinics</i> , 2011, 66, 493-499. | 0.6 | 36 |
| 157 | Prognostic Value of [18F]-Fluoro-Deoxy-Glucose PET/CT, S100 or MIA for Assessment of Cancer-Associated Mortality in Patients with High Risk Melanoma. <i>PLoS ONE</i> , 2011, 6, e24632. | 1.1 | 20 |
| 158 | A darkly pigmented lesion with recent changes. <i>BMJ: British Medical Journal</i> , 2011, 343, d5375-d5375. | 2.4 | 0 |
| 159 | Autoimmunity and treatment outcome in melanoma. <i>Current Opinion in Oncology</i> , 2011, 23, 170-176. | 1.1 | 48 |
| 160 | Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. <i>Current Opinion in Oncology</i> , 2011, 23, 183-188. | 1.1 | 28 |
| 162 | Restoration of tumor equilibrium after immunotherapy for advanced melanoma. <i>Melanoma Research</i> , 2011, 21, 152-159. | 0.6 | 11 |
| 163 | Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. <i>Melanoma Research</i> , 2011, 21, 431-437. | 0.6 | 5 |
| 164 | The Magic of Numbers: Malignant Melanoma Between Science and Pseudoscience. <i>American Journal of Dermatopathology</i> , 2011, 33, 371-378. | 0.3 | 13 |
| 165 | CO27. Interest of Cetuximab in the treatment of cutaneous squamous cell carcinoma. <i>Melanoma Research</i> , 2011, 21, e16-e17. | 0.6 | 0 |
| 166 | Beclin-1 and LC3A expression in cutaneous malignant melanomas. <i>Melanoma Research</i> , 2011, 21, 188-195. | 0.6 | 67 |
| 167 | Clinical Relevance of Detection of Lymphovascular Invasion in Primary Melanoma Using Endothelial Markers D2-40 and CD34. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1441-1449. | 2.1 | 58 |
| 168 | Infantile Melanoma—A Triple Threat. <i>Annals of Plastic Surgery</i> , 2011, 67, 85-89. | 0.5 | 7 |
| 169 | P001. What's the best therapy for treating resected stage III melanoma patients?. <i>Melanoma Research</i> , 2011, 21, e17. | 0.6 | 0 |
| 170 | Defining fast-growing melanomas. <i>Melanoma Research</i> , 2011, 21, 131-138. | 0.6 | 46 |
| 171 | Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. <i>Melanoma Research</i> , 2011, 21, 228-234. | 0.6 | 29 |
| 172 | Identification of Nodal Metastases in Melanoma Using Sox-10. <i>American Journal of Dermatopathology</i> , 2011, 33, 474-482. | 0.3 | 47 |
| 173 | Differentiation of melanoma and benign nevi by fluorescence in-situ hybridization. <i>Melanoma Research</i> , 2011, 21, 426-430. | 0.6 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 175 | Evaluation and surgical management of melanoma of the head and neck. JAAPA: Official Journal of the American Academy of Physician Assistants, 2011, 24, 37-38. | 0.1 | 0 |
| 176 | Glycans in melanoma screening. Part 1. The role of β 1,6-branched N-linked oligosaccharides in melanoma. Biochemical Society Transactions, 2011, 39, 370-373. | 1.6 | 11 |
| 177 | Dermoscopy for the diagnosis of melanoma: primary care diagnostic technology update. British Journal of General Practice, 2011, 61, 416-417. | 0.7 | 13 |
| 178 | Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. Expert Review of Dermatology, 2011, 6, 355-357. | 0.3 | 2 |
| 179 | Critical Analysis of the Ultrasonographic Criteria for Diagnosing Lymph Node Metastasis in Patients With Cutaneous Melanoma. Journal of Ultrasound in Medicine, 2011, 30, 547-560. | 0.8 | 22 |
| 181 | Is Radiotherapy An Effective Treatment Option for Recurrent Metastatic Malignant Melanoma? a Case Report of Short-Course, Large-Fraction Radiation and a Literature Review. Canadian Journal of Plastic Surgery, 2011, 19, 153-155. | 0.4 | 1 |
| 182 | Noninvasive genomic detection of melanoma. British Journal of Dermatology, 2011, 164, 797-806. | 1.4 | 92 |
| 183 | Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. British Journal of Dermatology, 2011, 164, 1235-1240. | 1.4 | 31 |
| 184 | Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma. British Journal of Dermatology, 2011, 165, 506-512. | 1.4 | 29 |
| 185 | Sentinel Node Biopsy Should Be Offered in Thin Melanoma with Mitotic Rate Greater than One. Dermatologic Surgery, 2011, 37, 1080-1088. | 0.4 | 26 |
| 186 | Internet Use and Anxiety in People with Melanoma and Nonmelanoma Skin Cancer. Dermatologic Surgery, 2011, 37, 1252-1259. | 0.4 | 15 |
| 187 | Calculating Microscope Field Area is Important for Accurately Determining Melanoma Mitotic Rate. Dermatologic Surgery, 2011, 37, 1820-1821. | 0.4 | 1 |
| 188 | Prognostic value of galectin-3 in primary cutaneous melanoma. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1174-1181. | 1.3 | 25 |
| 189 | Is primary melanoma ulceration a factor of good response to adoptive immunotherapy?. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1311-1317. | 1.3 | 0 |
| 190 | AJCC melanoma staging update: impact on dermatopathology practice and patient management. Journal of Cutaneous Pathology, 2011, 38, 394-400. | 0.7 | 48 |
| 191 | A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. Experimental Dermatology, 2011, 20, 29-34. | 1.4 | 46 |
| 192 | Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. JDDG - Journal of the German Society of Dermatology, 2011, 9, 690-699. | 0.4 | 26 |
| 195 | Embryonic signaling in melanoma: potential for diagnosis and therapy. Laboratory Investigation, 2011, 91, 819-824. | 1.7 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 196 | Upregulated ankyrin repeat-rich membrane spanning protein contributes to tumour progression in cutaneous melanoma. <i>British Journal of Cancer</i> , 2011, 104, 982-988. | 2.9 | 13 |
| 197 | Optimizing the management of cutaneous melanoma in the elderly. <i>Surgery</i> , 2011, 150, 828-835. | 1.0 | 7 |
| 198 | Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: A single centre observational cohort study. <i>Surgical Oncology</i> , 2011, 20, 259-264. | 0.8 | 31 |
| 199 | In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells. <i>Journal of Immunological Methods</i> , 2011, 365, 76-86. | 0.6 | 6 |
| 200 | Shave Biopsy Is a Safe and Accurate Method for the Initial Evaluation of Melanoma. <i>Journal of the American College of Surgeons</i> , 2011, 212, 454-460. | 0.2 | 74 |
| 201 | Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single Institution. <i>Journal of the American College of Surgeons</i> , 2011, 213, 306-316. | 0.2 | 91 |
| 202 | Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities. <i>Clinical Oncology</i> , 2011, 23, 572-578. | 0.6 | 9 |
| 203 | Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities. <i>Clinical Oncology</i> , 2011, 23, 569-571. | 0.6 | 1 |
| 204 | Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 4550-4557. | 3.2 | 1,823 |
| 205 | In Reply: Sentinel Lymph Node Biopsy in Melanoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 598-599. | 0.7 | 2 |
| 206 | Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up. <i>Annals of Surgical Oncology</i> , 2011, 18, 514-520. | 0.7 | 33 |
| 207 | Therapeutic Surgical Management of Palpable Melanoma Groin Metastases: Superficial or Combined Superficial and Deep Groin Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2011, 18, 3300-3308. | 0.7 | 54 |
| 211 | Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 487-493. | 2.0 | 51 |
| 212 | Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1153-1160. | 2.0 | 57 |
| 213 | Outcomes for Lymph Node-Positive Cutaneous Melanoma Over Two Decades. <i>World Journal of Surgery</i> , 2011, 35, 1567-1572. | 0.8 | 10 |
| 214 | Prognostic significance of autoimmunity during treatment of melanoma with interferon. <i>Seminars in Immunopathology</i> , 2011, 33, 385-391. | 2.8 | 143 |
| 215 | Skin Cancer Education for Primary Care Physicians: A Systematic Review of Published Evaluated Interventions. <i>Journal of General Internal Medicine</i> , 2011, 26, 1027-1035. | 1.3 | 61 |
| 216 | Opportunistic screening for skin cancer using a mobile unit in Brazil. <i>BMC Dermatology</i> , 2011, 11, 12. | 2.1 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Thick primary melanoma has a heterogeneous tumor biology: an institutional series. <i>World Journal of Surgical Oncology</i> , 2011, 9, 40. | 0.8 | 13 |
| 218 | Cutaneous melanoma: A model to study cancer metastasis. <i>Journal of Surgical Oncology</i> , 2011, 103, 538-549. | 0.8 | 38 |
| 219 | Can lymphatic drainage of head and neck melanoma be predicted?. <i>Journal of Surgical Oncology</i> , 2011, 103, 751-755. | 0.8 | 14 |
| 220 | Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate. <i>Journal of Surgical Oncology</i> , 2011, 104, 379-385. | 0.8 | 112 |
| 221 | Neoadjuvant therapy for high-risk bulky regional melanoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 386-390. | 0.8 | 22 |
| 222 | Does metastasectomy improve survival in patients with stage IV melanoma? a cancer registry analysis of outcomes. <i>Journal of Surgical Oncology</i> , 2011, 104, 111-115. | 0.8 | 86 |
| 223 | Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 420-424. | 0.8 | 47 |
| 224 | Evidence-based treatment of early-stage melanoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 341-353. | 0.8 | 59 |
| 225 | Local and intralesional therapy of in-transit melanoma metastases. <i>Journal of Surgical Oncology</i> , 2011, 104, 391-396. | 0.8 | 77 |
| 226 | Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. <i>Cancer</i> , 2011, 117, 1711-1720. | 2.0 | 83 |
| 227 | A phase 2 trial of complete resection for stage IV melanoma. <i>Cancer</i> , 2011, 117, 4740-4746. | 2.0 | 136 |
| 228 | Association between melanoma thickness, clinical skin examination and socioeconomic status: Results of a large population-based study. <i>International Journal of Cancer</i> , 2011, 128, 2158-2165. | 2.3 | 45 |
| 229 | Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. <i>International Journal of Cancer</i> , 2011, 129, 1435-1442. | 2.3 | 43 |
| 230 | Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma. <i>British Journal of Surgery</i> , 2011, 98, 1400-1407. | 0.1 | 9 |
| 231 | Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma (Br J Surg 2011;) | 0.1 | 9 |
| 232 | The Evolving Role of Radiation Therapy in the Management of Malignant Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 645-654. | 0.4 | 58 |
| 233 | Gene Regulatory and Clinical Effects of Interferon γ in Patients with Metastatic Melanoma: A Phase II Trial. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 433-440. | 0.5 | 25 |
| 234 | Clinical Correlates of <i>NRAS</i> and <i>BRAF</i> Mutations in Primary Human Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 229-235. | 3.2 | 237 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Improved Evidence Will Support Sound Decision Making but Will Not Solve the Problem of Cost Containment in Oncology. <i>Journal of Clinical Oncology</i> , 2011, 29, 3943-3943. | 0.8 | 1 |
| 236 | Is It Good or Bad to Find a <i>BRAF</i> Mutation?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1229-1230. | 0.8 | 10 |
| 237 | Re-inventing intratumoral immunotherapy for melanoma. <i>Immunotherapy</i> , 2011, 3, 653-671. | 1.0 | 20 |
| 238 | Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 4882-4891. | 3.2 | 48 |
| 239 | Melanoma Prognosis: A REMARK-Based Systematic Review and Bioinformatic Analysis of Immunohistochemical and Gene Microarray Studies. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1520-1528. | 1.9 | 50 |
| 240 | Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management. <i>Biomarkers in Medicine</i> , 2011, 5, 333-360. | 0.6 | 6 |
| 241 | Towards new therapeutic approaches for malignant melanoma. <i>Expert Reviews in Molecular Medicine</i> , 2011, 13, e33. | 1.6 | 38 |
| 242 | Plasma Markers for Identifying Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 2417-2425. | 3.2 | 80 |
| 243 | Risk and Survival of Cutaneous Melanoma Diagnosed Subsequent to a Previous Cancer. <i>Archives of Dermatology</i> , 2011, 147, 1395. | 1.7 | 37 |
| 244 | Melanoma Imaging with Highly Specific PET Probes: Ready for Prime Time?. <i>Journal of Nuclear Medicine</i> , 2011, 52, 5-7. | 2.8 | 8 |
| 245 | Prognostic Parameters for the Primary Care of Melanoma Patients: What Is Really Risky in Melanoma?. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-13. | 0.5 | 6 |
| 246 | Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms. <i>ISRN Dermatology</i> , 2011, 2011, 1-8. | 1.9 | 26 |
| 247 | Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database. <i>Journal of Clinical Oncology</i> , 2011, 29, 2199-2205. | 0.8 | 313 |
| 248 | Melanoma Staging: Implications of Histologic Sectioning Procedures. <i>Journal of Clinical Oncology</i> , 2011, 29, 3943-3944. | 0.8 | 0 |
| 249 | Debulking surgery in advanced melanoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1703-1712. | 1.1 | 9 |
| 250 | False-Negative Sentinel Lymph Node Biopsy in Head and Neck Melanoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 145, 606-611. | 1.1 | 46 |
| 251 | Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies. <i>PLoS ONE</i> , 2011, 6, e19330. | 1.1 | 72 |
| 252 | Sentinel Lymph Node Biopsy Status Is a Key Parameter to Stratify the Prognostic Heterogeneity of Malignant Melanoma in High-Risk Tumors >4.0 mm. <i>Dermatology</i> , 2011, 222, 59-66. | 0.9 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 253 | A High Proliferative Index of Recurrent Melanoma Is Associated with Worse Survival. <i>Oncology</i> , 2011, 80, 181-187. | 0.9 | 17 |
| 254 | Enrollment in Clinical Trials Correlates with Improved Survival in Metastatic Melanoma. <i>Oncology</i> , 2011, 81, 403-409. | 0.9 | 3 |
| 255 | High-Resolution Ultrasound Combined with Power Doppler Sonography Can Reduce the Number of Sentinel Lymph Node Biopsies in Cutaneous Melanoma. <i>Dermatology</i> , 2011, 222, 180-188. | 0.9 | 14 |
| 256 | Tumor-infiltrating T cells "ready for prime time in melanoma?". <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 449-450. | 12.5 | 0 |
| 257 | Prognostic Usefulness of Sentinel Lymph Node Biopsy for Patients Who Have Clinically Node Negative, Localized, Primary Invasive Cutaneous Melanoma. <i>Archives of Dermatology</i> , 2011, 147, 408. | 1.7 | 15 |
| 258 | Parameters Predicting Prognosis in Melanoma Sentinel Nodes. <i>Journal of Clinical Oncology</i> , 2011, 29, 3588-3590. | 0.8 | 7 |
| 259 | Mitotic Rate and Sentinel Lymph Node Tumor Burden Topography: Integration Into Melanoma Staging and Stratification Use in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 2137-2141. | 0.8 | 8 |
| 260 | New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances. <i>Clinical Cancer Research</i> , 2011, 17, 4922-4928. | 3.2 | 34 |
| 261 | Specific challenges in the management of subungual melanoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 749-761. | 1.1 | 16 |
| 262 | TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome. <i>British Journal of Cancer</i> , 2011, 105, 1726-1732. | 2.9 | 45 |
| 263 | Metastatic melanoma in the older patient: immunologic insights and treatment outcomes. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 185-193. | 0.7 | 17 |
| 265 | New developments in melanoma: utility of ultrasound imaging (initial staging, follow-up and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 | 1.9 | 42 |
| 266 | Gastrointestinal Stromal Tumor Markers in Cutaneous Melanomas. <i>American Journal of Clinical Pathology</i> , 2011, 136, 74-80. | 0.4 | 6 |
| 267 | Ten-year Audit of Melanoma in a Central England Population*. <i>Acta Dermato-Venereologica</i> , 2011, 91, 440-443. | 0.6 | 7 |
| 268 | Fine Needle Aspiration Cytology of Palpable and Nonpalpable Lymph Nodes to Detect Metastatic Melanoma. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1771-1777. | 3.0 | 39 |
| 269 | Decoding Melanoma Metastasis. <i>Cancers</i> , 2011, 3, 126-163. | 1.7 | 142 |
| 270 | Interval Sentinel Lymph Nodes: An Unusual Localization in Patients with Cutaneous Melanoma. <i>Dermatology Research and Practice</i> , 2011, 2011, 1-3. | 0.3 | 5 |
| 271 | Gender Differences in Melanoma Survival: Female Patients Have a Decreased Risk of Metastasis. <i>Journal of Investigative Dermatology</i> , 2011, 131, 719-726. | 0.3 | 207 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 272 | Cutaneous Melanoma In Situ: Translational Evidence from a Large Population-Based Study. <i>Oncologist</i> , 2011, 16, 896-903. | 1.9 | 68 |
| 273 | Sorafenib and pegylated interferon- β 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. <i>Annals of Oncology</i> , 2011, 22, 1667-1674. | 0.6 | 27 |
| 274 | Post-Embryonic Nerve-Associated Precursors to Adult Pigment Cells: Genetic Requirements and Dynamics of Morphogenesis and Differentiation. <i>PLoS Genetics</i> , 2011, 7, e1002044. | 1.5 | 119 |
| 275 | Salvage surgery for a giant melanoma on the back. <i>Rare Tumors</i> , 2011, 3, 90-91. | 0.3 | 8 |
| 276 | Drug targets and predictive biomarkers in the management of metastatic melanoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 139. | 0.4 | 3 |
| 277 | Tracking and Treating Malignant Melanoma Metastases. <i>Dermatology Research and Practice</i> , 2012, 2012, 1-2. | 0.3 | 1 |
| 278 | H3K79me3 is a Novel Histone Dual Modification and a Mitotic Indicator in Melanoma. <i>Journal of Skin Cancer</i> , 2012, 2012, 1-9. | 0.5 | 12 |
| 279 | BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance. <i>Clinical Cancer Research</i> , 2012, 18, 33-39. | 3.2 | 120 |
| 280 | Previous pregnancy is a favourable prognostic factor in women with localised cutaneous melanoma. <i>Acta Oncologica</i> , 2012, 51, 662-668. | 0.8 | 10 |
| 281 | Mining Gene Expression Signature for the Detection of Pre-Malignant Melanocytes and Early Melanomas with Risk for Metastasis. <i>PLoS ONE</i> , 2012, 7, e44800. | 1.1 | 20 |
| 282 | Kinesin Family Member 20A is a Novel Melanoma-associated Antigen. <i>Acta Dermato-Venereologica</i> , 2012, 92, 593-597. | 0.6 | 35 |
| 283 | Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii86-vii91. | 0.6 | 336 |
| 284 | Chronology of Metastasis in Cutaneous Melanoma: Growth Rate Model. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1215-1221. | 0.3 | 24 |
| 285 | Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma. <i>Journal of Biological Chemistry</i> , 2012, 287, 28087-28098. | 1.6 | 171 |
| 286 | Marges d'exercice et recommandations. , 2012, , 113-121. | | 0 |
| 287 | Engineering Melanoma Progression in a Humanized Environment In Vivo. <i>Journal of Investigative Dermatology</i> , 2012, 132, 144-153. | 0.3 | 21 |
| 288 | Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1247-1252. | 0.3 | 56 |
| 289 | Investigation of the Effect of MDM2 SNP309 and TP53 Arg72Pro Polymorphisms on the Age of Onset of Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1471-1478. | 0.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 290 | Identifying Early Melanomas at Higher Risk for Metastases. <i>Journal of Clinical Oncology</i> , 2012, 30, 1406-1407. | 0.8 | 18 |
| 291 | Targeted Therapy for Brain Metastases. <i>Advances in Pharmacology</i> , 2012, 65, 109-142. | 1.2 | 11 |
| 293 | Polarization speckle imaging as a potential technique for <i>in vivo</i> skin cancer detection. <i>Journal of Biomedical Optics</i> , 2012, 18, 061211. | 1.4 | 31 |
| 294 | Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2012, 30, 2912-2918. | 0.8 | 301 |
| 295 | Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects. <i>Cancer Research</i> , 2012, 72, 716-725. | 0.4 | 16 |
| 296 | CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 2039-2047. | 3.2 | 459 |
| 297 | Population-Based 20-Year Survival Among People Diagnosed With Thin Melanomas in Queensland, Australia. <i>Journal of Clinical Oncology</i> , 2012, 30, 1462-1467. | 0.8 | 160 |
| 298 | Superficial spreading and nodular melanoma are distinct biological entities. <i>Melanoma Research</i> , 2012, 22, 1-8. | 0.6 | 73 |
| 299 | A brief history of melanoma. <i>Melanoma Research</i> , 2012, 22, 114-122. | 0.6 | 111 |
| 300 | Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. <i>Melanoma Research</i> , 2012, 22, 287-293. | 0.6 | 48 |
| 301 | A rare case of primary rhabdoid melanoma of the urinary bladder treated with ipilimumab, an anti-CTLA 4 monoclonal antibody. <i>Melanoma Research</i> , 2012, 22, 320-325. | 0.6 | 11 |
| 302 | Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma. <i>Melanoma Research</i> , 2012, 22, 302-309. | 0.6 | 21 |
| 303 | Periodic acid Schiff loops and blood lakes associated with metastasis in cutaneous melanoma. <i>Melanoma Research</i> , 2012, 22, 424-429. | 0.6 | 19 |
| 304 | Vemurafenib-induced neutrophilic panniculitis. <i>Melanoma Research</i> , 2012, 22, 399-401. | 0.6 | 46 |
| 305 | Superficial-spreading and nodular melanomas in Norway. <i>Melanoma Research</i> , 2012, 22, 460-465. | 0.6 | 17 |
| 306 | Special Issue on Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 115-116. | 1.0 | 1 |
| 307 | Validation of the Self-Assessment of Melanoma Risk Score for a melanoma-targeted screening. <i>European Journal of Cancer Prevention</i> , 2012, 21, 588-595. | 0.6 | 30 |
| 308 | Variability in melanoma post-treatment surveillance practices by country and physician specialty. <i>Melanoma Research</i> , 2012, 22, 376-385. | 0.6 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 309 | Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. <i>Melanoma Research</i> , 2012, 22, 466-472. | 0.6 | 112 |
| 310 | Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. <i>Melanoma Research</i> , 2012, 22, 169-175. | 0.6 | 15 |
| 311 | Outcome following local recurrence or in-transit metastases in cutaneous melanoma. <i>Melanoma Research</i> , 2012, 22, 447-453. | 0.6 | 11 |
| 312 | Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. <i>Annals of Oncology</i> , 2012, 23, 524-530. | 0.6 | 109 |
| 313 | Multicohort model for prevalence estimation of advanced malignant melanoma in the USA. <i>Melanoma Research</i> , 2012, 22, 454-459. | 0.6 | 7 |
| 314 | Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. <i>Journal of Clinical Oncology</i> , 2012, 30, 2375-2383. | 0.8 | 216 |
| 315 | Advances in the treatment of melanoma. <i>Clinical Medicine</i> , 2012, 12, 168-171. | 0.8 | 12 |
| 316 | Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. <i>Journal of Oncology Practice</i> , 2012, 8, e65-e66. | 2.5 | 4 |
| 317 | Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2678-2683. | 0.8 | 691 |
| 318 | Long-Term Prognosis and Significance of the Sentinel Lymph Node in Head and Neck Melanoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 147, 699-706. | 1.1 | 40 |
| 319 | Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3810-3818. | 0.8 | 254 |
| 320 | Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 1386-1394. | 3.2 | 589 |
| 321 | Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. <i>Science Translational Medicine</i> , 2012, 4, 127ra37. | 5.8 | 1,837 |
| 323 | Targeting CD20 in Melanoma Patients at High Risk of Disease Recurrence. <i>Molecular Therapy</i> , 2012, 20, 1056-1062. | 3.7 | 69 |
| 324 | Is Skin Self-Examination for Cutaneous Melanoma Detection Still Adequate? A Retrospective Study. <i>Dermatology</i> , 2012, 225, 31-36. | 0.9 | 20 |
| 325 | Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 4026-4036. | 3.2 | 96 |
| 326 | Advances in sentinel lymph node mapping for patients with melanoma. <i>Future Oncology</i> , 2012, 8, 191-203. | 1.1 | 0 |
| 327 | The Contribution of Health Services Research to Improved Dermatologic Care. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1003-1007. | 0.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 328 | RASSF10 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin but Uncommon in Nevus Cell Nevi. <i>Journal of Investigative Dermatology</i> , 2012, 132, 687-694. | 0.3 | 42 |
| 329 | Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site. <i>Neuro-Oncology</i> , 2012, 14, 849-858. | 0.6 | 16 |
| 330 | High endothelial venules (HEVs) in human melanoma lesions. <i>Oncolmmunology</i> , 2012, 1, 829-839. | 2.1 | 161 |
| 331 | Targeted treatment for melanoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1113-1115. | 1.1 | 1 |
| 332 | Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. <i>Modern Pathology</i> , 2012, 25, 828-837. | 2.9 | 43 |
| 333 | Heat and β -adrenergic responsiveness in human skeletal muscle feed arteries: the role of nitric oxide. <i>Journal of Applied Physiology</i> , 2012, 113, 1690-1698. | 1.2 | 28 |
| 335 | Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. <i>Modern Pathology</i> , 2012, 25, 493-504. | 2.9 | 105 |
| 336 | Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. <i>British Journal of Cancer</i> , 2012, 107, 422-428. | 2.9 | 129 |
| 337 | Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 7067-7072. | 3.3 | 39 |
| 338 | <i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2522-2529. | 0.8 | 419 |
| 339 | Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i> -Mutant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 3242-3249. | 3.2 | 405 |
| 340 | Molecular targets in melanoma: time for "ethnic personalization". <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 601-608. | 1.1 | 8 |
| 344 | Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 274-283. | 0.3 | 52 |
| 345 | Head and Neck Melanoma. <i>ISRN Surgery</i> , 2012, 2012, 1-7. | 1.4 | 37 |
| 346 | Lymphatic Invasion Is Independently Prognostic of Metastasis in Primary Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 229-237. | 3.2 | 56 |
| 347 | Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases. <i>Dermatology Research and Practice</i> , 2012, 2012, 1-14. | 0.3 | 17 |
| 348 | Smouldering Malignant Melanoma and Metastatic Dormancy: An Update and Review. <i>Dermatology Research and Practice</i> , 2012, 2012, 1-6. | 0.3 | 7 |
| 349 | Histology and outcomes of newly detected lung lesions in melanoma patients. <i>Annals of Oncology</i> , 2012, 23, 577-582. | 0.6 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 350 | The prognostic value of a reverse transcriptase-PCR assay of sentinel lymph node biopsy for patients with cutaneous melanoma. <i>Melanoma Research</i> , 2012, 22, 38-44. | 0.6 | 16 |
| 351 | Ipilimumab in advanced melanoma. <i>Melanoma Research</i> , 2012, 22, 263-270. | 0.6 | 47 |
| 352 | The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival. <i>Melanoma Research</i> , 2012, 22, 386-391. | 0.6 | 26 |
| 353 | Surgery for Distant Melanoma Metastasis. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 176-184. | 1.0 | 81 |
| 354 | Sentinel Lymph Node Biopsy in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 185-191. | 1.0 | 28 |
| 355 | Superior Outcome of Women With Stage I/II Cutaneous Melanoma: Pooled Analysis of Four European Organisation for Research and Treatment of Cancer Phase III Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 2240-2247. | 0.8 | 158 |
| 356 | Plaques on a Butcher's Fingers—Diagnosis. <i>Archives of Dermatology</i> , 2012, 148, 531. | 1.7 | 1 |
| 357 | Prediction of Sentinel Lymph Node Positivity by Growth Rate of Cutaneous Melanoma. <i>Archives of Dermatology</i> , 2012, 148, 577-84. | 1.7 | 31 |
| 358 | Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases. <i>Pathology</i> , 2012, 44, 661-664. | 0.3 | 3 |
| 359 | Systemic Therapy for Metastatic Melanoma in 2012: Dawn of a New Era. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 403-412. | 2.3 | 22 |
| 360 | Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 11-31. | 1.0 | 8 |
| 361 | Squamoproliferative Lesions Arising in the Setting of BRAF Inhibition. <i>American Journal of Dermatopathology</i> , 2012, 34, 822-826. | 0.3 | 44 |
| 362 | Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 66-72. | 1.2 | 111 |
| 363 | Characterization of T-cell Receptors Directed Against HLA-A*01-restricted and C*07-restricted Epitopes of MAGE-A3 and MAGE-A12. <i>Journal of Immunotherapy</i> , 2012, 35, 680-688. | 1.2 | 7 |
| 364 | Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma. <i>Annals of Surgery</i> , 2012, 255, 1165-1170. | 2.1 | 62 |
| 365 | Melphalan in Regional Chemotherapy for Locally Recurrent Metastatic Melanoma. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 53-60. | 1.0 | 19 |
| 366 | Lower tumour burden and better overall survival in melanoma patients with regional lymph node metastases and negative preoperative ultrasound. <i>Radiology and Oncology</i> , 2012, 46, 60-8. | 0.6 | 9 |
| 367 | Improvement in Patient Performance of Skin Self-examinations After Intervention With Interactive Education and Telecommunication Reminders. <i>Archives of Dermatology</i> , 2012, 148, 1266. | 1.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 368 | Cellular blue naevus involving the urinary bladder. <i>Pathology</i> , 2012, 44, 664-668. | 0.3 | 5 |
| 369 | Unanswered Questions About Margin Recommendations for Primary Cutaneous Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 357-365. | 2.3 | 10 |
| 370 | Controversies in the Management of Regional Nodes in Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 414-421. | 2.3 | 3 |
| 371 | Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. <i>BMJ, The</i> , 2012, 345, e4110-e4110. | 3.0 | 61 |
| 372 | Management of Melanomas in Children and Young Adults. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, S51-S54. | 0.3 | 27 |
| 373 | Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?. <i>Current Opinion in Oncology</i> , 2012, 24, 137-140. | 1.1 | 43 |
| 374 | pHH3 Immunostaining Improves Interobserver Agreement of Mitotic Index in Thin Melanomas. <i>American Journal of Dermatopathology</i> , 2012, 34, 266-269. | 0.3 | 52 |
| 375 | Diffuse cutaneous uptake of 18F-fluorodeoxyglucose is associated with adverse prognosis in patients with melanoma. <i>Nuclear Medicine Communications</i> , 2012, 33, 1300-1306. | 0.5 | 0 |
| 376 | Tumor Necrosis Is a Prognostic Factor in Thick Cutaneous Melanoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1477-1482. | 2.1 | 21 |
| 377 | Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. <i>Annals of Surgery</i> , 2012, 255, 128-133. | 2.1 | 103 |
| 378 | Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy. <i>Journal of Immunotherapy</i> , 2012, 35, 641-649. | 1.2 | 72 |
| 379 | Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. <i>Journal of Immunotherapy</i> , 2012, 35, 711-715. | 1.2 | 24 |
| 380 | Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 345-356. | 2.3 | 117 |
| 382 | Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 366-400. | 2.3 | 63 |
| 383 | Effect of Teledermatology on the Prognosis of Patients With Cutaneous Melanoma. <i>Archives of Dermatology</i> , 2012, 148, 1025. | 1.7 | 59 |
| 385 | The Contribution of Nodular Subtype to Melanoma Mortality in the United States, 1978 to 2007. <i>Archives of Dermatology</i> , 2012, 148, 30. | 1.7 | 86 |
| 386 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2012, 379, 1893-1901. | 6.3 | 856 |
| 387 | Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3819-3826. | 0.8 | 77 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 388 | Human skeletal muscle feed arteries: evidence of regulatory potential. <i>Acta Physiologica</i> , 2012, 206, 135-141. | 1.8 | 12 |
| 389 | Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 630-638. | 1.5 | 52 |
| 390 | The patient journey: a report of skin cancer care across Europe. <i>British Journal of Dermatology</i> , 2012, 167, 43-52. | 1.4 | 16 |
| 391 | Molecular Diagnostics of Melanoma Fine-Needle Aspirates. <i>American Journal of Clinical Pathology</i> , 2012, 138, 670-677. | 0.4 | 29 |
| 392 | Improving triage and management of patients with skin cancer: challenges and considerations for the future. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 609-621. | 1.1 | 12 |
| 393 | Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, 267-273. | 1.6 | 48 |
| 394 | Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. <i>Pharmacological Research</i> , 2012, 65, 9-22. | 3.1 | 119 |
| 395 | New Diagnostic Aids for Melanoma. <i>Dermatologic Clinics</i> , 2012, 30, 535-545. | 1.0 | 49 |
| 396 | Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 248-258. | 1.5 | 98 |
| 397 | Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma. <i>Cancer Research</i> , 2012, 72, 1070-1080. | 0.4 | 461 |
| 398 | Melanoma molecular classes and prognosis in the postgenomic era. <i>Lancet Oncology</i> , The, 2012, 13, e205-e211. | 5.1 | 29 |
| 399 | A tale of two tumours and a plea for progress. <i>Lancet Oncology</i> , The, 2012, 13, 124-125. | 5.1 | 2 |
| 400 | Raf Kinase Inhibitor RKIP Inhibits MDA-9/Syntenin-Mediated Metastasis in Melanoma. <i>Cancer Research</i> , 2012, 72, 6217-6226. | 0.4 | 55 |
| 403 | Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging?. <i>European Radiology</i> , 2012, 22, 2451-2457. | 2.3 | 28 |
| 404 | A novel mouse model of isolated limb perfusion for extremity melanoma. <i>Journal of Surgical Research</i> , 2012, 178, 294-298. | 0.8 | 6 |
| 405 | The role of CCND1 alterations during the progression of cutaneous malignant melanoma. <i>Tumor Biology</i> , 2012, 33, 2189-2199. | 0.8 | 45 |
| 407 | Sentinel node status predicts survival in thick melanomas: The Oxford perspective. <i>European Journal of Surgical Oncology</i> , 2012, 38, 936-942. | 0.5 | 22 |
| 408 | Melanoma Brain Metastases: The Impact of Nodal Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S655. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 409 | The Effect of Metastatic Site and Decade of Diagnosis on the Individual Burden of Metastatic Melanoma: Contemporary Estimates of Average Years of Life Lost. <i>Cancer Investigation</i> , 2012, 30, 637-641. | 0.6 | 6 |
| 410 | Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1087-1099. | 1.4 | 22 |
| 411 | Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports. <i>Cancer Investigation</i> , 2012, 30, 712-720. | 0.6 | 10 |
| 412 | Sentinel Node Biopsy is Indicated for Thin Melanomas ≤ 0.76 mm. <i>Annals of Surgical Oncology</i> , 2012, 19, 3335-3342. | 0.7 | 64 |
| 413 | Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. <i>Annals of Surgical Oncology</i> , 2012, 19, 3313-3324. | 0.7 | 101 |
| 414 | Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3325-3334. | 0.7 | 59 |
| 415 | Melanoma: New Insights and New Therapies. <i>Journal of Investigative Dermatology</i> , 2012, 132, 854-863. | 0.3 | 136 |
| 416 | Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 841-846. | 1.7 | 14 |
| 417 | Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3913-3918. | 0.7 | 23 |
| 418 | Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2012, 19, 4314-4321. | 0.7 | 91 |
| 419 | Can We Better Identify Thin Cutaneous Melanomas That are Likely to Metastasize and Cause Death?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3310-3312. | 0.7 | 7 |
| 420 | Is a "Merkel" Just Like a Melanoma? The Pathologic Analysis of Merkel Cell Carcinoma Specimens. <i>Annals of Surgical Oncology</i> , 2012, 19, 3304-3306. | 0.7 | 1 |
| 421 | The Unique Clinical Characteristics of Melanoma Diagnosed in Children. <i>Annals of Surgical Oncology</i> , 2012, 19, 3888-3895. | 0.7 | 66 |
| 422 | The Challenge of Defining Guidelines for Sentinel Lymph Node Biopsy in Patients with Thin Primary Cutaneous Melanomas. <i>Annals of Surgical Oncology</i> , 2012, 19, 3301-3303. | 0.7 | 36 |
| 423 | Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. <i>Modern Pathology</i> , 2012, 25, 1000-1010. | 2.9 | 61 |
| 424 | Malignant Melanoma: Advances in Diagnosis, Prognosis, and Treatment. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, 45-49. | 1.6 | 7 |
| 425 | Dermoscopy: An Aid to the Detection of Amelanotic Cutaneous Melanoma Metastases. <i>Dermatologic Surgery</i> , 2012, 38, 1437-1444. | 0.4 | 22 |
| 426 | Association Between Sentinel Lymph Node Excision With or Without Preoperative SPECT/CT and Metastatic Node Detection and Disease-Free Survival in Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1007. | 3.8 | 119 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 427 | A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 1066-1078. | 2.2 | 43 |
| 428 | Tumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond. Expert Review of Proteomics, 2012, 9, 415-423. | 1.3 | 9 |
| 429 | Pediatric melanomas and the atypical spitzoid melanocytic neoplasms. American Journal of Surgery, 2012, 203, 761-767. | 0.9 | 30 |
| 430 | Lymphatic drainage patterns of head and neck cutaneous melanoma: does primary melanoma site correlate with anatomic distribution of pathologically involved lymph nodes?. International Journal of Oral and Maxillofacial Surgery, 2012, 41, 413-420. | 0.7 | 29 |
| 431 | Neuropeptide Y expression in cutaneous melanoma. Journal of the American Academy of Dermatology, 2012, 66, e201-e208. | 0.6 | 19 |
| 432 | Mechanism of putative neo-antigen formation from N-propionyl-4-S-cysteaminyphenol, a tyrosinase substrate, in melanoma models. Biochemical Pharmacology, 2012, 84, 646-653. | 2.0 | 15 |
| 433 | Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients. Cancer Epidemiology, 2012, 36, 303-305. | 0.8 | 8 |
| 434 | Polymorphisms in base excision DNA repair genes and association with melanoma risk in a pilot study on Central-South Italian population. Clinica Chimica Acta, 2012, 413, 1519-1524. | 0.5 | 11 |
| 435 | Association of galectin-3 expression with melanoma progression and prognosis. European Journal of Cancer, 2012, 48, 865-874. | 1.3 | 50 |
| 436 | Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. European Journal of Cancer, 2012, 48, 218-225. | 1.3 | 182 |
| 437 | Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. European Journal of Cancer, 2012, 48, 1842-1852. | 1.3 | 74 |
| 438 | Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline "Update 2012. European Journal of Cancer, 2012, 48, 2375-2390. | 1.3 | 407 |
| 439 | The current status of S-100B as a biomarker in melanoma. European Journal of Surgical Oncology, 2012, 38, 281-285. | 0.5 | 43 |
| 440 | HEDGEHOG-GLI Signaling Drives Self-Renewal and Tumorigenicity of Human Melanoma-Initiating Cells. Stem Cells, 2012, 30, 1808-1818. | 1.4 | 134 |
| 441 | Sentinel lymph node biopsy in melanoma: Our 8-year clinical experience in a single French institute (2002-2009). BMC Dermatology, 2012, 12, 21. | 2.1 | 18 |
| 442 | Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians' perspectives and models of care. BMC Health Services Research, 2012, 12, 468. | 0.9 | 19 |
| 443 | Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib. World Journal of Surgical Oncology, 2012, 10, 155. | 0.8 | 8 |
| 444 | Serum microRNAs as biomarkers for recurrence in melanoma. Journal of Translational Medicine, 2012, 10, 155. | 1.8 | 116 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 445 | Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. <i>Journal of Translational Medicine</i> , 2012, 10, 185. | 1.8 | 49 |
| 446 | Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. <i>Journal of Translational Medicine</i> , 2012, 10, 192. | 1.8 | 52 |
| 448 | RACK1, a clue to the diagnosis of cutaneous melanomas in horses. <i>BMC Veterinary Research</i> , 2012, 8, 95. | 0.7 | 17 |
| 449 | Arginine deprivation therapy for malignant melanoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 11. | 0.8 | 23 |
| 450 | Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2012, 167, 1153-1160. | 1.4 | 163 |
| 451 | Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes. <i>Dermatologic Clinics</i> , 2012, 30, 113-124. | 1.0 | 58 |
| 452 | Surgical Treatment of Malignant Melanoma. <i>Dermatologic Clinics</i> , 2012, 30, 487-501. | 1.0 | 29 |
| 453 | Prognostic Factors for Melanoma. <i>Dermatologic Clinics</i> , 2012, 30, 469-485. | 1.0 | 30 |
| 454 | Cutaneous Head and Neck Squamous Cell Carcinoma with Regional Metastases: The Prognostic Importance of Soft Tissue Metastases and Extranodal Spread. <i>Annals of Surgical Oncology</i> , 2012, 19, 274-279. | 0.7 | 57 |
| 455 | The Impact of Primary Melanoma Thickness and Microscopic Tumor Burden in Sentinel Lymph Nodes on Melanoma Patient Survival. <i>Annals of Surgical Oncology</i> , 2012, 19, 1034-1042. | 0.7 | 14 |
| 456 | Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?. <i>Dermatologic Therapy</i> , 2012, 25, 443-451. | 0.8 | 10 |
| 457 | New therapeutical strategies in the treatment of metastatic disease. <i>Dermatologic Therapy</i> , 2012, 25, 452-457. | 0.8 | 11 |
| 458 | Vemurafenib. <i>Drugs</i> , 2012, 72, 2207-2222. | 4.9 | 89 |
| 459 | Melanoma Staging. <i>Dermatologic Clinics</i> , 2012, 30, 581-592. | 1.0 | 11 |
| 460 | Targeted Therapies for Metastatic Melanoma. <i>Dermatologic Clinics</i> , 2012, 30, 517-524. | 1.0 | 5 |
| 461 | Patterns of Recurrence Following Complete Response to Regional Chemotherapy for In-Transit Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 2563-2571. | 0.7 | 18 |
| 462 | Skin cancer in organ transplant recipients. <i>Expert Review of Dermatology</i> , 2012, 7, 37-45. | 0.3 | 1 |
| 463 | A new era for the management of metastatic melanoma. <i>Expert Review of Dermatology</i> , 2012, 7, 27-35. | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 464 | BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF ^{V600E} mutation. <i>Future Oncology</i> , 2012, 8, 499-507. | 1.1 | 69 |
| 465 | Melanoma of the Skin. , 2012, , 385-416. | | 7 |
| 466 | EORTC Melanoma Group achievements. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 112-119. | 2.2 | 0 |
| 467 | Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1087-1095. | 5.1 | 841 |
| 468 | Recognition of melanoma: A dermatologic clinical competency in medical student education. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 606-611. | 0.6 | 29 |
| 469 | Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 717-726. | 0.6 | 63 |
| 470 | Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 727-735. | 0.6 | 44 |
| 471 | N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model. <i>Journal of Dermatological Science</i> , 2012, 67, 51-60. | 1.0 | 16 |
| 472 | Expression of AP-2 [±] , AP-2 ^β and ESDN in primary melanomas: Correlation with histopathological features and potential prognostic value. <i>Journal of Dermatological Science</i> , 2012, 68, 202-204. | 1.0 | 13 |
| 473 | Relation of Serum Lactate Dehydrogenase to Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2012, 110, 1717-1722. | 0.7 | 23 |
| 474 | Unique prognostic factors in acral lentiginous melanoma. <i>American Journal of Surgery</i> , 2012, 204, 874-880. | 0.9 | 36 |
| 475 | Setting up an effective and efficient sentinel node biopsy service for malignant melanoma within the NHS. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2012, 65, 351-355. | 0.5 | 6 |
| 476 | Sentinel lymph node biopsy in thick malignant melanoma: A 10-year single unit experience. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2012, 65, 1396-1402. | 0.5 | 14 |
| 477 | Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study). <i>European Journal of Cancer</i> , 2012, 48, 3205-3214. | 1.3 | 24 |
| 478 | Outcomes and prognostic factors in nodular melanomas. <i>Surgery</i> , 2012, 152, 652-660. | 1.0 | 14 |
| 479 | Co-development of a companion diagnostic for targeted cancer therapy. <i>New Biotechnology</i> , 2012, 29, 682-688. | 2.4 | 40 |
| 480 | Protein and non-protein biomarkers in melanoma: a critical update. <i>Amino Acids</i> , 2012, 43, 2203-2230. | 1.2 | 54 |
| 481 | Spirooxindole Derivative SOID-8 Induces Apoptosis Associated with Inhibition of JAK2/STAT3 Signaling in Melanoma Cells. <i>PLoS ONE</i> , 2012, 7, e49306. | 1.1 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 482 | Driving transcriptional regulators in melanoma metastasis. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 621-632. | 2.7 | 38 |
| 483 | The Pathology of Melanoma. <i>Dermatologic Clinics</i> , 2012, 30, 445-468. | 1.0 | 22 |
| 484 | Screening and Prevention Measures for Melanoma: Is There a Survival Advantage?. <i>Current Oncology Reports</i> , 2012, 14, 458-467. | 1.8 | 54 |
| 485 | Melanoma with unknown primary: report and analysis of 24 patients. <i>Medical Oncology</i> , 2012, 29, 2978-2984. | 1.2 | 11 |
| 487 | Progression of cutaneous melanoma: implications for treatment. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 775-796. | 1.7 | 32 |
| 488 | A potential role for nilotinib in <i>KIT</i> -mutated melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 861-869. | 1.9 | 21 |
| 489 | On Analyzing Process Compliance in Skin Cancer Treatment: An Experience Report from the Evidence-Based Medical Compliance Cluster (EBMC2). <i>Notes on Numerical Fluid Mechanics and Multidisciplinary Design</i> , 2012, , 398-413. | 0.2 | 20 |
| 491 | Prognostic value of the standardized uptake value for 18F-fluorodeoxyglucose in patients with stage IIIB melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1592-1598. | 3.3 | 24 |
| 492 | Human Melanoma Metastasis in NSG Mice Correlates with Clinical Outcome in Patients. <i>Science Translational Medicine</i> , 2012, 4, 159ra149. | 5.8 | 98 |
| 493 | Dabrafenib and its potential for the treatment of metastatic melanoma. <i>Drug Design, Development and Therapy</i> , 2012, 6, 391. | 2.0 | 102 |
| 494 | TGF- β 2 Signaling, Activated Stromal Fibroblasts, and Cysteine Cathepsins B and L Drive the Invasive Growth of Human Melanoma Cells. <i>American Journal of Pathology</i> , 2012, 181, 2202-2216. | 1.9 | 65 |
| 495 | Rare Tumors In Children and Adolescents. <i>Pediatric Oncology</i> , 2012, , . | 0.5 | 8 |
| 496 | Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma. <i>PLoS ONE</i> , 2012, 7, e29791. | 1.1 | 14 |
| 497 | Cell Cycle Gene Networks Are Associated with Melanoma Prognosis. <i>PLoS ONE</i> , 2012, 7, e34247. | 1.1 | 32 |
| 498 | A Seven-Marker Signature and Clinical Outcome in Malignant Melanoma: A Large-Scale Tissue-Microarray Study with Two Independent Patient Cohorts. <i>PLoS ONE</i> , 2012, 7, e38222. | 1.1 | 67 |
| 499 | A Multi-Factorial Genetic Model for Prognostic Assessment of High Risk Melanoma Patients Receiving Adjuvant Interferon. <i>PLoS ONE</i> , 2012, 7, e40805. | 1.1 | 16 |
| 500 | CD3 expression in plasma cell neoplasm (multiple myeloma): A diagnostic pitfall. <i>Pathology</i> , 2012, 44, 668-670. | 0.3 | 9 |
| 502 | Adjuvant Therapy for Resected Stage III Melanoma Patients: High-Dose Interferon-Alpha versus Ipilimumab Combined with Kinases Inhibitors. <i>Tumori</i> , 2012, 98, 185-190. | 0.6 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 503 | The Role of Angiogenesis Inhibitors in the Management of Melanoma. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 32-49. | 1.0 | 19 |
| 504 | Impact of Molecular Weight on Lymphatic Drainage of a Biopolymer-Based Imaging Agent. <i>Pharmaceutics</i> , 2012, 4, 276-295. | 2.0 | 30 |
| 505 | Radiation Therapy and Skin Cancer. , 2012, , . | | 1 |
| 506 | Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas. <i>Korean Journal of Pathology</i> , 2012, 46, 246. | 1.2 | 12 |
| 507 | Ten Years of Progress in Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 932-935. | 2.3 | 3 |
| 508 | Clinicopathologic and Survival Differences between Upper and Lower Extremity Melanomas. <i>American Surgeon</i> , 2012, 78, 779-787. | 0.4 | 11 |
| 509 | Early Recurrence in Sentinel Lymph Node Positive Stage III Melanoma Patients. <i>American Surgeon</i> , 2012, 78, 808-813. | 0.4 | 4 |
| 510 | Melanoma and Nonmelanoma Skin Cancers. , 2012, , 1329-1334. | | 1 |
| 511 | Melanoma Prevention: Are We Doing Enough? A Canadian Perspective. <i>Current Oncology</i> , 2012, 19, 462-467. | 0.9 | 10 |
| 512 | Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. <i>Wspolczesna Onkologia</i> , 2012, 6, 532-545. | 0.7 | 8 |
| 513 | Completeness of TNM cancer staging for melanoma in the Danish Cancer Registry, 2004–2009. <i>Clinical Epidemiology</i> , 2012, 4 Suppl 2, 5. | 1.5 | 15 |
| 514 | Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. <i>Cancer Management and Research</i> , 2012, 4, 243. | 0.9 | 50 |
| 515 | Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. <i>Cancer Management and Research</i> , 2012, 4, 299. | 0.9 | 64 |
| 516 | 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters. <i>Annals of Surgical Oncology</i> , 2012, 19, 627-635. | 0.7 | 61 |
| 517 | Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 620-626. | 0.7 | 18 |
| 518 | Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. <i>Journal of Translational Medicine</i> , 2012, 10, 69. | 1.8 | 84 |
| 519 | Advances in cutaneous melanoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 325-332. | 1.2 | 6 |
| 520 | Sentinel lymph node biopsy for thin melanoma. <i>Journal of Surgical Oncology</i> , 2012, 106, 217-218. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 521 | Role of sentinel lymphadenectomy in thin cutaneous melanomas with positive deep margins on initial biopsy. <i>Journal of Surgical Oncology</i> , 2012, 106, 363-368. | 0.8 | 18 |
| 522 | Geographic variation in utilization of sentinel lymph node biopsy for intermediate thickness cutaneous melanoma. <i>Journal of Surgical Oncology</i> , 2012, 106, 807-810. | 0.8 | 11 |
| 523 | Melanoma: from mutations to medicine. <i>Genes and Development</i> , 2012, 26, 1131-1155. | 2.7 | 415 |
| 524 | Sylatron: A Pegylated Interferon for Use in Melanoma. <i>Annals of Pharmacotherapy</i> , 2012, 46, 830-838. | 0.9 | 16 |
| 525 | Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. <i>Cancer</i> , 2012, 118, 2476-2485. | 2.0 | 219 |
| 526 | Behavioral determinants of successful early melanoma detection. <i>Cancer</i> , 2012, 118, 3725-3734. | 2.0 | 112 |
| 527 | <i>NRAS</i> mutation status is an independent prognostic factor in metastatic melanoma. <i>Cancer</i> , 2012, 118, 4014-4023. | 2.0 | 589 |
| 528 | Single versus multiple primary melanomas. <i>Cancer</i> , 2012, 118, 4184-4192. | 2.0 | 52 |
| 529 | Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. <i>Cancer</i> , 2012, 118, 4519-4529. | 2.0 | 29 |
| 530 | Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective. <i>Supportive Care in Cancer</i> , 2012, 20, 1601-1611. | 1.0 | 10 |
| 531 | Integrating New Therapies in the Treatment of Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2012, 13, 327-339. | 1.3 | 8 |
| 532 | Targeting Metastatic Melanoma. <i>Annual Review of Medicine</i> , 2012, 63, 171-183. | 5.0 | 57 |
| 533 | Insights into melanoma: targeting the mTOR pathway for therapeutics. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 689-705. | 1.5 | 34 |
| 534 | MMP2 expression is a prognostic marker for primary melanoma patients. <i>Cellular Oncology (Dordrecht)</i> , 2012, 35, 207-216. | 2.1 | 68 |
| 535 | Advocating Sentinel Node Biopsy in the Management of Cutaneous Melanoma. <i>Current Dermatology Reports</i> , 2012, 1, 76-81. | 1.1 | 0 |
| 536 | CCL2's CCR10 and CXCL12's CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 625-637. | 1.7 | 27 |
| 537 | Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma. <i>Medical Oncology</i> , 2012, 29, 1304-1307. | 1.2 | 16 |
| 538 | Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain. <i>Clinical and Translational Oncology</i> , 2012, 14, 237-240. | 1.2 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 539 | Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness < 1.00 mm). <i>Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 581-588. | 3.3 | 16 |
| 540 | Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness > 4.00 mm): outcome analysis from a single institution. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1316-1325. | 3.3 | 8 |
| 541 | Estimating the whole bone-marrow asset in humans by a computational approach to integrated PET/CT imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1326-1338. | 3.3 | 51 |
| 542 | Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1033-1043. | 2.0 | 63 |
| 544 | Upcoming strategies for the treatment of metastatic melanoma. <i>Archives of Dermatological Research</i> , 2012, 304, 177-184. | 1.1 | 44 |
| 545 | A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma. <i>Archives of Dermatological Research</i> , 2012, 304, 397-400. | 1.1 | 21 |
| 546 | Quantified Visual Scoring of Metastatic Melanoma Patient Treatment Response Using Computed Tomography: Improving on the Current Standard. <i>Journal of Digital Imaging</i> , 2012, 25, 258-265. | 1.6 | 1 |
| 547 | Disease progression in melanoma patients with negative sentinel lymph node: does false-negative specimens entirely account for this phenomenon?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 242-248. | 1.3 | 19 |
| 548 | Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1084-1091. | 1.3 | 20 |
| 549 | Sentinel lymph node biopsy for melanoma is becoming a consensus: a national survey of French centres involved in melanoma care in 2008. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1230-1235. | 1.3 | 14 |
| 550 | A single centre melanoma thickness trend (1985-2009) in relation to skin areas accessible and non-accessible to self-inspection. <i>Australasian Journal of Dermatology</i> , 2012, 53, 32-36. | 0.4 | 9 |
| 551 | Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous melanoma: A multi-institutional study of 450 patients in Japan. <i>Journal of Dermatology</i> , 2012, 39, 130-137. | 0.6 | 24 |
| 552 | The cutaneous manifestations of metastatic malignant melanoma. <i>International Journal of Dermatology</i> , 2012, 51, 243-249. | 0.5 | 12 |
| 553 | Prognostic tissue markers in melanoma. <i>Histopathology</i> , 2012, 60, 679-689. | 1.6 | 13 |
| 554 | Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 324-330. | 0.7 | 39 |
| 555 | Indocyanine green fluorescence-guided sentinel lymph node biopsy in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 51-57. | 0.4 | 21 |
| 556 | Fluoreszenz-Markierung mittels Indocyanin-Grün bei der Sentinel-Lymphknoten-Exstirpation in der Dermatookologie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 51-58. | 0.4 | 12 |
| 557 | A Novel and Accurate Computer Model of Melanoma Prognosis for Patients Staged by Sentinel Lymph Node Biopsy: Comparison with the American Joint Committee on Cancer Model. <i>Journal of the American College of Surgeons</i> , 2012, 214, 608-617. | 0.2 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 559 | Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 89-102. | 3.3 | 46 |
| 560 | Recent Advances in Pathologic Evaluation and Reporting of Melanoma. <i>Seminars in Oncology</i> , 2012, 39, 184-191. | 0.8 | 9 |
| 561 | Vaccines for Melanoma and Renal Cell Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 263-275. | 0.8 | 29 |
| 562 | Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. <i>Histopathology</i> , 2012, 61, 702-710. | 1.6 | 29 |
| 563 | Commentary on C. Garbe et al.: "Histopathological diagnostics of malignant melanomas in accordance with the AJCC classification 2009: Revision of the literature and recommendations for general practice". <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 203-204. | 0.4 | 0 |
| 564 | Current advances and perspectives in the treatment of advanced melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 319-325. | 0.4 | 15 |
| 565 | Aktuelle Fortschritte und Ausblicke in der Therapie des metastasierten Melanoms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 319-325. | 0.4 | 13 |
| 566 | The sweet and bitter sides of galectins in melanoma progression. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 592-601. | 1.5 | 32 |
| 567 | Digital image analysis: a review of reproducibility, stability and basic requirements for optimal results. <i>Apmis</i> , 2012, 120, 276-289. | 0.9 | 37 |
| 568 | Small-diameter melanoma: toward a conceptual and practical reappraisal. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 721-723. | 0.7 | 13 |
| 569 | Expression of vascular endothelial growth factor in primary cutaneous melanoma predicts sentinel lymph node positivity. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 826-834. | 0.7 | 27 |
| 570 | Importancia del Índice mitótico en el manejo del melanoma. <i>Piel</i> , 2012, 27, 111-112. | 0.0 | 0 |
| 571 | Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. <i>British Journal of Dermatology</i> , 2012, 166, 1319-1326. | 1.4 | 8 |
| 572 | Improving care for patients with melanoma. <i>ANZ Journal of Surgery</i> , 2012, 82, 3-5. | 0.3 | 1 |
| 573 | Surgical Management of Melanoma Lung Metastasis: An Analysis of Survival Outcomes in 292 Consecutive Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 1774-1781. | 0.7 | 39 |
| 574 | Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 1782-1789. | 0.7 | 30 |
| 575 | Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. <i>Cancer</i> , 2012, 118, 1040-1047. | 2.0 | 79 |
| 576 | Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990-2006. <i>International Journal of Cancer</i> , 2012, 130, 170-178. | 2.3 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 577 | Surgical resection for bulky or recurrent axillary metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2012, 105, 21-25. | 0.8 | 8 |
| 578 | Melanoma in a patient in treatment with eculizumab. <i>Annals of Hematology</i> , 2012, 91, 135-136. | 0.8 | 6 |
| 579 | Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 436-441. | 1.3 | 9 |
| 580 | Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. <i>Psycho-Oncology</i> , 2013, 22, 721-736. | 1.0 | 51 |
| 581 | Increase lymphangiogenesis in melanoma during pregnancy: correlation with the prolactin signalling pathway. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e144-5. | 1.3 | 13 |
| 582 | MicroRNAs in the pathogenesis of malignant melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 142-150. | 1.3 | 28 |
| 583 | Correlation among metallothionein expression, intratumoural macrophage infiltration and the risk of metastasis in human cutaneous malignant melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e320-7. | 1.3 | 37 |
| 585 | Immune cell profile of sentinel lymph nodes in patients with malignant melanoma – FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome. <i>Journal of Translational Medicine</i> , 2013, 11, 43. | 1.8 | 39 |
| 586 | Histopathology Specimens. , 2013, , . | | 51 |
| 587 | Cutaneous melanoma metastases arising in the donor and recipient sites of a skin graft: case report and review of the literature. <i>European Journal of Plastic Surgery</i> , 2013, 36, 45-48. | 0.3 | 7 |
| 588 | Malignant Tumors of the Penis. <i>Dermatologic Surgery</i> , 2013, 39, 527-547. | 0.4 | 46 |
| 590 | The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma. <i>Clinical Biochemistry</i> , 2013, 46, 518-523. | 0.8 | 13 |
| 591 | Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?. <i>Cancer Treatment Reviews</i> , 2013, 39, 305-312. | 3.4 | 13 |
| 592 | Current Treatment of Locoregional Recurrence of Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 465-472. | 1.8 | 25 |
| 593 | Assessment of the XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro) and GSTP1 (Ile105Val) polymorphisms in the risk of cutaneous melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1199-1206. | 1.2 | 14 |
| 594 | Sentinel Node Biopsy in Thin and Thick Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 2780-2786. | 0.7 | 72 |
| 595 | S-100B: A Stronger Prognostic Biomarker than LDH in Stage III B – C Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 2772-2779. | 0.7 | 40 |
| 596 | Local Immune Response Predicts Survival in Patients with Thick (T4) Melanomas. <i>Annals of Surgical Oncology</i> , 2013, 20, 3610-3617. | 0.7 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 597 | Prognosis of Acral Melanoma: A Series of 281 Patients. <i>Annals of Surgical Oncology</i> , 2013, 20, 3618-3625. | 0.7 | 123 |
| 598 | Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases. <i>Annals of Surgical Oncology</i> , 2013, 20, 3961-3968. | 0.7 | 146 |
| 599 | Reproducibility of AJCC Staging Parameters in Primary Cutaneous Melanoma: An Analysis of 4,924 Cases. <i>Annals of Surgical Oncology</i> , 2013, 20, 3969-3975. | 0.7 | 20 |
| 600 | An Opportunity to Ensure High-Quality Melanoma Care Through the Use of a Preoperative Treatment Algorithm. <i>Annals of Surgical Oncology</i> , 2013, 20, 3976-3983. | 0.7 | 4 |
| 601 | KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis. <i>Immunogenetics</i> , 2013, 65, 333-343. | 1.2 | 14 |
| 602 | Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?. <i>European Radiology</i> , 2013, 23, 3466-3476. | 2.3 | 39 |
| 603 | Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. <i>International Journal of Cancer</i> , 2013, 133, 1653-1663. | 2.3 | 107 |
| 606 | A 10-year, single-institution analysis of clinicopathologic features and sentinel lymph node biopsy in thin melanomas. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 693-699. | 0.6 | 22 |
| 607 | New therapeutic options in systemic treatment of advanced cutaneous melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 181-190. | 1.9 | 12 |
| 608 | Early mobilization after ilio-inguinal lymph node dissection for melanoma does not increase the wound complication rate. <i>European Journal of Surgical Oncology</i> , 2013, 39, 185-190. | 0.5 | 12 |
| 610 | The Cost-Effectiveness of a Novel SIAscopic Diagnostic Aid for the Management of Pigmented Skin Lesions in Primary Care: A Decision-Analytic Model. <i>Value in Health</i> , 2013, 16, 356-366. | 0.1 | 22 |
| 611 | Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences. <i>Human Pathology</i> , 2013, 44, 1472-1478. | 1.1 | 31 |
| 612 | A Purine Nucleotide Biosynthesis Enzyme Guanosine Monophosphate Reductase Is a Suppressor of Melanoma Invasion. <i>Cell Reports</i> , 2013, 5, 493-507. | 2.9 | 45 |
| 613 | Adjuvant therapy for high-risk melanoma. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 106-108. | 2.2 | 0 |
| 614 | Melanoma incidence rises for children and adolescents: An epidemiologic review of pediatric melanoma in the United States. <i>Journal of Pediatric Surgery</i> , 2013, 48, 2207-2213. | 0.8 | 93 |
| 615 | Assessing rural-urban disparities in the use of sentinel lymph node biopsy for melanoma. <i>Journal of Surgical Research</i> , 2013, 184, 1157-1160. | 0.8 | 15 |
| 616 | Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. <i>Journal of Immunology</i> , 2013, 190, 6034-6042. | 0.4 | 145 |
| 618 | Registro nacional de melanoma cutáneo. Características del tumor en el momento del diagnóstico: 15 años de experiencia. <i>Actas Dermo-sifilográficas</i> , 2013, 104, 789-799. | 0.2 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 619 | Risk Factors for the Development of Locoregional Cutaneous Metastases as the Sole Form of Recurrence in Patients With Melanoma. <i>Actas Dermo-sifiliogr</i> , 2013, 104, 53-60. | 0.2 | 3 |
| 620 | Management of Primary Cutaneous and Metastatic Melanoma. <i>Seminars in Oncology Nursing</i> , 2013, 29, 195-205. | 0.7 | 14 |
| 621 | Hypoxia-induced senescence contributes to the regulation of microenvironment in melanomas. <i>Pathology Research and Practice</i> , 2013, 209, 640-647. | 1.0 | 19 |
| 622 | Immunotherapy for advanced melanoma: Fulfilling the promise. <i>Cancer Treatment Reviews</i> , 2013, 39, 879-885. | 3.4 | 44 |
| 623 | Exploitation of Long-Lived ³ IL Excited States for Metal-Organic Photodynamic Therapy: Verification in a Metastatic Melanoma Model. <i>Journal of the American Chemical Society</i> , 2013, 135, 17161-17175. | 6.6 | 265 |
| 624 | Dermatologic Ultrasound with Clinical and Histologic Correlations. , 2013, , . | | 61 |
| 625 | Diagnosis, Staging, and Follow-up. , 2013, , 29-51. | | 0 |
| 627 | <i>In vivo</i> confocal microscopy in dermatology: from research to clinical application. <i>Journal of Biomedical Optics</i> , 2013, 18, 061212. | 1.4 | 42 |
| 628 | Malignant melanoma and melanocortin 1 receptor. <i>Biochemistry (Moscow)</i> , 2013, 78, 1228-1237. | 0.7 | 53 |
| 629 | Anaesthetic techniques for unique cancer surgery procedures. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2013, 27, 513-526. | 1.7 | 14 |
| 630 | Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. <i>British Journal of Dermatology</i> , 2013, 168, 779-786. | 1.4 | 40 |
| 631 | Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome. <i>International Journal of Cancer</i> , 2013, 133, 3000-3007. | 2.3 | 14 |
| 632 | Cutaneous melanoma follow-up: appropriateness of requests for ultrasound tests – the S.Gallicano National Referral Centre Experience. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 73. | 3.5 | 7 |
| 633 | Clinical impact of 18F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience. <i>Insights Into Imaging</i> , 2013, 4, 701-709. | 1.6 | 10 |
| 634 | Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 202. | 1.8 | 31 |
| 635 | SLN melanoma micrometastasis predictivity of nodal status: a long term retrospective study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 47. | 3.5 | 4 |
| 636 | Outcome of Clinical Stage III Melanoma Patients with FDG-PET and Whole-Body CT Added to the Diagnostic Workup. <i>Annals of Surgical Oncology</i> , 2013, 20, 3098-3105. | 0.7 | 24 |
| 637 | Stage IV Melanoma: Completely Resectable Patients are Scarce. <i>Annals of Surgical Oncology</i> , 2013, 20, 2352-2356. | 0.7 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 638 | Use of SPECT/CT for improved sentinel lymph node localization in endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 129, 42-48. | 0.6 | 39 |
| 639 | Multiple types of data are required to identify the mechanisms influencing the spatial expansion of melanoma cell colonies. <i>BMC Systems Biology</i> , 2013, 7, 137. | 3.0 | 53 |
| 640 | Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma – a case report. <i>Diagnostic Pathology</i> , 2013, 8, 192. | 0.9 | 8 |
| 641 | Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2013, 31, 1121-1129. | 1.7 | 16 |
| 642 | Anorectal malignant melanoma in a hemorrhoidal nodule: a diagnostic and therapeutic problem. <i>Wiener Medizinische Wochenschrift</i> , 2013, 163, 499-504. | 0.5 | 0 |
| 643 | Targeting MAPK pathway in melanoma therapy. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 567-584. | 2.7 | 72 |
| 644 | Melanoma risk loci as determinants of melanoma recurrence and survival. <i>Journal of Translational Medicine</i> , 2013, 11, 279. | 1.8 | 30 |
| 645 | Cutaneous Adverse Events to Type I BRAF Inhibitors: An Analysis of Effects Associated with Each Inhibitor and Therapeutic Time Interval to Onset. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 461-471. | 3.3 | 13 |
| 646 | Current management of melanoma. <i>Current Problems in Surgery</i> , 2013, 50, 351-382. | 0.6 | 36 |
| 647 | Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. <i>European Journal of Cancer</i> , 2013, 49, 3229-3241. | 1.3 | 40 |
| 648 | Synthesis, Radiofluorination, and <i>in Vivo</i> Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8455-8467. | 2.9 | 22 |
| 649 | Interferon alpha for the adjuvant treatment of cutaneous melanoma. <i>The Cochrane Library</i> , 2015, 2015, CD008955. | 1.5 | 110 |
| 650 | Impact of Age on the Management of Primary Melanoma Patients. <i>Oncology</i> , 2013, 85, 173-181. | 0.9 | 14 |
| 651 | The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 588-598. | 12.5 | 177 |
| 652 | Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. <i>Future Oncology</i> , 2013, 9, 245-253. | 1.1 | 12 |
| 653 | Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 179-194. | 3.3 | 89 |
| 654 | Plasma Cytokine Analysis in Patients with Advanced Extremity Melanoma Undergoing Isolated Limb Infusion. <i>Annals of Surgical Oncology</i> , 2013, 20, 1128-1135. | 0.7 | 21 |
| 655 | Follow-up of early stage melanoma: Specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals. <i>Journal of Surgical Oncology</i> , 2013, 107, 463-468. | 0.8 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 656 | Ultrathin primary is a marker for worse prognosis in lymph node–positive cutaneous melanoma. <i>Cancer</i> , 2013, 119, 1860-1867. | 2.0 | 7 |
| 657 | Prognostic Value of Sentinel Lymph Node Biopsy Compared with that of Breslow Thickness: Implications for Informed Consent in Patients with Invasive Melanoma. <i>Dermatologic Surgery</i> , 2013, 39, 1800-1812. | 0.4 | 17 |
| 658 | Response to a costly revolution for a subgroup of patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2013, 168, 470-471. | 1.4 | 0 |
| 659 | Too much surgery and too little benefit? Sentinel node biopsy for melanoma as it currently stands. <i>British Journal of Dermatology</i> , 2013, 169, 233-235. | 1.4 | 6 |
| 662 | BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 1225-1231. | 3.2 | 832 |
| 663 | Targeting Oncogenic Drivers and the Immune System in Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 499-506. | 0.8 | 98 |
| 664 | Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin-Embedded Cutaneous Melanomas. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 70-80. | 1.2 | 68 |
| 665 | The characterization and potential impact of melanoma cases with unknown thickness in the United States™ Surveillance, Epidemiology, and End Results Program, 1989–2008. <i>Cancer Epidemiology</i> , 2013, 37, 64-70. | 0.8 | 25 |
| 666 | Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination. <i>Cancer Research</i> , 2013, 73, 19-29. | 0.4 | 131 |
| 667 | Diagnosis and management of melanoma with regional lymph node metastases: a population–based study in France. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1081-1087. | 1.3 | 3 |
| 668 | Relevance of multiple basin drainage and primary histologic regression in prognosis of trunk melanoma patients with negative sentinel lymph nodes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1132-1137. | 1.3 | 17 |
| 669 | The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1052-1062. | 0.3 | 49 |
| 670 | Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. <i>Archives of Dermatological Research</i> , 2013, 305, 59-67. | 1.1 | 27 |
| 671 | A nine-gene signature predicting clinical outcome in cutaneous melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 249-258. | 1.2 | 77 |
| 672 | Surgery and the management of cutaneous melanoma. <i>British Journal of Surgery</i> , 2013, 100, 313-315. | 0.1 | 2 |
| 673 | Sentinel lymph node biopsy for melanoma: A critical update for dermatologists after two decades of experience. <i>Clinics in Dermatology</i> , 2013, 31, 298-310. | 0.8 | 25 |
| 674 | Melanoma Characteristics at Diagnosis From The Spanish National Cutaneous Melanoma Registry: 15 Years of Experience. <i>Actas Dermo-sifiligráficas</i> , 2013, 104, 789-799. | 0.2 | 16 |
| 675 | β-Blocker use and all-cause mortality of melanoma patients: Results from a population-based Dutch cohort study. <i>European Journal of Cancer</i> , 2013, 49, 3863-3871. | 1.3 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 676 | Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. <i>Biochemical Pharmacology</i> , 2013, 85, 325-334. | 2.0 | 70 |
| 677 | Mãĩrgenes de resecciã³n oncolã³gica en cirugã³a dermatolã³gica. <i>EMC - Dermatologã³a</i> , 2013, 47, 1-9. | 0.1 | 0 |
| 678 | Effect of Î²-Blockers and Other Antihypertensive Drugs On the Risk of Melanoma Recurrence and Death. <i>Mayo Clinic Proceedings</i> , 2013, 88, 1196-1203. | 1.4 | 66 |
| 679 | The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs. <i>International Journal of Surgery Case Reports</i> , 2013, 4, 40-43. | 0.2 | 1 |
| 680 | CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. <i>Journal of Dermatological Science</i> , 2013, 69, 105-113. | 1.0 | 15 |
| 681 | The lymph node ratio has limited prognostic significance in melanoma. <i>Journal of Surgical Research</i> , 2013, 179, 10-17. | 0.8 | 4 |
| 682 | Incidence of Sentinel Lymph Node Involvement in a Modern, Large Series of Desmoplastic Melanoma. <i>Journal of the American College of Surgeons</i> , 2013, 217, 37-44. | 0.2 | 18 |
| 683 | Targeting BRAF in melanoma: Biological and clinical challenges. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 239-255. | 2.0 | 41 |
| 684 | Do vitamin A serum levels moderate outcome or the protective effect of vitamin DÃ³n outcome from malignant melanoma?. <i>Clinical Nutrition</i> , 2013, 32, 1012-1016. | 2.3 | 7 |
| 685 | Stage III Melanoma in the Axilla: Patterns of Regional Recurrence After Surgery With and Without Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 702-708. | 0.4 | 8 |
| 686 | Sentinel Lymph Node Biopsy for Melanoma in Pregnant Women. <i>Annals of Surgical Oncology</i> , 2013, 20, 689-696. | 0.7 | 45 |
| 687 | Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 4252-4259. | 0.8 | 232 |
| 688 | Atypical fibroxanthoma-like amelanotic malignant melanoma: A case report and literature review. <i>Dermatologica Sinica</i> , 2013, 31, 140-144. | 0.2 | 7 |
| 689 | Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor. <i>Academic Radiology</i> , 2013, 20, 423-429. | 1.3 | 6 |
| 690 | Expression of the vitamin Dã³activating enzyme 1Î±-hydroxylase (CYP27B1) decreases during melanoma progression. <i>Human Pathology</i> , 2013, 44, 374-387. | 1.1 | 73 |
| 691 | The analysis of the outcomes and factors related to iliacã³obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases. <i>European Journal of Surgical Oncology</i> , 2013, 39, 304-310. | 0.5 | 11 |
| 692 | Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. <i>European Journal of Surgical Oncology</i> , 2013, 39, 179-184. | 0.5 | 22 |
| 693 | Melanoma epidemiology, biology and prognosis. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 81-91. | 2.2 | 178 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 694 | Factores de riesgo para el desarrollo de met stasis cut neas locorregionales como forma  nica de reca da en los pacientes con melanoma. <i>Actas Dermo-sifiliogr ficas</i> , 2013, 104, 53-60. | 0.2 | 8 |
| 695 | MST1 activation by curcumin mediates JNK activation, Foxo3a nuclear translocation and apoptosis in melanoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 441, 53-58. | 1.0 | 50 |
| 696 | Surgical Treatment of Melanoma Liver Metastases. <i>Cirug a Espa ola (English Edition)</i> , 2013, 91, 4-8. | 0.1 | 0 |
| 697 | Mitotic rate in melanoma should be recorded as the number of mitoses per mm2 (not per high power) Tj ETQq1 1 0,784314 rgBT /Over | 0.9 | 17 |
| 699 | Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 149-161. | 2.0 | 33 |
| 700 | Analysis of sentinel lymph node positivity in patients with thin primary melanoma. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 560-567. | 0.6 | 51 |
| 701 | Selective sentinel lymph node dissection in head and neck cutaneous melanoma. <i>Operative Techniques in Otolaryngology - Head and Neck Surgery</i> , 2013, 24, 13-18. | 0.1 | 0 |
| 702 | A novel o-naphtoquinone inhibits N-cadherin expression and blocks melanoma cell invasion via AKT signaling. <i>Toxicology in Vitro</i> , 2013, 27, 2076-2083. | 1.1 | 16 |
| 703 | Translational Research in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 785-804. | 0.6 | 0 |
| 705 | Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay. <i>Cancer Letters</i> , 2013, 334, 202-210. | 3.2 | 17 |
| 706 | Amelanotic acral melanomas: Clinicopathological, BRAF mutation, and KIT aberration analyses. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 700-707. | 0.6 | 32 |
| 707 | Outcomes and prognostic factors in superficial spreading melanoma. <i>American Journal of Surgery</i> , 2013, 206, 861-868. | 0.9 | 18 |
| 708 | The challenge of developing useful blood-based biomarkers in melanoma. <i>British Journal of Dermatology</i> , 2013, 168, 3-3. | 1.4 | 4 |
| 709 |  "Monster cell ™ melanoma with pulmonary metastasis and cyclin <sc>D1</sc> amplification. <i>Journal of Cutaneous Pathology</i> , 2013, 40, 61-65. | 0.7 | 10 |
| 710 | DNA repair and replication proteins as prognostic markers in melanoma. <i>Histopathology</i> , 2013, 62, 343-350. | 1.6 | 21 |
| 711 | A 10 year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long term follow up. <i>International Journal of Dermatology</i> , 2013, 52, 220-230. | 0.5 | 13 |
| 712 | Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients. <i>Cancer Research</i> , 2013, 73, 1063-1075. | 0.4 | 295 |
| 713 | TNF-alpha and melphalan modulate a specific group of early expressed genes in a murine melanoma model. <i>Cytokine</i> , 2013, 62, 217-225. | 1.4 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 714 | Diversity of Stage III Melanoma in the Era of Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2013, 20, 956-963. | 0.7 | 25 |
| 715 | Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 643-656. | 1.4 | 27 |
| 716 | Melanoma. <i>Facial Plastic Surgery Clinics of North America</i> , 2013, 21, 33-42. | 0.9 | 22 |
| 717 | Detection and Analysis of Irregular Streaks in Dermoscopic Images of Skin Lesions. <i>IEEE Transactions on Medical Imaging</i> , 2013, 32, 849-861. | 5.4 | 95 |
| 718 | Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. <i>Modern Pathology</i> , 2013, 26, 1153-1160. | 2.9 | 67 |
| 719 | Melanoma immunotherapy: historical precedents, recent successes and future prospects. <i>Immunotherapy</i> , 2013, 5, 169-182. | 1.0 | 27 |
| 720 | Developing melanoma therapeutics: overview and update. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2013, 5, 257-271. | 6.6 | 13 |
| 721 | Is Head and Neck Melanoma Different from Trunk and Extremity Melanomas with Respect to Sentinel Lymph Node Status and Clinical Outcome?. <i>Annals of Surgical Oncology</i> , 2013, 20, 3089-3097. | 0.7 | 82 |
| 722 | Vemurafenib in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 513-522. | 1.1 | 9 |
| 723 | Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. <i>Clinics in Dermatology</i> , 2013, 31, 237-250. | 0.8 | 40 |
| 724 | 1 or 2cm Margins of Excision for T2 Melanomas: Do They Impact Recurrence or Survival?. <i>Annals of Surgical Oncology</i> , 2013, 20, 346-351. | 0.7 | 40 |
| 725 | Molecular networks in melanoma invasion and metastasis. <i>Future Oncology</i> , 2013, 9, 713-726. | 1.1 | 41 |
| 726 | Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. <i>Cancer Treatment Reviews</i> , 2013, 39, 27-43. | 3.4 | 14 |
| 727 | Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 1.e1-1.e9. | 0.6 | 13 |
| 728 | Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. <i>Cell Death and Disease</i> , 2013, 4, e719-e719. | 2.7 | 129 |
| 730 | Ipilimumab and Its Toxicities: A Multidisciplinary Approach. <i>Oncologist</i> , 2013, 18, 733-743. | 1.9 | 288 |
| 731 | Molecularly targeted therapies for melanoma. <i>International Journal of Dermatology</i> , 2013, 52, 523-530. | 0.5 | 13 |
| 733 | Structure-Based Design of Altered MHC Class II Restricted Peptide Ligands with Heterogeneous Immunogenicity. <i>Journal of Immunology</i> , 2013, 191, 5097-5106. | 0.4 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 734 | Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1063-1073. | 1.2 | 24 |
| 735 | Intracerebral metastases of malignant melanoma and their recurrences—A clinical analysis. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1721-1728. | 0.6 | 18 |
| 736 | MEK Inhibition in the Treatment of Advanced Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 473-482. | 1.8 | 21 |
| 737 | Complex General Surgical Oncology: A Case-Based Approach - Volume 1. , 2013, , . | | 0 |
| 738 | Poor correlation between spectrophotometric intracutaneous analysis and histopathology in melanoma and nonmelanoma lesions. <i>Journal of Biomedical Optics</i> , 2013, 18, 061223. | 1.4 | 18 |
| 739 | Nestin is highly expressed in advanced-stage melanomas and neurotized nevi. <i>Oncology Reports</i> , 2013, 29, 1595-1599. | 1.2 | 17 |
| 740 | CYFRA21-1 as a serum tumor marker for follow-up patients with squamous cell lung carcinoma and oropharynx squamous cell carcinoma. <i>Biomarkers in Medicine</i> , 2013, 7, 591-599. | 0.6 | 14 |
| 741 | A Clinicopathologic Analysis of 177 Acral Melanomas in Koreans. <i>JAMA Dermatology</i> , 2013, 149, 1281. | 2.0 | 129 |
| 742 | Using the 7-point checklist as a diagnostic aid for pigmented skin lesions in general practice: a diagnostic validation study. <i>British Journal of General Practice</i> , 2013, 63, e345-e353. | 0.7 | 58 |
| 743 | Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. <i>Modern Pathology</i> , 2013, 26, 404-413. | 2.9 | 79 |
| 744 | Polymorphisms of Nucleotide Excision Repair Genes Predict Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1813-1821. | 0.3 | 43 |
| 745 | B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2050-2058. | 0.3 | 121 |
| 746 | Pathophysiological Characteristics of Melanoma In-Transit Metastasis in a Lymphedema Mouse Model. <i>Journal of Investigative Dermatology</i> , 2013, 133, 537-544. | 0.3 | 13 |
| 747 | Methods to Improve Adoptive T-Cell Therapy for Melanoma: IFN- γ Enhances Anticancer Responses of Cell Products for Infusion. <i>Journal of Investigative Dermatology</i> , 2013, 133, 545-552. | 0.3 | 36 |
| 748 | Plasma MicroRNA-21 Is Associated with Tumor Burden in Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1381-1384. | 0.3 | 38 |
| 749 | Age-related telomere uncapping is associated with cellular senescence and inflammation independent of telomere shortening in human arteries. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 305, H251-H258. | 1.5 | 90 |
| 750 | Interobserver Variability of Histopathological Prognostic Parameters in Cutaneous Malignant Melanoma: Impact on Patient Management. <i>Acta Dermato-Venereologica</i> , 2013, 93, 411-416. | 0.6 | 21 |
| 751 | Sentinel lymph node biopsy for cutaneous melanoma: A 6 years study. <i>Indian Journal of Plastic Surgery</i> , 2013, 46, 092-097. | 0.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 752 | Immune Toxicities and Long Remission Duration after Ipilimumab Therapy for Metastatic Melanoma: Two Illustrative Cases. <i>Current Oncology</i> , 2013, 20, 165-169. | 0.9 | 33 |
| 753 | Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. <i>Annals of Oncology</i> , 2013, 24, 1697-1703. | 0.6 | 280 |
| 754 | Lack of Standards for the Detection of Melanoma in Sentinel Lymph Nodes: A Survey and Recommendations. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1603-1609. | 1.2 | 23 |
| 755 | The Immunocytokine L19â€“IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF. <i>Journal of Investigative Dermatology</i> , 2013, 133, 751-758. | 0.3 | 86 |
| 756 | Aggravating cough in a patient with suspected sarcoidosis. <i>Thorax</i> , 2013, 68, 117-118. | 2.7 | 2 |
| 757 | Jatrorrhizine hydrochloride inhibits the proliferation and neovascularization of C8161 metastatic melanoma cells. <i>Anti-Cancer Drugs</i> , 2013, 24, 667-676. | 0.7 | 38 |
| 758 | Prognostic significance of drainage to pelvic nodes at sentinel lymph node mapping in patients with extremity melanoma. <i>Melanoma Research</i> , 2013, 23, 40-46. | 0.6 | 10 |
| 759 | Socioeconomic status as a predictor of melanoma survival in a series of 1083 cases from Brazil. <i>Melanoma Research</i> , 2013, 23, 199-205. | 0.6 | 16 |
| 760 | Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis. <i>Melanoma Research</i> , 2013, 23, 461-467. | 0.6 | 24 |
| 761 | Ambiguous Melanocytic Tumors in a Tertiary Referral Center. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1783-1796. | 2.1 | 31 |
| 762 | Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. <i>Melanoma Research</i> , 2013, 23, 47-54. | 0.6 | 54 |
| 763 | Characteristics and survival of patients with invasive amelanotic melanoma in the USA. <i>Melanoma Research</i> , 2013, 23, 408-413. | 0.6 | 42 |
| 764 | Update on the role of ipilimumab in melanoma and first data on new combination therapies. <i>Current Opinion in Oncology</i> , 2013, 25, 166-172. | 1.1 | 27 |
| 765 | Indicators of the standard of care for melanoma. <i>Melanoma Research</i> , 2013, 23, 283-289. | 0.6 | 9 |
| 766 | Completion lymph node dissection after a positive sentinel node. <i>Current Opinion in Oncology</i> , 2013, 25, 152-159. | 1.1 | 24 |
| 767 | Opportunistic screening strategy for cutaneous melanoma does not change the incidence of nodular and thick lesions nor reduce mortality. <i>Melanoma Research</i> , 2013, 23, 402-407. | 0.6 | 19 |
| 768 | Molecular biomarkers of prognosis in melanoma. <i>Melanoma Research</i> , 2013, 23, 423-425. | 0.6 | 3 |
| 769 | Multiple primary cutaneous melanomas: recent studies highlight features associated with more indolent behaviour. <i>Pathology</i> , 2013, 45, 1-3. | 0.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 770 | New developments in biomarkers for melanoma. <i>Current Opinion in Oncology</i> , 2013, 25, 145-151. | 1.1 | 20 |
| 771 | High hERG1 expression in advanced melanoma. <i>Melanoma Research</i> , 2013, 23, 185-190. | 0.6 | 6 |
| 772 | Is the mitotic rate of 1/mm ² the correct cutoff point for performing sentinel lymph node biopsy in pregnant patients with thin melanoma?. <i>Melanoma Research</i> , 2013, 23, 420-421. | 0.6 | 0 |
| 773 | Long-term survival and outcome of patients originally given <i>Mycobacterium vaccae</i> for metastatic malignant melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2427-2433. | 1.4 | 12 |
| 774 | Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4387-4393. | 0.8 | 204 |
| 775 | Preoperative risk factors of lymph node metastasis in cutaneous squamous cell carcinoma. <i>Journal of Plastic Surgery and Hand Surgery</i> , 2013, 47, 204-208. | 0.4 | 7 |
| 776 | Identification of a Novel Complex BRAF Mutation Associated With Major Clinical Response to Vemurafenib in a Patient With Metastatic Melanoma. <i>JAMA Dermatology</i> , 2013, 149, 1403. | 2.0 | 20 |
| 777 | Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. <i>Annals of Oncology</i> , 2013, 24, 2174-2180. | 0.6 | 150 |
| 778 | B-Mode Ultrasound Imaging, Doppler Imaging, and Real-Time Elastography in Cutaneous Malignant Melanoma and Lymph Node Metastases. <i>Healthcare (Switzerland)</i> , 2013, 1, 84-95. | 1.0 | 11 |
| 779 | Host Risk Factors, Ultraviolet Index of Residence, and Incident Malignant Melanoma In Situ Among US Women and Men. <i>American Journal of Epidemiology</i> , 2013, 177, 997-1005. | 1.6 | 18 |
| 780 | Who Should Be Offered a Sentinel Node Biopsy for Melanoma Less Than 1 mm in Thickness?. <i>Journal of Clinical Oncology</i> , 2013, 31, 4385-4386. | 0.8 | 4 |
| 781 | Gene Variants in Angiogenesis and Lymphangiogenesis and Cutaneous Melanoma Progression. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 827-834. | 1.1 | 17 |
| 782 | Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells. <i>Science Signaling</i> , 2013, 6, ra7. | 1.6 | 114 |
| 783 | Melanoma Survival Disadvantage in Young, Non-Hispanic White Males Compared With Females. <i>JAMA Dermatology</i> , 2013, 149, 912. | 2.0 | 70 |
| 784 | Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 105-118. | 1.4 | 45 |
| 785 | BRAF in Melanoma: Current Strategies and Future Directions. <i>Clinical Cancer Research</i> , 2013, 19, 4326-4334. | 3.2 | 76 |
| 786 | New combinations and immunotherapies for melanoma: latest evidence and clinical utility. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 278-285. | 1.4 | 26 |
| 787 | Clinical Characteristics and Survival Data of Melanoma Patients With Nevus Cell Aggregates Within Sentinel Lymph Nodes. <i>American Journal of Clinical Pathology</i> , 2013, 139, 566-573. | 0.4 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 788 | Real-life Experience With Pegylated Interferon and Conventional Interferon in Adjuvant Melanoma Therapy. <i>Journal of Immunotherapy</i> , 2013, 36, 52-56. | 1.2 | 6 |
| 789 | Comments and controversies. <i>Melanoma Research</i> , 2013, 23, 181-184. | 0.6 | 3 |
| 790 | Dabrafenib for treatment of BRAF-mutant melanoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 7, 21. | 0.4 | 14 |
| 791 | Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas. <i>BioMed Research International</i> , 2013, 2013, 1-7. | 0.9 | 15 |
| 792 | Immunotherapy in advanced cutaneous melanoma patients. <i>Przegląd Menopauzalny</i> , 2013, 5, 429-433. | 0.6 | 0 |
| 793 | Immunotherapy in the management of melanoma: current status. <i>ImmunoTargets and Therapy</i> , 2013, 2, 1. | 2.7 | 3 |
| 794 | Accuracy of Diagnostic Biopsy for Cutaneous Melanoma: Implications for Surgical Oncologists. <i>International Journal of Surgical Oncology</i> , 2013, 2013, 1-7. | 0.3 | 20 |
| 795 | Sentinel Lymph Node Biopsy in Patients with Thick Primary Cutaneous Melanoma: Patterns of Use and Underuse Utilizing a Population-Based Model. <i>ISRN Dermatology</i> , 2013, 2013, 1-5. | 1.9 | 4 |
| 796 | Melanoma-Targeted Chemothermotherapy and <i>In Situ</i> Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles. <i>Journal of Skin Cancer</i> , 2013, 2013, 1-12. | 0.5 | 13 |
| 797 | Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management. <i>Scientifica</i> , 2013, 2013, 1-19. | 0.6 | 186 |
| 798 | Gene Therapy for Advanced Melanoma: Selective Targeting and Therapeutic Nucleic Acids. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-15. | 2.5 | 18 |
| 799 | Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre. <i>Journal of Skin Cancer</i> , 2013, 2013, 1-7. | 0.5 | 8 |
| 800 | Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 3977-3986. | 3.2 | 153 |
| 801 | Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. <i>Oncolmmunology</i> , 2013, 2, e25564. | 2.1 | 6 |
| 802 | Sex Is an Independent Prognostic Indicator for Survival and Relapse/Progression-Free Survival in Metastasized Stage III to IV Melanoma: A Pooled Analysis of Five European Organisation for Research and Treatment of Cancer Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 2337-2346. | 0.8 | 150 |
| 803 | Favourable prognostic role of regression of primary melanoma in AJCC stage I-III patients. <i>British Journal of Dermatology</i> , 2013, 169, 1240-1245. | 1.4 | 52 |
| 804 | Clinicopathologic analysis of 66 Japanese thin melanomas with metastasis of sentinel or regional lymph node. <i>Journal of Cutaneous Pathology</i> , 2013, 40, 1027-1034. | 0.7 | 5 |
| 805 | Importance of Vertical Pathology of Debulking Specimens During Mohs Micrographic Surgery for Lentigo Maligna and Melanoma in Situ. <i>Dermatologic Surgery</i> , 2013, 39, 365-371. | 0.4 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 806 | Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment. <i>Australasian Journal of Dermatology</i> , 2013, 54, 163-172. | 0.4 | 13 |
| 807 | Dynamic prognostication using conditional survival estimates. <i>Cancer</i> , 2013, 119, 3589-3592. | 2.0 | 94 |
| 808 | Expression analysis of ovostatin 2 reveals its involvement in proliferation, invasion and angiogenesis of cutaneous malignant melanoma. <i>Journal of Dermatology</i> , 2013, 40, 901-910. | 0.6 | 4 |
| 809 | A costly revolution for a subgroup of patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2013, 168, 467-470. | 1.4 | 3 |
| 810 | CD133+ cell content correlates with tumour growth in melanomas from skin with chronic sun-induced damage. <i>British Journal of Dermatology</i> , 2013, 169, 830-837. | 1.4 | 11 |
| 811 | Commentary: Transecting Melanomas: Does it Matter?. <i>Dermatologic Surgery</i> , 2013, 39, 616-617. | 0.4 | 0 |
| 812 | Serum epidermal growth factor receptor levels in patients with malignant melanoma. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 172-177. | 0.6 | 3 |
| 813 | Prognostic sub-classifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark level of invasion. Results of a population-based study from the Swedish Melanoma Register. <i>British Journal of Dermatology</i> , 2013, 168, 685-686. | 1.4 | 1 |
| 814 | Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 708-722. | 1.5 | 12 |
| 815 | Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. <i>Cancer Medicine</i> , 2013, 2, 76-85. | 1.3 | 126 |
| 816 | Malignancies of the eyelid: a review of primary and metastatic cancers. <i>International Journal of Dermatology</i> , 2013, 52, 903-926. | 0.5 | 9 |
| 817 | Prognosis of Patients with Transected Melanomas. <i>Dermatologic Surgery</i> , 2013, 39, 605-615. | 0.4 | 9 |
| 818 | Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases. <i>British Journal of Dermatology</i> , 2013, 169, 172-176. | 1.4 | 23 |
| 819 | Icariside II Induces Apoptosis of Melanoma Cells Through the Downregulation of Survival Pathways. <i>Nutrition and Cancer</i> , 2013, 65, 110-117. | 0.9 | 26 |
| 820 | Vemurafenib enhances MHC induction in BRAF ^{V600E} homozygous melanoma cells. <i>Oncology</i> , 2013, 2, e22890. | 2.1 | 127 |
| 821 | LONGITUDINAL MELANONYCHIA: DETECTION AND MANAGEMENT OF NAIL MELANOMA. <i>Hand Surgery</i> , 2013, 18, 133-139. | 0.6 | 30 |
| 822 | Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. <i>Journal of Medical Economics</i> , 2013, 16, 202-212. | 1.0 | 44 |
| 823 | Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 33-46. | 3.0 | 85 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 824 | Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients. <i>British Journal of Cancer</i> , 2013, 108, 1641-1647. | 2.9 | 20 |
| 825 | The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987â€“2009: a registry-based cohort study. <i>British Journal of Cancer</i> , 2013, 109, 265-271. | 2.9 | 34 |
| 826 | Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3831-3837. | 0.8 | 88 |
| 827 | BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 509-517. | 0.3 | 156 |
| 829 | Malignes Melanom S3-Leitlinie â€œDiagnostik, Therapie und Nachsorge des Melanomsâ€: JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-126. | 0.4 | 9 |
| 830 | Malignant Melanoma S3-Guideline â€œDiagnosis, Therapy and Follow-up of Melanomaâ€: JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-116. | 0.4 | 122 |
| 831 | The epidemiology of melanoma in young adults. <i>Expert Review of Dermatology</i> , 2013, 8, 707-716. | 0.3 | 0 |
| 832 | Call for a balanced view on sentinel node biopsy for melanoma. <i>BMJ, The</i> , 2013, 346, f648-f648. | 3.0 | 2 |
| 833 | Metastatic Volume: An Old Oncologic Concept and a New Prognostic Factor for Stage IV Melanoma Patients. <i>Dermatology</i> , 2013, 227, 55-61. | 0.9 | 16 |
| 834 | Recent Advances in the Treatment of Melanoma. <i>Cancer Control</i> , 2013, 20, 244-245. | 0.7 | 2 |
| 835 | New Targeted Therapies in Melanoma. <i>Cancer Control</i> , 2013, 20, 282-288. | 0.7 | 11 |
| 836 | Care and monitoring of a mouse model of melanoma. <i>Lab Animal</i> , 2013, 42, 92-98. | 0.2 | 4 |
| 837 | Surgical Management of Subungual Melanoma. <i>Annals of Plastic Surgery</i> , 2013, 71, 346-354. | 0.5 | 53 |
| 838 | Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. <i>Dermatology</i> , 2013, 226, 22-27. | 0.9 | 4 |
| 839 | Adoptive Cell Transfer for Patients with Metastatic Melanoma: The Potential and Promise of Cancer Immunotherapy. <i>Cancer Control</i> , 2013, 20, 289-297. | 0.7 | 95 |
| 840 | Staging of Regional Lymph Nodes in Melanoma. <i>JAMA Surgery</i> , 2013, 148, 879. | 2.2 | 48 |
| 841 | Predicting Disease Progression After Regional Therapy for In-Transit Melanoma. <i>JAMA Surgery</i> , 2013, 148, 493. | 2.2 | 10 |
| 843 | Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor. <i>American Journal of Dermatopathology</i> , 2013, 35, 125-128. | 0.3 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 844 | Differences in Tumor Thickness Between Hematoxylin and Eosin and Melan-A Immunohistochemically Stained Primary Cutaneous Melanomas. <i>American Journal of Dermatopathology</i> , 2013, 35, 56-63. | 0.3 | 15 |
| 845 | Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 61-65. | 2.1 | 289 |
| 846 | S3â€œGuideline â€œDiagnosis, therapy and followâ€up of melanomaâ€•â€ short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 563-602. | 0.4 | 63 |
| 847 | The New AJCC Guidelines in Practice. <i>American Journal of Surgical Pathology</i> , 2013, 37, 933-937. | 2.1 | 11 |
| 848 | Risk Assessment for Atypical Spitzoid Melanocytic Neoplasms Using FISH to Identify Chromosomal Copy Number Aberrations. <i>American Journal of Surgical Pathology</i> , 2013, 37, 676-684. | 2.1 | 175 |
| 849 | Mitotic Rate in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 882-889. | 2.1 | 36 |
| 850 | Managing Malignant Melanoma. <i>Plastic and Reconstructive Surgery</i> , 2013, 132, 446e-460e. | 0.7 | 53 |
| 851 | Evidence-Based Medicine. <i>Plastic and Reconstructive Surgery</i> , 2013, 132, 1631-1643. | 0.7 | 10 |
| 852 | Anal Versus Rectal Melanoma. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 150-157. | 0.7 | 57 |
| 853 | Survival for Patients With Single and Multiple Primary Melanomas. <i>JAMA Dermatology</i> , 2013, 149, 921. | 2.0 | 33 |
| 854 | Plasma osteopontin concentrations in patients with cutaneous melanoma. <i>Oncology Reports</i> , 2013, 30, 1575-1580. | 1.2 | 13 |
| 856 | Melanoma epidemiology of Austria reveals gender-related differences. <i>European Journal of Dermatology</i> , 2013, 23, 872-878. | 0.3 | 13 |
| 857 | Clinical experience with ipilimumab 10Âmg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 82. | 3.5 | 23 |
| 858 | Leukoplakia. , 2013, , 1463-1463. | | 0 |
| 859 | Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases. <i>Cancer Imaging</i> , 2013, 13, 306-313. | 1.2 | 35 |
| 860 | A biÃ³psia de linfonodo sentinela nÃ£o deve ser recomendada para pacientes portadores de melanoma espesso. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2013, 40, 127-129. | 0.3 | 7 |
| 861 | Dermoscopic features of thin melanomas: a comparative study of melanoma in situ and invasive melanomas smaller than or equal to 1mm. <i>Anais Brasileiros De Dermatologia</i> , 2013, 88, 712-717. | 0.5 | 35 |
| 862 | Melanoma follow up: time to generate the evidence. <i>Australian Health Review</i> , 2013, 37, 501. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 863 | Accuracy of Preoperative MRI with Microscopy Coil in Evaluation of Primary Tumor Thickness of Malignant Melanoma of the Skin with Histopathologic Correlation. Korean Journal of Radiology, 2013, 14, 287. | 1.5 | 7 |
| 864 | Epidemiological aspects of melanoma at a university hospital dermatology center over a period of 20 years. Anais Brasileiros De Dermatologia, 2013, 88, 344-353. | 0.5 | 14 |
| 865 | Primary Dermal Melanoma Latent for More than 10 Years. Annals of Dermatology, 2013, 25, 385. | 0.3 | 2 |
| 866 | Diagnostic implications of loss of 5-hydroxymethylcytosine for melanoma. Expert Review of Dermatology, 2013, 8, 99-101. | 0.3 | 5 |
| 867 | Electron Paramagnetic Resonance Spectrometry and Imaging in Melanomas: Comparison between Pigmented and Nonpigmented Human Malignant Melanomas. Molecular Imaging, 2013, 12, 7290.2012.00037. | 0.7 | 18 |
| 868 | Integrative Genomics Identifies Gene Signature Associated with Melanoma Ulceration. PLoS ONE, 2013, 8, e54958. | 1.1 | 28 |
| 869 | A Patient-Centered Methodology That Improves the Accuracy of Prognostic Predictions in Cancer. PLoS ONE, 2013, 8, e56435. | 1.1 | 4 |
| 870 | Hazard-Rate Analysis and Patterns of Recurrence in Early Stage Melanoma: Moving towards a Rationally Designed Surveillance Strategy. PLoS ONE, 2013, 8, e57665. | 1.1 | 36 |
| 871 | Lipopeptide Biosurfactant Pseudofactin II Induced Apoptosis of Melanoma A 375 Cells by Specific Interaction with the Plasma Membrane. PLoS ONE, 2013, 8, e57991. | 1.1 | 59 |
| 872 | Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis. PLoS ONE, 2013, 8, e63137. | 1.1 | 26 |
| 873 | Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour. PLoS ONE, 2013, 8, e66953. | 1.1 | 22 |
| 874 | In-Depth Characterization of microRNA Transcriptome in Melanoma. PLoS ONE, 2013, 8, e72699. | 1.1 | 109 |
| 875 | Decreased Expression of Nuclear p300 Is Associated with Disease Progression and Worse Prognosis of Melanoma Patients. PLoS ONE, 2013, 8, e75405. | 1.1 | 18 |
| 876 | Joint Effect of Multiple Common SNPs Predicts Melanoma Susceptibility. PLoS ONE, 2013, 8, e85642. | 1.1 | 40 |
| 877 | 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma. Nuklearmedizin - NuclearMedicine, 2013, 52, 198-203. | 0.3 | 22 |
| 878 | Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Wspolczesna Onkologia, 2013, 3, 257-262. | 0.7 | 11 |
| 879 | Treatment Outcomes of Advanced Stage Malignant Melanoma in Hand and Foot after Amputation in Korean Patients. Clinics in Orthopedic Surgery, 2013, 5, 314. | 0.8 | 2 |
| 880 | Penile primary melanoma: analysis of 6 patients treated at Brazilian national cancer institute in the last eight years. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 823-831. | 0.7 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 881 | Signal Transduction in Human Cutaneous Melanoma and Target Drugs. <i>Current Cancer Drug Targets</i> , 2013, 13, 843-866. | 0.8 | 56 |
| 882 | Overcoming Resistance to BRAF and MEK Inhibitors by Simultaneous Suppression of CDK4. , 0, , . | | 0 |
| 883 | Challenges involved in risk assessment of atypical Spitz tumors. <i>Expert Review of Dermatology</i> , 2013, 8, 217-219. | 0.3 | 0 |
| 884 | Acquired Resistance to Targeted MAPK Inhibition in Melanoma. , 2013, , . | | 0 |
| 885 | Current Management of Malignant Melanoma: State of the Art. , 0, , . | | 4 |
| 886 | Prevalence of <i>BRAF</i> and <i>NRAS</i> Mutations and a Comparative Analysis in Primary and Metastatic Melanoma of Korean Patients. <i>The Ewha Medical Journal</i> , 2014, 37, 30. | 0.1 | 3 |
| 887 | BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2014, 124, 5074-5084. | 3.9 | 56 |
| 888 | Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. <i>Cancer Management and Research</i> , 2014, 6, 279. | 0.9 | 23 |
| 889 | Benign Melanocytic Lesions and Melanoma. , 2014, , 1182-1192. | | 0 |
| 890 | Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma. <i>PLoS ONE</i> , 2014, 9, e86194. | 1.1 | 42 |
| 891 | A Natural Bacterial-Derived Product, the Metalloprotease Arazyme, Inhibits Metastatic Murine Melanoma by Inducing MMP-8 Cross-Reactive Antibodies. <i>PLoS ONE</i> , 2014, 9, e96141. | 1.1 | 17 |
| 892 | Insulin-Like-Growth-Factor-Binding-Protein-3 (IGFBP-3) Contrasts Melanoma Progression In Vitro and In Vivo. <i>PLoS ONE</i> , 2014, 9, e98641. | 1.1 | 17 |
| 893 | Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 346-356. | 2.2 | 57 |
| 894 | Sentinel lymph node biopsy for melanoma: an important risk-stratification tool. <i>Medical Journal of Australia</i> , 2014, 201, 442-444. | 0.8 | 1 |
| 895 | Polypoid melanoma and superficial spreading melanoma different subtypes in the same lesion. <i>Anais Brasileiros De Dermatologia</i> , 2014, 89, 666-668. | 0.5 | 13 |
| 896 | Malignant Melanoma. <i>Healthcare (Switzerland)</i> , 2014, 2, 1-19. | 1.0 | 39 |
| 897 | Established and Emerging Biomarkers in Cutaneous Malignant Melanoma. <i>Healthcare (Switzerland)</i> , 2014, 2, 60-73. | 1.0 | 7 |
| 898 | Update and Review on the Surgical Management of Primary Cutaneous Melanoma. <i>Healthcare (Switzerland)</i> , 2014, 2, 234-249. | 1.0 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 899 | Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. <i>Frontiers in Immunology</i> , 2014, 5, 165. | 2.2 | 127 |
| 900 | STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFN α Therapy in Stage III Melanoma Patients. <i>Frontiers in Medicine</i> , 2014, 1, 47. | 1.2 | 3 |
| 901 | Mucosal melanomas in the elderly: challenging cases and review of the literature. <i>Clinical Interventions in Aging</i> , 2014, 9, 929. | 1.3 | 22 |
| 902 | Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study. <i>Chinese Journal of Cancer</i> , 2014, 33, 356-64. | 4.9 | 45 |
| 903 | Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study. <i>Annals of Dermatology</i> , 2014, 26, 195. | 0.3 | 26 |
| 904 | The clinical features and optimal treatment of anorectal malignant melanoma. <i>Annals of Surgical Treatment and Research</i> , 2014, 87, 113. | 0.4 | 35 |
| 905 | Long-Term Survival Analysis and Clinical Follow-Up in Acral Lentiginous Malignant Melanoma Undergoing Sentinel Lymph Node Biopsy in Korean Patients. <i>Annals of Dermatology</i> , 2014, 26, 177. | 0.3 | 9 |
| 906 | Clinicopathological Predictive Factors of Melanoma Lung Metastases. <i>Journal of Integrative Oncology</i> , 2014, 03, . | 0.3 | 0 |
| 907 | Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure. <i>Annals of Dermatology</i> , 2014, 26, 485. | 0.3 | 22 |
| 908 | Melanoma developed during pregnancy - A case report. <i>Anais Brasileiros De Dermatologia</i> , 2014, 89, 157-159. | 0.5 | 3 |
| 909 | Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. <i>Oncology Reports</i> , 2014, 32, 808-814. | 1.2 | 6 |
| 910 | Dormancy of growth-stunted malignant melanoma: sustainable and smoldering patterns. <i>Oncology Reviews</i> , 2014, 8, 252. | 0.8 | 9 |
| 911 | An incidental finding of a nodal recurrence of cutaneous malignant melanoma after a 45-year disease-free period. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204289-bcr2014204289. | 0.2 | 3 |
| 912 | Health-related quality of life in patients with melanoma expressed as utilities and disability weights. <i>British Journal of Dermatology</i> , 2014, 171, 1443-1450. | 1.4 | 25 |
| 913 | Biomarkers in melanoma: where are we now?. <i>Melanoma Management</i> , 2014, 1, 139-150. | 0.1 | 1 |
| 914 | Excision of fascia in melanoma thicker than 2mm: no evidence for improved clinical outcome. <i>British Journal of Dermatology</i> , 2014, 171, 1391-1396. | 1.4 | 14 |
| 915 | The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis. <i>Annals of Oncology</i> , 2014, 25, 240-246. | 0.6 | 34 |
| 917 | A pilot study of extralevator abdominoperineal excision for primary melanoma of the anorectum. <i>Techniques in Coloproctology</i> , 2014, 18, 1113-1116. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 918 | HF ultrasound vs PET-CT and telethermography in the diagnosis of In-transit metastases from melanoma: a prospective study and review of the literature. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 96. | 3.5 | 22 |
| 919 | The role of skin self-examination at the Swiss skin cancer day. <i>BMC Health Services Research</i> , 2014, 14, 581. | 0.9 | 7 |
| 920 | Risk Prediction Models for Melanoma: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1450-1463. | 1.1 | 107 |
| 922 | Malignant melanoma metastasis to the colon: a curable lesion. <i>Techniques in Coloproctology</i> , 2014, 18, 1189-1190. | 0.8 | 2 |
| 923 | Prognostic Impact of p62 Expression in Cutaneous Malignant Melanoma. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1476-1478. | 0.3 | 39 |
| 924 | Molecular pathology of cutaneous melanoma. <i>Melanoma Management</i> , 2014, 1, 151-164. | 0.1 | 4 |
| 925 | Successes and Limitations of Targeted Cancer Therapy in Melanoma. <i>Progress in Tumor Research</i> , 2014, 41, 78-88. | 0.1 | 4 |
| 926 | Sentinel lymph node biopsy in melanoma: controversies and current guidelines. <i>Future Oncology</i> , 2014, 10, 429-442. | 1.1 | 14 |
| 927 | Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 151-154. | 0.4 | 0 |
| 928 | A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1359-1368. | 0.3 | 40 |
| 929 | Prognostic Impact of PHIP Copy Number in Melanoma: Linkage to Ulceration. <i>Journal of Investigative Dermatology</i> , 2014, 134, 783-790. | 0.3 | 14 |
| 930 | Effects of <i>BRAF</i> Mutations and <i>BRAF</i> Inhibition on Immune Responses to Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2769-2783. | 1.9 | 73 |
| 931 | Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Investigation</i> , 2014, 32, 144-149. | 0.6 | 90 |
| 932 | Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II-III Resectable Disease. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2202-2211. | 0.3 | 51 |
| 933 | Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. <i>Annals of Oncology</i> , 2014, 25, 747-753. | 0.6 | 47 |
| 934 | Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 1601-1609. | 3.2 | 222 |
| 935 | Vemurafenib. <i>Recent Results in Cancer Research</i> , 2014, 201, 215-225. | 1.8 | 30 |
| 936 | Primary anorectal malignant melanoma treated with neoadjuvant chemoradiotherapy and sphincter-sparing surgery: A case report. <i>Oncology Letters</i> , 2014, 7, 1605-1607. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 937 | Melanoma Cells Break Down LPA to Establish Local Gradients That Drive Chemotactic Dispersal. <i>PLoS Biology</i> , 2014, 12, e1001966. | 2.6 | 111 |
| 938 | Association of TNFRSF10D DNA-Methylation with the Survival of Melanoma Patients. <i>International Journal of Molecular Sciences</i> , 2014, 15, 11984-11995. | 1.8 | 8 |
| 939 | Vaccines against Cancer. , 2014, , . | | 0 |
| 940 | Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas. <i>JAMA Dermatology</i> , 2014, 150, 1306. | 2.0 | 142 |
| 941 | A single institution retrospective analysis of malignant melanoma. <i>Journal of Cancer Research and Therapeutics</i> , 2014, 10, 38. | 0.3 | 11 |
| 942 | Quantitative Measurement of Melanoma Spread in Sentinel Lymph Nodes and Survival. <i>PLoS Medicine</i> , 2014, 11, e1001604. | 3.9 | 52 |
| 943 | Ipilimumab in Melanoma Patients with Brain Metastasis: A Retrospective Multicentre Evaluation of Thirty-eight Patients. <i>Acta Dermato-Venereologica</i> , 2014, 94, 45-49. | 0.6 | 41 |
| 944 | Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. <i>New England Journal of Medicine</i> , 2014, 370, 599-609. | 13.9 | 1,203 |
| 945 | Association of Sentinel Lymph Node Biopsy With Survival for Head and Neck Melanoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 1101. | 1.2 | 38 |
| 946 | 'This isn't what mine looked like': a qualitative study of symptom appraisal and help seeking in people recently diagnosed with melanoma. <i>BMJ Open</i> , 2014, 4, e005566-e005566. | 0.8 | 62 |
| 947 | Key regulators of apoptosis execution as biomarker candidates in melanoma. <i>Molecular and Cellular Oncology</i> , 2014, 1, e964037. | 0.3 | 13 |
| 948 | Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. <i>Journal of Chemotherapy</i> , 2014, 26, 193-201. | 0.7 | 17 |
| 949 | High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. <i>Melanoma Management</i> , 2014, 1, 7-10. | 0.1 | 1 |
| 950 | Tree Structure for Modeling Skin Lesion Growth. , 2014, , 191-209. | | 0 |
| 951 | Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2014, , . | 1.5 | 12 |
| 952 | Molecular Pathology of Skin Neoplasms of the Head and Neck. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 759-787. | 1.2 | 50 |
| 953 | Adenovirus-Mediated FKHRL1/TM Sensitizes Melanoma Cells to Apoptosis Induced by Temozolomide. <i>Human Gene Therapy Clinical Development</i> , 2014, 25, 186-195. | 3.2 | 9 |
| 954 | Budget impact analysis of a novel gene expression assay for the diagnosis of malignant melanoma. <i>Journal of Medical Economics</i> , 2014, 17, 782-791. | 1.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 955 | Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 1056-1064. | 3.4 | 178 |
| 956 | Epigenetic Markers of Prognosis in Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 481-499. | 0.4 | 6 |
| 957 | Metastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab. <i>Radiology</i> , 2014, 270, 425-434. | 3.6 | 25 |
| 958 | Histopathological characteristics of subsequent melanomas in patients with multiple primary melanomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 58-64. | 1.3 | 19 |
| 959 | Increased frequencies of CD11b ⁺ CD33 ⁺ CD14 ⁺ HLA-DR ⁺ myeloid-derived suppressor cells are an early event in melanoma patients. <i>Experimental Dermatology</i> , 2014, 23, 202-204. | 1.4 | 35 |
| 960 | Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3210-3218. | 1.9 | 21 |
| 961 | Caspase 3 Promotes Surviving Melanoma Tumor Cell Growth after Cytotoxic Therapy. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1686-1692. | 0.3 | 94 |
| 962 | Vemurafenib significantly decreases glomerular filtration rate. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 978-979. | 1.3 | 24 |
| 963 | Breslow Thickness, Clark Index and Ulceration Are Associated with Sentinel Lymph Node Metastasis in Melanoma Patients: A Cohort Analysis of 612 Patients. <i>Dermatology</i> , 2014, 229, 183-189. | 0.9 | 16 |
| 964 | Metastatic melanoma to the upper aerodigestive tract. <i>Laryngoscope</i> , 2014, 124, 1143-1149. | 1.1 | 17 |
| 965 | Impact of <i>in vivo</i> reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions. <i>British Journal of Dermatology</i> , 2014, 170, 802-808. | 1.4 | 137 |
| 966 | Inherited variation in the PARP1 gene and survival from melanoma. <i>International Journal of Cancer</i> , 2014, 135, 1625-1633. | 2.3 | 24 |
| 967 | Treatment of in-transit melanoma with intralesional interleukin-2: A systematic review. <i>Journal of Surgical Oncology</i> , 2014, 110, 770-775. | 0.8 | 53 |
| 968 | To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?. <i>International Journal of Clinical Practice</i> , 2014, 68, 761-770. | 0.8 | 33 |
| 969 | Survival After Cutaneous Melanoma in Kidney Transplant Recipients: A Population-Based Matched Cohort Study. <i>American Journal of Transplantation</i> , 2014, 14, 1368-1375. | 2.6 | 42 |
| 970 | Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. <i>Annals of Oncology</i> , 2014, 25, 2052-2058. | 0.6 | 53 |
| 971 | Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study. <i>British Journal of Dermatology</i> , 2014, 170, 930-938. | 1.4 | 53 |
| 972 | Loss of XRCC1 confers a metastatic phenotype to melanoma cells and is associated with poor survival in patients with melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 366-375. | 1.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 973 | The association of host and genetic melanoma risk factors with Breslow thickness in the Western Australian Melanoma Health Study. <i>British Journal of Dermatology</i> , 2014, 170, 851-857. | 1.4 | 12 |
| 974 | Intralesional therapy with PV α 10 (Rose Bengal) for in α transit melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 314-319. | 0.8 | 36 |
| 975 | Combined clearance of pelvic and superficial nodes for clinical groin melanoma. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2014, 67, 1711-1718. | 0.5 | 5 |
| 976 | Mucosal Melanoma of the Head and Neck: A α Systematic Review of the Literature. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1108-1118. | 0.4 | 97 |
| 977 | High expression of FOXP3 in primary melanoma is associated with tumour progression. <i>British Journal of Dermatology</i> , 2014, 170, 103-109. | 1.4 | 54 |
| 978 | Australian multi α center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 780-785. | 0.8 | 23 |
| 979 | Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. <i>British Journal of Dermatology</i> , 2014, 170, 20-30. | 1.4 | 61 |
| 980 | The α talian α uromelanoma α ay: evaluation of results and implications for future prevention campaigns. <i>International Journal of Dermatology</i> , 2014, 53, 699-706. | 0.5 | 17 |
| 981 | Why is melanoma so metastatic?. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 19-36. | 1.5 | 113 |
| 982 | High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 53-57. | 0.7 | 14 |
| 983 | Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice. <i>International Journal of Dermatology</i> , 2014, 53, e499-506. | 0.5 | 5 |
| 984 | Podoplanin expression in cancer α associated fibroblasts predicts aggressive behavior in melanoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 561-567. | 0.7 | 38 |
| 985 | Assessment of α IA α scopy in the triage of suspicious skin tumours. <i>Skin Research and Technology</i> , 2014, 20, 440-444. | 0.8 | 14 |
| 986 | Clinical and prognostic factors for melanoma of the skin using SEER registries: Collaborative stage data collection system, version 1 and version 2. <i>Cancer</i> , 2014, 120, 3807-3814. | 2.0 | 46 |
| 987 | Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19 α IL2 Results in Sustained Clinical and Systemic Immunologic Responses. <i>Cancer Immunology Research</i> , 2014, 2, 668-678. | 1.6 | 81 |
| 988 | Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. <i>Annals of Oncology</i> , 2014, 25, 2277-2284. | 0.6 | 119 |
| 989 | Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1355-1364. | 1.5 | 17 |
| 990 | The use of vemurafenib in α ustralian patients with unresectable or metastatic melanoma containing the α 600 α i>BRAF α i</i> gene mutation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 1-15. | 0.7 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 991 | Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma. <i>British Journal of Dermatology</i> , 2014, 171, 403-408. | 1.4 | 13 |
| 992 | Quality assurance for care of melanoma patients based on guideline-derived quality indicators and certification. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 139-147. | 0.4 | 15 |
| 993 | Expression and prognostic significance of CIP2A in cutaneous malignant melanoma. <i>Biomarkers</i> , 2014, 19, 70-76. | 0.9 | 13 |
| 994 | Characteristics and Associations of High-Mitotic-Rate Melanoma. <i>JAMA Dermatology</i> , 2014, 150, 1048. | 2.0 | 60 |
| 995 | Association between sleep disordered breathing and aggressiveness markers of malignant cutaneous melanoma. <i>European Respiratory Journal</i> , 2014, 43, 1661-1668. | 3.1 | 89 |
| 996 | MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1599-1610. | 1.9 | 21 |
| 997 | A Probabilistic Analysis of Mitotic Counts in Melanoma. <i>American Journal of Clinical Pathology</i> , 2014, 141, 213-218. | 0.4 | 9 |
| 998 | New Options for the Adjuvant Treatment of Cutaneous Melanoma?. <i>Current Oncology Reports</i> , 2014, 16, 409. | 1.8 | 7 |
| 999 | Distinguishing between Benign and Malignant Melanocytic Nevi by <i>In Vivo</i> Multiphoton Microscopy. <i>Cancer Research</i> , 2014, 74, 2688-2697. | 0.4 | 95 |
| 1000 | Prognostic differences across sexes in melanoma patients. <i>Melanoma Research</i> , 2014, 24, 568-576. | 0.6 | 20 |
| 1001 | Melanomas of unknown primary frequently harbor TERT-promoter mutations. <i>Melanoma Research</i> , 2014, 24, 131-136. | 0.6 | 31 |
| 1002 | Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. <i>Melanoma Research</i> , 2014, 24, 150-157. | 0.6 | 12 |
| 1003 | Inpatient Homogeneity of BRAFV600E Expression in Melanoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 377-382. | 2.1 | 66 |
| 1004 | Mitotic Rate for Thin Melanomas. <i>Dermatologic Surgery</i> , 2014, 40, 937-945. | 0.4 | 21 |
| 1005 | Cutaneous Malignant Melanoma. <i>American Journal of Dermatopathology</i> , 2014, 36, 363-379. | 0.3 | 124 |
| 1006 | A qualitative assessment of psychosocial impact, coping and adjustment in high-risk melanoma patients and caregivers. <i>Melanoma Research</i> , 2014, 24, 252-260. | 0.6 | 35 |
| 1007 | Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. <i>Melanoma Research</i> , 2014, 24, 468-474. | 0.6 | 42 |
| 1008 | EGFR and cyclin D1 in nodular melanoma. <i>Melanoma Research</i> , 2014, 24, 584-591. | 0.6 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1009 | Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node?. <i>Melanoma Research</i> , 2014, 24, 454-461. | 0.6 | 42 |
| 1010 | BRAF Mutations in Metastatic Malignant Melanoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 648-651. | 0.6 | 20 |
| 1011 | Histopathologic Evaluation of the Sentinel Lymph Node for Malignant Melanoma. <i>American Journal of Dermatopathology</i> , 2014, 36, 80-87. | 0.3 | 24 |
| 1012 | Role of arterial telomere dysfunction in hypertension. <i>Journal of Hypertension</i> , 2014, 32, 1293-1299. | 0.3 | 58 |
| 1013 | Long-term Survival after Metastatic Childhood Melanoma. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2014, 2, e163. | 0.3 | 6 |
| 1014 | Shared decision making in dermato-oncology. <i>Melanoma Research</i> , 2014, 24, 68-74. | 0.6 | 33 |
| 1015 | Multiple primary melanomas versus single melanoma of the head and neck. <i>Melanoma Research</i> , 2014, 24, 267-272. | 0.6 | 4 |
| 1016 | Effectiveness and Tolerability of Ipilimumab. <i>Journal of Immunotherapy</i> , 2014, 37, 374-381. | 1.2 | 23 |
| 1017 | Pigmentation in the sentinel node correlates with increased sentinel node tumor burden in melanoma patients. <i>Melanoma Research</i> , 2014, 24, 261-266. | 0.6 | 6 |
| 1018 | Histomorphologic Assessment and Interobserver Diagnostic Reproducibility of Atypical Spitzoid Melanocytic Neoplasms With Long-term Follow-up. <i>American Journal of Surgical Pathology</i> , 2014, 38, 934-940. | 2.1 | 142 |
| 1019 | Health-related Quality of Life, Fatigue, and Depression Under Low-Dose IFN- γ Therapy in Melanoma Patients. <i>Journal of Immunotherapy</i> , 2014, 37, 461-467. | 1.2 | 10 |
| 1020 | Current Systemic Therapies for Melanoma. <i>Dermatologic Surgery</i> , 2014, 40, 948-963. | 0.4 | 29 |
| 1021 | Analysis of Tumor Mitotic Rate in Thin Metastatic Melanomas Compared With Thin Melanomas Without Metastasis Using Both the Hematoxylin and Eosin and Anti-phosphohistone 3 IHC Stain. <i>American Journal of Dermatopathology</i> , 2014, 36, 64-67. | 0.3 | 10 |
| 1022 | Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients. <i>Melanoma Research</i> , 2014, 24, 295-304. | 0.6 | 45 |
| 1023 | Immunohistochemistry for Histone H3 Lysine 9 Methyltransferase and Demethylase Proteins in Human Melanomas. <i>American Journal of Dermatopathology</i> , 2014, 36, 211-216. | 0.3 | 17 |
| 1024 | Management of melanomas of the gynaecological tract. <i>Current Opinion in Oncology</i> , 2014, 26, 508-513. | 1.1 | 19 |
| 1025 | Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases. <i>Melanoma Research</i> , 2014, 24, 349-353. | 0.6 | 34 |
| 1026 | Caring for patients with melanoma in the primary care setting. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2014, 27, 25-30. | 0.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1027 | Management of conjunctival malignant melanoma: a review and update. Expert Review of Ophthalmology, 2014, 9, 185-204. | 0.3 | 116 |
| 1028 | Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression. Cancer Research, 2014, 74, 130-140. | 0.4 | 27 |
| 1029 | WNT5A-mediated β -catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis, 2014, 35, 784-794. | 1.3 | 42 |
| 1030 | Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation. Medical Decision Making, 2014, 34, 343-351. | 1.2 | 54 |
| 1031 | Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Annals of Oncology, 2014, 25, 246-250. | 0.6 | 47 |
| 1032 | Clinical Skin Examination Outcomes After a Video-Based Behavioral Intervention. JAMA Dermatology, 2014, 150, 372. | 2.0 | 25 |
| 1033 | Correlation of Histologic Regression in Primary Melanoma With Sentinel Node Status. JAMA Dermatology, 2014, 150, 828. | 2.0 | 27 |
| 1034 | Dermatopathology. , 2014, , . | | 4 |
| 1035 | Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. British Journal of Dermatology, 2014, 171, 1099-1107. | 1.4 | 158 |
| 1036 | The Clinical Presentation of the High-Mitotic-Rate Melanoma. JAMA Dermatology, 2014, 150, 1047. | 2.0 | 0 |
| 1037 | International Multi-institutional Management and Outcome of Melanoma Patients with Positive Sentinel Lymph Nodes in More than One Nodal Basin. Annals of Surgical Oncology, 2014, 21, 4324-4329. | 0.7 | 13 |
| 1038 | Prognostic Factors in Cutaneous Melanoma. , 2014, , 569-602. | | 3 |
| 1039 | Evaluating biomarkers in melanoma. Frontiers in Oncology, 2014, 4, 383. | 1.3 | 38 |
| 1040 | Gene Expression Differences Predict Treatment Outcome of Merkel Cell Carcinoma Patients. Journal of Skin Cancer, 2014, 2014, 1-10. | 0.5 | 7 |
| 1041 | Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma. Journal of Skin Cancer, 2014, 2014, 1-5. | 0.5 | 12 |
| 1042 | Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival. Frontiers in Oncology, 2014, 3, 333. | 1.3 | 16 |
| 1043 | BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT. Acta Medica Medianae, 2014, , 39-41. | 0.0 | 0 |
| 1044 | Cytodiagnosis of epithelioid malignant melanoma (amelanotic) and diagnostic dilemmas. Journal of Cytology, 2014, 31, 207. | 0.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1045 | Increasing the Efficacy of SLNB in Cases of Malignant Melanoma Located in Close Proximity to the Lymphatic Basin. <i>ISRN Dermatology</i> , 2014, 2014, 1-4. | 1.9 | 0 |
| 1046 | Prognostic Stratification of Ulcerated Melanoma. <i>American Journal of Clinical Pathology</i> , 2014, 142, 845-856. | 0.4 | 28 |
| 1047 | Four cases of rituximab-associated melanoma. <i>Melanoma Research</i> , 2014, 24, 401-403. | 0.6 | 18 |
| 1048 | Melanoma in Children, Adolescents, and Young Adults. <i>American Journal of Dermatopathology</i> , 2014, 36, 620-628. | 0.3 | 7 |
| 1049 | <scp>DNA</scp> methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1097-1105. | 1.5 | 19 |
| 1050 | Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1106-1116. | 1.5 | 16 |
| 1051 | Cutaneous melanoma. <i>Lancet, The</i> , 2014, 383, 816-827. | 6.3 | 465 |
| 1052 | Melanoma depth in patients with an established dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 841-846. | 0.6 | 13 |
| 1053 | Are we seeing the effects of public awareness campaigns? A 10-year analysis of Breslow thickness at presentation of malignant melanoma in the South West of England. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2014, 67, 324-330. | 0.5 | 15 |
| 1054 | Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 1036-1044.e3. | 0.6 | 15 |
| 1055 | Clinical impact of sentinel lymph node biopsy in patients with thick (>4mm) melanomas. <i>American Journal of Surgery</i> , 2014, 207, 702-707. | 0.9 | 15 |
| 1056 | Estadificaci3n y seguimiento de los pacientes con melanoma: 2 qu3 exploraciones y a qu3 pacientes?. <i>Actas Dermo-sifilogr3ficas</i> , 2014, 105, 531-534. | 0.2 | 2 |
| 1058 | Stage IIIC Solitary Dermal Melanoma. <i>Actas Dermo-sifilogr3ficas</i> , 2014, 105, 433-434. | 0.2 | 0 |
| 1059 | Comparison of Sentinel Lymph Node Micrometastatic Tumor Burden Measurements in Melanoma. <i>Journal of the American College of Surgeons</i> , 2014, 218, 519-528. | 0.2 | 38 |
| 1060 | Cutaneous melanoma: Medical specialists' opinions on follow-up and sentinel lymph node biopsy. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1276-1283. | 0.5 | 8 |
| 1061 | Melanoma d3rmico solitario y estadio IIIC. <i>Actas Dermo-sifilogr3ficas</i> , 2014, 105, 433-434. | 0.2 | 0 |
| 1062 | Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma. <i>American Journal of Surgery</i> , 2014, 207, 549-554. | 0.9 | 33 |
| 1063 | Automated quantification of MART1-verified Ki-67 indices: useful diagnostic aid in melanocytic lesions. <i>Human Pathology</i> , 2014, 45, 1153-1161. | 1.1 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1064 | Sentinel Lymph Node Status in Melanoma: Prognostic Value in a Tertiary Hospital and Correlation with Mitotic Activity. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 60-68. | 0.2 | 1 |
| 1065 | Immunological Basis of Melanoma-Associated Vitiligo-Like Depigmentation. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 122-127. | 0.2 | 2 |
| 1066 | Hot or not? The 10% rule in sentinel lymph node biopsy for malignant melanoma revisited. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2014, 67, 316-319. | 0.5 | 13 |
| 1067 | Targeted Therapies for Cutaneous Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 491-505. | 0.9 | 11 |
| 1068 | Increased Levels of Circulating Microparticles Are Associated with Increased Procoagulant Activity in Patients with Cutaneous Malignant Melanoma. <i>Journal of Investigative Dermatology</i> , 2014, 134, 176-182. | 0.3 | 44 |
| 1069 | Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma. <i>Medical Molecular Morphology</i> , 2014, 47, 8-13. | 0.4 | 2 |
| 1070 | Melanoma brain metastases: the impact of nodal disease. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 81-85. | 1.7 | 7 |
| 1071 | Surgical Management of Intraabdominal Metastases From Melanoma: Role of the Neutrophil to Lymphocyte Ratio as a Potential Prognostic Factor. <i>World Journal of Surgery</i> , 2014, 38, 1542-1550. | 0.8 | 27 |
| 1072 | Patterns of Recurrence and Survival After Lymphadenectomy in Melanoma Patients: Clarifying the Effects of Timing of Surgery and Lymph Node Tumor Burden. <i>Annals of Surgical Oncology</i> , 2014, 21, 292-299. | 0.7 | 28 |
| 1073 | Non-squamous cell carcinoma of the penis: single-center, 15-year experience. <i>World Journal of Urology</i> , 2014, 32, 1347-1353. | 1.2 | 14 |
| 1074 | Emerging insights into resistance to BRAF inhibitors in melanoma. <i>Biochemical Pharmacology</i> , 2014, 87, 381-389. | 2.0 | 70 |
| 1075 | Association between genetic polymorphisms in apoptosis-related genes and risk of cutaneous melanoma in women and men. <i>Journal of Dermatological Science</i> , 2014, 74, 135-141. | 1.0 | 8 |
| 1076 | Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients. <i>Annals of Surgical Oncology</i> , 2014, 21, 1075-1081. | 0.7 | 123 |
| 1077 | Prognosis of Patients with Melanoma and Microsatellitosis Undergoing Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2014, 21, 1016-1023. | 0.7 | 37 |
| 1078 | Resection of Residual Disease after Isolated Limb Infusion (ILI) Is Equivalent to a Complete Response after ILI-Alone in Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 650-655. | 0.7 | 23 |
| 1079 | Clark Level Risk Stratifies Patients with Mitogenic Thin Melanomas for Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2014, 21, 643-649. | 0.7 | 42 |
| 1080 | A four-marker signature of TNF-RII, TGF- β , TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. <i>Journal of Translational Medicine</i> , 2014, 12, 19. | 1.8 | 42 |
| 1081 | Tissue prognostic biomarkers in primary cutaneous melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 265-281. | 1.4 | 43 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1082 | Human relevance of NRAS/BRAF mouse melanoma models. <i>European Journal of Cell Biology</i> , 2014, 93, 82-86. | 1.6 | 19 |
| 1083 | Topical application of Gallic acid suppresses the 7,12-DMBA/Croton oil induced two-step skin carcinogenesis by modulating anti-oxidants and MMP-2/MMP-9 in Swiss albino mice. <i>Food and Chemical Toxicology</i> , 2014, 66, 44-55. | 1.8 | 51 |
| 1084 | Metastatic Melanoma in the Chest and Abdomen: The Great Radiologic Imitator. <i>Seminars in Ultrasound, CT and MRI</i> , 2014, 35, 272-289. | 0.7 | 7 |
| 1085 | Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. <i>Lancet Oncology</i> , The, 2014, 15, e178-e183. | 5.1 | 137 |
| 1086 | BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. <i>Clinical Cancer Research</i> , 2014, 20, 1965-1977. | 3.2 | 447 |
| 1087 | Extracellular adenosine metabolism in immune cells in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1073-1080. | 2.0 | 53 |
| 1088 | Perioral Lesions and Dermatoses. <i>Dental Clinics of North America</i> , 2014, 58, 401-435. | 0.8 | 8 |
| 1089 | Management of regional metastatic disease in head and neck cutaneous malignancy. 2. Cutaneous malignant melanoma. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2014, 52, 301-307. | 0.4 | 11 |
| 1090 | Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas. <i>Journal of Surgical Research</i> , 2014, 187, 518-524. | 0.8 | 28 |
| 1091 | The scope of nanoparticle therapies for future metastatic melanoma treatment. <i>Lancet Oncology</i> , The, 2014, 15, e22-e32. | 5.1 | 75 |
| 1092 | Molecular Testing in Cancer. , 2014, , . | | 2 |
| 1093 | Expression of proteins involved in epigenetic regulation in human cutaneous melanoma and peritumoral skin. <i>Tumor Biology</i> , 2014, 35, 8225-8233. | 0.8 | 18 |
| 1094 | Mobile Medical Applications for Melanoma Risk Assessment: False Assurance or Valuable Tool?. , 2014, , . | | 9 |
| 1095 | Epigenetic biomarkers in skin cancer. <i>Cancer Letters</i> , 2014, 342, 170-177. | 3.2 | 69 |
| 1096 | Biopsia de ganglio centinela en melanoma. Valor pronóstico y correlación con el Índice mitótico. Experiencia en un hospital terciario. <i>Actas Dermo-sifilográficas</i> , 2014, 105, 60-68. | 0.2 | 5 |
| 1097 | Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis. <i>Methods in Molecular Biology</i> , 2014, 1102, 287-324. | 0.4 | 78 |
| 1098 | Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. <i>Clinica Chimica Acta</i> , 2014, 429, 168-174. | 0.5 | 20 |
| 1099 | Advances in Adjuvant Therapy: Potential for Prognostic and Predictive Biomarkers. <i>Methods in Molecular Biology</i> , 2014, 1102, 45-69. | 0.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-------|-----------|
| 1100 | Concepts in Breast and Melanoma Surgery. , 2014, , 969-978. | | 0 |
| 1101 | A Practical Guide to Human Cancer Genetics. , 2014, , . | | 8 |
| 1102 | Sex disparities in melanoma outcomes: The role of biology. Archives of Biochemistry and Biophysics, 2014, 563, 42-50. | 1.4 | 53 |
| 1103 | Section IV: Non-“small cell lung cancer and malignant melanoma. Current Problems in Cancer, 2014, 38, 180-198. | 1.0 | 2 |
| 1104 | Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis. British Journal of Surgery, 2014, 101, 811-819. | 0.1 | 19 |
| 1105 | Intralesional interleukin-2 therapy for in transit melanoma. Journal of Surgical Oncology, 2014, 109, 327-331. | 0.8 | 33 |
| 1106 | Recent developments in the medical and surgical treatment of melanoma. Ca-A Cancer Journal for Clinicians, 2014, 64, 171-185. | 157.7 | 56 |
| 1107 | Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. British Journal of Dermatology, 2014, 170, 87-95. | 1.4 | 11 |
| 1108 | Inverse regulation of melanoma growth and migration by <i>ORAI1</i> / <i>STIM2</i> -dependent calcium entry. Pigment Cell and Melanoma Research, 2014, 27, 442-453. | 1.5 | 84 |
| 1109 | Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. Journal of the American Academy of Dermatology, 2014, 71, 1102-1109.e1. | 0.6 | 67 |
| 1110 | MicroRNA-mediated regulation of melanoma. British Journal of Dermatology, 2014, 171, 234-241. | 1.4 | 32 |
| 1111 | Autophagy induced by resveratrol suppresses α -MSH-induced melanogenesis. Experimental Dermatology, 2014, 23, 204-206. | 1.4 | 39 |
| 1113 | Pigmentation of axillary sentinel nodes from extensive skin tattoo mimics metastatic melanoma: case report. International Journal of Dermatology, 2014, 53, 773-776. | 0.5 | 17 |
| 1114 | Isolated limb infusion as a model to test new agents to treat metastatic melanoma. Journal of Surgical Oncology, 2014, 109, 357-365. | 0.8 | 9 |
| 1115 | Increased frequency of minimal homozygous deletions is associated with poor prognosis in primary malignant melanoma patients. Genes Chromosomes and Cancer, 2014, 53, 487-496. | 1.5 | 7 |
| 1116 | Observational study on the mitotic rate and other prognostic factors in cutaneous primary melanoma arising from naevi and from melanoma <i>de novo</i> . Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1738-1741. | 1.3 | 11 |
| 1117 | Clinical implications of distinct metastasizing preferences of different melanoma subtypes. European Journal of Dermatology, 2014, 24, 236-241. | 0.3 | 15 |
| 1119 | Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. Modern Pathology, 2014, 27, 1468-1478. | 2.9 | 54 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1120 | Primary dermal melanoma: A unique subtype of melanoma to be distinguished from cutaneous metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1083-1092. | 0.6 | 28 |
| 1121 | Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with <i>BRAF</i> V600 Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 5527-5536. | 3.2 | 145 |
| 1122 | Isolated hepatic perfusion for metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 383-388. | 0.8 | 9 |
| 1123 | Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3771-3778. | 0.8 | 99 |
| 1124 | Accurate detection of <i>BRAF</i> p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. <i>Human Pathology</i> , 2014, 45, 2281-2293. | 1.1 | 53 |
| 1125 | Is <i>BRAF</i> a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection. <i>British Journal of Dermatology</i> , 2014, 171, 108-114. | 1.4 | 26 |
| 1126 | Segmentation of Pigmented Melanocytic Skin Lesions Based on Learned Dictionaries and Normalized Graph Cuts. , 2014, , . | | 4 |
| 1127 | Feasibility Study on Measuring Selected Proteins in Malignant Melanoma Tissue by SRM Quantification. <i>Journal of Proteome Research</i> , 2014, 13, 1315-1326. | 1.8 | 9 |
| 1128 | High-frequency ultrasonography but not 930-nm optical coherence tomography reliably evaluates melanoma thickness <i>in vivo</i> : a prospective validation study. <i>British Journal of Dermatology</i> , 2014, 171, 799-805. | 1.4 | 39 |
| 1129 | The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. <i>Archives of Biochemistry and Biophysics</i> , 2014, 563, 28-34. | 1.4 | 109 |
| 1130 | PET Imaging of Very Late Antigen-4 in Melanoma: Comparison of ⁶⁸ Ga- and ⁶⁴ Cu-Labeled NODAGA and CB-TE1A1P-LLP2A Conjugates. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1856-1863. | 2.8 | 46 |
| 1131 | No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. <i>Molecular Oncology</i> , 2014, 8, 1140-1158. | 2.1 | 47 |
| 1132 | A new look at drugs targeting malignant melanoma—An application for mass spectrometry imaging. <i>Proteomics</i> , 2014, 14, 1963-1970. | 1.3 | 28 |
| 1133 | Analysis of clinical, dermoscopic and histopathological features of primary melanomas of patients with metastatic disease—a retrospective study at the Department of Dermatology, Medical University of Graz, 2000–2010. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1776-1781. | 1.3 | 10 |
| 1134 | Primary Melanoma Tumors from <i>CDKN2A</i> Mutation Carriers Do Not Belong to a Distinct Molecular Subclass. <i>Journal of Investigative Dermatology</i> , 2014, 134, 3000-3003. | 0.3 | 8 |
| 1135 | Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 955-967. | 1.4 | 20 |
| 1136 | Contemporary controversies and perspectives in the staging and treatment of patients with lymph node metastasis from melanoma, especially with regards positive sentinel lymph node biopsy. <i>Cancer Treatment Reviews</i> , 2014, 40, 893-899. | 3.4 | 18 |
| 1137 | Management of melanoma. <i>British Medical Bulletin</i> , 2014, 111, 149-162. | 2.7 | 61 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1138 | Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2479-2485. | 0.8 | 103 |
| 1139 | Systemic treatment for BRAF-mutant melanoma: where do we go next?. <i>Lancet Oncology</i> , The, 2014, 15, e371-e381. | 5.1 | 130 |
| 1140 | Ultrasound-guided fine needle aspiration cytology as an addendum to sentinel lymph node biopsy can perfect the staging strategy in melanoma patients. <i>European Journal of Cancer</i> , 2014, 50, 2280-2288. | 1.3 | 47 |
| 1141 | Surviving Cutaneous Melanoma. <i>Surgical Clinics of North America</i> , 2014, 94, 989-1002. | 0.5 | 35 |
| 1142 | Impact of mitotic activity on the pathological substaging of pT1 cutaneous melanoma. <i>British Journal of Dermatology</i> , 2014, 170, 874-877. | 1.4 | 8 |
| 1143 | Melanocytic Lesions. , 2014, , . | | 2 |
| 1144 | Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. <i>BMC Cancer</i> , 2014, 14, 560. | 1.1 | 30 |
| 1145 | Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. , 2014, 2, 27. | | 7 |
| 1146 | Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 816-823. | 0.8 | 20 |
| 1147 | Locoregional Therapies in Melanoma. <i>Surgical Clinics of North America</i> , 2014, 94, 1003-1015. | 0.5 | 27 |
| 1148 | Principles of Surgical Treatment of Malignant Melanoma. <i>Surgical Clinics of North America</i> , 2014, 94, 973-988. | 0.5 | 13 |
| 1149 | Unusual Presentations of Melanoma. <i>Surgical Clinics of North America</i> , 2014, 94, 1059-1073. | 0.5 | 8 |
| 1150 | Head and Neck Melanoma. <i>Surgical Clinics of North America</i> , 2014, 94, 1091-1113. | 0.5 | 16 |
| 1151 | Metabolic Dysregulation in Melanoma: Cause or Consequence?. <i>Cancer Discovery</i> , 2014, 4, 390-391. | 7.7 | 9 |
| 1152 | Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 449-58. | 2.0 | 253 |
| 1153 | Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683. | 2.0 | 230 |
| 1154 | Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 77-84. | 1.1 | 29 |
| 1155 | Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. <i>Archives of Dermatological Research</i> , 2014, 306, 521-526. | 1.1 | 31 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1156 | Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 603-612. | 1.4 | 12 |
| 1157 | Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. <i>Nature Communications</i> , 2014, 5, 4255. | 5.8 | 140 |
| 1158 | Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 30. | 3.5 | 97 |
| 1159 | Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2525-2531. | 0.7 | 13 |
| 1160 | Pathology Review Significantly Affects Diagnosis and Treatment of Melanoma Patients: An Analysis of 5011 Patients Treated at a Melanoma Treatment Center. <i>Annals of Surgical Oncology</i> , 2014, 21, 2245-2251. | 0.7 | 35 |
| 1161 | Sentinel Node Location in Trunk and Extremity Melanomas: Uncommon or Multiple Lymph Drainage Does Not Affect Survival. <i>Annals of Surgical Oncology</i> , 2014, 21, 3386-3394. | 0.7 | 8 |
| 1162 | Factors Influencing the Use of Sentinel Lymph Node Biopsy in the Netherlands. <i>Annals of Surgical Oncology</i> , 2014, 21, 3395-3400. | 0.7 | 11 |
| 1163 | Discordance in Histopathologic Evaluation of Melanoma Sentinel Lymph Node Biopsy with Clinical Follow-Up: Results from a Prospectively Collected Database. <i>Annals of Surgical Oncology</i> , 2014, 21, 3406-3411. | 0.7 | 7 |
| 1164 | Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site. <i>Annals of Surgical Oncology</i> , 2014, 21, 4317-4323. | 0.7 | 23 |
| 1165 | Primary Melanoma Location on the Scalp is an Important Risk Factor for Brain Metastasis: A Study of 1,687 Patients with Cutaneous Head and Neck Melanomas. <i>Annals of Surgical Oncology</i> , 2014, 21, 3985-3991. | 0.7 | 35 |
| 1166 | Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma – implications for therapeutic strategies and targeted therapies. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 621-639. | 1.1 | 17 |
| 1167 | Distinct melanoma types based on reflectance confocal microscopy. <i>Experimental Dermatology</i> , 2014, 23, 414-418. | 1.4 | 67 |
| 1168 | High Expression of the Mismatch Repair Protein MSH6 Is Associated With Poor Patient Survival in Melanoma. <i>American Journal of Clinical Pathology</i> , 2014, 142, 121-132. | 0.4 | 22 |
| 1169 | Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. <i>European Journal of Cancer</i> , 2014, 50, 1120-1124. | 1.3 | 15 |
| 1170 | What Is the Role of Chemotherapy in the Treatment of Melanoma?. <i>Current Treatment Options in Oncology</i> , 2014, 15, 321-335. | 1.3 | 20 |
| 1171 | Update on Vaccines for High-Risk Melanoma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 269-280. | 1.3 | 10 |
| 1172 | Thin melanoma and late recurrences: it is never too thin and never too late. <i>Medical Oncology</i> , 2014, 31, 909. | 1.2 | 11 |
| 1173 | Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2014, 16, 362-373. | 1.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1174 | Melanoma in Pregnancy: Therapeutic Challenges. <i>Current Dermatology Reports</i> , 2014, 3, 149-152. | 1.1 | 0 |
| 1175 | A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma. <i>BMC Cancer</i> , 2014, 14, 398. | 1.1 | 21 |
| 1176 | Discrepant alterations in main candidate genes among multiple primary melanomas. <i>Journal of Translational Medicine</i> , 2014, 12, 117. | 1.8 | 24 |
| 1177 | TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, . | 3.0 | 204 |
| 1178 | BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy. <i>European Journal of Cancer</i> , 2014, 50, 2668-2676. | 1.3 | 67 |
| 1179 | Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations. <i>Advances in Therapy</i> , 2014, 31, 945-960. | 1.3 | 35 |
| 1180 | Melanoma: immune checkpoint blockade story gets better. <i>Lancet, The</i> , 2014, 384, 1078-1079. | 6.3 | 10 |
| 1181 | Red meat and fruit intake is prognostic among patients with localized cutaneous melanomas more than 1mm thick. <i>Cancer Epidemiology</i> , 2014, 38, 599-607. | 0.8 | 11 |
| 1182 | Isolation and Molecular Characterization of Circulating Melanoma Cells. <i>Cell Reports</i> , 2014, 7, 645-653. | 2.9 | 91 |
| 1183 | Lymphoscintigraphy in clinical routine practice: Reproducibility and accuracy in melanoma patients with a long-term follow-up. <i>European Journal of Surgical Oncology</i> , 2014, 40, 55-60. | 0.5 | 23 |
| 1184 | Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 435-442. | 0.6 | 28 |
| 1185 | Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 637-643. | 0.6 | 108 |
| 1186 | Bases inmunológicas de la hipopigmentación vitiligoide asociada a melanoma. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 122-127. | 0.2 | 3 |
| 1187 | Commentary: Molecular testing in melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 863-870. | 0.6 | 4 |
| 1188 | Pediatric Melanoma, Moles, and Sun Safety. <i>Pediatric Clinics of North America</i> , 2014, 61, 279-291. | 0.9 | 14 |
| 1189 | Curcumin-induced melanoma cell death is associated with mitochondrial permeability transition pore (mPTP) opening. <i>Biochemical and Biophysical Research Communications</i> , 2014, 448, 15-21. | 1.0 | 70 |
| 1190 | Rôle de la TEP/TDM dans la prise en charge du mélanome. <i>Medecine Nucleaire</i> , 2014, 38, 216-220. | 0.2 | 0 |
| 1191 | The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients. <i>European Journal of Cancer</i> , 2014, 50, 111-120. | 1.3 | 127 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1192 | Lymphatics in nanophysiology. <i>Advanced Drug Delivery Reviews</i> , 2014, 74, 12-18. | 6.6 | 14 |
| 1193 | Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 986-997. | 0.4 | 142 |
| 1194 | Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. <i>Lancet Oncology</i> , The, 2014, 15, 620-630. | 5.1 | 96 |
| 1195 | Residual melanoma after an excisional biopsy is an independent prognostic factor for local recurrence and overall survival. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1271-1275. | 0.5 | 12 |
| 1196 | Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology</i> , The, 2014, 15, 436-444. | 5.1 | 242 |
| 1197 | Cutaneous Melanoma in Children and Adolescents: The Italian Rare Tumors in Pediatric Age Project Experience. <i>Journal of Pediatrics</i> , 2014, 164, 376-382.e2. | 0.9 | 47 |
| 1198 | Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study. <i>Cancer Epidemiology</i> , 2014, 38, 93-99. | 0.8 | 20 |
| 1199 | Nomograms to predict recurrence and survival in stage IIIB and IIIC melanoma after therapeutic lymphadenectomy. <i>European Journal of Cancer</i> , 2014, 50, 1301-1309. | 1.3 | 24 |
| 1200 | TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2251-2257. | 0.3 | 105 |
| 1201 | MSLT-1 is a biomarker, not a therapeutic intervention. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 248-249. | 12.5 | 12 |
| 1202 | Treatments for Noncutaneous Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 507-521. | 0.9 | 12 |
| 1203 | A Review of Novel Therapies for Melanoma. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 323-337. | 3.3 | 55 |
| 1204 | Surgical Management of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 455-470. | 0.9 | 14 |
| 1205 | Melanoma Adjuvant Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 471-489. | 0.9 | 13 |
| 1206 | The role of accessibility policies and other determinants of health care provision in the initial prognosis of malignant melanoma: A cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 507-515. | 0.6 | 25 |
| 1207 | Understanding the Biology of Melanoma and Therapeutic Implications. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 437-453. | 0.9 | 33 |
| 1208 | Staging and Follow-Up of Patients With Melanoma: Which Tests for Which Patients?. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 531-534. | 0.2 | 2 |
| 1209 | State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 415-435. | 0.9 | 32 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1210 | Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127. | 1.3 | 149 |
| 1211 | The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. <i>Acta Pharmaceutica Sinica B</i> , 2014, 4, 105-111. | 5.7 | 48 |
| 1212 | Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 210-218. | 2.4 | 169 |
| 1213 | Melanoma metastasis: new concepts and evolving paradigms. <i>Oncogene</i> , 2014, 33, 2413-2422. | 2.6 | 120 |
| 1214 | Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: A 5-year survival analysis. <i>Oncology Reports</i> , 2014, 32, 2735-2743. | 1.2 | 23 |
| 1216 | The future of elderly care in Turkey. <i>British Journal of General Practice</i> , 2014, 64, 14.3-15. | 0.7 | 2 |
| 1217 | Diagnostic biopsy of melanoma: primary or secondary care?. <i>British Journal of General Practice</i> , 2014, 64, 14.1-14. | 0.7 | 1 |
| 1218 | Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome. <i>Oncology Letters</i> , 2014, 8, 47-54. | 0.8 | 34 |
| 1219 | Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review). <i>Oncology Reports</i> , 2014, 32, 875-886. | 1.2 | 37 |
| 1220 | Subcutaneous metastases from melanoma: a discussion of clinical experience. <i>Melanoma Management</i> , 2014, 1, 31-40. | 0.1 | 2 |
| 1221 | Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma. , 2014, , 911-928. | | 0 |
| 1222 | The role of chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2014, 1, 173-184. | 0.1 | 8 |
| 1223 | Tumor Volume as a Prognostic Factor in Resectable Malignant Melanoma. <i>Dermatology</i> , 2014, 228, 66-70. | 0.9 | 24 |
| 1224 | Advances in targeted therapy for melanoma: a focus on MEK inhibition. <i>Clinical Investigation</i> , 2014, 4, 903-913. | 0.0 | 0 |
| 1225 | Follow-up in patients with low-risk cutaneous melanoma: is it worth it?. <i>Melanoma Management</i> , 2014, 1, 115-125. | 0.1 | 2 |
| 1226 | Maspin expression and melanoma progression: a matter of sub-cellular localization. <i>Modern Pathology</i> , 2014, 27, 412-419. | 2.9 | 16 |
| 1227 | BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies. <i>Cancer Control</i> , 2014, 21, 221-230. | 0.7 | 80 |
| 1228 | Unanswered Questions in the Management of Stage I-III Merkel Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 425-431. | 2.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1229 | The Optimum Excision Margin and Regional Node Management for Primary Cutaneous T3 Melanomas (2â€“4 mm in Thickness). <i>Annals of Surgery</i> , 2014, 260, 1095-1102. | 2.1 | 12 |
| 1230 | Advances in molecular profiling of malignant melanoma: ready for clinical practice?. <i>Melanoma Management</i> , 2014, 1, 3-6. | 0.1 | 0 |
| 1231 | Outcome Following Sentinel Node Biopsy Plus Wide Local Excision Versus Wide Local Excision Only for Primary Cutaneous Melanoma. <i>Annals of Surgery</i> , 2014, 260, 149-157. | 2.1 | 36 |
| 1232 | Leitlinienbasierte QualitÃtsindikatoren und Zertifizierung als Grundlage fÃ¼r die QualitÃtssicherung der Versorgung von Patienten mit Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 139-147. | 0.4 | 8 |
| 1233 | Indocyanine Green SPY Eliteâ€“Assisted Sentinel Lymph Node Biopsy in Cutaneous Melanoma. <i>Plastic and Reconstructive Surgery</i> , 2014, 133, 914-922. | 0.7 | 61 |
| 1234 | Is Surveillance Imaging Effective for Detecting Surgically Treatable Recurrences in Patients With Melanoma? A Comparative Analysis of Stage-Specific Surveillance Strategies. <i>Annals of Surgery</i> , 2014, 259, 1215-1222. | 2.1 | 46 |
| 1235 | Melanoma and nuclear medicine. <i>Melanoma Management</i> , 2014, 1, 57-74. | 0.1 | 9 |
| 1236 | Foudroyant metastasierendes, Vemurafenibtherapieresistentes malignes Melanom mit einer seltenen BRAF-Alteration. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 151-154. | 0.4 | 2 |
| 1237 | Long non-coding RNAs drive metastatic progression in melanoma (Review). <i>International Journal of Oncology</i> , 2014, 45, 2181-2186. | 1.4 | 9 |
| 1238 | Income-associated discrepancies in melanoma survival. <i>Cancer Treatment Communications</i> , 2015, 4, 143-147. | 0.4 | 4 |
| 1239 | Predicting the outcome of melanoma: can we tell the future of a patientâ€™s melanoma?. <i>Melanoma Management</i> , 2015, 2, 217-224. | 0.1 | 5 |
| 1240 | Morphogenesis of early stage melanoma. <i>European Physical Journal Plus</i> , 2015, 130, 1. | 1.2 | 1 |
| 1241 | Multi-center evaluation of the novel fully-automated PCR-based Idyllaâ„¢ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. <i>Experimental and Molecular Pathology</i> , 2015, 99, 485-491. | 0.9 | 44 |
| 1242 | Revisiting determinants of prognosis in cutaneous melanoma. <i>Cancer</i> , 2015, 121, 4108-4123. | 2.0 | 75 |
| 1243 | Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years. <i>International Journal of Cancer</i> , 2015, 136, 2453-2457. | 2.3 | 41 |
| 1244 | 25â€“Hydroxyvitamin D₂/D₃ levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort. <i>International Journal of Cancer</i> , 2015, 136, 2890-2899. | 2.3 | 61 |
| 1245 | Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma. <i>The Cochrane Library</i> , 2017, 2017, CD010307. | 1.5 | 24 |
| 1246 | Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma. <i>European Journal of Dermatology</i> , 2015, 25, 392-403. | 0.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1248 | Tests to assist in the diagnosis of cutaneous melanoma in adults: a generic protocol. The Cochrane Library, 0, , . | 1.5 | 19 |
| 1249 | Long-term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma. <i>Annals of Surgery</i> , 2015, 262, 456-464. | 2.1 | 26 |
| 1250 | Global Pattern Classification in Dermoscopic Images. , 2015, , 199-226. | | 5 |
| 1251 | MelanozytÄre NÄvi und Melanom. , 2015, , 1-87. | | 0 |
| 1252 | Morphology of melanocytic lesions in situ. <i>Scientific Reports</i> , 2014, 4, 3622. | 1.6 | 16 |
| 1253 | FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor. <i>Pathology</i> , 2015, 47, 557-563. | 0.3 | 25 |
| 1254 | Icariside II inhibits cell proliferation and induces cell cycle arrest through the ROS-p38-p53 signaling pathway in A375 human melanoma cells. <i>Molecular Medicine Reports</i> , 2015, 11, 410-416. | 1.1 | 24 |
| 1256 | The wound inflammatory response exacerbates growth of preneoplastic cells and progression to cancer. <i>EMBO Journal</i> , 2015, 34, 2219-2236. | 3.5 | 210 |
| 1257 | Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update. <i>Dermatopathology (Basel)</i> , Tj ETQq0 0 0 rgBT_/Overlock 10 Tf 50 | 0.7 | 68 |
| 1258 | Clinicopathologic features of primary cutaneous melanoma: a single centre analysis of a Swiss regional population. <i>European Journal of Dermatology</i> , 2015, 25, 127-132. | 0.3 | 1 |
| 1259 | Sentinel lymph node biopsy in thick malignant melanoma: A 16-year single unit experience. <i>European Journal of Dermatology</i> , 2015, 25, 472-476. | 0.3 | 6 |
| 1260 | BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. <i>Melanoma Research</i> , 2015, 25, 486-495. | 0.6 | 73 |
| 1261 | The Prognostic Role of the Preoperative Absolute Lymphocyte Count and Absolute Monocyte Count in Patients With Resected Advanced Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 252-258. | 0.6 | 26 |
| 1262 | Sentinel lymph node biopsy in melanoma: Our experience over 8 years in a university hospital. <i>CirurgÄa Y Cirujanos (English Edition)</i> , 2015, 83, 378-385. | 0.0 | 2 |
| 1263 | Workflow for large-scale analysis of melanoma tissue samples. <i>EuPA Open Proteomics</i> , 2015, 8, 78-84. | 2.5 | 4 |
| 1264 | Primary Melanoma of Infra Temporal Fossa: A Case Report. <i>Indian Journal of Surgical Oncology</i> , 2015, 6, 276-279. | 0.3 | 0 |
| 1265 | Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch. <i>Medicina (Lithuania)</i> , 2015, 51, 133-145. | 0.8 | 12 |
| 1266 | Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 319. | 1.8 | 27 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1267 | Focal invasiveness in complete histological analyses of a large acral lentiginous melanoma. <i>Diagnostic Pathology</i> , 2015, 10, 73. | 0.9 | 1 |
| 1268 | A single-center retrospective study on 659 re-excisions of melanoma and 769 sentinel node biopsies in 2008â€“2012. <i>European Journal of Plastic Surgery</i> , 2015, 38, 471-478. | 0.3 | 2 |
| 1269 | Prospective study of patterns of surgical management in adults with primary cutaneous melanoma at high risk of spread, in Queensland, Australia. <i>Journal of Surgical Oncology</i> , 2015, 112, 359-365. | 0.8 | 27 |
| 1270 | Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia. <i>Psycho-Oncology</i> , 2015, 24, 763-770. | 1.0 | 49 |
| 1271 | Novel CDKN2A mutations in Austrian melanoma patients. <i>Melanoma Research</i> , 2015, 25, 412-420. | 0.6 | 10 |
| 1272 | Hair shaft mi<scp>RNA</scp>â€“21 levels as a new tumor marker of malignant melanoma. <i>Journal of Dermatology</i> , 2015, 42, 198-201. | 0.6 | 7 |
| 1273 | Sentinel lymph node biopsy for 102 patients with primary cutaneous melanoma at a single Japanese institute. <i>Journal of Dermatology</i> , 2015, 42, 954-961. | 0.6 | 3 |
| 1274 | Melanoma of the lower extremities: foot site is an independent risk factor for clinical outcome. <i>International Journal of Dermatology</i> , 2015, 54, 1023-1029. | 0.5 | 13 |
| 1275 | Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 912-918. | 1.3 | 8 |
| 1276 | Increased mortality for pregnancyâ€“associated melanoma: systematic review and metaâ€“analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1457-1466. | 1.3 | 54 |
| 1277 | From personalized to patient-specific treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 193-197. | 0.1 | 0 |
| 1278 | Epigenetic markers in melanoma. <i>Melanoma Management</i> , 2015, 2, 367-382. | 0.1 | 4 |
| 1279 | TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines. <i>BMC Cancer</i> , 2015, 15, 777. | 1.1 | 23 |
| 1280 | The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique. <i>World Journal of Surgical Oncology</i> , 2015, 13, 299. | 0.8 | 10 |
| 1281 | Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 351. | 1.8 | 56 |
| 1282 | Utility of sentinel lymph node biopsy for solitary dermal melanomas. <i>Journal of Surgical Oncology</i> , 2015, 111, 800-807. | 0.8 | 7 |
| 1283 | Results of secondâ€“stage screening for skin cancers in Oita Prefecture, Japan. <i>Journal of Dermatology</i> , 2015, 42, 1160-1164. | 0.6 | 3 |
| 1284 | MSLT â€“: it's all about the lymph nodesâ€“. <i>British Journal of Dermatology</i> , 2015, 173, 626-627. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1285 | Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity. <i>Clinical Physiology and Functional Imaging</i> , 2015, 35, 301-305. | 0.5 | 6 |
| 1286 | Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. <i>European Journal of Cancer Care</i> , 2015, 24, 724-733. | 0.7 | 31 |
| 1287 | Evaluation of Melanoma Features and Their Relationship with Nodal Disease: The Importance of the Pathological Report. <i>Tumori</i> , 2015, 101, 501-505. | 0.6 | 14 |
| 1288 | Ultrasound-guided core needle biopsy of superficial lymph nodes. <i>Melanoma Research</i> , 2015, 25, 519-527. | 0.6 | 19 |
| 1289 | Melanomasâ€™ fatal attraction to lysophosphatidic acid trails: a new prognostic and therapeutic approach?. <i>Melanoma Management</i> , 2015, 2, 97-100. | 0.1 | 0 |
| 1290 | Surgical management of malignant melanoma of the lung. <i>Melanoma Management</i> , 2015, 2, 301-303. | 0.1 | 1 |
| 1291 | A populationâ€™based assessment of melanoma: Does treatment in a regional cancer center make a difference?. <i>Journal of Surgical Oncology</i> , 2015, 112, 173-178. | 0.8 | 7 |
| 1292 | Prognostic significance of tumor mitotic rate in T2 melanoma staged with sentinel lymphadenectomy. <i>Journal of Surgical Oncology</i> , 2015, 111, 711-715. | 0.8 | 6 |
| 1293 | Is histopathological overdiagnosis of melanoma a good insurance for the future?. <i>Melanoma Management</i> , 2015, 2, 21-25. | 0.1 | 5 |
| 1294 | The role of <i>BRAF</i> mutations in primary melanoma growth rate and survival. <i>British Journal of Dermatology</i> , 2015, 173, 76-82. | 1.4 | 35 |
| 1295 | Systemic therapy of metastatic melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1223-1237. | 0.4 | 12 |
| 1296 | Association between tumor size and Breslowâ€™s thickness in malignant melanoma. <i>Melanoma Research</i> , 2015, 25, 450-452. | 0.6 | 20 |
| 1297 | Does Pregnancy After a Diagnosis of Melanoma Affect Prognosis? Systematic Review and Meta-analysis. <i>Dermatologic Surgery</i> , 2015, 41, 875-882. | 0.4 | 25 |
| 1298 | Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases. <i>Melanoma Research</i> , 2015, 25, 427-431. | 0.6 | 14 |
| 1299 | Controversies in Sentinel Lymph Node Biopsy for Ocular Neoplasms. <i>International Ophthalmology Clinics</i> , 2015, 55, 73-79. | 0.3 | 7 |
| 1300 | Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma. <i>Medicine (United States)</i> , 2015, 94, e1433. | 0.4 | 18 |
| 1301 | Systemtherapie des metastasierten malignen Melanoms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1223-1238. | 0.4 | 7 |
| 1302 | In vivo visualization of mesoscopic anatomy of healthy and pathological lymph nodes using 7T MRI: A feasibility study. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1405-1412. | 1.9 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1303 | Primary dermal melanoma: a West Australian cohort. ANZ Journal of Surgery, 2015, 85, 664-667. | 0.3 | 14 |
| 1304 | Impact of the 2009 AJCC staging guidelines for melanoma on the number of mitotic figures reported by dermatopathologists at one institution. Journal of Cutaneous Pathology, 2015, 42, 536-541. | 0.7 | 5 |
| 1305 | Diagnostic accuracy of ¹⁸ F-FDG PET/CT in early and late stages of high-risk cutaneous malignant melanoma. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1938-1944. | 1.3 | 21 |
| 1306 | Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. International Journal of Cancer, 2015, 137, 2607-2617. | 2.3 | 28 |
| 1307 | Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of ¹⁸ F-FDG PET and ¹⁸ F-FLT PET. Contrast Media and Molecular Imaging, 2015, 10, 203-210. | 0.4 | 7 |
| 1308 | Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 2015, 121, 3826-3835. | 2.0 | 40 |
| 1309 | Prognostic value of S100/CD31 and S100/podoplanin double immunostaining in mucosal malignant melanoma of the head and neck. Head and Neck, 2015, 37, 1368-1374. | 0.9 | 13 |
| 1310 | Genetic variants in Hippo pathway genes <i>YAP1</i> , <i>TEAD1</i> and <i>TEAD4</i> are associated with melanoma-specific survival. International Journal of Cancer, 2015, 137, 638-645. | 2.3 | 48 |
| 1311 | Use of clinical next-generation sequencing to identify melanomas harboring <i>SMARCB1</i> mutations. Journal of Cutaneous Pathology, 2015, 42, 308-317. | 0.7 | 11 |
| 1312 | Peritumoral D2-40 Chalkley score independently predicts metastases and survival in patients with cutaneous malignant melanoma. Journal of Cutaneous Pathology, 2015, 42, 699-711. | 0.7 | 11 |
| 1313 | Venous Free Flaps for the Treatment of Skin Cancers of the Digits. Annals of Plastic Surgery, 2015, 74, 536-542. | 0.5 | 11 |
| 1314 | The cost of ipilimumab toxicity. Melanoma Research, 2015, 25, 259-264. | 0.6 | 22 |
| 1315 | Tumor-infiltrating lymphocytes predict cutaneous melanoma survival. Melanoma Research, 2015, 25, 306-311. | 0.6 | 66 |
| 1316 | BRAF mutation screening in melanoma. Melanoma Research, 2015, 25, 328-334. | 0.6 | 9 |
| 1317 | Complete remission of metastatic melanoma upon BRAF inhibitor treatment – what happens after discontinuation?. Melanoma Research, 2015, 25, 362-366. | 0.6 | 27 |
| 1318 | Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Research, 2015, 25, 503-509. | 0.6 | 59 |
| 1319 | Management of melanoma. , 0, , 499-512. | | 0 |
| 1321 | Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma. Molecular Medicine Reports, 2015, 12, 2668-2676. | 1.1 | 26 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1322 | Classification of clinical outcomes using high-throughput informatics: Part 1 – nonparametric method reviews. <i>Model Assisted Statistics and Applications</i> , 2015, 10, 3-23. | 0.2 | 8 |
| 1323 | Evaluation of outpatient discharge in patients with cutaneous melanoma. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2015, 42, 70-74. | 0.3 | 1 |
| 1324 | Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis. <i>Patient Related Outcome Measures</i> , 2015, 6, 229. | 0.7 | 22 |
| 1325 | Comparative Aspects of BRAF Mutations in Canine Cancers. <i>Veterinary Sciences</i> , 2015, 2, 231-245. | 0.6 | 25 |
| 1326 | The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial. <i>Wspolczesna Onkologia</i> , 2015, 4, 280-283. | 0.7 | 3 |
| 1327 | The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β^2 and interferon β^3 in metastatic lymph nodes in malignant melanoma. <i>Polish Journal of Pathology</i> , 2015, 4, 376-382. | 0.1 | 14 |
| 1328 | Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells. <i>OncoTargets and Therapy</i> , 2015, 8, 1043. | 1.0 | 10 |
| 1329 | The Role of Nuclear Medicine in Malignant Melanoma. <i>Journal of Nuclear Medicine & Radiation Therapy</i> , 2015, 06, . | 0.2 | 0 |
| 1330 | Role of Age and Sex in the Diagnosis of Early-stage Malignant Melanoma: A Cross-Sectional study. <i>Acta Dermato-Venereologica</i> , 2015, 95, 940-942. | 0.6 | 6 |
| 1331 | CUÁNDO Y CÁNMO REALIZAR UNA BIOPSIA DE LAS LESIONES CUTÁNEAS FRECUENTES: LO QUE EL CIRUJANO DEBE SABER. <i>Revista Chilena De Cirugía</i> , 2015, 67, 538-544. | 0.1 | 0 |
| 1332 | New developments in the management of advanced melanoma – role of pembrolizumab. <i>OncoTargets and Therapy</i> , 2015, 8, 2535. | 1.0 | 16 |
| 1333 | From dismal prognosis to rising star: melanoma leads the way with new generation cancer therapies. <i>Medical Journal of Australia</i> , 2015, 202, 115-116. | 0.8 | 2 |
| 1334 | Neoadjuvant Therapy for Melanoma: A Promising Therapeutic Approach and an Ideal Platform in Drug Development. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e535-e542. | 1.8 | 8 |
| 1335 | Perfusion and Infusion for Melanoma In-Transit Metastases in the Era of Effective Systemic Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e528-e534. | 1.8 | 19 |
| 1336 | Melanoma in the Italian Population and Regional Environmental Influences: A National Retrospective Survey on 2001–2008 Hospitalization Records. <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 9102-9118. | 1.2 | 7 |
| 1337 | Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. <i>Frontiers in Oncology</i> , 2015, 5, 183. | 1.3 | 80 |
| 1338 | CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. <i>Frontiers in Oncology</i> , 2015, 5, 234. | 1.3 | 8 |
| 1339 | Hedgehog-Gli signaling in basal cell carcinoma and other skin cancers: prospects for therapy. <i>Research and Reports in Biology</i> , 0, , 55. | 0.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1340 | Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma - Part I. <i>Anais Brasileiros De Dermatologia</i> , 2015, 90, 851-861. | 0.5 | 19 |
| 1341 | Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells. <i>PLoS ONE</i> , 2015, 10, e0117021. | 1.1 | 19 |
| 1342 | Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. <i>PLoS ONE</i> , 2015, 10, e0118564. | 1.1 | 197 |
| 1343 | Inherited Variation at MC1R and Histological Characteristics of Primary Melanoma. <i>PLoS ONE</i> , 2015, 10, e0119920. | 1.1 | 22 |
| 1344 | A Protein Deep Sequencing Evaluation of Metastatic Melanoma Tissues. <i>PLoS ONE</i> , 2015, 10, e0123661. | 1.1 | 19 |
| 1345 | Vitamin D Deficiency at Melanoma Diagnosis Is Associated with Higher Breslow Thickness. <i>PLoS ONE</i> , 2015, 10, e0126394. | 1.1 | 42 |
| 1346 | Periostin Is a Key Niche Component for Wound Metastasis of Melanoma. <i>PLoS ONE</i> , 2015, 10, e0129704. | 1.1 | 45 |
| 1347 | Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. <i>PLoS ONE</i> , 2015, 10, e0133363. | 1.1 | 14 |
| 1348 | Computer-Aided Decision Support for Melanoma Detection Applied on Melanocytic and Nonmelanocytic Skin Lesions: A Comparison of Two Systems Based on Automatic Analysis of Dermoscopic Images. <i>BioMed Research International</i> , 2015, 2015, 1-8. | 0.9 | 15 |
| 1349 | Targeted Therapies Compared to Dacarbazine for Treatment of BRAF ^{V600E} Metastatic Melanoma: A Cost-Effectiveness Analysis. <i>Journal of Skin Cancer</i> , 2015, 2015, 1-8. | 0.5 | 17 |
| 1350 | MHC Class I Chain-Related Gene A Diversity in Patients with Cutaneous Malignant Melanoma from Southeastern Spain. <i>Disease Markers</i> , 2015, 2015, 1-6. | 0.6 | 5 |
| 1351 | Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. <i>Oncology Issues</i> , 2015, 30, 48-57. | 0.0 | 3 |
| 1352 | Surgery and Staging of Melanoma. , 2015, , . | | 0 |
| 1353 | Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era. <i>Current Molecular Pharmacology</i> , 2015, 7, 33-43. | 0.7 | 3 |
| 1354 | Psychological Stress and Immunological Modulations in Early-stage Melanoma Patients. <i>Acta Dermato-Venereologica</i> , 2015, 95, 691-695. | 0.6 | 5 |
| 1355 | RAGE and Its Ligands in Melanoma. , 0, , . | | 0 |
| 1356 | Melanocytic tumour with unknown malignant potential “a Danish study of 67 patients. <i>Melanoma Research</i> , 2015, 25, 64-67. | 0.6 | 6 |
| 1357 | The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival. <i>Seminars in Oncology</i> , 2015, 42, 387-401. | 0.8 | 24 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1358 | Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2521-2526. | 3.3 | 16 |
| 1359 | Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. Future Oncology, 2015, 11, 997-1009. | 1.1 | 2 |
| 1360 | Dermoscopic Appearance of Intraluminal Hematogenous and Lymphatic Patterns of Cutaneous Melanoma Metastases. JAMA Dermatology, 2015, 151, 103. | 2.0 | 1 |
| 1361 | Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model. Nutrition and Cancer, 2015, 67, 761-770. | 0.9 | 44 |
| 1362 | Cancer of the Vulva and Vagina. , 2015, , 85-131. | | 0 |
| 1363 | Serum markers in early-stage and locally advanced melanoma. Tumor Biology, 2015, 36, 8277-8285. | 0.8 | 33 |
| 1364 | Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness. Tumor Biology, 2015, 36, 8593-8600. | 0.8 | 29 |
| 1365 | Implications of the MSLT-1 for sentinel lymph node biopsy in cutaneous head and neck melanoma. Oral Oncology, 2015, 51, 629-633. | 0.8 | 6 |
| 1366 | Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Therapeutic Advances in Medical Oncology, 2015, 7, 107-121. | 1.4 | 8 |
| 1367 | Uncertainties in the management of melanoma nodal metastasis. European Journal of Surgical Oncology, 2015, 41, 811-813. | 0.5 | 2 |
| 1369 | Clinical Significance of Microscopic Melanoma Metastases in the Nonhottest Sentinel Lymph Nodes. JAMA Surgery, 2015, 150, 465. | 2.2 | 9 |
| 1370 | Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression. European Journal of Cancer, 2015, 51, 642-652. | 1.3 | 30 |
| 1371 | Nail apparatus melanoma: A comparative, clinicoprognostic study of the initial clinical and morphological characteristics of 49 patients. Journal of the American Academy of Dermatology, 2015, 73, 213-220. | 0.6 | 24 |
| 1372 | Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. Expert Opinion on Therapeutic Targets, 2015, 19, 733-745. | 1.5 | 22 |
| 1373 | Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Future Oncology, 2015, 11, 133-140. | 1.1 | 9 |
| 1374 | Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Future Oncology, 2015, 11, 579-589. | 1.1 | 16 |
| 1375 | Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients. Journal of Translational Medicine, 2015, 13, 120. | 1.8 | 38 |
| 1376 | C-Reactive Protein As a Marker of Melanoma Progression. Journal of Clinical Oncology, 2015, 33, 1389-1396. | 0.8 | 71 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1377 | Lymph-Node Ratio in Patients with Cutaneous Melanoma: A Multi-Institution Prognostic Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 2127-2134. | 0.7 | 18 |
| 1378 | How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center?. <i>Annals of Surgical Oncology</i> , 2015, 22, 1164-1171. | 0.7 | 11 |
| 1379 | Enhanced FHL2 and TGF- β 21 Expression Is Associated With Invasive Growth and Poor Survival in Malignant Melanomas. <i>American Journal of Clinical Pathology</i> , 2015, 143, 248-256. | 0.4 | 11 |
| 1380 | Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 712-720. | 3.2 | 225 |
| 1381 | ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. <i>Molecular Cancer Research</i> , 2015, 13, 1206-1217. | 1.5 | 44 |
| 1382 | A retrospective study of 1- versus 2-cm excision margins for cutaneous malignant melanomas thicker than 2 mm. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1054-1059. | 0.6 | 15 |
| 1383 | Association Between <i>NRAS</i> and <i>BRAF</i> Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. <i>JAMA Oncology</i> , 2015, 1, 359. | 3.4 | 164 |
| 1384 | Specialized Surveillance for Individuals at High Risk for Melanoma. <i>JAMA Dermatology</i> , 2015, 151, 178. | 2.0 | 25 |
| 1385 | Increased CCL17 serum levels are associated with improved survival in advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1075-1082. | 2.0 | 16 |
| 1386 | Functional Variants in Notch Pathway Genes <i>NCOR2</i> , <i>NCSTN</i> , and <i>MAML2</i> Predict Survival of Patients with Cutaneous Melanoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1101-1110. | 1.1 | 20 |
| 1387 | Emerging clinical applications of selected biomarkers in melanoma. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2015, 8, 35. | 0.8 | 18 |
| 1388 | Lymphoscintigraphy and Sentinel Nodes. <i>Journal of Nuclear Medicine</i> , 2015, 56, 901-907. | 2.8 | 51 |
| 1389 | Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. <i>Melanoma Research</i> , 2015, 25, 421-426. | 0.6 | 98 |
| 1390 | Nab-paclitaxel in patients with metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1371-1377. | 1.1 | 8 |
| 1391 | Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v126-v132. | 0.6 | 308 |
| 1392 | Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging. <i>Science Translational Medicine</i> , 2015, 7, 317ra199. | 5.8 | 239 |
| 1393 | The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation. <i>Science Signaling</i> , 2015, 8, ra124. | 1.6 | 46 |
| 1394 | Prognostic score for patients with advanced melanoma treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2785-2791. | 1.3 | 53 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1395 | Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study. <i>BMJ Open</i> , 2015, 5, e007471. | 0.8 | 12 |
| 1397 | The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 353-366. | 0.1 | 1 |
| 1398 | Erfolge und Grenzen zielgerichteter Krebstherapien beim Melanom. <i>Karger Kompass Dermatologie</i> , 2015, 3, 65-72. | 0.0 | 0 |
| 1399 | T cnica e indicaci n del ganglio centinela en la cirug a de los tumores cut neos. <i>EMC - Cirug a Pl stica Reparadora Y Est tica</i> , 2015, 23, 1-13. | 0.0 | 0 |
| 1400 | Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. <i>Ophthalmology</i> , 2015, 122, 1907-1916. | 2.5 | 69 |
| 1401 | Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2257-2263. | 0.9 | 9 |
| 1402 | Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 181-191. | 1.4 | 20 |
| 1403 | Detection of mitotic figures in thin melanomas  Immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin-eosin stain. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 637-644. | 0.6 | 16 |
| 1404 | Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 969-975. | 1.1 | 38 |
| 1405 | Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv264. | 3.0 | 43 |
| 1406 | Increasing time trends of thin melanomas in The Netherlands: What are the explanations of recent accelerations?. <i>European Journal of Cancer</i> , 2015, 51, 2833-2841. | 1.3 | 36 |
| 1408 | A 10-Year Follow-Up Study of Subjects Recruited in a Health Campaign for the Early Diagnosis of Cutaneous Melanoma: Suggestions for the Screening Timetable. <i>Dermatology</i> , 2015, 231, 345-352. | 0.9 | 7 |
| 1409 | Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression. <i>International Journal of Oncology</i> , 2015, 46, 1667-1676. | 1.4 | 53 |
| 1410 | Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation. <i>Dermatology</i> , 2015, 231, 378-384. | 0.9 | 45 |
| 1411 | Malignant melanoma in elderly patients: biological, surgical and medical issues. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 101-108. | 1.1 | 27 |
| 1412 | Circulating Biomarkers in Malignant Melanoma. <i>Advances in Clinical Chemistry</i> , 2015, 69, 47-89. | 1.8 | 34 |
| 1413 | Pathology of Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 229-237. | 0.6 | 10 |
| 1414 | Who and how to screen for cancer in at-risk inflammatory bowel disease patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 731-746. | 1.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1415 | Identification of Metastasis-Suppressive microRNAs in Primary Melanoma. Journal of the National Cancer Institute, 2015, 107, . | 3.0 | 47 |
| 1416 | Diagnostic Imaging in Dermatology: Utility of PET-CT in Cutaneous Melanoma. Actas Dermo-sifiliogrÁficas, 2015, 106, 29-34. | 0.2 | 2 |
| 1417 | Lymphangiogenesis: Implications for Diagnosis, Treatment, and Prognosis in Patients With Melanoma. Actas Dermo-sifiliogrÁficas, 2015, 106, 7-16. | 0.2 | 1 |
| 1418 | Commentary: Mitotic counts in thin melanomas. Journal of the American Academy of Dermatology, 2015, 72, 410-411. | 0.6 | 1 |
| 1419 | Assessment of tumor mitotic rate in primary cutaneous malignant melanomas 1 mm or less in thickness. Journal of the American Academy of Dermatology, 2015, 72, 405-409. | 0.6 | 4 |
| 1421 | Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Letters, 2015, 359, 20-35. | 3.2 | 67 |
| 1422 | Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research, 2015, 25, 208-224. | 5.7 | 143 |
| 1423 | Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Annals of Oncology, 2015, 26, 415-421. | 0.6 | 78 |
| 1424 | Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. Journal of Medical Genetics, 2015, 52, 231-239. | 1.5 | 17 |
| 1425 | EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. Cancer Discovery, 2015, 5, 274-287. | 7.7 | 107 |
| 1426 | Sentinel node in melanoma and breast cancer. Current considerations. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 30-44. | 0.1 | 3 |
| 1427 | Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 769-794. | 1.7 | 94 |
| 1428 | Infrared imaging of primary melanomas reveals hints of regional and distant metastases. Analyst, The, 2015, 140, 2144-2155. | 1.7 | 33 |
| 1429 | Molecular Basis for Treating Cutaneous Melanoma. , 2015, , 591-600.e3. | | 0 |
| 1430 | TRIB2 as a biomarker for diagnosis and progression of melanoma. Carcinogenesis, 2015, 36, 469-477. | 1.3 | 31 |
| 1431 | Determination of prognosis in metastatic melanoma through integration of clinicoâ€pathologic, mutation, mRNA, microRNA, and protein information. International Journal of Cancer, 2015, 136, 863-874. | 2.3 | 67 |
| 1432 | The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell and Melanoma Research, 2015, 28, 94-104. | 1.5 | 26 |
| 1433 | RSK1 Activation Promotes Invasion in Nodular Melanoma. American Journal of Pathology, 2015, 185, 704-716. | 1.9 | 26 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1434 | Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 2135-2142. | 0.7 | 126 |
| 1435 | Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. <i>Physical Biology</i> , 2015, 12, 016008. | 0.8 | 39 |
| 1436 | Prognosis associated with cutaneous melanoma metastases. <i>Australasian Journal of Dermatology</i> , 2015, 56, 25-28. | 0.4 | 8 |
| 1437 | Tumor thickness as a prognostic factor in extramammary Paget's disease. <i>Journal of Dermatology</i> , 2015, 42, 269-275. | 0.6 | 51 |
| 1438 | Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role?. <i>Annals of Surgical Oncology</i> , 2015, 22, 1967-1973. | 0.7 | 69 |
| 1439 | Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 482-488. | 0.7 | 36 |
| 1440 | Quality of Life After Isolated Limb Infusion for In-Transit Melanoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2015, 22, 1694-1700. | 0.7 | 24 |
| 1441 | Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?. <i>Annals of Surgical Oncology</i> , 2015, 22, 4052-4059. | 0.7 | 10 |
| 1442 | The Contemporary Role of Major Amputation in the Management of Advanced Limb Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 4067-4072. | 0.7 | 14 |
| 1443 | Behaviour of four different <sc>B</sc>16 murine melanoma cell sublines: C57<sc>BL</sc>/6J skin. <i>International Journal of Experimental Pathology</i> , 2015, 96, 73-80. | 0.6 | 21 |
| 1444 | Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. <i>British Journal of Dermatology</i> , 2015, 172, 239-243. | 1.4 | 43 |
| 1445 | Melanoma of the Vulva and Vagina: Principles of Staging and Their Relevance to Management Based on a Clinicopathologic Analysis of 85 Cases. <i>Annals of Surgical Oncology</i> , 2015, 22, 1959-1966. | 0.7 | 73 |
| 1446 | Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 773-781. | 0.8 | 501 |
| 1447 | Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed?. <i>Annals of Surgical Oncology</i> , 2015, 22, 2978-2987. | 0.7 | 28 |
| 1448 | Sex Differences in Melanoma Survival are Not Related to Mitotic Rate of the Primary Tumor. <i>Annals of Surgical Oncology</i> , 2015, 22, 1598-1603. | 0.7 | 20 |
| 1449 | Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696. | 13.5 | 2,562 |
| 1450 | Evolving Concepts: Immunity in Oncology from Targets to Treatments. <i>Journal of Oncology</i> , 2015, 2015, 1-15. | 0.6 | 23 |
| 1451 | SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma. <i>British Journal of Cancer</i> , 2015, 113, 91-98. | 2.9 | 26 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1452 | Primary Gastric Melanoma: Case Report of a Rare Malignancy. <i>Rare Tumors</i> , 2015, 7, 46-49. | 0.3 | 18 |
| 1453 | Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1049-1060. | 5.1 | 173 |
| 1454 | Malignant Melanoma With Osteoclast-Like Differentiation. <i>International Journal of Surgical Pathology</i> , 2015, 23, 478-482. | 0.4 | 10 |
| 1455 | ¹⁸ F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. <i>American Journal of Roentgenology</i> , 2015, 205, 259-270. | 1.0 | 57 |
| 1456 | Predictors of Sentinel Lymph Node Status in Cutaneous Melanoma: A Classification and Regression Tree Analysis. <i>Actas Dermo-sifiliogrÁficas</i> , 2015, 106, 208-218. | 0.2 | 5 |
| 1457 | Cost Analysis of Sentinel Lymph Node Biopsy in Melanoma. <i>Actas Dermo-sifiliogrÁficas</i> , 2015, 106, 201-207. | 0.2 | 1 |
| 1458 | Portable Gamma Camera Guidance in Sentinel Lymph Node Biopsy: Prospective Observational Study of Consecutive Cases. <i>Actas Dermo-sifiliogrÁficas</i> , 2015, 106, 408-414. | 0.2 | 1 |
| 1459 | Melanoma: Advances in Targeted Therapy and Molecular Markers. <i>Annals of Surgical Oncology</i> , 2015, 22, 3451-3458. | 0.7 | 15 |
| 1461 | The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. <i>EBioMedicine</i> , 2015, 2, 671-680. | 2.7 | 86 |
| 1462 | Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2086-2094. | 1.3 | 45 |
| 1463 | Pembrolizumab for the treatment of melanoma. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 515-527. | 1.3 | 2 |
| 1464 | Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 616-622. | 1.2 | 2 |
| 1465 | Activin A Is Anti-Lymphangiogenic in a Melanoma Mouse Model. <i>Journal of Investigative Dermatology</i> , 2015, 135, 212-221. | 0.3 | 23 |
| 1466 | ^{99m} Tc-DTPA-bis-c(RGDfK) a potential alpha(v)beta3 integrin based homobivalent radioligand for imaging neoangiogenesis in malignant glioma and melanoma. <i>RSC Advances</i> , 2015, 5, 60161-60171. | 1.7 | 4 |
| 1467 | More People Die from Thin Melanomas (≤1mm) than from Thick Melanomas (>4mm) in Queensland, Australia. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1190-1193. | 0.3 | 142 |
| 1468 | Photodynamic therapy of melanoma using new, synthetic porphyrins and phthalocyanines as photosensitisers - a comparative study. <i>Medicine and Pharmacy Reports</i> , 2015, 88, 175-180. | 0.2 | 14 |
| 1469 | Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. <i>Scientific Reports</i> , 2015, 5, 11198. | 1.6 | 150 |
| 1470 | A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. <i>Clinical Cancer Research</i> , 2015, 21, 4903-4912. | 3.2 | 73 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1471 | A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. <i>Annals of Oncology</i> , 2015, 26, 573-582. | 0.6 | 19 |
| 1472 | Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1193-1203. | 2.0 | 18 |
| 1473 | High-Resolution Microscopy-Coil MR Imaging of Skin Tumors: Techniques and Novel Clinical Applications. <i>Radiographics</i> , 2015, 35, 1077-1090. | 1.4 | 21 |
| 1474 | Metabolic reprogramming supports the invasive phenotype in malignant melanoma. <i>Cancer Letters</i> , 2015, 366, 71-83. | 3.2 | 70 |
| 1475 | Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 5222-5234. | 3.2 | 4 |
| 1476 | Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. <i>Immunotherapy</i> , 2015, 7, 611-619. | 1.0 | 141 |
| 1477 | Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2509-2515. | 0.8 | 59 |
| 1479 | Melanoma in situ. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 181-190. | 0.6 | 83 |
| 1480 | Antineoplastic effects of <i>Rhodiola crenulata</i> treatment on B16-F10 melanoma. <i>Tumor Biology</i> , 2015, 36, 9795-9805. | 0.8 | 11 |
| 1481 | Accuracy of Self-Reported Nevus and Pigmentation Phenotype Compared with Clinical Assessment in a Population-Based Study of Young Australian Adults. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 736-743. | 1.1 | 15 |
| 1482 | Topical therapies for skin cancer and actinic keratosis. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 77, 279-289. | 1.9 | 46 |
| 1483 | Metastatic Melanoma – A Review of Current and Future Treatment Options. <i>Acta Dermato-Venereologica</i> , 2015, 95, 516-524. | 0.6 | 186 |
| 1484 | Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 169-177. | 1.6 | 28 |
| 1485 | Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. <i>European Journal of Cancer</i> , 2015, 51, 1780-1793. | 1.3 | 24 |
| 1486 | Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 175-183. | 3.2 | 227 |
| 1487 | Magnetic guidance for cancer surgery. <i>British Journal of Surgery</i> , 2015, 102, e12-e14. | 0.1 | 5 |
| 1488 | Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. <i>Cancer</i> , 2015, 121, 1628-1636. | 2.0 | 43 |
| 1489 | Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. <i>Pharmacoeconomics</i> , 2015, 33, 893-904. | 1.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1490 | 443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. <i>European Journal of Cancer</i> , 2015, 51, 861-868. | 1.3 | 45 |
| 1491 | Prospective evaluation of follow-up in melanoma patients in Germany – Results of a multicentre and longitudinal study. <i>European Journal of Cancer</i> , 2015, 51, 653-667. | 1.3 | 46 |
| 1492 | Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma. <i>Biomaterials</i> , 2015, 56, 129-139. | 5.7 | 27 |
| 1493 | Enhancement of Customary Dermoscopy Education With Spaced Education e-Learning. <i>JAMA Dermatology</i> , 2015, 151, 847. | 2.0 | 29 |
| 1494 | Tecnica e indicazione del linfonodo sentinella nella chirurgia dei tumori cutanei. <i>EMC - Tecniche Chirurgiche - Chirurgia Plastica, Ricostruttiva Ed Estetica</i> , 2015, 13, 1-13. | 0.0 | 0 |
| 1495 | Factores predictivos del estado del ganglio centinela en el melanoma cutáneo: análisis mediante un árbol de clasificación y regresión. <i>Actas Dermo-sifilográficas</i> , 2015, 106, 208-218. | 0.2 | 15 |
| 1496 | Sentinel node biopsy in cutaneous melanoma: time for consensus to better inform patient choice. <i>British Journal of Dermatology</i> , 2015, 172, 552-554. | 1.4 | 14 |
| 1497 | The impact of nodal tumour burden on lymphoscintigraphic imaging in patients with melanomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 231-240. | 3.3 | 11 |
| 1498 | Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 381-388. | 2.0 | 70 |
| 1499 | Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 769-776. | 2.0 | 3 |
| 1500 | The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy. <i>Medical Oncology</i> , 2015, 32, 440. | 1.2 | 6 |
| 1501 | Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management. <i>British Journal of Dermatology</i> , 2015, 172, 571-573. | 1.4 | 21 |
| 1502 | Prognostic survival model for people diagnosed with invasive cutaneous melanoma. <i>BMC Cancer</i> , 2015, 15, 27. | 1.1 | 22 |
| 1503 | Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. <i>BMC Research Notes</i> , 2015, 8, 4. | 0.6 | 41 |
| 1504 | Deep Lymph Node Metastases in the Groin Significantly Affects Prognosis, Particularly in Sentinel Node-Positive Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2015, 22, 279-286. | 0.7 | 10 |
| 1505 | In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 475-481. | 0.7 | 131 |
| 1506 | Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease. <i>Annals of Surgical Oncology</i> , 2015, 22, 1950-1958. | 0.7 | 16 |
| 1508 | Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival. <i>Annals of Surgical Oncology</i> , 2015, 22, 4073-4080. | 0.7 | 28 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1509 | Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma. <i>Pathology Research and Practice</i> , 2015, 211, 521-527. | 1.0 | 9 |
| 1510 | Ganglion sentinelle et mÃ©lanome. <i>Medecine Nucleaire</i> , 2015, 39, 339-347. | 0.2 | 0 |
| 1511 | Long-Term Outcomes and Prognostic Factors of High-Risk Malignant Melanoma Patients after Surgery and Adjuvant High-Dose Interferon Treatment: A Single-Center Experience. <i>Chemotherapy</i> , 2015, 60, 228-238. | 0.8 | 7 |
| 1512 | Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 780-785.e3. | 0.6 | 148 |
| 1513 | Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: Tissue processing methodology to optimize pathologic staging and margin assessment. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 840-850. | 0.6 | 122 |
| 1514 | Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. <i>Cancer</i> , 2015, 121, 51-59. | 2.0 | 92 |
| 1515 | Cutaneous Malignancy of the Head and Neck. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 593-613. | 0.6 | 17 |
| 1516 | Regional Therapies for In-transit Disease. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 309-322. | 0.6 | 9 |
| 1517 | Metastasectomy for Stage IV Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 279-298. | 0.6 | 23 |
| 1518 | Sentinel Lymph Node Mapping in Melanoma in the Twenty-first Century. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 249-260. | 0.6 | 23 |
| 1519 | Current Staging and Prognostic Factors in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 215-227. | 0.6 | 51 |
| 1520 | New KRAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e52-e56. | 0.8 | 28 |
| 1521 | Vulvar cancer: a review for dermatologists. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 164-177. | 0.5 | 24 |
| 1522 | CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. <i>Cancer Research</i> , 2015, 75, 1897-1907. | 0.4 | 22 |
| 1523 | Combination therapy of melanoma using kinase inhibitors. <i>Current Opinion in Oncology</i> , 2015, 27, 134-140. | 1.1 | 18 |
| 1524 | Surgical management of metastatic melanoma in the era of targeted systemic therapies. <i>Melanoma Research</i> , 2015, 25, 1-8. | 0.6 | 5 |
| 1525 | Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1889-1894. | 0.8 | 1,809 |
| 1526 | Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq1 1 0,784314 rgBT /Overl... | 5.1 | 1,093 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1527 | Absolute quantitative PCR for detection of molecular biomarkers in melanoma patients: A preliminary report. <i>Clinica Chimica Acta</i> , 2015, 444, 242-249. | 0.5 | 7 |
| 1528 | Vemurafenib beyond progression in a patient with metastatic melanoma. <i>Anti-Cancer Drugs</i> , 2015, 26, 464-468. | 0.7 | 2 |
| 1529 | Awareness, Attitude, and Adherence to Preventive Measures in Patients at High Risk of Melanoma. A Cross-Sectional Study on 185 Patients. <i>Journal of Cancer Education</i> , 2015, 30, 552-566. | 0.6 | 11 |
| 1530 | BRAF V600 mutations and pathological features in Japanese melanoma patients. <i>Melanoma Research</i> , 2015, 25, 9-14. | 0.6 | 43 |
| 1531 | Pathologic Evaluation of Sentinel Nodes. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 33-38. | 1.0 | 4 |
| 1532 | Who Benefits Most From Adjuvant Interferon Treatment for Melanoma?. <i>American Journal of Therapeutics</i> , 2015, 22, 54-60. | 0.5 | 17 |
| 1533 | Rho Kinase Inhibitors Block Melanoma Cell Migration and Inhibit Metastasis. <i>Cancer Research</i> , 2015, 75, 2272-2284. | 0.4 | 114 |
| 1534 | MMP16 Mediates a Proteolytic Switch to Promote Cell-Cell Adhesion, Collagen Alignment, and Lymphatic Invasion in Melanoma. <i>Cancer Research</i> , 2015, 75, 2083-2094. | 0.4 | 61 |
| 1535 | Systemic oxidative profile after tumor removal and the tumor microenvironment in melanoma patients. <i>Cancer Letters</i> , 2015, 361, 226-232. | 3.2 | 24 |
| 1536 | Population-based method for investigating adherence to international recommendations for pathology reporting of primary cutaneous melanoma: Results of a EURO CARE-5 high resolution study. <i>Cancer Epidemiology</i> , 2015, 39, 424-429. | 0.8 | 5 |
| 1537 | Case Reports of Fatal or Metastasizing Melanoma in Children and Adolescents: A Systematic Analysis of the Literature. <i>Pediatric Dermatology</i> , 2015, 32, 13-22. | 0.5 | 55 |
| 1538 | Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma. <i>Biomarkers in Medicine</i> , 2015, 9, 13-23. | 0.6 | 14 |
| 1539 | Acral Lentiginous Melanoma of the Foot Misdiagnosed as a Traumatic Ulcer. <i>Journal of the American Podiatric Medical Association</i> , 2015, 105, 189-194. | 0.2 | 9 |
| 1541 | HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growth. <i>Cell Death and Differentiation</i> , 2015, 22, 2006-2019. | 5.0 | 39 |
| 1542 | Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. <i>Modern Pathology</i> , 2015, 28, 1535-1544. | 2.9 | 76 |
| 1543 | Gender Disparity and Mutation Burden in Metastatic Melanoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv221. | 3.0 | 114 |
| 1544 | Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. <i>Oncologist</i> , 2015, 20, 648-652. | 1.9 | 38 |
| 1545 | Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates. <i>Bioinformatics</i> , 2016, 32, 50-57. | 1.8 | 26 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1546 | Dabrafenib for the treatment of melanoma. Expert Opinion on Orphan Drugs, 2015, 3, 1075-1084. | 0.5 | 0 |
| 1547 | <i>In vivo</i> profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. OncoImmunology, 2015, 4, e988458. | 2.1 | 12 |
| 1548 | Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Annals of Oncology, 2015, 26, 2173-2179. | 0.6 | 74 |
| 1549 | Pump-probe imaging of pigmented cutaneous melanoma primary lesions gives insight into metastatic potential. Biomedical Optics Express, 2015, 6, 3631. | 1.5 | 27 |
| 1550 | Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma—challenges in management. International Journal of Colorectal Disease, 2015, 30, 1595-1602. | 1.0 | 5 |
| 1551 | Brain metastasis from melanoma; the prognostic value of varying sites of extracranial disease. Journal of Neuro-Oncology, 2015, 125, 411-418. | 1.4 | 14 |
| 1552 | Drug compound characterization by mass spectrometry imaging in cancer tissue. Archives of Pharmacal Research, 2015, 38, 1718-1727. | 2.7 | 22 |
| 1553 | Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study. British Journal of Dermatology, 2015, 172, 175-186. | 1.4 | 42 |
| 1554 | CD271 is expressed in melanomas with more aggressive behaviour, with correlation of characteristic morphology by <i>in vivo</i> reflectance confocal microscopy. British Journal of Dermatology, 2015, 172, 662-668. | 1.4 | 15 |
| 1555 | Thinner melanomas and improved survival among men in Sweden from 1997 to 2011. British Journal of Dermatology, 2015, 172, 559-560. | 1.4 | 0 |
| 1556 | Association between autoimmune disease and cutaneous melanoma with regard to melanoma prognosis. Clinical and Experimental Dermatology, 2015, 40, 254-259. | 0.6 | 6 |
| 1557 | Role of obesity on the thickness of primary cutaneous melanoma. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 262-269. | 1.3 | 38 |
| 1558 | Feasibility and diagnostic accuracy of teledermatology in <i>Swiss</i> primary care: process analysis of a randomized controlled trial. Journal of Evaluation in Clinical Practice, 2015, 21, 326-331. | 0.9 | 23 |
| 1559 | Primary melanoma of the prostate: case report and review of the literature. BMC Urology, 2015, 15, 68. | 0.6 | 14 |
| 1560 | Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. Journal of Translational Medicine, 2015, 13, 139. | 1.8 | 36 |
| 1561 | Survival outcomes in patients with multiple primary melanomas. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2120-2127. | 1.3 | 21 |
| 1562 | The Melanoma care study: protocol of a randomised controlled trial of a psycho-educational intervention for melanoma survivors at high risk of developing new primary disease. BMC Psychology, 2015, 3, 23. | 0.9 | 14 |
| 1563 | Long term survival with the combination of interferon and chemotherapy in metastatic melanoma. Journal of the Egyptian National Cancer Institute, 2015, 27, 161-163. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1565 | Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. <i>Oncolmmunology</i> , 2015, 4, e1032492. | 2.1 | 53 |
| 1566 | Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases: Can the Extent of Surgery be Safely Minimized?. <i>Annals of Surgical Oncology</i> , 2015, 22, 1172-1180. | 0.7 | 14 |
| 1568 | Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. <i>Immunotherapy</i> , 2015, 7, 981-997. | 1.0 | 5 |
| 1569 | 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 645-654. | 0.6 | 42 |
| 1570 | Use of optical skin phantoms for preclinical evaluation of laser efficiency for skin lesion therapy. <i>Journal of Biomedical Optics</i> , 2015, 20, 085003. | 1.4 | 25 |
| 1571 | Gauging the Long-Term Benefits of Ipilimumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1865-1866. | 0.8 | 41 |
| 1572 | Association of Histologic Regression in Primary Melanoma With Sentinel Lymph Node Status. <i>JAMA Dermatology</i> , 2015, 151, 1301. | 2.0 | 61 |
| 1573 | EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1750-1766. | 3.3 | 110 |
| 1574 | Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 187-194. | 0.7 | 20 |
| 1575 | Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis. <i>American Journal of Roentgenology</i> , 2015, 205, W283-W293. | 1.0 | 51 |
| 1576 | A Novel Fully Humanized 3D Skin Equivalent to Model Early Melanoma Invasion. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2665-2673. | 1.9 | 72 |
| 1577 | Survival advantage of women in localized melanoma mainly relies on clinical-pathological differences by sex. A retrospective study of 1,607 patients in Valencia, Spain. <i>European Journal of Dermatology</i> , 2015, 25, 247-254. | 0.3 | 6 |
| 1578 | Melanoma survival is superior in females across all tumour stages but is influenced by age. <i>Archives of Dermatological Research</i> , 2015, 307, 731-740. | 1.1 | 33 |
| 1580 | TGF- β 2-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination. <i>Current Biology</i> , 2015, 25, 2899-2914. | 1.8 | 106 |
| 1581 | Evaluaci3n del coste econ3mico de la t3cnica de la biopsia selectiva del ganglio centinela en melanoma. <i>Actas Dermo-sifilogr3ficas</i> , 2015, 106, 201-207. | 0.2 | 12 |
| 1582 | Biopsia selectiva del ganglio centinela radioguiada mediante gammac3mara port3til. Estudio observacional sobre serie de casos incluidos prospectivamente de forma consecutiva. <i>Actas Dermo-sifilogr3ficas</i> , 2015, 106, 408-414. | 0.2 | 9 |
| 1584 | Cutaneous malignant melanoma in the Swedish organ transplantation cohort: A study of clinicopathological characteristics and mortality. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 106-113.e2. | 0.6 | 28 |
| 1585 | The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma. <i>International Immunopharmacology</i> , 2015, 28, 313-321. | 1.7 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1586 | EGFR activated cell mobility – A link to melanoma ulceration. <i>Medical Hypotheses</i> , 2015, 85, 498-499. | 0.8 | 3 |
| 1587 | Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy. <i>Surgical Oncology</i> , 2015, 24, 353-358. | 0.8 | 37 |
| 1588 | MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 254-266. | 1.5 | 59 |
| 1589 | BRAF Targets in Melanoma. <i>Cancer Drug Discovery and Development</i> , 2015, , . | 0.2 | 2 |
| 1590 | A review of sentinel lymph node biopsy for thin melanoma. <i>Irish Journal of Medical Science</i> , 2015, 184, 119-123. | 0.8 | 11 |
| 1591 | Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada. <i>Pharmacoeconomics</i> , 2015, 33, 367-380. | 1.7 | 19 |
| 1592 | Is sentinel lymph node biopsy the standard of care for cutaneous head and neck melanoma?. <i>Laryngoscope</i> , 2015, 125, 153-160. | 1.1 | 14 |
| 1594 | Vulvar Pathology. , 2015, , . | | 11 |
| 1595 | Metastatic melanomas of unknown primary show better prognosis than those of known primary: A systematic review and meta-analysis of observational studies. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 59-70. | 0.6 | 87 |
| 1596 | Acral lentiginous melanoma: Who benefits from sentinel lymph node biopsy?. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 71-77. | 0.6 | 55 |
| 1597 | Outcome of patients with de novo versus nevus-associated melanoma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 54-58. | 0.6 | 71 |
| 1598 | Benefit of adjuvant interferon alfa-2b (IFN- β) therapy in melanoma patients with high serum MMP-8 levels. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 173-180. | 2.0 | 9 |
| 1599 | Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. <i>British Journal of Dermatology</i> , 2015, 172, 33-47. | 1.4 | 115 |
| 1600 | Dermoscopy structures as predictors of sentinel lymph node positivity in cutaneous melanoma. <i>British Journal of Dermatology</i> , 2015, 172, 1269-1277. | 1.4 | 18 |
| 1602 | Diagnóstico por imagen en dermatología: utilidad de la tomografía por emisión de positrones-tomografía computarizada en el melanoma cutáneo. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 29-34. | 0.2 | 4 |
| 1603 | Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia. <i>International Journal of Cancer</i> , 2015, 136, 603-609. | 2.3 | 62 |
| 1604 | Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 415-421. | 0.8 | 10 |
| 1605 | La linfangiogenesis. Sus implicaciones en el diagnóstico, tratamiento y pronóstico del melanoma. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 7-16. | 0.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1608 | Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 82-93. | 1.5 | 50 |
| 1609 | Lymphatic and blood vasculature in primary cutaneous melanomas of the scalp and neck. <i>Head and Neck</i> , 2015, 37, 1596-1602. | 0.9 | 12 |
| 1610 | Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. <i>Oncogene</i> , 2015, 34, 2951-2957. | 2.6 | 99 |
| 1611 | Genetic Variants in Fanconi Anemia Pathway Genes BRCA2 and FANCA Predict Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2015, 135, 542-550. | 0.3 | 28 |
| 1612 | Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. <i>American Surgeon</i> , 2016, 82, 1009-1013. | 0.4 | 25 |
| 1613 | Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216426. | 0.2 | 20 |
| 1614 | 6. Malignes Melanom der Vulva. , 2016, , . | | 0 |
| 1615 | Addison's disease as a presentation of metastatic malignant melanoma. <i>Annals of the Royal College of Surgeons of England</i> , 2016, 98, e11-e12. | 0.3 | 4 |
| 1617 | Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma. <i>Biologics: Targets and Therapy</i> , 2016, Volume 10, 89-98. | 3.0 | 1 |
| 1618 | ROR α and ROR β expression inversely correlates with human melanoma progression. <i>Oncotarget</i> , 2016, 7, 63261-63282. | 0.8 | 55 |
| 1619 | Epidemiological and clinical characteristics of malignant melanoma in Southeast Anatolia in Turkey. <i>Pan African Medical Journal</i> , 2016, 24, 22. | 0.3 | 5 |
| 1620 | Prognostic significance of the expression of nuclear eukaryotic translation initiation factor 5A2 in human melanoma. <i>Oncology Letters</i> , 2016, 12, 3089-3100. | 0.8 | 7 |
| 1621 | Malignant melanoma: diagnosis, treatment and cancer stem cells. <i>Neoplasma</i> , 2016, 63, 510-517. | 0.7 | 57 |
| 1622 | Current trends in the treatment of malignant melanoma. <i>Neoplasma</i> , 2016, 63, 333-341. | 0.7 | 11 |
| 1623 | Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma. <i>Acta Dermato-Venereologica</i> , 2016, 96, 29-34. | 0.6 | 39 |
| 1624 | The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. <i>Journal of Immunology Research</i> , 2016, 2016, 1-11. | 0.9 | 20 |
| 1625 | Pneumonitis with Nonspecific Interstitial Pneumonia Pattern Caused by Nivolumab in a Patient with Metastatic Melanoma. , 2016, 06, . | | 0 |
| 1626 | Optimal Selection of Targeted Therapies for Melanoma Patients. , 2016, , 169-183. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1627 | Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e505-e514. | 1.8 | 10 |
| 1628 | MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 4760-4769. | 0.8 | 56 |
| 1629 | Melanoma Disparities among US Hispanics: Use of the Social Ecological Model to Contextualize Reasons for Inequitable Outcomes and Frame a Research Agenda. <i>Journal of Skin Cancer</i> , 2016, 2016, 1-9. | 0.5 | 13 |
| 1630 | Targeted Nanoparticles for Drug Delivery to Melanoma. , 2016, , 203-215. | | 3 |
| 1632 | Polarization Speckles and Skin Applications. , 2016, , 77-87. | | 1 |
| 1633 | Brazilian guidelines for diagnosis, treatment and follow-up of primary cutaneous melanoma - Part II. <i>Anais Brasileiros De Dermatologia</i> , 2016, 91, 49-58. | 0.5 | 13 |
| 1634 | Cutaneous Melanoma in Asians. <i>Chonnam Medical Journal</i> , 2016, 52, 185. | 0.5 | 36 |
| 1635 | InÂVivo Reflectance Confocal Microscopy in Dermatology. , 2016, , 169-186. | | 0 |
| 1636 | Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development Strategy. <i>Frontiers in Nutrition</i> , 2016, 3, 48. | 1.6 | 41 |
| 1637 | Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2016, 6, 236. | 1.3 | 55 |
| 1638 | Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma. <i>Cancers</i> , 2016, 8, 110. | 1.7 | 43 |
| 1639 | microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. <i>Genes</i> , 2016, 7, 124. | 1.0 | 8 |
| 1640 | Melanoma to the Heart. <i>Baylor University Medical Center Proceedings</i> , 2016, 29, 428-429. | 0.2 | 2 |
| 1641 | Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma. <i>PLoS ONE</i> , 2016, 11, e0147431. | 1.1 | 12 |
| 1642 | Skewed Differentiation of Circulating $\sqrt{1}^{39}\sqrt{1}^{2}$ T Lymphocytes in Melanoma and Impact on Clinical Outcome. <i>PLoS ONE</i> , 2016, 11, e0149570. | 1.1 | 18 |
| 1643 | Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations. <i>PLoS ONE</i> , 2016, 11, e0156115. | 1.1 | 13 |
| 1644 | Use of a Tissue Engineered Human Skin Model to Investigate the Effects of Wounding and of an Anti-Inflammatory on Melanoma Cell Invasion. <i>PLoS ONE</i> , 2016, 11, e0156931. | 1.1 | 11 |
| 1645 | Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. <i>Molecular and Clinical Oncology</i> , 2016, 5, 458-462. | 0.4 | 23 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1646 | Cutaneous melanoma " guidelines for diagnostics and therapy in 2016. Przegląd Dermatologiczny, 2016, 1, 1-18. | 0.0 | 0 |
| 1647 | The Danish Melanoma Database. Clinical Epidemiology, 2016, Volume 8, 543-548. | 1.5 | 17 |
| 1648 | The Role of the Receptor for Advanced Glycation End Products in Malignant Melanoma. , 2016, , 119-132. | | 0 |
| 1650 | SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma. Oncotarget, 2016, 7, 10117-10132. | 0.8 | 12 |
| 1651 | Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. , 2016, , 267-297. | | 11 |
| 1652 | Long-term Survival of Patients With Invasive Ultra-thin Cutaneous Melanoma. Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock 10 | 0.4 | 10 |
| 1653 | BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma. Advances in Anatomic Pathology, 2016, 23, 244-271. | 2.4 | 19 |
| 1654 | Localization of the Sentinel Lymph Node in Melanoma Without Blue Dye. Annals of Surgery, 2016, 263, 588-592. | 2.1 | 10 |
| 1655 | An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. British Journal of Dermatology, 2016, 175, 966-978. | 1.4 | 8 |
| 1656 | Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. Journal of Immunotherapy, 2016, 39, 241-248. | 1.2 | 26 |
| 1657 | Metastatic area ratio can help predict nonsentinel node positivity in melanoma patients. Melanoma Research, 2016, 26, 42-45. | 0.6 | 6 |
| 1658 | Decreased expression of class III β -tubulin is associated with unfavourable prognosis in patients with malignant melanoma. Melanoma Research, 2016, 26, 29-34. | 0.6 | 17 |
| 1659 | BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma. Melanoma Research, 2016, 26, 83-87. | 0.6 | 21 |
| 1660 | Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Research, 2016, 26, 367-376. | 0.6 | 22 |
| 1661 | Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. Melanoma Research, 2016, 26, 354-360. | 0.6 | 13 |
| 1662 | Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma. American Journal of Dermatopathology, 2016, 38, 338-346. | 0.3 | 24 |
| 1663 | Digit-Sparing Mohs Surgery for Melanoma. Dermatologic Surgery, 2016, 42, 83-93. | 0.4 | 27 |
| 1664 | Risk Factors Predicting Positive Margins at Primary Wide Local Excision of Cutaneous Melanoma. Dermatologic Surgery, 2016, 42, 646-652. | 0.4 | 32 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1665 | Proportions of blood-borne VÎ1+ and VÎ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2016, 64, 116-126. | 1.3 | 54 |
| 1666 | Pembrolizumab (Keytruda). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2777-2789. | 1.4 | 237 |
| 1667 | Mohs Micrographic Surgery Using MART-1 Immunostain in the Treatment of Invasive Melanoma and Melanoma In Situ. <i>Dermatologic Surgery</i> , 2016, 42, 733-744. | 0.4 | 84 |
| 1668 | The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients â€“ An EORTC Melanoma Group study. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1906-1913. | 0.5 | 25 |
| 1669 | Recognizing melanoma. <i>Nurse Practitioner</i> , 2016, 41, 24-29. | 0.2 | 0 |
| 1670 | Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival. <i>International Journal of Cancer</i> , 2016, 139, 1297-1302. | 2.3 | 14 |
| 1671 | Vitronectin and dermcidin serum levels predict the metastatic progression of <sc>AJCC lâ€“II</sc> earlyâ€“stage melanoma. <i>International Journal of Cancer</i> , 2016, 139, 1598-1607. | 2.3 | 32 |
| 1672 | Prognostic significance of hematological profiles in melanoma patients. <i>International Journal of Cancer</i> , 2016, 139, 1618-1625. | 2.3 | 40 |
| 1673 | Review of the role of sentinel node biopsy in cutaneous head and neck melanoma. <i>ANZ Journal of Surgery</i> , 2016, 86, 348-355. | 0.3 | 9 |
| 1674 | The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma. <i>British Journal of Dermatology</i> , 2016, 175, 1210-1220. | 1.4 | 32 |
| 1675 | Intratatumoral multinucleated giant cells are not a prognostic pathologic feature in cutaneous melanoma. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 821-829. | 0.7 | 4 |
| 1676 | Learning from mistakes: errors in approaches to melanoma and the urgent need for updated national guidelines. <i>International Journal of Dermatology</i> , 2016, 55, 970-976. | 0.5 | 7 |
| 1677 | A metaâ€“analysis of reflectance confocal microscopy for the diagnosis of malignant skin tumours. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1295-1302. | 1.3 | 55 |
| 1678 | TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma. <i>Oncology Letters</i> , 2016, 12, 275-280. | 0.8 | 6 |
| 1679 | Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2016, 8, 535-553. | 3.3 | 49 |
| 1680 | Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas. <i>Melanoma Research</i> , 2016, 26, 524-527. | 0.6 | 7 |
| 1681 | Genetic variants in the vitamin <sc>D</sc> pathway genes <i><sc>VDBP</sc></i> and <i><sc>RXRA</sc></i> modulate cutaneous melanoma diseaseâ€“specific survival. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 176-185. | 1.5 | 19 |
| 1682 | New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 419-426. | 1.1 | 30 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1683 | Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline â€œ Update 2016. <i>European Journal of Cancer</i> , 2016, 63, 201-217. | 1.3 | 330 |
| 1684 | Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known<i>BRAF</i> mutation status. <i>British Journal of Dermatology</i> , 2016, 174, 823-830. | 1.4 | 26 |
| 1685 | Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with<i>BRAF</i>-mutant melanoma. <i>British Journal of Dermatology</i> , 2016, 174, 716-717. | 1.4 | 2 |
| 1686 | Eignung und Probleme von Serum S100B als Biomarker zur Verlaufskontrolle bei Hochrisikoâ€™Melanompatienten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 158-165. | 0.4 | 0 |
| 1687 | Clinical significance of <scp>BRAF</scp> mutation status in circulating tumor <scp>DNA</scp> of metastatic melanoma patients at baseline. <i>Experimental Dermatology</i> , 2016, 25, 783-788. | 1.4 | 34 |
| 1688 | The proportion cured of patients diagnosed with Stage IIIâ€™IV cutaneous malignant melanoma in <scp>S</scp>weden 1990â€™2007: A populationâ€™based study. <i>International Journal of Cancer</i> , 2016, 138, 2829-2836. | 2.3 | 8 |
| 1689 | Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience. <i>British Journal of Dermatology</i> , 2016, 174, 1141-1142. | 1.4 | 9 |
| 1690 | End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study. <i>British Journal of Dermatology</i> , 2016, 175, 583-592. | 1.4 | 19 |
| 1691 | EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma. <i>Experimental Dermatology</i> , 2016, 25, 618-622. | 1.4 | 13 |
| 1692 | Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. <i>Stem Cells</i> , 2016, 34, 832-846. | 1.4 | 27 |
| 1694 | Molecular markers to complement sentinel node status in predicting survival in patients with high-risk locally invasive melanoma. <i>International Journal of Cancer</i> , 2016, 139, 664-672. | 2.3 | 7 |
| 1695 | Intralesional PVâ€™10 for inâ€™transit melanomaâ€™A singleâ€™center experience. <i>Journal of Surgical Oncology</i> , 2016, 114, 380-384. | 0.8 | 19 |
| 1696 | Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells. <i>Stem Cells</i> , 2016, 34, 2449-2460. | 1.4 | 21 |
| 1697 | Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma. <i>Melanoma Research</i> , 2016, 26, 254-260. | 0.6 | 24 |
| 1698 | Superficial spreading melanoma: an analysis of 97â€™%702 cases using the SEER database. <i>Melanoma Research</i> , 2016, 26, 395-400. | 0.6 | 18 |
| 1699 | Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 355-357. | 1.2 | 9 |
| 1700 | Excision margins and sentinel lymph node status as prognostic factors in thick melanoma of the head and neck: A retrospective analysis. <i>Head and Neck</i> , 2016, 38, 1373-1379. | 0.9 | 10 |
| 1701 | Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden. <i>International Journal of Cancer</i> , 2016, 139, 543-553. | 2.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1702 | Reply: Increased mortality for pregnancy-associated melanoma: systematic review and meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1618-1619. | 1.3 | 4 |
| 1703 | Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in Northern Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1491-1496. | 1.3 | 20 |
| 1704 | The role of Orai-stim calcium channels in melanocytes and melanoma. <i>Journal of Physiology</i> , 2016, 594, 2825-2835. | 1.3 | 29 |
| 1705 | Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 450-473. | 2.3 | 203 |
| 1706 | Molecular Profiling in Cutaneous Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 475-480. | 2.3 | 3 |
| 1707 | miR-194 is a negative regulator of GEF-H1 pathway in melanoma. <i>Oncology Reports</i> , 2016, 36, 2412-2420. | 1.2 | 19 |
| 1708 | Intramammary metastatic melanoma of unknown primary origin in a 58-year old patient: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 363. | 0.4 | 2 |
| 1709 | Protocol for a within-trial economic evaluation of a psychoeducational intervention tailored to people at high risk of developing a second or subsequent melanoma. <i>BMJ Open</i> , 2016, 6, e012153. | 0.8 | 6 |
| 1710 | Characterization of sentinel lymph nodes using dual-targeted microbubbles. , 2016, , . | | 0 |
| 1711 | Making decisions on resectability and injectability status of lesions in the management of advanced melanoma in Germany, France and the UK. <i>European Journal of Dermatology</i> , 2016, 26, 477-486. | 0.3 | 1 |
| 1712 | Generation of metastatic melanoma specific antibodies by affinity purification. <i>Scientific Reports</i> , 2016, 6, 37253. | 1.6 | 3 |
| 1713 | Dendritic cell vaccines for melanoma: past, present and future. <i>Melanoma Management</i> , 2016, 3, 273-289. | 0.1 | 20 |
| 1714 | Vaccine therapy + dasatinib for the treatment of patients with stage IIIb-IV melanoma. <i>Melanoma Management</i> , 2016, 3, 251-254. | 0.1 | 4 |
| 1715 | Chirurgische Behandlung von Melanomen in der Schwangerschaft: eine praktische Anleitung. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 585-594. | 0.4 | 0 |
| 1716 | Sentinel Lymph Node Biopsy in Cutaneous Melanoma. <i>Clinical Nuclear Medicine</i> , 2016, 41, e498-e507. | 0.7 | 34 |
| 1717 | Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib) Tj ETQq1 1 0,784314 6gBT /Over 0,1 | | |
| 1718 | A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence. <i>European Journal of Dermatology</i> , 2016, 26, 586-591. | 0.3 | 4 |
| 1719 | Value of sentinel lymph node biopsy and adjuvant interferon treatment in thick (>4 mm) cutaneous melanoma: an observational study. <i>European Journal of Dermatology</i> , 2016, 26, 34-48. | 0.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1720 | Unknown Primary Melanoma: Worldwide Survey on Clinical Management. <i>Dermatology</i> , 2016, 232, 704-707. | 0.9 | 20 |
| 1722 | Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1858-1865. | 0.3 | 27 |
| 1723 | Neoadjuvant treatment for melanoma: current challenges and future perspectives. <i>Melanoma Management</i> , 2016, 3, 149-159. | 0.1 | 1 |
| 1724 | The role of radiation therapy in the management of cutaneous melanoma. <i>Melanoma Management</i> , 2016, 3, 61-72. | 0.1 | 2 |
| 1725 | Response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation", <i>Cancer Treatment Reviews</i> . <i>Cancer Treatment Reviews</i> , 2016, 45, 76. | 3.4 | 5 |
| 1726 | Role of SPECT-CT in sentinel lymph node biopsy in patients diagnosed with head and neck melanoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 22-28. | 0.1 | 3 |
| 1727 | Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. <i>Genomics</i> , 2016, 107, 223-230. | 1.3 | 57 |
| 1728 | What Is New in Melanoma Genetics and Treatment?. <i>Dermatology</i> , 2016, 232, 259-264. | 0.9 | 25 |
| 1729 | The effect of time to sentinel lymph node biopsy on cutaneous melanoma survival. <i>American Journal of Surgery</i> , 2016, 212, 935-940. | 0.9 | 15 |
| 1731 | Clinical Significance of Circulating CD33+CD11b+HLA-DR ⁺ Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 5661-5672. | 3.2 | 170 |
| 1732 | Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries. <i>Journal of Medical Economics</i> , 2016, 19, 587-595. | 1.0 | 2 |
| 1733 | Radioguided Sentinel Lymph Node Mapping and Biopsy in Cutaneous Melanoma. , 2016, , 151-163. | | 1 |
| 1734 | Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496. | 3.2 | 480 |
| 1735 | Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. <i>Current Medical Research and Opinion</i> , 2016, 32, 1599-1604. | 0.9 | 55 |
| 1736 | The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 705-715. | 1.1 | 8 |
| 1737 | Pembrolizumab for the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 867-873. | 0.5 | 10 |
| 1738 | The Diagnostic Value of PET/CT Imaging in Melanoma Groin Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 2323-2329. | 0.7 | 5 |
| 1739 | Evaluation of toxicity on epithelial and tumor cells of biaryl dipeptide tyrosines. <i>European Journal of Medicinal Chemistry</i> , 2016, 114, 1-7. | 2.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1740 | Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data. <i>Journal of Biomedical Informatics</i> , 2016, 60, 104-113. | 2.5 | 20 |
| 1741 | Melanoma of the Foot. <i>Clinics in Podiatric Medicine and Surgery</i> , 2016, 33, 409-422. | 0.2 | 12 |
| 1742 | Advances in immunotherapy for melanoma. <i>BMC Medicine</i> , 2016, 14, 20. | 2.3 | 111 |
| 1743 | Managing Melanoma During Pregnancy. , 2016, , 123-134. | | 0 |
| 1744 | Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. <i>Oncology Letters</i> , 2016, 11, 3354-3360. | 0.8 | 67 |
| 1745 | Critical Assessment of Clinical Prognostic Tools in Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2753-2761. | 0.7 | 44 |
| 1746 | Pembrolizumab in a <i>BRAF</i> -mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab. <i>Immunotherapy</i> , 2016, 8, 687-692. | 1.0 | 7 |
| 1747 | Worse outcome for patients with recurrent melanoma after negative sentinel lymph biopsy as compared to sentinel-positive patients. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1420-1426. | 0.5 | 8 |
| 1748 | Melanoma and Other Skin Cancers. , 2016, , 395-411. | | 0 |
| 1749 | Treatment patterns of advanced malignant melanoma (stage III-IV) – A review of current standards in Europe. <i>European Journal of Cancer</i> , 2016, 60, 179-189. | 1.3 | 47 |
| 1750 | The Prognosis of Nail Apparatus Melanoma: 20 Years of Experience from a Single Institute. <i>Dermatology</i> , 2016, 232, 177-184. | 0.9 | 33 |
| 1751 | Time and tumor type (primary or metastatic) do not influence the detection of <i>BRAF</i> / <i>NRAS</i> mutations in formalin fixed paraffin embedded samples from melanomas. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1733-1738. | 1.4 | 2 |
| 1752 | Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register. <i>European Journal of Cancer</i> , 2016, 59, 171-178. | 1.3 | 12 |
| 1753 | From melanocytes to melanomas. <i>Nature Reviews Cancer</i> , 2016, 16, 345-358. | 12.8 | 596 |
| 1754 | Biomarkers associated with checkpoint inhibitors. <i>Annals of Oncology</i> , 2016, 27, 1199-1206. | 0.6 | 142 |
| 1755 | Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management. <i>Annals of Surgical Oncology</i> , 2016, 23, 2658-2663. | 0.7 | 17 |
| 1756 | The integration of radiation therapy and immunotherapy in melanoma management. <i>Journal of Radiation Oncology</i> , 2016, 5, 131-142. | 0.7 | 2 |
| 1757 | Zebrafish Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2016, 916, 439-450. | 0.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1758 | Lymphatics, Cancer and Zebrafish. <i>Advances in Experimental Medicine and Biology</i> , 2016, 916, 199-218. | 0.8 | 8 |
| 1759 | T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. <i>Cancer Research</i> , 2016, 76, 3496-3506. | 0.4 | 33 |
| 1760 | Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 1321-1326. | 2.5 | 5 |
| 1761 | Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades. <i>Oncolmmunology</i> , 2016, 5, e1219826. | 2.1 | 9 |
| 1762 | Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. , 2016, 4, 38. | | 22 |
| 1763 | Genetic variants in the PIWIâ€piRNA pathway gene <i><i>DCP1A</i></i> predict melanoma diseaseâ€specific survival. <i>International Journal of Cancer</i> , 2016, 139, 2730-2737. | 2.3 | 21 |
| 1764 | Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-III B cutaneous melanoma. <i>Acta OncolÃ³gica</i> , 2016, 55, 1355-1359. | 0.8 | 29 |
| 1765 | Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 910-915. | 0.4 | 12 |
| 1766 | Mandibular metastasis of cutaneous melanoma. <i>Journal of Oral Biology and Craniofacial Research</i> , 2016, 6, 250-252. | 0.8 | 3 |
| 1767 | Isolated asymptomatic masseter muscle metastasis as first sign of metastatic disease in a patient with known melanoma. <i>JPRAS Open</i> , 2016, 10, 1-4. | 0.4 | 1 |
| 1768 | Clinicopathological features and pituitary homeobox 1 gene expression in the progression and prognosis of cutaneous malignant melanoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 494-500. | 0.8 | 7 |
| 1769 | Contemporary use of sentinel lymph node biopsy in the head and neck. <i>World Journal of Otorhinolaryngology - Head and Neck Surgery</i> , 2016, 2, 117-125. | 0.7 | 20 |
| 1772 | A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis. <i>Cell Reports</i> , 2016, 15, 1884-1892. | 2.9 | 21 |
| 1773 | Acral melanoma mimicking subungual hematoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e181-e183. | 0.6 | 7 |
| 1774 | PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. <i>Oncolmmunology</i> , 2016, 5, e1235107. | 2.1 | 104 |
| 1775 | Vitamin D, vitamin A, the primary melanoma transcriptome and survival. <i>British Journal of Dermatology</i> , 2016, 175, 30-34. | 1.4 | 11 |
| 1776 | Immunotherapy of Melanoma. <i>Oncology Research and Treatment</i> , 2016, 39, 369-376. | 0.8 | 14 |
| 1777 | Associations between childhood height and morphologically different variants of melanoma in adulthood. <i>European Journal of Cancer</i> , 2016, 67, 99-105. | 1.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1778 | Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival. <i>European Journal of Cancer</i> , 2016, 67, 164-173. | 1.3 | 30 |
| 1779 | High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2444-2452. | 0.3 | 27 |
| 1780 | Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. <i>International Immunopharmacology</i> , 2016, 40, 466-473. | 1.7 | 25 |
| 1781 | Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 158. | 0.4 | 9 |
| 1782 | Cutaneous malignant melanoma in children and adolescents treated in pediatric oncology units. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1922-1927. | 0.8 | 21 |
| 1783 | Pediatric melanoma. <i>Seminars in Pediatric Surgery</i> , 2016, 25, 290-298. | 0.5 | 25 |
| 1784 | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855. | 13.9 | 1,140 |
| 1785 | Advantages of dayâ€before lymphoscintigraphy and undiluted methylene blue dye injections for sentinel lymph node biopsies for melanoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 947-950. | 0.8 | 3 |
| 1786 | Melanoma: Kids are not just little people. <i>Clinics in Dermatology</i> , 2016, 34, 742-748. | 0.8 | 12 |
| 1787 | Rapid and objective CT scan prognostic scoring identifiesÂmetastatic patients with long-term clinical benefit on anti-PD-1/L1 therapy. <i>European Journal of Cancer</i> , 2016, 65, 33-42. | 1.3 | 58 |
| 1788 | Longâ€term treatment with the oncolytic ECHOâ€7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patientâ€three case reports. <i>Apmis</i> , 2016, 124, 896-904. | 0.9 | 47 |
| 1789 | Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1248-1260. | 5.1 | 832 |
| 1790 | Surgical treatment of melanoma in pregnancy: a practical guideline. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 585-593. | 0.4 | 6 |
| 1791 | <sc>BH</sc>3â€only protein Bim predicts advanced stage of cutaneous melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1926-1929. | 1.3 | 2 |
| 1792 | National Evaluation of Hospital Performance on the New Commission on Cancer Melanoma Quality Measures. <i>Annals of Surgical Oncology</i> , 2016, 23, 3548-3557. | 0.7 | 13 |
| 1793 | Intravenous highâ€dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: metaâ€analysis of three trials. <i>Cancer Medicine</i> , 2016, 5, 17-23. | 1.3 | 14 |
| 1794 | Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and metaâ€analysis of antiâ€CTLAâ€4 and antiâ€PDâ€1 agents trials. <i>Cancer Medicine</i> , 2016, 5, 1481-1491. | 1.3 | 86 |
| 1795 | Quantitative changes of melanomaâ€associated antigens as a biomarker for targeted therapy response. <i>Experimental Dermatology</i> , 2016, 25, 727-729. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-------|-----------|
| 1796 | FMNL2/FMNL3 formins are linked with oncogenic pathways and predict melanoma outcome. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 41-52. | 1.3 | 28 |
| 1797 | High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. <i>British Journal of Dermatology</i> , 2016, 174, 146-151. | 1.4 | 132 |
| 1798 | Biomarkers in melanoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S104-S112. | 0.6 | 8 |
| 1799 | Epidemiology of cutaneous melanoma in Sweden—Stage-specific survival and rate of recurrence. <i>International Journal of Cancer</i> , 2016, 139, 2722-2729. | 2.3 | 49 |
| 1800 | Trends in melanoma in the elderly in Denmark, 1980–2012. <i>Acta Oncologica</i> , 2016, 55, 52-58. | 0.8 | 6 |
| 1801 | Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). <i>Annals of Oncology</i> , 2016, 27, 1947. | 0.6 | 21 |
| 1802 | Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. <i>European Journal of Cancer</i> , 2016, 67, 38-45. | 1.3 | 10 |
| 1803 | Defining recurrence of nonmelanoma skin cancer after Mohs micrographic surgery: Report of the American College of Mohs Surgery Registry and Outcomes Committee. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1022-1031. | 0.6 | 23 |
| 1804 | Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. <i>EBioMedicine</i> , 2016, 10, 85-100. | 2.7 | 56 |
| 1805 | Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1176-1186.e4. | 0.6 | 38 |
| 1806 | State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 460-480. | 157.7 | 140 |
| 1807 | Applied Immunohistochemistry in the Evaluation of Skin Neoplasms. , 2016, , . | | 1 |
| 1808 | Tissue inhibitor of metalloproteinase-3 (TIMP3) expression decreases during melanoma progression and inhibits melanoma cell migration. <i>European Journal of Cancer</i> , 2016, 66, 34-46. | 1.3 | 20 |
| 1809 | Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. <i>Immunotherapy</i> , 2016, 8, 1033-1044. | 1.0 | 47 |
| 1810 | Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 525-527. | 0.6 | 6 |
| 1811 | The Prognostic Significance of Sentinel Lymph Node Status for Patients with Thick Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 938-945. | 0.7 | 28 |
| 1812 | Detection of Occult Invasion in Melanoma In Situ. <i>JAMA Dermatology</i> , 2016, 152, 1201. | 2.0 | 30 |
| 1813 | Nowadays a histological sub-typing of thin melanoma is demanded for a proper patient management. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2016, 69, 1563-1564. | 0.5 | 16 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1814 | Clinical Prognostic Markers in Stage IIIB Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 4195-4202. | 0.7 | 4 |
| 1815 | Advances in immunotherapy for melanoma management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2501-2511. | 1.4 | 15 |
| 1816 | Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. <i>Human Pathology</i> , 2016, 57, 116-125. | 1.1 | 71 |
| 1817 | Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 744-754. | 1.6 | 131 |
| 1818 | A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between <i>CDC42</i> and <i>SCIN</i> genetic variants. <i>International Journal of Cancer</i> , 2016, 139, 2012-2020. | 2.3 | 8 |
| 1819 | Regression in cutaneous melanoma: a comprehensive review from diagnosis to prognosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 2030-2037. | 1.3 | 74 |
| 1820 | Sentinel node biopsy in patients with primary cutaneous melanoma of any thickness: A cost-effectiveness analysis. <i>Surgical Oncology</i> , 2016, 25, 205-211. | 0.8 | 9 |
| 1821 | Imaging Patterns of Metastatic Melanoma. , 2016, , 505-517. | | 0 |
| 1822 | Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , The, 2016, 17, 1743-1754. | 5.1 | 266 |
| 1823 | IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. <i>Scientific Reports</i> , 2016, 6, 29736. | 1.6 | 52 |
| 1824 | Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. <i>ESMO Open</i> , 2016, 1, e000068. | 2.0 | 54 |
| 1825 | Talimogene laherparepvec: overview, combination therapy and current practices. <i>Melanoma Management</i> , 2016, 3, 267-272. | 0.1 | 8 |
| 1826 | Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma. <i>Oncology Letters</i> , 2016, 11, 293-298. | 0.8 | 15 |
| 1827 | Acral Melanoma in Chinese: A Clinicopathological and Prognostic Study of 142 cases. <i>Scientific Reports</i> , 2016, 6, 31432. | 1.6 | 92 |
| 1829 | Lethal melanoma in children: a clinicopathological study of 12 cases. <i>Pathology</i> , 2016, 48, 705-711. | 0.3 | 8 |
| 1830 | The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients. <i>EJNMMI Research</i> , 2016, 6, 73. | 1.1 | 10 |
| 1831 | Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168. | 2.3 | 106 |
| 1832 | Host kinin B1 receptor plays a protective role against melanoma progression. <i>Scientific Reports</i> , 2016, 6, 22078. | 1.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1833 | Adjuvant ipilimumab in stage III melanoma: New landscape, new questions. <i>European Journal of Cancer</i> , 2016, 69, 39-42. | 1.3 | 15 |
| 1834 | Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der Immunhistologie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 910-916. | 0.4 | 12 |
| 1835 | An observational study regarding the rate of growth in vertical and radial growth phase superficial spreading melanomas. <i>Oncology Letters</i> , 2016, 12, 2099-2102. | 0.8 | 9 |
| 1836 | Automated quantification of Ki67/MART1 stains may prevent false-negative melanoma diagnoses. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 956-962. | 0.7 | 7 |
| 1837 | Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy. <i>Cancer Medicine</i> , 2016, 5, 2832-2840. | 1.3 | 19 |
| 1838 | Retrospective chart analysis of incidental findings detected by ¹⁸ F-fluorodeoxyglucose PET/CT in patients with cutaneous malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 807-816. | 0.4 | 8 |
| 1839 | P-Hydroxycinnamaldehyde Induces B16-F1 Melanoma Cell Differentiation via the RhoA-MAPK Signaling Pathway. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 2247-2260. | 1.1 | 19 |
| 1840 | Inference of the drivers of collective movement in two cell types: Dictyostelium and melanoma. <i>Journal of the Royal Society Interface</i> , 2016, 13, 20160695. | 1.5 | 13 |
| 1841 | Combined Therapy with Dabrafenib and Trametinib in BRAF-Mutated Metastatic Melanoma in a Real-Life Setting: The INT Milan Experience. <i>Tumori</i> , 2016, 102, 501-507. | 0.6 | 6 |
| 1842 | Comparative Expression Analysis of Putative Cancer Stem Cell Markers CD44 and ALDH1A1 in Various Skin Cancer Subtypes. <i>International Journal of Biological Markers</i> , 2016, 31, 53-61. | 0.7 | 38 |
| 1843 | Alternol inhibits the proliferation and induces the differentiation of the mouse melanoma B16F0 cell line. <i>Oncology Reports</i> , 2016, 36, 1150-1156. | 1.2 | 2 |
| 1844 | Retrospektive Analyse von Zufallsbefunden, die bei Patienten mit kutanem malignen Malignom durch ¹⁸ F-Fluorodeoxyglucose PET/CT erhoben wurden. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 807-817. | 0.4 | 7 |
| 1845 | Recent developments in melanoma management. <i>Trends in Urology & Men's Health</i> , 2016, 7, 8-12. | 0.2 | 0 |
| 1848 | Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma. <i>Melanoma Research</i> , 2016, 26, 448-456. | 0.6 | 16 |
| 1849 | Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis. <i>Medicine (United States)</i> , 2016, 95, e4332. | 0.4 | 35 |
| 1850 | Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65. | 1.8 | 12 |
| 1852 | Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels. <i>Melanoma Research</i> , 2016, 26, 551-564. | 0.6 | 8 |
| 1853 | Immature mediastinal teratoma with unusual histopathology. <i>Medicine (United States)</i> , 2016, 95, e3378. | 0.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1854 | Competing risks survival of older patients with metastatic cutaneous melanoma: a SEER population-based study. <i>Melanoma Research</i> , 2016, 26, 505-512. | 0.6 | 8 |
| 1855 | Histopathological determination of thin melanomas at risk for metastasis. <i>Melanoma Research</i> , 2016, 26, 635-635. | 0.6 | 18 |
| 1856 | The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. <i>Melanoma Research</i> , 2016, 26, 595-603. | 0.6 | 31 |
| 1857 | A small multimarker panel using simple immunohistochemistry methods is an adjunct to stage for cutaneous melanoma prognosis. <i>Melanoma Research</i> , 2016, 26, 580-587. | 0.6 | 5 |
| 1858 | Thin melanoma subtyping fits well with the American Joint Committee on Cancer staging system. <i>Melanoma Research</i> , 2016, 26, 636-636. | 0.6 | 10 |
| 1859 | Delay in cutaneous melanoma diagnosis. <i>Medicine (United States)</i> , 2016, 95, e4396. | 0.4 | 30 |
| 1860 | Phenotypic characterization and prognostic impact of circulating β 2-microglobulin cells in metastatic malignant melanoma. <i>International Journal of Cancer</i> , 2016, 138, 698-704. | 2.3 | 24 |
| 1861 | Isolated limb perfusion in Merkel cell carcinoma offers high rate of complete response and durable local regional control: Systematic review and institutional experience. <i>Journal of Surgical Oncology</i> , 2016, 114, 187-192. | 0.8 | 6 |
| 1864 | Parotid melanoma of unknown primary. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1529-1537. | 1.2 | 3 |
| 1865 | Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. <i>Oncolmmunology</i> , 2016, 5, e1191732. | 2.1 | 17 |
| 1866 | The Combination of Vemurafenib and Procaspace-3 Activation Is Synergistic in Mutant BRAF Melanomas. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1859-1869. | 1.9 | 16 |
| 1867 | Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. <i>Oncolmmunology</i> , 2016, 5, e1201625. | 2.1 | 21 |
| 1868 | Germline <i>CDKN2A</i> Mutation Status and Survival in Familial Melanoma Cases. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw135. | 3.0 | 47 |
| 1869 | 18F-FDG-PET/CT in the Staging and Management of Melanoma. <i>Clinical Nuclear Medicine</i> , 2016, 41, 189-193. | 0.7 | 22 |
| 1870 | Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?. <i>Melanoma Management</i> , 2016, 3, 9-12. | 0.1 | 2 |
| 1871 | The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 907-916. | 2.5 | 111 |
| 1872 | Combining immune checkpoint inhibitors for advanced melanoma: the key to optimizing treatment outcomes?. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 329-333. | 0.6 | 0 |
| 1873 | <i>In vivo</i> imaging of melanoma-implanted magnetic nanoparticles using contrast-enhanced magneto-motive optical Doppler tomography. <i>Journal of Biomedical Optics</i> , 2016, 21, 064001. | 1.4 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1874 | Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. <i>British Journal of Cancer</i> , 2016, 115, 145-155. | 2.9 | 50 |
| 1875 | Ipilimumab in anti-PD1 refractory metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 153-156. | 0.6 | 18 |
| 1876 | miR-146a Exerts Differential Effects on Melanoma Growth and Metastatization. <i>Molecular Cancer Research</i> , 2016, 14, 548-562. | 1.5 | 39 |
| 1877 | Radioguided Monitoring of Systemic Leakage During Isolated Limb Perfusion for Melanoma. , 2016, , 359-369. | | 0 |
| 1878 | 47 Diagnosis and Treatment of Cutaneous Malignancies. , 2016, , . | | 0 |
| 1880 | Sentinel Lymph Node Biopsy in T4 Melanoma: An Important Risk-Stratification Tool. <i>Annals of Surgical Oncology</i> , 2016, 23, 579-584. | 0.7 | 27 |
| 1881 | Influence of different positioning of a local pain catheter on postoperative pain after paramedian laparotomy—a blinded, randomized trial. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 419-426. | 0.8 | 0 |
| 1882 | Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China. <i>Tumor Biology</i> , 2016, 37, 10339-10348. | 0.8 | 14 |
| 1883 | MiR-330-5p regulates tyrosinase and PDIA3 expression and suppresses cell proliferation and invasion in cutaneous malignant melanoma. <i>Journal of Surgical Research</i> , 2016, 203, 434-440. | 0.8 | 36 |
| 1884 | Adoption of ipilimumab in the United States: a Medicare study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 439-440. | 0.7 | 0 |
| 1885 | Ten-Year Survival after Multiple Invasive Melanomas Is Worse than after a Single Melanoma: a Population-Based Study. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2270-2276. | 0.3 | 45 |
| 1886 | Sex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (USASurveillance.) Tj ETQq1 1 0.784314 rgBT /Ov | 0.3 | 0 |
| 1887 | Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2330-2335. | 0.7 | 49 |
| 1888 | Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival. <i>BMC Cancer</i> , 2016, 16, 186. | 1.1 | 13 |
| 1889 | SOX5 is involved in balanced MITF regulation in human melanoma cells. <i>BMC Medical Genomics</i> , 2016, 9, 10. | 0.7 | 34 |
| 1890 | T-Cell Therapy Using Interleukin-21—Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. <i>Journal of Clinical Oncology</i> , 2016, 34, 3787-3795. | 0.8 | 98 |
| 1891 | Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016, 21, 848-854. | 1.9 | 154 |
| 1892 | Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 951-959. | 2.0 | 62 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1893 | Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma. <i>Diagnostic Pathology</i> , 2016, 11, 35. | 0.9 | 11 |
| 1894 | Is a Wider Margin (2Âcm vs. 1Âcm) for a 1.01â€“2.0Âmm Melanoma Necessary?. <i>Annals of Surgical Oncology</i> , 2016, 23, 2336-2342. | 0.7 | 15 |
| 1895 | Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?. <i>Clinical Cancer Research</i> , 2016, 22, 3992-3998. | 3.2 | 48 |
| 1896 | miR-199a-5p induces cell invasion by suppressing E-cadherin expression in cutaneous squamous cell carcinoma. <i>Oncology Letters</i> , 2016, 12, 97-101. | 0.8 | 18 |
| 1897 | Clinical and biological determinants of melanoma progression: Should all be considered for clinical management?. <i>Australasian Journal of Dermatology</i> , 2016, 57, 175-181. | 0.4 | 8 |
| 1898 | Recommendations for Solid Organ Transplantation for Transplant Candidates With a Pretransplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: A Consensus Opinion From the International Transplant Skin Cancer Collaborative (ITSCC). <i>American Journal of Transplantation</i> , 2016, 16, 407-413. | 2.6 | 37 |
| 1899 | Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 158-164. | 0.4 | 26 |
| 1900 | Open questions and novel concepts in oral cancer surgery. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 1975-1985. | 0.8 | 8 |
| 1901 | Antitumor and antimetastatic effects of pemetrexed-loaded targeted nanoparticles in B ₁₆ bearing mice. <i>Drug Delivery</i> , 2016, 23, 2566-2574. | 2.5 | 10 |
| 1903 | Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1â€“2Âmm in Thickness): Analysis of 2131 Patients Treated at a Single Center. <i>Annals of Surgical Oncology</i> , 2016, 23, 1071-1081. | 0.7 | 31 |
| 1904 | The Role of Neutrophilic Inflammation, Angiotropism, and Pericytic Mimicry in Melanoma Progression and Metastasis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 372-377. | 0.3 | 25 |
| 1905 | Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2016, 114, 256-261. | 2.9 | 256 |
| 1906 | Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. <i>Annals of Oncology</i> , 2016, 27, 732-738. | 0.6 | 321 |
| 1907 | Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600E Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878. | 0.8 | 266 |
| 1908 | A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects. <i>Journal of Controlled Release</i> , 2016, 223, 165-177. | 4.8 | 89 |
| 1909 | Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. <i>Molecular Oncology</i> , 2016, 10, 450-463. | 2.1 | 79 |
| 1910 | CT imaging of bone and bone marrow infiltration in malignant melanomaâ€”Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. <i>European Journal of Radiology</i> , 2016, 85, 732-738. | 1.2 | 43 |
| 1911 | Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 389-396. | 1.4 | 35 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1912 | Melanoma: Clinical Presentations. <i>Cancer Treatment and Research</i> , 2016, 167, 107-129. | 0.2 | 59 |
| 1913 | Rendimiento de la tomografía computarizada en la estadificación basal del paciente con melanoma. <i>Actas Dermo-sifilográficas</i> , 2016, 107, 55-61. | 0.2 | 3 |
| 1914 | Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918. | 3.2 | 459 |
| 1915 | Sentinel lymph node biopsy staging for cutaneous malignant melanoma of the head and neck. <i>Acta Oto-Laryngologica</i> , 2016, 136, 312-318. | 0.3 | 9 |
| 1916 | Excision margins for melanomas: how wide is enough?. <i>Lancet Oncology</i> , The, 2016, 17, 127-128. | 5.1 | 12 |
| 1917 | Discordance of histopathologic parameters in cutaneous melanoma: Clinical implications. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 75-80. | 0.6 | 54 |
| 1918 | A comparative study of proliferative activity and tumor stage of pregnancy-associated melanoma (PAM) and non-PAM in gestational age women. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 88-93. | 0.6 | 11 |
| 1919 | The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 1-10. | 3.3 | 8 |
| 1920 | Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation. <i>Cancer Treatment Reviews</i> , 2016, 42, 73-81. | 3.4 | 64 |
| 1921 | Varying Mutational Alterations in Multiple Primary Melanomas. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 75-83. | 1.2 | 17 |
| 1922 | A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 94-101. | 0.6 | 50 |
| 1923 | Downregulation of pyrroline-5-carboxylate reductase-2 induces the autophagy of melanoma cells via AMPK/mTOR pathway. <i>Tumor Biology</i> , 2016, 37, 6485-6491. | 0.8 | 17 |
| 1924 | Acid Ceramidase in Melanoma. <i>Journal of Biological Chemistry</i> , 2016, 291, 2422-2434. | 1.6 | 72 |
| 1925 | Adjuvant Therapy of Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 181-208. | 0.2 | 17 |
| 1926 | Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. <i>Oncolmmunology</i> , 2016, 5, 1136045. | 2.1 | 22 |
| 1927 | Axillary web syndrome: an underappreciated complication of sentinel node biopsy in melanoma. <i>American Journal of Surgery</i> , 2016, 211, 846-849. | 0.9 | 14 |
| 1928 | miR-146a Exerts Differential Effects on Melanoma Growth and Metastatization. <i>Molecular Cancer Research</i> , 2016, , . | 1.5 | 0 |
| 1929 | Toward in vivo biopsy of melanoma based on photoacoustic and ultrasound dual imaging with an integrated detector. <i>Biomedical Optics Express</i> , 2016, 7, 279. | 1.5 | 52 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1930 | Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. <i>Journal of Clinical Oncology</i> , 2016, 34, 1741-1747. | 0.8 | 64 |
| 1931 | Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy. <i>Journal of Surgical Oncology</i> , 2016, 113, 98-102. | 0.8 | 11 |
| 1932 | Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma. <i>Advances in Therapy</i> , 2016, 33, 643-657. | 1.3 | 10 |
| 1933 | Molecular techniques for predicting behaviour in melanocytic neoplasms. <i>Pathology</i> , 2016, 48, 142-146. | 0.3 | 7 |
| 1934 | Clinical Patterns of Melanoma in Asians. <i>Annals of Plastic Surgery</i> , 2016, 77, S6-S11. | 0.5 | 18 |
| 1935 | Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature. <i>Cancer Treatment Reviews</i> , 2016, 45, 120-128. | 3.4 | 8 |
| 1936 | High Aspect Ratio Nanotubes Formed by Tobacco Mosaic Virus for Delivery of Photodynamic Agents Targeting Melanoma. <i>ACS Biomaterials Science and Engineering</i> , 2016, 2, 838-844. | 2.6 | 47 |
| 1937 | Skin self-examination and long-term melanoma survival. <i>Melanoma Research</i> , 2016, 26, 401-408. | 0.6 | 43 |
| 1938 | Recognizing melanoma. <i>Nurse Practitioner</i> , 2016, 41, 29-30. | 0.2 | 4 |
| 1939 | Germline determinants of clinical outcome of cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 15-26. | 1.5 | 12 |
| 1940 | Cobimetinib and vemurafenib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1005-1011. | 0.9 | 21 |
| 1941 | Evolution of Metastatic Disease: The Need for Monitoring and Emerging Therapeutic Opportunities. <i>Current Cancer Research</i> , 2016, , 271-292. | 0.2 | 0 |
| 1942 | Risk factors and outcomes of cutaneous melanoma in women less than 50 years of age. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 731-738. | 0.6 | 34 |
| 1943 | Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1002-1011. | 0.3 | 51 |
| 1944 | Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 994-1001. | 0.3 | 27 |
| 1945 | Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 985-993. | 0.3 | 44 |
| 1946 | Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw004. | 3.0 | 28 |
| 1947 | Advances in melanoma: revolutionary progress delivering improved patient management and outcomes. <i>Pathology</i> , 2016, 48, 105-107. | 0.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1948 | Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. <i>Lancet Oncology</i> , The, 2016, 17, 184-192. | 5.1 | 116 |
| 1949 | Opposing Roles of JNK and p38 in Lymphangiogenesis in Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 967-977. | 0.3 | 14 |
| 1950 | Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3016-3024. | 3.2 | 39 |
| 1951 | A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping. <i>European Journal of Surgical Oncology</i> , 2016, 42, 466-473. | 0.5 | 127 |
| 1952 | Yield of Computed Tomography at Baseline Staging of Melanoma. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2016, 107, 55-61. | 0.2 | 1 |
| 1953 | Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. <i>Oncolmmunology</i> , 2016, 5, e1057673. | 2.1 | 67 |
| 1954 | Circulating Tumor Cells. <i>Current Cancer Research</i> , 2016, , . | 0.2 | 6 |
| 1955 | Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIBâ€“III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. <i>European Journal of Cancer</i> , 2016, 55, 111-121. | 1.3 | 80 |
| 1956 | The impact of sequencing on diagnosis and treatment of malignant melanoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 423-433. | 1.5 | 4 |
| 1957 | Early-Onset Vemurafenib-Induced DRESS Syndrome. <i>Dermatology</i> , 2016, 232, 126-128. | 0.9 | 25 |
| 1958 | Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes. <i>Surgery</i> , 2016, 159, 1412-1421. | 1.0 | 23 |
| 1959 | Melanoma Thickness and Survival Trends in the United States, 1989â€“2009. <i>Journal of the National Cancer Institute</i> , 2016, 108, . | 3.0 | 121 |
| 1960 | Sentinel Lymph Node Biopsy in Thin Cutaneous Melanoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 4178-4188. | 0.7 | 91 |
| 1961 | Localized melanoma in older patients, the impact of increasing age and comorbid medical conditions. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1359-1366. | 0.5 | 21 |
| 1963 | Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. <i>Pathology</i> , 2016, 48, 194-202. | 0.3 | 19 |
| 1964 | The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Caseâ€“Control Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1082-1089. | 0.7 | 43 |
| 1966 | Melanoma burden by melanoma stage: Assessment through a disease transition model. <i>European Journal of Cancer</i> , 2016, 53, 33-41. | 1.3 | 20 |
| 1967 | Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. <i>Cancer Discovery</i> , 2016, 6, 286-299. | 7.7 | 208 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1968 | Prospective Randomized Study to Compare Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Therapeutic Lymph Node Dissection With or Without the Use of an Ultrasonic Scalpel. <i>Annals of Surgical Oncology</i> , 2016, 23, 1716-1720. | 0.7 | 21 |
| 1969 | Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 623-643. | 2.6 | 30 |
| 1970 | Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv406. | 3.0 | 61 |
| 1971 | The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 91-99. | 2.0 | 87 |
| 1972 | Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. <i>Genetics in Medicine</i> , 2016, 18, 727-736. | 1.1 | 31 |
| 1973 | Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2155-2166. | 3.2 | 211 |
| 1974 | Stemming the Rising Incidence of Melanoma: Calling Prevention to Action. <i>Journal of the National Cancer Institute</i> , 2016, 108, . | 3.0 | 61 |
| 1975 | Association of TIMP3 expression with vessel density, macrophage infiltration and prognosis in human malignant melanoma. <i>European Journal of Cancer</i> , 2016, 53, 135-143. | 1.3 | 19 |
| 1976 | Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 482-488. | 3.3 | 37 |
| 1977 | In vivo assessment of optical properties of melanocytic skin lesions and differentiation of melanoma from non-malignant lesions by high-definition optical coherence tomography. <i>Archives of Dermatological Research</i> , 2016, 308, 7-20. | 1.1 | 51 |
| 1978 | Principles of Melanoma Staging. <i>Cancer Treatment and Research</i> , 2016, 167, 131-148. | 0.2 | 29 |
| 1979 | Identification of melanoma cells and lymphocyte subpopulations in lymph node metastases by FTIR imaging histopathology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 202-212. | 1.8 | 28 |
| 1980 | Methods of Melanoma Detection. <i>Cancer Treatment and Research</i> , 2016, 167, 51-105. | 0.2 | 31 |
| 1981 | Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 251-259. | 1.3 | 18 |
| 1982 | Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. <i>Annals of Surgical Oncology</i> , 2016, 23, 250-256. | 0.7 | 27 |
| 1983 | Metastatic patterns and metastatic sites in mucosal melanoma: a retrospective study. <i>European Radiology</i> , 2016, 26, 1826-1834. | 2.3 | 13 |
| 1984 | How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population-based analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 73-76. | 1.2 | 11 |
| 1985 | Cancers of the Vulva and Vagina. , 2016, , 1230-1263.e6. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1986 | Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study. <i>Carcinogenesis</i> , 2016, 37, 30-38. | 1.3 | 54 |
| 1987 | Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. <i>JAMA Dermatology</i> , 2016, 152, 45. | 2.0 | 539 |
| 1988 | Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 245-254. | 0.3 | 82 |
| 1989 | The role of regional chemotherapy in the management of extremity soft tissue malignancies. <i>European Journal of Surgical Oncology</i> , 2016, 42, 7-17. | 0.5 | 15 |
| 1990 | XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro), and GSTP1 (Ile105Val) polymorphisms in prognosis of cutaneous melanoma. <i>Tumor Biology</i> , 2016, 37, 3163-3171. | 0.8 | 2 |
| 1991 | Sensitivity of plasma BRAF ^{mutant} and NRAS ^{mutant} cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. <i>Molecular Oncology</i> , 2016, 10, 157-165. | 2.1 | 63 |
| 1992 | Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 300-306. | 1.0 | 15 |
| 1993 | Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. <i>Oncogene</i> , 2016, 35, 2166-2177. | 2.6 | 49 |
| 1994 | Predictive factors for sentinel lymph nodes and non-sentinel lymph nodes metastatic involvement: a database study of 1,041 melanoma patients. <i>American Journal of Surgery</i> , 2016, 211, 89-94. | 0.9 | 20 |
| 1995 | Aportación de la tomografía por emisión de fotón Simple/tomografía computadorizada a la biopsia selectiva del ganglio centinela en pacientes diagnosticados de melanoma de cabeza y cuello. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 22-28. | 0.0 | 2 |
| 1996 | Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma. <i>ANZ Journal of Surgery</i> , 2017, 87, 44-48. | 0.3 | 20 |
| 1998 | Sentinel lymph node biopsy versus ¹⁸ F-NaF PET/CT in AJCC stages I and II of melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e54-e55. | 1.3 | 4 |
| 1999 | Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 207-213. | 0.6 | 7 |
| 2000 | Coping Strategies at the Time of Diagnosis and Quality of Life 2 Years Later. <i>Cancer Nursing</i> , 2017, 40, E45-E53. | 0.7 | 11 |
| 2001 | Scalp melanoma: Distinctive high risk clinical and histological features. <i>Australasian Journal of Dermatology</i> , 2017, 58, 181-188. | 0.4 | 38 |
| 2002 | Genomic analysis and clinical management of adolescent cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 307-316. | 1.5 | 12 |
| 2003 | <i>IRF4</i> rs12203592 functional variant and melanoma survival. <i>International Journal of Cancer</i> , 2017, 140, 1845-1849. | 2.3 | 11 |
| 2004 | Contemporary Management of Early-Stage Melanoma. <i>JAMA Facial Plastic Surgery</i> , 2017, 19, 232-238. | 2.2 | 28 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2005 | Implementation of the 7th edition <sc>AJCC</sc> staging system: Effects on staging and survival for pT1 melanoma. A Dutch population based study. <i>International Journal of Cancer</i> , 2017, 140, 1802-1808. | 2.3 | 10 |
| 2006 | Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 818-825.e3. | 0.6 | 44 |
| 2007 | Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma. <i>Pathology Research and Practice</i> , 2017, 213, 522-530. | 1.0 | 4 |
| 2008 | Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States. <i>Journal of Dermatological Treatment</i> , 2017, 28, 549-553. | 1.1 | 6 |
| 2009 | Polymorphisms in apoptosis-related genes in cutaneous melanoma prognosis: sex disparity. <i>Medical Oncology</i> , 2017, 34, 19. | 1.2 | 4 |
| 2010 | Estudio descriptivo de costes en melanoma cutáneo de diferentes estadios. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 229-236. | 0.2 | 15 |
| 2012 | KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth. <i>Oncogene</i> , 2017, 36, 3322-3333. | 2.6 | 75 |
| 2013 | An expert system for selecting wart treatment method. <i>Computers in Biology and Medicine</i> , 2017, 81, 167-175. | 3.9 | 112 |
| 2014 | Analysis of sentinel node positivity in primary cutaneous melanoma: an 8-year single institution experience. <i>Irish Journal of Medical Science</i> , 2017, 186, 847-853. | 0.8 | 6 |
| 2015 | Self-detection frequency and recognition patterns in medium to high-risk cutaneous melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 61-67. | 0.4 | 2 |
| 2016 | Phase III Randomized Study of 4 Weeks of High-Dose Interferon- β in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). <i>Journal of Clinical Oncology</i> , 2017, 35, 885-892. | 0.8 | 42 |
| 2017 | Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 393-403. | 5.1 | 91 |
| 2018 | Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. <i>Cancer Immunology Research</i> , 2017, 5, 170-179. | 1.6 | 23 |
| 2019 | Intralesional treatment of metastatic melanoma: a review of therapeutic options. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 647-656. | 2.0 | 34 |
| 2020 | Using global gene expression to discriminate thin melanomas with poor outcomes. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1253527. | 0.3 | 1 |
| 2021 | Mitotic figures and the evolving staging of melanoma. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 358-359. | 0.7 | 4 |
| 2022 | Topical immunotherapy with diphenylpicryl ether (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 383-388. | 1.3 | 15 |
| 2023 | Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 1378-1385. | 0.7 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2024 | Potential therapeutic targets of epithelialâ€“mesenchymal transition in melanoma. <i>Cancer Letters</i> , 2017, 391, 125-140. | 3.2 | 117 |
| 2025 | Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. <i>European Journal of Cancer</i> , 2017, 75, 24-32. | 1.3 | 162 |
| 2026 | Results of a phase II, openâ€“label, nonâ€“comparative study of intralesional PVâ€“10 followed by radiotherapy for the treatment of inâ€“transit or metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2017, 115, 891-897. | 0.8 | 18 |
| 2027 | Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 1997-2005. | 0.7 | 29 |
| 2028 | The Mole Mapper Study, mobile phone skin imaging and melanoma risk data collected using ResearchKit. <i>Scientific Data</i> , 2017, 4, 170005. | 2.4 | 60 |
| 2029 | Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. <i>European Journal of Cancer</i> , 2017, 75, 47-55. | 1.3 | 145 |
| 2030 | Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years. <i>Value in Health</i> , 2017, 20, 593-601. | 0.1 | 16 |
| 2031 | Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. <i>Oncolmmunology</i> , 2017, 6, e1299303. | 2.1 | 20 |
| 2032 | A pulmonary metastatic model of murine melanoma assessed by magnetic resonance imaging. <i>Experimental Dermatology</i> , 2017, 26, 619-621. | 1.4 | 2 |
| 2033 | Mechanisms of Drug Resistance in Melanoma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 91-108. | 0.9 | 63 |
| 2034 | Quantity-guided drain management reduces seroma formation and wound infections after radical lymph node dissection: results of a comparative observational study of 374 melanoma patients. <i>Acta Chirurgica Belgica</i> , 2017, 117, 238-244. | 0.2 | 5 |
| 2035 | Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146. <i>Cell Death Discovery</i> , 2017, 3, 17005. | 2.0 | 29 |
| 2036 | Attenuated in vitro effects of IFN-Î±, IL-2 and IL-12 on functional and receptor characteristics of peripheral blood lymphocytes in metastatic melanoma patients. <i>Cytokine</i> , 2017, 96, 30-40. | 1.4 | 15 |
| 2037 | Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma. <i>British Journal of Surgery</i> , 2017, 104, 726-733. | 0.1 | 5 |
| 2038 | Long-term results of ultrasound guided fine needle aspiration cytology in conjunction with sentinel node biopsy support step-wise approach in melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1509-1516. | 0.5 | 13 |
| 2039 | Correlations of EGF G1380A, bFGF C754G and VEGF T460C polymorphisms with malignant melanoma susceptibility and prognosis: A case-control study. <i>Gene</i> , 2017, 617, 44-53. | 1.0 | 6 |
| 2040 | iDermatoPath â€“ a novel software tool for mitosis detection in H&Eâ€“stained tissue sections of malignant melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1137-1147. | 1.3 | 16 |
| 2041 | Higher predictive value of sentinel lymph node biopsy in patients with histological subcategorization of thin melanoma. <i>International Journal of Dermatology</i> , 2017, 56, e93-e94. | 0.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2043 | The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. <i>Current Oncology Reports</i> , 2017, 19, 17. | 1.8 | 30 |
| 2044 | Improved detection of melanoma metastases by iodine maps from dual energy CT. <i>European Journal of Radiology</i> , 2017, 90, 27-33. | 1.2 | 14 |
| 2045 | Reconstruction of Heel Soft Tissue Defects Using Medial Plantar Artery Island Pedicle Flap: Clinical Experience and Outcomes Analysis. <i>Journal of Foot and Ankle Surgery</i> , 2017, 56, 226-229. | 0.5 | 21 |
| 2046 | Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017, 73, 61-70. | 1.3 | 88 |
| 2047 | Clinical and pathologic factors associated with subclinical spread of invasive melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 714-721. | 0.6 | 30 |
| 2048 | Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma. <i>Journal of the American College of Surgeons</i> , 2017, 224, 652-659. | 0.2 | 26 |
| 2049 | Dermoscopic features predicting the presence of mitoses in thin melanoma. <i>Journal of Dermatological Science</i> , 2017, 86, 158-161. | 1.0 | 7 |
| 2050 | Combined <i>in vivo</i> reflectance confocal microscopy and digital dermoscopy for follow up of patients at high risk of malignant melanoma: A prospective case series study. <i>Journal of Dermatology</i> , 2017, 44, 681-689. | 0.6 | 8 |
| 2051 | Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF- κ B Pathway in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 4831-4842. | 3.2 | 33 |
| 2052 | Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells. <i>Oncology Reports</i> , 2017, 37, 2277-2285. | 1.2 | 89 |
| 2053 | Detection of melanoma metastases with PET—Comparison of 18 F-5-FPN with 18 F—FDG. <i>Nuclear Medicine and Biology</i> , 2017, 50, 33-38. | 0.3 | 17 |
| 2054 | T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017, 545, 60-65. | 13.7 | 1,280 |
| 2056 | Melphalan hypoxic perfusion with hemofiltration for melanoma locoregional metastases in the pelvis. <i>Journal of Surgical Research</i> , 2017, 215, 114-124. | 0.8 | 7 |
| 2057 | M1 and M2 macrophages—clinical significance in cutaneous melanoma. <i>Melanoma Research</i> , 2017, 27, 200-210. | 0.6 | 88 |
| 2058 | Neuropathic pain and quality of life after wide local excision and sentinel lymph node biopsy for melanoma: a multicentre study. <i>Melanoma Research</i> , 2017, 27, 121-125. | 0.6 | 6 |
| 2059 | Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. <i>Clinical Epigenetics</i> , 2017, 9, 34. | 1.8 | 129 |
| 2060 | Increasing Frequency of Seborrheic Keratosis Diagnoses as a Favorable Consequence of Tele dermatology-Based Skin Cancer Screening: A Cross-sectional Study of 34,553 Patients. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 681-685. | 3.3 | 20 |
| 2061 | Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients. <i>Melanoma Research</i> , 2017, 27, 277-280. | 0.6 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2062 | Pigmented epithelioid melanocytoma (animal-type melanoma): An institutional experience. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 328-332. | 0.6 | 19 |
| 2063 | Affinity Proteomics Exploration of Melanoma Identifies Proteins in Serum with Associations to T-Stage and Recurrence. <i>Translational Oncology</i> , 2017, 10, 385-395. | 1.7 | 8 |
| 2064 | Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. <i>Laboratory Investigation</i> , 2017, 97, 130-145. | 1.7 | 40 |
| 2065 | Clinical prognostic markers in stage IIIC melanoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 244-251. | 0.8 | 7 |
| 2066 | Commentary: The quest for an improved risk stratification tool for patients with melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 826-828. | 0.6 | 2 |
| 2067 | Indicators of responsiveness to immune checkpoint inhibitors. <i>Scientific Reports</i> , 2017, 7, 807. | 1.6 | 70 |
| 2068 | PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study. <i>Melanoma Research</i> , 2017, 27, 251-257. | 0.6 | 16 |
| 2069 | Automatic Skin Lesion Segmentation Using Deep Fully Convolutional Networks With Jaccard Distance. <i>IEEE Transactions on Medical Imaging</i> , 2017, 36, 1876-1886. | 5.4 | 463 |
| 2070 | Adjuvant Therapy for Melanoma. <i>Current Oncology Reports</i> , 2017, 19, 36. | 1.8 | 26 |
| 2072 | Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1749-1756. | 0.3 | 5 |
| 2073 | Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy. <i>Melanoma Research</i> , 2017, 27, 97-103. | 0.6 | 1 |
| 2075 | Is pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas?. <i>American Journal of Surgery</i> , 2017, 213, 921-925. | 0.9 | 4 |
| 2076 | Woman With Left Shoulder Bumps. <i>Annals of Emergency Medicine</i> , 2017, 69, 519-529. | 0.3 | 0 |
| 2077 | Melanoma antigens and related immunological markers. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 36-49. | 2.0 | 54 |
| 2078 | Circulating cell-free microRNAs as clinical cancer biomarkers. <i>Biomolecular Concepts</i> , 2017, 8, 61-81. | 1.0 | 130 |
| 2079 | Immunobiology and Immune Based Therapies of Melanoma. , 2017, , 871-890. | | 0 |
| 2080 | Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes?. <i>Journal of the American College of Surgeons</i> , 2017, 225, 149-158. | 0.2 | 13 |
| 2081 | Does adjuvant ipilimumab have little adverse effect on quality of life?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 395-396. | 12.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2082 | Prognostic Value of the Staging System for Eyelid Tumors in the 7th Edition of the American Joint Committee on Cancer Staging Manual. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2017, 33, 317-324. | 0.4 | 18 |
| 2083 | Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma – from the population-based Swedish melanoma register. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1468-1474. | 1.3 | 24 |
| 2084 | An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. <i>Journal of Experimental Medicine</i> , 2017, 214, 1691-1710. | 4.2 | 71 |
| 2085 | Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. <i>European Radiology</i> , 2017, 27, 4372-4378. | 2.3 | 30 |
| 2086 | Further evidence supporting the need for improved risk stratification of thin melanoma. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2017, 70, 967-968. | 0.5 | 1 |
| 2087 | BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. <i>Journal of Clinical Pathology</i> , 2017, 70, 935-940. | 1.0 | 16 |
| 2088 | STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma. <i>BioFactors</i> , 2017, 43, 347-370. | 2.6 | 34 |
| 2089 | BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases. <i>Pathology</i> , 2017, 49, 55-61. | 0.3 | 38 |
| 2090 | Resistance to PD1/PDL1 checkpoint inhibition. <i>Cancer Treatment Reviews</i> , 2017, 52, 71-81. | 3.4 | 437 |
| 2091 | The influence of tumor regression, solar elastosis, and patient age on pathologists'™ interpretation of melanocytic skin lesions. <i>Laboratory Investigation</i> , 2017, 97, 187-193. | 1.7 | 3 |
| 2092 | Increasing Morbidity with Extent of Lymphadenectomy for Primary Malignant Melanoma. <i>Lymphatic Research and Biology</i> , 2017, 15, 146-152. | 0.5 | 7 |
| 2093 | Lymphatic invasion and the Shields index in predicting melanoma metastases. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2017, 70, 1646-1652. | 0.5 | 4 |
| 2094 | Improved boundary segmentation of skin lesions in high-frequency 3D ultrasound. <i>Computers in Biology and Medicine</i> , 2017, 87, 302-310. | 3.9 | 11 |
| 2095 | Genetic variants in the genes encoding rho GTPases and related regulators predict cutaneous melanoma-specific survival. <i>International Journal of Cancer</i> , 2017, 141, 721-730. | 2.3 | 8 |
| 2096 | Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. <i>Oncologist</i> , 2017, 22, 963-971. | 1.9 | 145 |
| 2097 | Frozen shoulder and risk of cancer: a population-based cohort study. <i>British Journal of Cancer</i> , 2017, 117, 144-147. | 2.9 | 12 |
| 2098 | Tadalafil has biologic activity in human melanoma. Results of a pilot trial with tadalafil in patients with metastatic Melanoma (TaMe). <i>Oncolmmunology</i> , 2017, 6, e1326440. | 2.1 | 74 |
| 2099 | Does pregnancy influence melanoma prognosis? A meta-analysis. <i>Melanoma Research</i> , 2017, 27, 289-299. | 0.6 | 32 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2100 | Metastatic Melanoma With Papillary Features: A Mimic and Possible Diagnostic Pitfall. <i>American Journal of Dermatopathology</i> , 2017, 39, 468-470. | 0.3 | 3 |
| 2102 | The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 933-940. | 1.0 | 14 |
| 2103 | S3 Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms – Update 2015/2016, Kurzversion 2.0. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, e1-e41. | 0.4 | 29 |
| 2104 | Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma. <i>International Journal of Cancer</i> , 2017, 141, 1345-1354. | 2.3 | 8 |
| 2105 | Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55. | 1.3 | 160 |
| 2106 | Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. <i>Clinical and Translational Oncology</i> , 2017, 19, 1478-1488. | 1.2 | 46 |
| 2107 | Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. <i>European Journal of Cancer</i> , 2017, 81, 36-44. | 1.3 | 76 |
| 2108 | Dacarbazine-Loaded Hollow Mesoporous Silica Nanoparticles Grafted with Folic Acid for Enhancing Antimetastatic Melanoma Response. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 21673-21687. | 4.0 | 53 |
| 2109 | Impact of the time interval between lymph node recurrence and lymphadenectomy on melanoma patient survival. <i>European Journal of Dermatology</i> , 2017, 27, 166-173. | 0.3 | 3 |
| 2110 | Podoplanin expression in peritumoral keratinocytes predicts aggressive behavior in extramammary Paget's disease. <i>Journal of Dermatological Science</i> , 2017, 87, 29-35. | 1.0 | 10 |
| 2111 | Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. <i>Melanoma Research</i> , 2017, 27, 358-368. | 0.6 | 20 |
| 2112 | Futility of imaging to stage melanoma patients with a positive sentinel lymph node. <i>Melanoma Research</i> , 2017, 27, 457-462. | 0.6 | 15 |
| 2113 | Cyclic AMP-Epac signaling pathway contributes to repression of PUMA transcription in melanoma cells. <i>Melanoma Research</i> , 2017, 27, 411-416. | 0.6 | 3 |
| 2114 | Ubiquitination in melanoma pathogenesis and treatment. <i>Cancer Medicine</i> , 2017, 6, 1362-1377. | 1.3 | 24 |
| 2115 | Melanoma patient imaging in the era of effective systemic therapies. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1517-1527. | 0.5 | 14 |
| 2116 | Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 473-482. | 2.3 | 25 |
| 2118 | Dominant lymph drainage patterns in the occipital and parietal regions: evaluation of lymph nodes in patients with skin cancer of the head. <i>International Journal of Clinical Oncology</i> , 2017, 22, 774-779. | 1.0 | 4 |
| 2119 | Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482. | 12.5 | 945 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2120 | Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. <i>American Journal of Dermatopathology</i> , 2017, 39, 1-13. | 0.3 | 10 |
| 2121 | A Novel Numerical Scoring System for Melanoma Tumor-infiltrating Lymphocytes Has Better Prognostic Value Than Standard Scoring. <i>American Journal of Surgical Pathology</i> , 2017, 41, 906-914. | 2.1 | 53 |
| 2122 | Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review. <i>Archives of Dermatological Research</i> , 2017, 309, 229-242. | 1.1 | 30 |
| 2123 | Cost of Cutaneous Melanoma by Tumor Stage: A descriptive analysis. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2017, 108, 229-236. | 0.2 | 6 |
| 2124 | Design and experimental evaluation of a quantified depth shave biopsy deviceâ€”Proof of concept. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2017, 70, 855-857. | 0.5 | 0 |
| 2125 | Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response. <i>World Neurosurgery</i> , 2017, 100, 632-640.e4. | 0.7 | 48 |
| 2126 | Reporting of mitotic rate in cutaneous melanoma: A study using the national cancer data base. <i>Journal of Surgical Oncology</i> , 2017, 115, 281-286. | 0.8 | 6 |
| 2127 | Immunotherapy in malignant melanoma: recent approaches and new perspectives. <i>Melanoma Management</i> , 2017, 4, 39-48. | 0.1 | 7 |
| 2128 | Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 1035-1046. | 1.7 | 7 |
| 2130 | Comparison of dermoscopy and reflectance confocal microscopy for the diagnosis of malignant skin tumours: a meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1627-1635. | 1.2 | 26 |
| 2131 | Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. <i>Journal of Translational Medicine</i> , 2017, 15, 39. | 1.8 | 9 |
| 2132 | Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1312-1318. | 3.3 | 23 |
| 2133 | Optimizing Outcomes for Cutaneous Head and Neck Melanoma. <i>JAMA Dermatology</i> , 2017, 153, 267. | 2.0 | 3 |
| 2134 | Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 2093-2104. | 3.2 | 48 |
| 2135 | Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison. <i>Advances in Therapy</i> , 2017, 34, 495-512. | 1.3 | 5 |
| 2136 | Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 703-708. | 1.2 | 4 |
| 2137 | Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients. <i>Pathology and Oncology Research</i> , 2017, 23, 181-188. | 0.9 | 4 |
| 2138 | Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 939-946. | 0.7 | 41 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2139 | Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 441-449. | 2.0 | 23 |
| 2140 | Primary cutaneous melanoma of the scalp: Patterns of recurrence. <i>Journal of Surgical Oncology</i> , 2017, 115, 449-454. | 0.8 | 16 |
| 2141 | Sentinel node metastasis mitotic rate (SN \times MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node–positive melanomas. <i>International Journal of Cancer</i> , 2017, 140, 1907-1917. | 2.3 | 9 |
| 2142 | Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments. <i>Journal of Dermatological Science</i> , 2017, 85, 226-234. | 1.0 | 44 |
| 2143 | Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , 2017, 72, 156-165. | 1.3 | 77 |
| 2144 | VGLL4 targets a TCF4–TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer. <i>Nature Communications</i> , 2017, 8, 14058. | 5.8 | 114 |
| 2145 | Wisely choosing thin melanomas for sentinel lymph node biopsy. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, e25. | 0.6 | 15 |
| 2146 | Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients. <i>Journal of Immunology</i> , 2017, 198, 927-936. | 0.4 | 33 |
| 2147 | Utility of hybrid \langle sc \rangle SPECT \rangle / \langle sc \rangle CT \rangle in primary melanoma lymphoscintigraphy: A retrospective case series. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 204-211. | 0.9 | 5 |
| 2148 | \langle sc \rangle TRPM1 \rangle (melastatin) expression is an independent predictor of overall survival in clinical \langle sc \rangle AJCC \rangle stage I and \langle sc \rangle II \rangle melanoma patients. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 328-337. | 0.7 | 13 |
| 2150 | Tests to assist in the staging of cutaneous squamous cell carcinoma: a generic protocol. <i>The Cochrane Library</i> , 2017, , . | 1.5 | 2 |
| 2151 | Tests to assist in the staging of cutaneous melanoma: a generic protocol. <i>The Cochrane Library</i> , 2017, , . | 1.5 | 1 |
| 2152 | The natural product mensacarcin induces mitochondrial toxicity and apoptosis in melanoma cells. <i>Journal of Biological Chemistry</i> , 2017, 292, 21102-21116. | 1.6 | 31 |
| 2153 | Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients. <i>Immunotherapy</i> , 2017, 9, 1165-1174. | 1.0 | 3 |
| 2154 | Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. <i>Nature Communications</i> , 2017, 8, 707. | 5.8 | 123 |
| 2155 | The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. <i>European Journal of Cancer</i> , 2017, 86, 101-105. | 1.3 | 51 |
| 2156 | Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5679-5686. | 3.2 | 57 |
| 2157 | The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. <i>Science Advances</i> , 2017, 3, eaao5268. | 4.7 | 38 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-------|-----------|
| 2158 | Cells to Surgery Quiz: October 2017. <i>Journal of Investigative Dermatology</i> , 2017, 137, e181. | 0.3 | 1 |
| 2159 | 001 INCOME-ASSOCIATED DISCREPANCIES IN MELANOMA SURVIVAL. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2017, 18, S85. | 0.8 | 0 |
| 2160 | Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria. <i>European Journal of Cancer</i> , 2017, 87, 212-215. | 1.3 | 22 |
| 2161 | A prognostic model for resectable acral melanoma patients on the basis of preoperative inflammatory markers. <i>Melanoma Research</i> , 2017, 27, 469-476. | 0.6 | 2 |
| 2162 | Volume and Tissue Composition Changes Measured with Dual-Energy X-Ray Absorptiometry in Melanoma-Related Limb Lymphedema. <i>Lymphatic Research and Biology</i> , 2017, 15, 274-283. | 0.5 | 5 |
| 2163 | Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492. | 157.7 | 1,662 |
| 2164 | Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP). <i>Klinische Padiatrie</i> , 2017, 229, 322-328. | 0.2 | 16 |
| 2165 | High frequency of brain metastases after adjuvant therapy for high-risk melanoma. <i>Cancer Medicine</i> , 2017, 6, 2576-2585. | 1.3 | 27 |
| 2166 | A novel stilbene-like compound that inhibits melanoma growth by regulating melanocyte differentiation and proliferation. <i>Toxicology and Applied Pharmacology</i> , 2017, 337, 30-38. | 1.3 | 4 |
| 2167 | Melanoma in pregnancy. <i>Obstetric Medicine</i> , 2017, 10, 107-112. | 0.5 | 33 |
| 2168 | Synthesis and Preclinical Evaluation of ¹⁸ F-PEG ₃ -FPN for the Detection of Metastatic Pigmented Melanoma. <i>Molecular Pharmaceutics</i> , 2017, 14, 3896-3905. | 2.3 | 15 |
| 2169 | Benefits of initial CT staging before sentinel lymph node biopsy in patients with head and neck cutaneous melanoma. <i>Head and Neck</i> , 2017, 39, 2301-2310. | 0.9 | 4 |
| 2170 | Recurrence Rates Over 20 Years in the Treatment of Malignant Melanoma: Immediate Versus Delayed Reconstruction. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2017, 5, e1378. | 0.3 | 23 |
| 2171 | A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 938-945.e4. | 0.6 | 144 |
| 2172 | A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma. <i>Melanoma Research</i> , 2017, 27, 429-438. | 0.6 | 6 |
| 2173 | Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. <i>British Journal of Cancer</i> , 2017, 117, 913-920. | 2.9 | 145 |
| 2174 | Multiple Lymph Node Basin Drainage in Trunk Melanoma Is Not Associated with Survival of Sentinel Lymph Node-Positive Patients. <i>Dermatology</i> , 2017, 233, 205-211. | 0.9 | 6 |
| 2175 | Clinical and pathologic factors associated with deep transection of biopsies of invasive melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 766-768. | 0.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2176 | Novel Additions to the AJCC's New Staging Systems for Skin Cancer. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 818-826. | 0.2 | 8 |
| 2177 | Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017, 8, 607. | 5.8 | 109 |
| 2178 | A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1 α and VEGF expressions. <i>Melanoma Research</i> , 2017, 27, 558-564. | 0.6 | 23 |
| 2179 | HLA class Ia and Ib molecules and FOXP3+ TILs in relation to the prognosis of malignant melanoma patients. <i>Clinical Immunology</i> , 2017, 183, 191-197. | 1.4 | 22 |
| 2180 | Prevention of Seroma After Inguinal Lymph Node Dissection by TachoSil Application: A Pilot Study. <i>Clinical Skin Cancer</i> , 2017, 2, 5-9. | 0.1 | 0 |
| 2181 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835. | 13.9 | 1,752 |
| 2183 | CD271 determines migratory properties of melanoma cells. <i>Scientific Reports</i> , 2017, 7, 9834. | 1.6 | 35 |
| 2184 | Immunotherapy in managing metastatic melanoma: which treatment when?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1523-1538. | 1.4 | 13 |
| 2185 | Associations of Statins and Diabetes with Diagnosis of Ulcerated Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2599-2605. | 0.3 | 12 |
| 2186 | Immunotherapies for advanced melanoma: as promising as they are expensive?. <i>Journal of the Royal Society of Medicine</i> , 2017, 110, 395-399. | 1.1 | 2 |
| 2187 | Melanoma in situ of penis. <i>Medicine (United States)</i> , 2017, 96, e7652. | 0.4 | 16 |
| 2188 | Skin Cancer: Genetics, Immunology, Treatments, and Psychological Care. , 2017, , 851-934. | | 9 |
| 2189 | Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination. <i>Melanoma Research</i> , 2017, 27, 485-491. | 0.6 | 88 |
| 2190 | Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. <i>Oncology</i> , 2017, 93, 164-176. | 0.9 | 6 |
| 2191 | Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1631-1642. | 2.0 | 16 |
| 2192 | Association Between Patient Age and Lymph Node Positivity in Thin Melanoma. <i>JAMA Dermatology</i> , 2017, 153, 866. | 2.0 | 50 |
| 2193 | Frequency of and risk factors for tumor upstaging after wide local excision of primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 341-348. | 0.6 | 46 |
| 2194 | Computer-assisted measurement of primary tumor area is prognostic of recurrence-free survival in stage IB melanoma patients. <i>Modern Pathology</i> , 2017, 30, 1402-1410. | 2.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2195 | Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. <i>Modern Pathology</i> , 2017, 30, 1538-1550. | 2.9 | 33 |
| 2196 | Dual-energy computed tomography in patients with cutaneous malignant melanoma: Comparison of noise-optimized and traditional virtual monoenergetic imaging. <i>European Journal of Radiology</i> , 2017, 95, 1-8. | 1.2 | 14 |
| 2197 | Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study. <i>Transplant International</i> , 2017, 30, 1172-1180. | 0.8 | 32 |
| 2198 | The importance of mitotic rate reporting in primary cutaneous melanoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 958-959. | 0.8 | 2 |
| 2199 | Lymphatic vessel density and VEGF-C expression as independent predictors of melanoma metastases. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2017, 70, 1653-1659. | 0.5 | 15 |
| 2200 | Raman spectroscopy for cancer detection and cancer surgery guidance: translation to the clinics. <i>Analyst</i> , 2017, 142, 3025-3047. | 1.7 | 134 |
| 2201 | Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. <i>Melanoma Research</i> , 2017, 27, 321-325. | 0.6 | 46 |
| 2202 | Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience. <i>Melanoma Research</i> , 2017, 27, 351-357. | 0.6 | 14 |
| 2203 | Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. <i>Cancer Science</i> , 2017, 108, 1223-1230. | 1.7 | 66 |
| 2204 | The natural history of thin melanoma and the utility of sentinel lymph node biopsy. <i>Journal of Surgical Oncology</i> , 2017, 116, 1185-1192. | 0.8 | 18 |
| 2205 | Precision Medicine and PET/Computed Tomography in Melanoma. <i>PET Clinics</i> , 2017, 12, 449-458. | 1.5 | 11 |
| 2207 | Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon. <i>Translational Oncology</i> , 2017, 10, 719-725. | 1.7 | 27 |
| 2208 | Clinical and palliative care outcomes for patients of poor performance status treated with anti-programmed death-1 monoclonal antibodies for advanced melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 385-390. | 0.7 | 27 |
| 2209 | Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma. <i>Melanoma Research</i> , 2017, 27, 463-468. | 0.6 | 19 |
| 2210 | A clinicopathological analysis of 153 acral melanomas and the relevance of mechanical stress. <i>Scientific Reports</i> , 2017, 7, 5564. | 1.6 | 39 |
| 2211 | Transcriptome Analysis of Canine Cutaneous Melanoma and Melanocytoma Reveals a Modulation of Genes Regulating Extracellular Matrix Metabolism and Cell Cycle. <i>Scientific Reports</i> , 2017, 7, 6386. | 1.6 | 28 |
| 2213 | Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma – A systematic review of the literature. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1760-1767. | 0.5 | 46 |
| 2214 | Vulvar Neoplasms, Benign and Malignant. <i>Obstetrics and Gynecology Clinics of North America</i> , 2017, 44, 339-352. | 0.7 | 35 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2215 | Los nuevos sistemas de estadificación del AJCC incorporan novedades en el cáncer cutáneo. Actas Dermo-sifiliográficas, 2017, 108, 818-826. | 0.2 | 13 |
| 2216 | Use of support services in a sample of patients with high-risk primary melanomas in urban, regional and rural Queensland. Australian and New Zealand Journal of Public Health, 2017, 41, 315-319. | 0.8 | 5 |
| 2217 | Häufigkeit und Muster der Tumorerkennung nach Selbstuntersuchung bei Mittel- bis Hochrisiko-Melanompatienten. JDDG - Journal of the German Society of Dermatology, 2017, 15, 61-69. | 0.4 | 0 |
| 2218 | Review of Targeted Therapies for Periocular Tumors. International Ophthalmology Clinics, 2017, 57, 153-168. | 0.3 | 3 |
| 2219 | Novel Targeted Therapies for Metastatic Melanoma. Cancer Journal (Sudbury, Mass), 2017, 23, 54-58. | 1.0 | 19 |
| 2220 | Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques. Melanoma Research, 2017, 27, 50-56. | 0.6 | 7 |
| 2221 | MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study. Melanoma Research, 2017, 27, 439-447. | 0.6 | 24 |
| 2222 | Nonvisualized sentinel lymph nodes on lymphoscintigraphy in melanoma. Nuclear Medicine Communications, 2017, 38, 383-387. | 0.5 | 13 |
| 2223 | Current status and future direction in the management of malignant melanoma. Melanoma Research, 2017, 27, 403-410. | 0.6 | 50 |
| 2224 | Malignant melanoma incidence trends in a Mediterranean population following socioeconomic transition and war: results of age-cohort analysis in Croatia, 1989-2013. Melanoma Research, 2017, 27, 498-502. | 0.6 | 6 |
| 2225 | Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study. Annals of Surgical Oncology, 2017, 24, 3245-3251. | 0.7 | 16 |
| 2226 | Subungual melanoma: Management in the modern era. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2017, 70, 1746-1752. | 0.5 | 26 |
| 2227 | Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status. Journal of the American Academy of Dermatology, 2017, 77, 893-901. | 0.6 | 29 |
| 2228 | Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clinical Cancer Research, 2017, 23, 6888-6892. | 3.2 | 29 |
| 2229 | Assessing Skin Cancer Using Epidermal Genetic Information Retrieved by Adhesive Patch Skin Surface Sampling. Dermatologic Clinics, 2017, 35, 521-524. | 1.0 | 4 |
| 2230 | Assessing Genetic Expression Profiles in Melanoma Diagnosis. Dermatologic Clinics, 2017, 35, 537-544. | 1.0 | 4 |
| 2231 | Assessing Genetic Expression Profiles in Melanoma Prognosis. Dermatologic Clinics, 2017, 35, 545-550. | 1.0 | 6 |
| 2232 | Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas: a nationwide, population-based study. International Journal of Cancer, 2017, 141, 2243-2252. | 2.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2233 | A prediction tool incorporating the biomarker S-100B for patient selection for completion lymph node dissection in stage III melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1753-1759. | 0.5 | 4 |
| 2234 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335. | 2.4 | 530 |
| 2235 | Inflammatory regulation of stem-like cells in melanoma. <i>Melanoma Research</i> , 2017, 27, 1-7. | 0.6 | 2 |
| 2236 | A Minimally Invasive Approach for Inguinal Lymphadenectomy in Melanoma and Genitourinary Malignancy: Long-Term Outcomes in an Attempted Randomized Control Trial. <i>Annals of Surgical Oncology</i> , 2017, 24, 3237-3244. | 0.7 | 19 |
| 2237 | Advances in the Management of Melanoma. <i>Current Dermatology Reports</i> , 2017, 6, 288-296. | 1.1 | 1 |
| 2238 | Axillary Metastatic Melanoma of Unknown Primary: A Case Report and Systematic Review. <i>Clinical Skin Cancer</i> , 2017, 2, 44-47. | 0.1 | 0 |
| 2239 | Atypical spleen tuberculosis in a melanoma patient accidentally detected during a 18F-FDG PET/CT study: Case report. <i>Molecular and Clinical Oncology</i> , 2017, 8, 89-92. | 0.4 | 2 |
| 2240 | The fragile X mental retardation protein regulates tumor invasiveness-related pathways in melanoma cells. <i>Cell Death and Disease</i> , 2017, 8, e3169-e3169. | 2.7 | 33 |
| 2241 | Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. <i>Melanoma Management</i> , 2017, 4, 61-68. | 0.1 | 20 |
| 2242 | Sentinel lymph node biopsy status is not the most powerful predictor of prognosis in cutaneous melanoma. <i>Australasian Journal of Dermatology</i> , 2017, 58, 256-258. | 0.4 | 11 |
| 2243 | Clinics, prognosis and new therapeutic options in patients with mucosal melanoma. <i>Medicine (United States)</i> , 2017, 96, 100-104. | 0.4 | 50 |
| 2244 | Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma. <i>Melanoma Research</i> , 2017, 27, 43-49. | 0.6 | 13 |
| 2245 | Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases: results of a prospective, non-randomized, single-centre study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2030-2037. | 1.3 | 20 |
| 2246 | Bilateral Huge Incidentalomas of Isolated Adrenal Metastases From Unknown Primary Melanoma Revealed by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, e51-e53. | 0.7 | 4 |
| 2247 | Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 848-855. | 0.8 | 25 |
| 2248 | Sentinel lymph node biopsy in early melanoma: comparison of two techniques for sentinel removal. <i>Wiener Medizinische Wochenschrift</i> , 2017, 167, 100-103. | 0.5 | 0 |
| 2249 | Primary oral malignant melanoma metastasis to the brain and breast: A case report and literature review. <i>Oncology Letters</i> , 2017, 14, 1275-1280. | 0.8 | 12 |
| 2250 | Melanoma Metastasis to the Mandible: Case Report and Comprehensive Literature Review. <i>Journal of Oral and Maxillofacial Surgery</i> , 2017, 75, 2025.e1-2025.e12. | 0.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2251 | Melanoma treatment guided by a panel of microRNA biomarkers. <i>Melanoma Management</i> , 2017, 4, 75-77. | 0.1 | 1 |
| 2252 | Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal. <i>Value in Health</i> , 2017, 20, 1065-1073. | 0.1 | 23 |
| 2253 | A surgical perspective report on melanoma management. <i>Melanoma Management</i> , 2017, 4, 105-112. | 0.1 | 5 |
| 2254 | The role for chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2017, 4, 125-136. | 0.1 | 26 |
| 2255 | Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma. <i>Melanoma Research</i> , 2017, 27, 140-144. | 0.6 | 34 |
| 2256 | Sentinel Lymph Nodes in Cutaneous Melanoma. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 417-430. | 0.7 | 18 |
| 2257 | Adjuvant interferon- γ for the treatment of high-risk melanoma: An individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 82, 171-183. | 1.3 | 159 |
| 2259 | Maligne melanoom en voorstadia. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2017, 33, 141-152. | 0.0 | 0 |
| 2261 | Glucose Oxidase- α -Polymer Nanogels for Synergistic Cancer-Starving and Oxidation Therapy. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 23528-23535. | 4.0 | 142 |
| 2262 | Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma. <i>Journal of the American College of Surgeons</i> , 2017, 225, 302-311. | 0.2 | 20 |
| 2263 | Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study. <i>BMC Cancer</i> , 2017, 17, 5. | 1.1 | 5 |
| 2264 | Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma. <i>BMC Medicine</i> , 2017, 15, 101. | 2.3 | 62 |
| 2265 | Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). <i>Oncologist</i> , 2017, 22, 951-962. | 1.9 | 13 |
| 2266 | Treatment of <i>NRAS</i> -mutated advanced or metastatic melanoma: rationale, current trials and evidence to date. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 481-492. | 1.4 | 45 |
| 2267 | Identification of TDP-43 as an oncogene in melanoma and its function during melanoma pathogenesis. <i>Cancer Biology and Therapy</i> , 2017, 18, 8-15. | 1.5 | 21 |
| 2268 | Role of FDG-PET/CT in stage 1-4 malignant melanoma patients. <i>European Journal of Plastic Surgery</i> , 2017, 40, 47-52. | 0.3 | 3 |
| 2269 | Usefulness of serum 5-hydroxycysteinyldopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma. <i>Journal of Dermatology</i> , 2017, 44, 449-454. | 0.6 | 14 |
| 2270 | Diagnosis and treatment of in-transit melanoma metastases. <i>European Journal of Surgical Oncology</i> , 2017, 43, 544-560. | 0.5 | 80 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2271 | Combinatorial immunotherapy for melanoma. <i>Cancer Gene Therapy</i> , 2017, 24, 141-147. | 2.2 | 24 |
| 2272 | Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 264-273.e2. | 0.6 | 41 |
| 2273 | Sentinel Lymph Node Genes to Predict Prognosis in Node-Positive Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 108-116. | 0.7 | 22 |
| 2274 | Epidemiology, management and survival outcomes of primary cutaneous melanoma: a ten-year overview. <i>Acta Chirurgica Belgica</i> , 2017, 117, 29-35. | 0.2 | 22 |
| 2275 | Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study. <i>Acta Oncologica</i> , 2017, 56, 52-58. | 0.8 | 23 |
| 2276 | Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. <i>Annals of Surgical Oncology</i> , 2017, 24, 952-959. | 0.7 | 23 |
| 2277 | Impact of scalp location on survival in head and neck melanoma: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 494-498.e2. | 0.6 | 21 |
| 2278 | D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress. <i>International Journal of Cancer</i> , 2017, 140, 914-921. | 2.3 | 24 |
| 2279 | (Neo)adjuvant systemic therapy for melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 534-543. | 0.5 | 52 |
| 2280 | Breslow density is a novel prognostic feature in cutaneous malignant melanoma. <i>Histopathology</i> , 2017, 70, 264-272. | 1.6 | 13 |
| 2281 | Outcome of Melanoma Patients Who Did Not Proceed to Sentinel Node Biopsy After Preoperative Lymphoscintigraphy. <i>Annals of Surgical Oncology</i> , 2017, 24, 117-126. | 0.7 | 11 |
| 2282 | Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. <i>Journal of Dermatology</i> , 2017, 44, 117-122. | 0.6 | 170 |
| 2283 | Survival of acral lentiginous melanoma in the National Cancer Institute of Colombia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 438-442. | 1.3 | 24 |
| 2284 | Melanoma antigens are biomarkers for ipilimumab response. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 252-259. | 1.3 | 9 |
| 2285 | MicroRNAs role as potential biomarkers and key regulators in melanoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 3-10. | 1.5 | 48 |
| 2286 | Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. <i>Medicinal Research Reviews</i> , 2017, 37, 98-148. | 5.0 | 92 |
| 2287 | Surgical outcomes in patients with cutaneous malignant melanoma in Europe – a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 603-615. | 1.3 | 24 |
| 2288 | Sentinel node biopsy in melanoma: Current controversies addressed. <i>European Journal of Surgical Oncology</i> , 2017, 43, 517-533. | 0.5 | 52 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2289 | Epidemiology of Melanoma. , 2017, , 591-611. | | 2 |
| 2290 | Pathology and Molecular Pathology of Melanoma. , 2017, , 613-653. | | 1 |
| 2291 | Management Controversies in Head and Neck Melanoma. JAMA Facial Plastic Surgery, 2017, 19, 53-62. | 2.2 | 19 |
| 2292 | Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 142-149. | 0.7 | 30 |
| 2293 | Low predictive value of sentinel lymph node biopsy in patients with thin melanoma. International Journal of Dermatology, 2017, 56, e6-e7. | 0.5 | 2 |
| 2294 | 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma. Modern Pathology, 2017, 30, 60-68. | 2.9 | 17 |
| 2295 | Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 2017, 28, 368-376. | 0.6 | 641 |
| 2296 | Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with <scp>LDH</scp> and S100B. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 636-642. | 1.3 | 17 |
| 2297 | Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. Oncoimmunology, 2017, 6, e1231291. | 2.1 | 29 |
| 2298 | Melanoma diagnosed in lesions previously treated by laser therapy. Journal of Dermatology, 2017, 44, 23-28. | 0.6 | 19 |
| 2299 | Complications of sentinel lymph node biopsy for melanoma – A systematic review of the literature. European Journal of Surgical Oncology, 2017, 43, 270-277. | 0.5 | 79 |
| 2300 | Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma. Cancer Immunology, Immunotherapy, 2017, 66, 299-308. | 2.0 | 11 |
| 2301 | Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013. Journal of the American Academy of Dermatology, 2017, 76, 258-263. | 0.6 | 88 |
| 2302 | Making decisions on sentinel lymph node biopsy for malignant melanoma: prioritization of determinants using a decision tree. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e247-e249. | 1.3 | 8 |
| 2303 | Metastatic pathways in patients with cutaneous melanoma. Pigment Cell and Melanoma Research, 2017, 30, 13-27. | 1.5 | 38 |
| 2304 | Lentigo Maligna Melanoma. , 2017, , . | | 0 |
| 2305 | Expression of PIWIL3 in primary and metastatic melanoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 433-437. | 1.2 | 16 |
| 2306 | Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). Journal of Cancer Research and Clinical Oncology, 2017, 143, 533-540. | 1.2 | 41 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2307 | Metastasectomy in cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 572-580. | 0.5 | 18 |
| 2308 | Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 54-59. | 0.6 | 10 |
| 2309 | Editorial: Should We Abandon TNM Staging in Favor of Gene Profiles in Node-Positive Melanoma?. <i>Annals of Surgical Oncology</i> , 2017, 24, 3-5. | 0.7 | 2 |
| 2310 | Oridonin inhibits migration, invasion, adhesion and TGF β ¹ -induced epithelial-mesenchymal transition of melanoma cells by inhibiting the activity of PI3K/Akt/GSK β signaling pathway. <i>Oncology Letters</i> , 2017, 15, 1362-1372. | 0.8 | 21 |
| 2312 | Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma. <i>Oncology Letters</i> , 2017, 15, 1839-1844. | 0.8 | 12 |
| 2313 | Factors Linked to the Metastatic Spread of Malignant Cutaneous Melanoma to the Lower Extremities in a Retrospective 18 F-FDG PET/CT Cohort. <i>Clinical Skin Cancer</i> , 2017, 2, 48-53. | 0.1 | 1 |
| 2314 | Melanoma cutaneo cervicofacial. <i>EMC - OtorrinolaringologĂa</i> , 2017, 46, 1-9. | 0.0 | 0 |
| 2315 | Melanomi cutanei cervicofacciali. <i>EMC - Otorinolarin角度iatria</i> , 2017, 16, 1-9. | 0.0 | 0 |
| 2316 | Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. <i>Bioinformatics and Biology Insights</i> , 2017, 11, 117793221769483. | 1.0 | 25 |
| 2317 | Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases—a phase II, single centre, randomised, pilot study. <i>BMJ Open</i> , 2017, 7, e016816. | 0.8 | 13 |
| 2318 | Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. <i>BMC Cancer</i> , 2017, 17, 536. | 1.1 | 113 |
| 2319 | Modernizing Analytics for Melanoma with a Large-Scale Research Dataset. , 2017, , . | | 7 |
| 2320 | Melanocyte-specific gene 1 promotes melanoma progression by enhancing the expression of Bcl-2. <i>Oncology Letters</i> , 2018, 15, 2413-2418. | 0.8 | 2 |
| 2321 | Matrix Metalloproteinases in Melanoma with and without Regression. , 2017, , . | | 0 |
| 2322 | The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab. <i>Annals of Research Hospitals</i> , 2017, 1, 1-1. | 0.0 | 1 |
| 2323 | Repressing CD147 is a novel therapeutic strategy for malignant melanoma. <i>Oncotarget</i> , 2017, 8, 25806-25813. | 0.8 | 30 |
| 2324 | Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 651-660. | 1.8 | 5 |
| 2326 | Conditional Survival-Based “Abbreviated” Routine Cancer Surveillance for Pathologic Stage IB Melanoma. <i>American Surgeon</i> , 2017, 83, 1256-1262. | 0.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2327 | Tumor Mitotic Rate and Association with Recurrence in Sentinel Lymph Node Negative Stage II Melanoma Patients. <i>American Surgeon</i> , 2017, 83, 972-978. | 0.4 | 13 |
| 2328 | Lethal Melanomas: A Population-based Registry Study in Western Sweden from 1990 to 2014. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1206-1211. | 0.6 | 7 |
| 2329 | Primary Oral Mucosal Melanomas – Two Case Reports and Comprehensive Literature Review. <i>Acta Clinica Croatica</i> , 2017, 56, 323-330. | 0.1 | 7 |
| 2330 | Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. <i>Oncotarget</i> , 2017, 8, 79809-79815. | 0.8 | 27 |
| 2331 | Diagnostic Efficacy of Digital Dermoscopy and Clinical Findings in Thin Melanoma of the Lower Limbs. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1100-1107. | 0.6 | 3 |
| 2332 | Down-regulated miR-23a Contributes to the Metastasis of Cutaneous Melanoma by Promoting Autophagy. <i>Theranostics</i> , 2017, 7, 2231-2249. | 4.6 | 81 |
| 2333 | Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1212-1218. | 0.6 | 29 |
| 2334 | Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2382. | 1.8 | 8 |
| 2335 | Function and Clinical Implications of Long Non-Coding RNAs in Melanoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 715. | 1.8 | 37 |
| 2336 | Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guérin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. <i>Frontiers in Immunology</i> , 2017, 8, 625. | 2.2 | 56 |
| 2337 | Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617. | 2.2 | 43 |
| 2338 | A Review of Black Salve: Cancer Specificity, Cure, and Cosmesis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-11. | 0.5 | 12 |
| 2339 | Management of the cutaneous adverse effects of antimelanoma therapy. <i>Melanoma Management</i> , 2017, 4, 187-202. | 0.1 | 5 |
| 2340 | Melanoma Staging. , 2017, , 81-90. | | 0 |
| 2341 | The Role of Neighborhood Characteristics in Late Stage Melanoma Diagnosis among Hispanic Men in California, Texas, and Florida, 1996–2012. <i>Journal of Cancer Epidemiology</i> , 2017, 2017, 1-15. | 0.5 | 16 |
| 2342 | Recent advances in diagnosis and therapy of skin cancers through nanotechnological approaches. , 2017, , 285-306. | | 8 |
| 2343 | Therapy of Melanoma. , 2017, , 91-142. | | 0 |
| 2344 | Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases. <i>Journal of Cancer</i> , 2017, 8, 3828-3837. | 1.2 | 23 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2345 | MAPK and Hippo signaling pathways crosstalk via the RAF-1/MST-2 interaction in malignant melanoma. <i>Oncology Reports</i> , 2017, 38, 1199-1205. | 1.2 | 23 |
| 2346 | Advances in radioguided surgery in oncology. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 247-270. | 0.4 | 48 |
| 2347 | Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma. <i>PLoS ONE</i> , 2017, 12, e0170025. | 1.1 | 12 |
| 2348 | Clinicopathological features and prognosis of patients with de novo versus nevus-associated melanoma in Taiwan. <i>PLoS ONE</i> , 2017, 12, e0177126. | 1.1 | 16 |
| 2349 | 31-Gene Expression Profile in Melanoma. <i>Journal of the Dermatology Nurses' Association</i> , 2017, 9, 248-250. | 0.1 | 3 |
| 2350 | Loss of the chromatin modifier Kdm2aa causes BrafV600E-independent spontaneous melanoma in zebrafish. <i>PLoS Genetics</i> , 2017, 13, e1006959. | 1.5 | 13 |
| 2351 | Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial. <i>BMC Cancer</i> , 2017, 17, 562. | 1.1 | 31 |
| 2352 | Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. <i>BMC Cancer</i> , 2017, 17, 584. | 1.1 | 11 |
| 2353 | Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2017, 15, 244. | 1.8 | 73 |
| 2354 | Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. <i>Journal of Hematology and Oncology</i> , 2017, 10, 152. | 6.9 | 63 |
| 2355 | Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability. <i>BMC Research Notes</i> , 2017, 10, 411. | 0.6 | 10 |
| 2356 | The small vesicular culprits: the investigation of extracellular vesicles as new targets for cancer treatment. <i>Clinical and Translational Medicine</i> , 2017, 6, 45. | 1.7 | 29 |
| 2357 | High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. , 2017, 5, 74. | | 45 |
| 2358 | The intriguing effect of delay time to sentinel lymph node biopsy on survival: a propensity score matching study on a cohort of melanoma patients. <i>European Journal of Dermatology</i> , 2017, 27, 487-495. | 0.3 | 5 |
| 2359 | Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 842-847. | 1.2 | 13 |
| 2360 | Nail apparatus melanoma in a Japanese population: a comparative study of surgical procedures and prognoses in a large series of 151 cases. <i>European Journal of Dermatology</i> , 2017, 27, 620-626. | 0.3 | 17 |
| 2361 | Can we improve melanoma detection methods?. <i>Melanoma Management</i> , 2017, 4, 139-142. | 0.1 | 2 |
| 2362 | An Update On Natural Compounds and Their Modern Formulations for the Management of Malignant Melanoma. , 2017, , . | | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2363 | Genetic variants of PDGF signaling pathway genes predict cutaneous melanoma survival. <i>Oncotarget</i> , 2017, 8, 74595-74606. | 0.8 | 3 |
| 2364 | Immunohistochemical evaluation of vitamin D receptor (VDR) expression in cutaneous melanoma tissues and four VDR gene polymorphisms. <i>Cancer Biology and Medicine</i> , 2017, 14, 162. | 1.4 | 14 |
| 2365 | AT-rich Interaction Domain-containing Protein 3B is a New Tumour Marker for Melanoma. <i>Acta Dermato-Venereologica</i> , 2017, 97, 112-114. | 0.6 | 4 |
| 2366 | Flavonoids: Promising Natural Products for Treatment of Skin Cancer (Melanoma). , 0, , . | | 5 |
| 2367 | An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma. <i>Vaccines</i> , 2017, 5, 38. | 2.1 | 14 |
| 2368 | Management of intracranial melanomas in the era of precision medicine. <i>Oncotarget</i> , 2017, 8, 89326-89347. | 0.8 | 16 |
| 2369 | Significance of serum neural precursor cell-expressed developmentally downregulated protein 9 in melanoma. <i>Molecular and Clinical Oncology</i> , 2017, 8, 204-208. | 0.4 | 3 |
| 2370 | Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1083-1088. | 0.4 | 12 |
| 2371 | Bsm1 (rs1544410) and Fok1 (rs2228570) vitamin D receptor polymorphisms, smoking, and body mass index as risk factors of cutaneous malignant melanoma in northeast Italy. <i>Cancer Biology and Medicine</i> , 2017, 14, 302. | 1.4 | 18 |
| 2372 | Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 63-71. | 0.8 | 66 |
| 2373 | Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686. | 0.8 | 42 |
| 2374 | Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. <i>Journal of Clinical Oncology</i> , 2017, 35, 1721-1729. | 0.8 | 40 |
| 2375 | Skin Cancer of the Head and Neck. , 2017, , 714-727. | | 1 |
| 2376 | Patient-Derived Xenografting of Human Melanoma. , 2017, , 341-363. | | 0 |
| 2377 | CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma. <i>Postepy Dermatologii i Alergologii</i> , 2017, 3, 233-239. | 0.4 | 3 |
| 2378 | Palliative radiotherapy for skin malignancies. <i>Annals of Palliative Medicine</i> , 2017, 6, 165-172. | 0.5 | 17 |
| 2379 | Targeting Melanoma with Cancer-Killing Viruses. <i>The Open Virology Journal</i> , 2017, 11, 28-47. | 1.8 | 8 |
| 2380 | Clinical decision support systems at the Vienna General Hospital using Arden Syntax: Design, implementation, and integration. <i>Artificial Intelligence in Medicine</i> , 2018, 92, 24-33. | 3.8 | 21 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2381 | Examining the Incidence and Presentation of Melanoma in the Cardiothoracic Transplant Population. <i>JAMA Dermatology</i> , 2018, 154, 589. | 2.0 | 9 |
| 2382 | ECCO essential requirements for quality cancer care: Melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 164-178. | 2.0 | 41 |
| 2383 | Breslow Density Is a Novel Prognostic Feature That Adds Value to Melanoma Staging. <i>American Journal of Surgical Pathology</i> , 2018, 42, 715-725. | 2.1 | 11 |
| 2385 | Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520. | 5.1 | 183 |
| 2386 | Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma. <i>Scientific Reports</i> , 2018, 8, 4044. | 1.6 | 53 |
| 2387 | Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. <i>Oncolimmunology</i> , 2018, 7, e1442166. | 2.1 | 57 |
| 2388 | Quantitative Analysis of Immune Infiltrates in Primary Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 481-493. | 1.6 | 92 |
| 2389 | Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. <i>Annals of Surgical Oncology</i> , 2018, 25, 2172-2177. | 0.7 | 16 |
| 2390 | Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. <i>Clinical Chemistry</i> , 2018, 64, 830-842. | 1.5 | 50 |
| 2392 | Do you know your guidelines? Diagnosis and management of cutaneous head and neck melanoma. <i>Head and Neck</i> , 2018, 40, 875-885. | 0.9 | 5 |
| 2393 | ERK5 is activated by oncogenic BRAF and promotes melanoma growth. <i>Oncogene</i> , 2018, 37, 2601-2614. | 2.6 | 50 |
| 2394 | STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon- γ . <i>Melanoma Research</i> , 2018, 28, 204-210. | 0.6 | 8 |
| 2395 | Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 825-834. | 2.0 | 91 |
| 2396 | Contemporary Treatment Approaches to Sinonasal Mucosal Melanoma. <i>Current Oncology Reports</i> , 2018, 20, 10. | 1.8 | 34 |
| 2397 | Unique Genes in Tumor-Positive Sentinel Lymph Nodes Associated with Nonsentinel Lymph Node Metastases in Melanoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1296-1303. | 0.7 | 8 |
| 2398 | The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. <i>Targeted Oncology</i> , 2018, 13, 363-370. | 1.7 | 4 |
| 2399 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801. | 13.9 | 1,441 |
| 2400 | Risk stratification of sentinel node- γ positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. <i>European Journal of Cancer</i> , 2018, 96, 25-33. | 1.3 | 59 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2401 | Association of Marital Status With T Stage at Presentation and Management of Early-Stage Melanoma. <i>JAMA Dermatology</i> , 2018, 154, 574. | 2.0 | 19 |
| 2402 | Association of Skin Examination Behaviors and Thinner Nodular vs Superficial Spreading Melanoma at Diagnosis. <i>JAMA Dermatology</i> , 2018, 154, 544. | 2.0 | 23 |
| 2403 | Disecci3n ganglionar en el paciente con melanoma y met3stasis en el ganglio centinela: propuesta de decisi3n basada en la evidencia actual. <i>Actas Dermo-sifilogr3ficas</i> , 2018, 109, 390-398. | 0.2 | 8 |
| 2404 | Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes. <i>Melanoma Research</i> , 2018, 28, 423-434. | 0.6 | 11 |
| 2405 | Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies. <i>Melanoma Research</i> , 2018, 28, 222-229. | 0.6 | 5 |
| 2406 | Patients with sentinel lymph node positive melanoma: Who needs completion lymph node dissection?. <i>American Journal of Surgery</i> , 2018, 215, 868-872. | 0.9 | 8 |
| 2408 | Completion lymphadenectomy for sentinel node positive cutaneous head & neck melanoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2018, 3, 43-48. | 0.6 | 8 |
| 2409 | Long-term survival with modern therapeutic agents against metastatic melanomaâ€”vemurafenib and ipilimumab in a daily life setting. <i>Medical Oncology</i> , 2018, 35, 24. | 1.2 | 13 |
| 2410 | Personal history of keratinocyte carcinoma is associated with reduced risk of death from invasive melanoma in men. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 957-963. | 0.6 | 5 |
| 2412 | Prognostic Role of BRAFV600E Cellular Localization in Melanoma. <i>Journal of the American College of Surgeons</i> , 2018, 226, 526-537. | 0.2 | 17 |
| 2413 | Hu antigen R (HuR) heterogeneous expression quantification as a prognostic marker of melanoma. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 333-336. | 0.7 | 3 |
| 2414 | Melanoma in the very elderly, management in patients 85 years of age and over. <i>Journal of Geriatric Oncology</i> , 2018, 9, 488-493. | 0.5 | 11 |
| 2415 | Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2020, 2020, CD011123. | 1.5 | 136 |
| 2416 | Anticarcinogenic activities of sulforaphane are influenced by Nerve Growth Factor in human melanoma A375 cells. <i>Food and Chemical Toxicology</i> , 2018, 113, 154-161. | 1.8 | 9 |
| 2417 | Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 942-948. | 0.6 | 29 |
| 2418 | Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 951-961. | 1.1 | 34 |
| 2419 | Brain metastases: epidemiology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 27-42. | 1.0 | 198 |
| 2420 | How breakthroughs in translational research have impacted treatment strategies for melanoma. <i>British Journal of Dermatology</i> , 2018, 178, 5-8. | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2421 | Predictors for Use of Sentinel Node Biopsy and the Association with Improved Survival in Melanoma Patients Who Have Nodal Staging. <i>Annals of Surgical Oncology</i> , 2018, 25, 903-911. | 0.7 | 30 |
| 2422 | Evaluation of the eighth American Joint Committee on Cancer staging system for malignant melanoma of the skin. <i>Future Oncology</i> , 2018, 14, 471-481. | 1.1 | 11 |
| 2423 | Circulating epithelial tumor cells as a prognostic tool for malignant melanoma. <i>Melanoma Research</i> , 2018, 28, 37-43. | 0.6 | 4 |
| 2424 | Melanoma of the Skin in the Danish Cancer Registry and the Danish Melanoma Database. <i>Epidemiology</i> , 2018, 29, 442-447. | 1.2 | 14 |
| 2425 | Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018, 105, e31-e47. | 0.1 | 3 |
| 2426 | Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 181-193. | 5.1 | 233 |
| 2427 | The role of nivolumab in melanoma. <i>Future Oncology</i> , 2018, 14, 1241-1252. | 1.1 | 12 |
| 2428 | Emerging Biomarkers in Cutaneous Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 203-218. | 1.6 | 35 |
| 2429 | High density of M2 macrophages in acral lentiginous melanoma compared to superficial spreading melanoma. <i>Histopathology</i> , 2018, 72, 1189-1198. | 1.6 | 8 |
| 2430 | Reevaluation of established and new criteria in differential diagnosis of Spitz nevus and melanoma. <i>Archives of Dermatological Research</i> , 2018, 310, 329-342. | 1.1 | 14 |
| 2431 | Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. <i>Nature Communications</i> , 2018, 9, 595. | 5.8 | 68 |
| 2432 | Pediatric patients with cutaneous melanoma: A European study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26974. | 0.8 | 26 |
| 2433 | Humanistic burden of disease for patients with advanced melanoma in Canada. <i>Supportive Care in Cancer</i> , 2018, 26, 1985-1991. | 1.0 | 7 |
| 2434 | A new era in holistic care: bridging the gap between dermatologists and oncologists for the treatment of malignant melanoma. <i>British Journal of Dermatology</i> , 2018, 178, 1-4. | 1.4 | 5 |
| 2435 | Quality of life patient-reported outcomes for locally advanced cutaneous melanoma. <i>Melanoma Research</i> , 2018, 28, 134-142. | 0.6 | 20 |
| 2436 | Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China. <i>Annals of Surgical Oncology</i> , 2018, 25, 885-893. | 0.7 | 7 |
| 2437 | Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2018, 7, 95-104. | 1.3 | 16 |
| 2438 | Mitotic rate is associated with positive lymph nodes in patients with thin melanomas. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 935-941. | 0.6 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2439 | The association between dermoscopic features and BRAF mutational status in cutaneous melanoma: Significance of the blue-white veil. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 920-926.e4. | 0.6 | 13 |
| 2440 | Histone deacetylase inhibitor (HDACi) upregulates activin A and activates the Smad signaling pathway in melanomas. <i>Journal of Dermatological Science</i> , 2018, 90, 13-20. | 1.0 | 3 |
| 2441 | Expert Elicitation of Multinomial Probabilities for Decision-Analytic Modeling: An Application to Rates of Disease Progression in Undiagnosed and Untreated Melanoma. <i>Value in Health</i> , 2018, 21, 669-676. | 0.1 | 11 |
| 2442 | Metastases to the parotid gland - A review of the clinicopathological evolution, molecular mechanisms and management. <i>Surgical Oncology</i> , 2018, 27, 44-53. | 0.8 | 8 |
| 2443 | Clinicopathological characteristics of cutaneous malignant melanoma in patients at a tertiary hospital in Macaronesia. Survival as a function of locoregional prognostic factors per the American Joint Committee on Cancer. <i>International Journal of Dermatology</i> , 2018, 57, 193-201. | 0.5 | 0 |
| 2444 | Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8mm Separates Higher-Risk and Lower-Risk Tumors. <i>Annals of Surgical Oncology</i> , 2018, 25, 894-902. | 0.7 | 69 |
| 2445 | A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 235-242. | 1.0 | 7 |
| 2446 | The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival. <i>European Journal of Cancer</i> , 2018, 91, 1-10. | 1.3 | 12 |
| 2447 | Stratifying SLN incidence in intermediate thickness melanoma patients. <i>American Journal of Surgery</i> , 2018, 215, 699-706. | 0.9 | 26 |
| 2448 | Management of Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 85-88. | 13.9 | 8 |
| 2449 | Redox/enzyme sensitive chondroitin sulfate-based self-assembled nanoparticles loading docetaxel for the inhibition of metastasis and growth of melanoma. <i>Carbohydrate Polymers</i> , 2018, 184, 82-93. | 5.1 | 61 |
| 2450 | Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 240-252. | 1.2 | 32 |
| 2451 | Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma. <i>Annals of Oncology</i> , 2018, 29, 490-496. | 0.6 | 124 |
| 2452 | Influence of variability in assessment of Breslow thickness, mitotic rate and ulceration among US pathologists interpreting invasive melanoma, for the purpose of AJCC staging. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 588-596. | 0.7 | 8 |
| 2453 | A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma. <i>Journal of Pharmaceutical Policy and Practice</i> , 2018, 11, 4. | 1.1 | 13 |
| 2454 | Immunohistochemical CD271 expression correlates with melanoma progress in a case-control study. <i>Pathology</i> , 2018, 50, 402-410. | 0.3 | 6 |
| 2455 | Feasibility of an online mindfulness-based program for patients with melanoma: study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 223. | 0.7 | 8 |
| 2456 | Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 48. | 0.4 | 30 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2457 | Neoadjuvant treatment for malignant and metastatic cutaneous melanoma. The Cochrane Library, 0, , . | 1.5 | 4 |
| 2458 | Clinical significance of tumor mitotic rate and lack of epidermal attachment in melanoma of the head and neck. <i>Head and Neck</i> , 2018, 40, 1691-1696. | 0.9 | 2 |
| 2459 | Clinical features and prognosis of Asian patients with acral lentiginous melanoma who have nodal nevi in their sentinel lymph node biopsy specimen. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 706-713. | 0.6 | 11 |
| 2460 | Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. <i>Cancer Medicine</i> , 2018, 7, 583-593. | 1.3 | 45 |
| 2461 | Downregulated TRPV1 Expression Contributes to Melanoma Growth via the Calcineurin-ATF3-p53 Pathway. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2205-2215. | 0.3 | 34 |
| 2462 | Targeted ultrasound and fine-needle aspiration cytology for sentinel node diagnostics in early-stage melanoma: a validation study. <i>Melanoma Research</i> , 2018, 28, 319-325. | 0.6 | 6 |
| 2464 | Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 52-59.e5. | 0.6 | 27 |
| 2465 | Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial. <i>Oncolmmunology</i> , 2018, 7, e1419113. | 2.1 | 29 |
| 2466 | Vertical Growth Phase as a Prognostic Factor for Sentinel Lymph Node Positivity in Thin Melanomas: A Systematic Review and Meta-Analysis. <i>Plastic and Reconstructive Surgery</i> , 2018, 141, 1529-1540. | 0.7 | 16 |
| 2467 | Imaging melanoma: when and why. A proposal for a modern approach. <i>Clinical and Translational Imaging</i> , 2018, 6, 123-134. | 1.1 | 0 |
| 2468 | Sentinel lymph node biopsy in cutaneous head and neck melanoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 1271-1279. | 0.8 | 15 |
| 2469 | Pregnancy and Melanoma: Recommendations for Clinical Scenarios. <i>International Journal of Women's Dermatology</i> , 2018, 4, 113-115. | 1.1 | 7 |
| 2470 | EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. <i>Journal of Controlled Release</i> , 2018, 277, 48-56. | 4.8 | 23 |
| 2471 | Upregulated deubiquitinase <sc>USP</sc>4 plays an oncogenic role in melanoma. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2944-2954. | 1.6 | 28 |
| 2472 | Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320. | 2.3 | 476 |
| 2473 | Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. <i>ESMO Open</i> , 2018, 3, e000317. | 2.0 | 12 |
| 2474 | Major prognostic factors for recurrence and survival independent of the American Joint Committee on Cancer eighth edition staging system in patients with cutaneous squamous cell carcinoma treated with multimodality therapy. <i>Head and Neck</i> , 2018, 40, 1406-1414. | 0.9 | 28 |
| 2475 | The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. <i>European Journal of Health Economics</i> , 2018, 19, 1163-1172. | 1.4 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2476 | Intralesional PV-10 for the treatment of in-transit melanoma metastases—Results of a prospective, non-randomized, single center study. <i>Journal of Surgical Oncology</i> , 2018, 117, 579-587. | 0.8 | 30 |
| 2477 | Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 90-94. | 0.6 | 8 |
| 2478 | Prognostic factors in head and neck mucosal malignant melanoma. <i>Auris Nasus Larynx</i> , 2018, 45, 135-142. | 0.5 | 6 |
| 2479 | Exploring Knowledge, Attitudes, and Practice Associated With Meditation Among Patients With Melanoma. <i>Integrative Cancer Therapies</i> , 2018, 17, 237-247. | 0.8 | 15 |
| 2480 | Folic Acid Modulates DMBA/TPA-Induced Changes in Skin of Mice: A Study Relevant to Carcinogenesis. <i>Journal of Dietary Supplements</i> , 2018, 15, 72-87. | 1.4 | 6 |
| 2481 | Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi. <i>American Journal of Dermatopathology</i> , 2018, 40, 259-264. | 0.3 | 20 |
| 2482 | Clinical correlates and prognostic value of different metastatic sites in patients with malignant melanoma of the skin: a SEER database analysis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 176-181. | 1.1 | 22 |
| 2483 | Metastatic Melanoma in Sentinel Node-Negative Patients: The Ottawa Experience. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 14-21. | 0.6 | 7 |
| 2484 | The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 82-94. | 1.5 | 3 |
| 2485 | Pleural Metastasis From Cutaneous Malignant Melanoma. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2018, 25, 54-56. | 0.8 | 2 |
| 2486 | Genital diseases in the mature woman. <i>Clinics in Dermatology</i> , 2018, 36, 208-221. | 0.8 | 11 |
| 2487 | Treatment and outcomes of melanoma in Asia: Results from the National Cancer Centre Singapore. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e95-e102. | 0.7 | 16 |
| 2488 | Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 87-96. | 3.0 | 89 |
| 2489 | Determining the False-Negative Rate Using Fluorescence Image-Assisted Sentinel Lymph Node Biopsy in Cutaneous Melanoma. <i>Annals of Plastic Surgery</i> , 2018, 80, 54-58. | 0.5 | 4 |
| 2490 | Association Between Oxidative Stress and Melanoma Progression. <i>Journal of Medical Biochemistry</i> , 2018, 37, 12-20. | 0.7 | 27 |
| 2491 | Antitumor activity and expression profiles of genes induced by sulforaphane in human melanoma cells. <i>European Journal of Nutrition</i> , 2018, 57, 2547-2569. | 1.8 | 30 |
| 2492 | Comprehensive histopathological comparison of epidermotropic/dermal metastatic melanoma and primary nodular melanoma. <i>Histopathology</i> , 2018, 72, 472-480. | 1.6 | 10 |
| 2493 | Pathology and genomics of pediatric melanoma: A critical reexamination and new insights. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26792. | 0.8 | 28 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2494 | Allogeneic stem cell transplantation as a risk factor for recurrent melanoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1750-1752. | 0.6 | 1 |
| 2495 | Morbidity and Outcomes Following Axillary Lymphadenectomy for Melanoma: Weighing the Risk of Surgery in the Era of MSLT-II. <i>Annals of Surgical Oncology</i> , 2018, 25, 465-470. | 0.7 | 19 |
| 2496 | Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. <i>European Journal of Cancer</i> , 2018, 88, 1-9. | 1.3 | 133 |
| 2497 | Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria: A Dutch population-based study. <i>European Journal of Cancer</i> , 2018, 92, 100-107. | 1.3 | 8 |
| 2498 | Primary bilateral uveal melanoma: a population-based study and systematic review. <i>Clinical and Experimental Ophthalmology</i> , 2018, 46, 502-510. | 1.3 | 9 |
| 2499 | A 14-protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700094. | 0.8 | 0 |
| 2500 | Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. <i>British Journal of Cancer</i> , 2018, 118, 495-508. | 2.9 | 47 |
| 2501 | Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Annals of Surgical Oncology</i> , 2018, 25, 356-377. | 0.7 | 130 |
| 2502 | Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIb-IVM1c melanoma. <i>Melanoma Research</i> , 2018, 28, 44-51. | 0.6 | 31 |
| 2503 | Wait Times for Melanoma Surgery: Is There an Association with Overall Survival?. <i>Annals of Surgical Oncology</i> , 2018, 25, 265-270. | 0.7 | 14 |
| 2504 | Surgical and Anatomic Considerations of Malignancies Affecting the Groin: Consideration for Melanoma. , 2018, , 63-74. | | 0 |
| 2505 | A systematic review and meta-analysis of utility estimates in melanoma. <i>British Journal of Dermatology</i> , 2018, 178, 384-393. | 1.4 | 12 |
| 2506 | Why target the tumor stroma in melanoma?. <i>Journal of Cell Communication and Signaling</i> , 2018, 12, 113-118. | 1.8 | 22 |
| 2507 | <i>PDCD1</i> gene polymorphisms as regulators of T-lymphocyte activity in cutaneous melanoma risk and prognosis. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 308-317. | 1.5 | 12 |
| 2508 | Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 303-317. | 3.3 | 78 |
| 2509 | Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 376-383. | 3.3 | 160 |
| 2510 | Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients. <i>British Journal of Cancer</i> , 2018, 118, 398-404. | 2.9 | 19 |
| 2511 | Clinicopathologic Factors Predictive of Occult Lymph Node Involvement in Cutaneous Head and Neck Melanoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 489-496. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2512 | Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell and Melanoma Research, 2018, 31, 73-81. | 1.5 | 25 |
| 2513 | Sentinel Lymph Node Characterization with a Dual-Targeted Molecular Ultrasound Contrast Agent. Molecular Imaging and Biology, 2018, 20, 221-229. | 1.3 | 16 |
| 2514 | Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease. JCO Precision Oncology, 2018, 2, 1-30. | 1.5 | 13 |
| 2515 | Conditional recurrence-free survival in patients with primary stage II cutaneous malignant melanoma – a population-based study. Melanoma Research, 2018, 28, 637-640. | 0.6 | 3 |
| 2516 | Management of In-Transit Melanoma: Present Challenges and Future Directions. Journal of Oncology Practice, 2018, 14, 304-305. | 2.5 | 2 |
| 2517 | Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update Summary. Journal of Oncology Practice, 2018, 14, 242-245. | 2.5 | 10 |
| 2518 | Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 399-413. | 0.8 | 190 |
| 2519 | Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2018, 36, 1668-1674. | 0.8 | 360 |
| 2520 | Atlas of PET-CT. , 2018, , . | | 0 |
| 2521 | Mechanisms of Drug Resistance in Cancer Therapy. Handbook of Experimental Pharmacology, 2018, , . | 0.9 | 1 |
| 2522 | Expression of 3q oncogene SEC62 in atypical fibroxanthoma – immunohistochemical analysis of 41 cases and correlation with clinical, viral and histopathologic features. Oncology Letters, 2018, 17, 1768-1776. | 0.8 | 8 |
| 2523 | Systematic review of advanced practice nurses' skin cancer detection knowledge and attitudes, clinical skin examination, lesion detection, and training. Journal of the American Association of Nurse Practitioners, 2018, 30, 43-58. | 0.5 | 13 |
| 2525 | Predictive genetic profiles for regional lymph node metastasis in primary cutaneous melanoma: a case-matched pilot study. Melanoma Research, 2018, 28, 555-561. | 0.6 | 1 |
| 2526 | Use of gene expression profile testing as a prognostic tool in early-stage cutaneous melanoma – compelling but not ready for primetime. Melanoma Research, 2018, 28, 652-654. | 0.6 | 0 |
| 2527 | A Case of Malignant Melanoma Arising in Mediastinal Malignant Teratoma. Case Reports in Pediatrics, 2018, 2018, 1-5. | 0.2 | 2 |
| 2528 | Possibilities for the Therapy of Melanoma: Current Knowledge and Future Directions. , 2018, , . | | 1 |
| 2529 | A Survey of Licensed Massage Therapists'™ Perceptions of Skin Cancer Prevention and Detection Activities. International Journal of Therapeutic Massage & Bodywork, 2018, 11, 4-10. | 0.1 | 4 |
| 2530 | Hospital-Based Study of Compliance with NCCN Guidelines and Predictive Factors of Sentinel Lymph Node Biopsy in the Setting of Thin Melanoma Using the National Cancer Database. American Surgeon, 2018, 84, 672-679. | 0.4 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2531 | Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. The Cochrane Library, 2018, 2018, CD013187. | 1.5 | 10 |
| 2532 | Optical coherence tomography for diagnosing skin cancer in adults. The Cochrane Library, 2018, 12, CD013189. | 1.5 | 59 |
| 2533 | Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma. The Cochrane Library, 2018, 2018, CD013192. | 1.5 | 76 |
| 2534 | Visual inspection for diagnosing cutaneous melanoma in adults. The Cochrane Library, 2018, 2018, CD013194. | 1.5 | 32 |
| 2535 | Recent Advances in Polymeric Nanosystems for Treating Cutaneous Melanoma and Its Metastasis. Current Pharmaceutical Design, 2018, 23, 5301-5314. | 0.9 | 6 |
| 2536 | Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative 18F-FDG PET/CT analysis. EJNMMI Research, 2018, 8, 101. | 1.1 | 18 |
| 2537 | Vitamin D receptor polymorphisms and melanoma (Review). Oncology Letters, 2019, 17, 4162-4169. | 0.8 | 20 |
| 2538 | Endogenous expression mapping of malignant melanoma by mass spectrometry imaging. Clinical and Translational Medicine, 2018, 7, 22. | 1.7 | 9 |
| 2539 | Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test. Dermatologic Surgery, 2018, 44, 1494-1500. | 0.4 | 44 |
| 2540 | Natural history of pain associated with melanoma surgery. Pain Reports, 2018, 3, e689. | 1.4 | 5 |
| 2541 | Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults. The Cochrane Library, 2018, 12, CD013190. | 1.5 | 41 |
| 2542 | Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma. BMC Medical Genomics, 2018, 11, 97. | 0.7 | 10 |
| 2543 | The long-term prognostic impact of sentinel lymph node biopsy in patients with primary cutaneous melanoma: a prospective study with 10-year follow-up. Annals of Surgical Treatment and Research, 2018, 95, 286. | 0.4 | 7 |
| 2544 | Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. Advances in Experimental Medicine and Biology, 2018, . | 0.8 | 0 |
| 2545 | Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients. Advances in Experimental Medicine and Biology, 2018, 1100, 83-95. | 0.8 | 10 |
| 2546 | Combatting mucosal melanoma: recent advances and future perspectives. Melanoma Management, 2018, 5, MMT11. | 0.1 | 75 |
| 2547 | Acral melanoma: a retrospective cohort from the Brazilian National Cancer Institute (INCA). Melanoma Research, 2018, 28, 458-464. | 0.6 | 22 |
| 2548 | Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nature Immunology, 2018, 19, 1319-1329. | 7.0 | 274 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2549 | Characterization of a B16-F10 melanoma model locally implanted into the ear pinnae of C57BL/6 mice. PLoS ONE, 2018, 13, e0206693. | 1.1 | 37 |
| 2550 | Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. PLoS ONE, 2018, 13, e0206942. | 1.1 | 35 |
| 2551 | Risk Factors for Regional and Systemic Metastases in Patients with Sentinel Lymph Node-negative Melanoma. Anticancer Research, 2018, 38, 6571-6577. | 0.5 | 4 |
| 2552 | Surgery of primary tumor improves the survival of newly diagnosed metastatic melanoma: a population-based, propensity-matched study. Cancer Management and Research, 2018, Volume 11, 339-346. | 0.9 | 4 |
| 2553 | Anorectal mucosal melanoma. Oncotarget, 2018, 9, 8785-8800. | 0.8 | 68 |
| 2554 | Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Frontiers in Medicine, 2018, 5, 351. | 1.2 | 67 |
| 2555 | Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. The Cochrane Library, 2018, 2018, CD011902. | 1.5 | 89 |
| 2556 | The existence of early stage oral mucosal melanoma: A 10-year retrospective analysis of 170 patients in a single institute. Oral Oncology, 2018, 87, 70-76. | 0.8 | 16 |
| 2557 | Immunotherapy for Melanoma. Advances in Experimental Medicine and Biology, 2018, 995, 43-63. | 0.8 | 25 |
| 2558 | Nonvisualization of Sentinel Lymph Nodes by Lymphoscintigraphy in Primary Cutaneous Melanoma. Plastic and Reconstructive Surgery, 2018, 142, 527e-534e. | 0.7 | 9 |
| 2561 | Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis. PLoS ONE, 2018, 13, e0207019. | 1.1 | 10 |
| 2562 | Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Management and Research, 2018, Volume 10, 5537-5544. | 0.9 | 1 |
| 2563 | Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nature Medicine, 2018, 24, 1655-1661. | 15.2 | 599 |
| 2564 | Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers. Archives of Dermatological Research, 2018, 310, 769-784. | 1.1 | 10 |
| 2565 | The Role of PPAR δ in Melanoma Metastasis. International Journal of Molecular Sciences, 2018, 19, 2860. | 1.8 | 17 |
| 2566 | Head and Neck Masses. Medical Clinics of North America, 2018, 102, 1013-1025. | 1.1 | 19 |
| 2567 | ASO Author Reflections: Treatment Approaches to Sinonasal Mucosal Melanoma. Annals of Surgical Oncology, 2018, 25, 890-891. | 0.7 | 6 |
| 2568 | Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. PLoS ONE, 2018, 13, e0204729. | 1.1 | 83 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2569 | Red nodular melanoma of the penile foreskin: A case report and literature review. <i>Molecular and Clinical Oncology</i> , 2018, 9, 449-452. | 0.4 | 5 |
| 2570 | Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 11048-11053. | 3.3 | 66 |
| 2571 | Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 3960-3965. | 0.7 | 67 |
| 2572 | Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. <i>European Journal of Cancer</i> , 2018, 105, 33-40. | 1.3 | 38 |
| 2574 | Predictors of quality of life in melanoma patients 4 years after diagnosis: Results of a nationwide cohort study in Germany. <i>Journal of Psychosocial Oncology</i> , 2018, 36, 734-753. | 0.6 | 2 |
| 2575 | Regression and Sentinel Lymph Node Status in Melanoma Progression. <i>Medical Science Monitor</i> , 2018, 24, 1359-1365. | 0.5 | 19 |
| 2576 | Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265. | 2.2 | 107 |
| 2577 | Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016. <i>Annales De Dermatologie Et De Venereologie</i> , 2018, 145, 649-658. | 0.5 | 3 |
| 2578 | A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky032. | 1.4 | 23 |
| 2579 | Targeted Therapy in Advanced Melanoma. , 2018, , 1-20. | | 0 |
| 2580 | Melanoma risk after in vitro fertilization: A review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1133-1140.e3. | 0.6 | 12 |
| 2581 | 11 Role of Dermatopathology in the Surgical Management of Skin Cancer. , 2018, , . | | 0 |
| 2582 | B cells and antibody production in melanoma. <i>Mammalian Genome</i> , 2018, 29, 790-805. | 1.0 | 19 |
| 2583 | The relationship between mitotic rate and depth of invasion in biopsies of malignant melanoma. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2018, Volume 11, 125-130. | 0.8 | 7 |
| 2584 | Performance and clinical impact of machine learning based lung nodule detection using vessel suppression in melanoma patients. <i>Clinical Imaging</i> , 2018, 52, 328-333. | 0.8 | 15 |
| 2585 | Synergistic Suppression of Melanoma Growth by a Combination of Natural dsRNA and Panaxadiolsaponins. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 378-387. | 0.5 | 1 |
| 2586 | A diagnostic autoantibody signature for primary cutaneous melanoma. <i>Oncotarget</i> , 2018, 9, 30539-30551. | 0.8 | 29 |
| 2587 | Melanoma. <i>Lancet, The</i> , 2018, 392, 971-984. | 6.3 | 1,016 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2588 | Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma. <i>Journal of Surgical Oncology</i> , 2018, 118, 915-921. | 0.8 | 16 |
| 2589 | Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. <i>Journal of Surgical Oncology</i> , 2018, 118, 599-605. | 0.8 | 13 |
| 2590 | Influence of socioeconomic factors and region of residence on cancer stage of malignant melanoma: a Danish nationwide population-based study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 799-807. | 1.5 | 11 |
| 2591 | Pre-treatment Serum Lactate Dehydrogenase is Predictive of Survival in Patients with Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy. <i>Journal of Cancer</i> , 2018, 9, 54-63. | 1.2 | 11 |
| 2592 | Targeting nucleotide exchange to inhibit constitutively active G protein $\beta\gamma$ subunits in cancer cells. <i>Science Signaling</i> , 2018, 11, . | 1.6 | 71 |
| 2593 | Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma. <i>Cancer Research</i> , 2018, 78, 5970-5979. | 0.4 | 236 |
| 2594 | The Multiple Roles of Tyrosinase-Related Protein-2/L- Dopachrome Tautomerase in Melanoma: Biomarker, Therapeutic Target, and Molecular Driver in Tumor Progression. , 0, , . | | 4 |
| 2595 | Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 144-153. | 3.4 | 27 |
| 2596 | LncRNAs as Biomarkers for Melanoma. , 2018, , . | | 1 |
| 2597 | Staging of Cutaneous Melanoma. <i>JAMA Network Open</i> , 2018, 1, e180086. | 2.8 | 4 |
| 2598 | Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma. <i>Melanoma Research</i> , 2018, 28, 304-310. | 0.6 | 9 |
| 2599 | Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 431-442. | 1.7 | 16 |
| 2600 | A 3D Organotypic Melanoma Spheroid Skin Model. <i>Journal of Visualized Experiments</i> , 2018, , . | 0.2 | 19 |
| 2601 | miRâ€‘204â€‘5p and miRâ€‘3065â€‘5p exert antitumor effects on melanoma cells. <i>Oncology Letters</i> , 2018, 15, 8269-8280. | 0.8 | 27 |
| 2602 | Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis. <i>Clinica Chimica Acta</i> , 2018, 484, 136-140. | 0.5 | 36 |
| 2603 | Lymph Node Dissection in Patients With Melanoma and Sentinel Lymph Node Metastasis: An Updated, Evidence-Based Decision Algorithm. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2018, 109, 390-398. | 0.2 | 2 |
| 2604 | The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. <i>Melanoma Research</i> , 2018, 28, 333-340. | 0.6 | 13 |
| 2605 | Prognostic factors in primary anorectal melanoma: a clinicopathological study of 60 cases in China. <i>Human Pathology</i> , 2018, 79, 77-85. | 1.1 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2606 | Skin lesion segmentation in dermoscopy images via deep full resolution convolutional networks. <i>Computer Methods and Programs in Biomedicine</i> , 2018, 162, 221-231. | 2.6 | 309 |
| 2607 | Survival outcomes and interval between lymphoscintigraphy and SLNB in cutaneous melanoma-findings of a large prospective cohort study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1768-1772. | 0.5 | 7 |
| 2608 | Essential Components of Melanoma Histopathological Reporting: The Surgical Oncologist's Perspective. <i>Journal of Skin Cancer</i> , 2018, 2018, 1-4. | 0.5 | 5 |
| 2609 | Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts Survival. <i>Clinical Chemistry</i> , 2018, 64, 1338-1346. | 1.5 | 9 |
| 2610 | KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature. <i>Oncology Letters</i> , 2018, 15, 9786-9792. | 0.8 | 10 |
| 2611 | Physician Skin Checks before the Diagnosis of Melanoma Correlate with Tumor Characteristics. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2288-2291. | 0.3 | 4 |
| 2613 | S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. <i>British Journal of Cancer</i> , 2018, 119, 339-346. | 2.9 | 83 |
| 2614 | Melanoma & nuclear medicine: new insights & advances. <i>Melanoma Management</i> , 2018, 5, MMT06. | 0.1 | 23 |
| 2615 | A Modeling Study of the Cost-Effectiveness of a Risk-Stratified Surveillance Program for Melanoma in the United Kingdom. <i>Value in Health</i> , 2018, 21, 658-668. | 0.1 | 14 |
| 2616 | Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2564-2572. | 1.1 | 6 |
| 2617 | Multiple Basal Cell Carcinoma Arising in a Verrucous Epidermal Naevus: Clinical, Histological and Therapeutic Observations. <i>Acta Dermato-Venereologica</i> , 2018, 98, 132-133. | 0.6 | 1 |
| 2618 | Quantitative characterization of turbidity by radiative transfer based reflectance imaging. <i>Biomedical Optics Express</i> , 2018, 9, 2081. | 1.5 | 9 |
| 2619 | Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma. <i>Acta Dermato-Venereologica</i> , 2018, 98, 406-410. | 0.6 | 31 |
| 2620 | Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600E Mutated Metastatic Melanoma. <i>JAMA Oncology</i> , 2018, 4, 1382. | 3.4 | 65 |
| 2621 | Nail Issues in Diverse Populations. , 2018, , 395-407. | | 0 |
| 2622 | Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma. <i>Metabolomics</i> , 2018, 14, 105. | 1.4 | 15 |
| 2623 | Common Skin Disorders in the Elderly. , 2018, , 783-794. | | 0 |
| 2624 | Malignant Melanoma: Diagnostic and Management Update. <i>Plastic and Reconstructive Surgery</i> , 2018, 142, 202e-216e. | 0.7 | 45 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2625 | Clinicopathological characteristics of malignant melanomas of the skin and gastrointestinal tract. <i>Oncology Letters</i> , 2018, 16, 2675-2681. | 0.8 | 7 |
| 2626 | SUV39H1/DNMT3A-dependent methylation of the <i>RB1</i> promoter stimulates PIN1 expression and melanoma development. <i>FASEB Journal</i> , 2018, 32, 5647-5660. | 0.2 | 22 |
| 2627 | Current perspectives on Mohs micrographic surgery for melanoma. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2018, Volume 11, 309-320. | 0.8 | 31 |
| 2628 | Vemurafenib. <i>Recent Results in Cancer Research</i> , 2018, 211, 77-89. | 1.8 | 52 |
| 2629 | Melanoma: clinical, evolutive and histopathological characteristics of a series of 136 cases. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 373-376. | 0.5 | 6 |
| 2630 | A meta-analysis of transcriptome datasets characterizes malignant transformation from melanocytes and nevi to melanoma. <i>Oncology Letters</i> , 2018, 16, 1899-1911. | 0.8 | 8 |
| 2631 | Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. <i>Frontiers in Immunology</i> , 2018, 9, 70. | 2.2 | 120 |
| 2632 | Melanoma Immunotherapy: Next-Generation Biomarkers. <i>Frontiers in Oncology</i> , 2018, 8, 178. | 1.3 | 53 |
| 2633 | Impact of primary care provider density on detection and diagnosis of cutaneous melanoma. <i>PLoS ONE</i> , 2018, 13, e0200097. | 1.1 | 12 |
| 2634 | The Emerging Therapeutic Landscape of Advanced Melanoma. <i>Current Pharmaceutical Design</i> , 2018, 24, 549-558. | 0.9 | 16 |
| 2635 | Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution. <i>Cancer Cell</i> , 2018, 34, 45-55.e4. | 7.7 | 157 |
| 2636 | Cutaneous Melanoma—A Long Road from Experimental Models to Clinical Outcome: A Review. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1566. | 1.8 | 67 |
| 2637 | Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1461-1472. | 2.0 | 68 |
| 2638 | Skin melanoma imaging using ultrasonography: a literature review. <i>Postepy Dermatologii i Alergologii</i> , 2018, 35, 238-242. | 0.4 | 10 |
| 2639 | Willingness to pay for a cure of low-risk melanoma patients in Germany. <i>PLoS ONE</i> , 2018, 13, e0197780. | 1.1 | 9 |
| 2640 | Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 503-520. | 1.7 | 9 |
| 2641 | Prognostic factors for metastasis in cutaneous melanoma. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 19-26. | 0.5 | 40 |
| 2642 | lncRNA-ATB functions as a competing endogenous RNA to promote YAP1 by sponging miR-590-5p in malignant melanoma. <i>International Journal of Oncology</i> , 2018, 53, 1094-1104. | 1.4 | 31 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2643 | Malignant Melanoma of the Nipple: A Case Report. <i>Journal of Breast Cancer</i> , 2018, 21, 96. | 0.8 | 9 |
| 2644 | Nodular Melanoma: A Histopathologic Entity?. <i>Acta Dermato-Venereologica</i> , 2018, 98, 460-462. | 0.6 | 22 |
| 2645 | Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients. <i>Diagnostic Pathology</i> , 2018, 13, 13. | 0.9 | 37 |
| 2646 | Perspective in Pigmentation Disorders. , 2018, , 363-400. | | 1 |
| 2647 | Gender and Dermatology. , 2018, , . | | 4 |
| 2649 | Malignant melanoma clinically mimicking pyogenic granuloma: comparison of clinical evaluation and histopathology. <i>Melanoma Research</i> , 2018, 28, 363-367. | 0.6 | 20 |
| 2651 | Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. <i>BMC Cancer</i> , 2018, 18, 130. | 1.1 | 117 |
| 2652 | Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data. <i>BMC Cancer</i> , 2018, 18, 145. | 1.1 | 16 |
| 2653 | Liquid biomarkers in melanoma: detection and discovery. <i>Molecular Cancer</i> , 2018, 17, 8. | 7.9 | 74 |
| 2654 | Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. , 2018, 6, 19. | | 45 |
| 2657 | Psychosocial consequences of skin cancer screening. <i>Preventive Medicine Reports</i> , 2018, 10, 310-316. | 0.8 | 20 |
| 2658 | Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2018, 25, 2184-2192. | 0.7 | 34 |
| 2659 | Surgical Considerations in Advance Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, and Cutaneous Melanoma: a Head and Neck Perspective. <i>Current Otorhinolaryngology Reports</i> , 2018, 6, 140-150. | 0.2 | 1 |
| 2660 | Functionalized nanoliposomes loaded with anti survivin and anti angiogenic agents to enhance the activity of chemotherapy against melanoma by 4-pronged action. <i>Medical Hypotheses</i> , 2018, 116, 141-146. | 0.8 | 4 |
| 2661 | Serum exosomal microRNAs as potent circulating biomarkers for melanoma. <i>Melanoma Research</i> , 2018, 28, 295-303. | 0.6 | 55 |
| 2662 | Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. <i>Oncolmmunology</i> , 2018, 7, e1428157. | 2.1 | 18 |
| 2663 | Biology and Sex Disparities in Melanoma Outcomes. , 2018, , 193-213. | | 0 |
| 2664 | Melanoma Adjuvant Treatment: Current Insight and Clinical Features. <i>Current Cancer Drug Targets</i> , 2018, 18, 442-456. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2666 | The role of routine imaging in pediatric cutaneous melanoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27412. | 0.8 | 7 |
| 2667 | Primary Middle Ear Mucosal Melanoma: Case Report and Comprehensive Literature Review of 21 Cases of Primary Middle Ear and Eustachian Tube Melanoma. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2018, 127, 856-863. | 0.6 | 14 |
| 2668 | miR-590-5p inhibits tumor growth in malignant melanoma by suppressing YAP1 expression. <i>Oncology Reports</i> , 2018, 40, 2056-2066. | 1.2 | 7 |
| 2669 | Differences in the diagnosis of primary cutaneous melanoma in the public and private healthcare systems in Joinville, Santa Catarina State, Brazil. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 507-512. | 0.5 | 5 |
| 2670 | Functionalized Caprolactone-Polyethylene Glycol Based Thermo-Responsive Hydrogels of Silibinin for the Treatment of Malignant Melanoma. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 21, 143-159. | 0.9 | 15 |
| 2671 | Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines. <i>Acta Dermato-Venereologica</i> , 2018, 98, 218-224. | 0.6 | 24 |
| 2672 | The presenting features of melanoma in New Zealand: implications for earlier detection. <i>Australian and New Zealand Journal of Public Health</i> , 2018, 42, 567-571. | 0.8 | 5 |
| 2673 | Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC) Tj ETQq1 1 0.7843 14sgBT /Overlock 10 | 0.7 | 10 |
| 2675 | High mortality due to cutaneous melanoma in Norway: a study of prognostic factors in a nationwide cancer registry. <i>Clinical Epidemiology</i> , 2018, Volume 10, 537-548. | 1.5 | 32 |
| 2676 | Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. <i>Melanoma Research</i> , 2018, 28, 442-450. | 0.6 | 14 |
| 2677 | Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. <i>Annals of Surgical Oncology</i> , 2018, 25, 2105-2110. | 0.7 | 338 |
| 2678 | Detection of melanoma metastases with the sentinel node biopsy: the legacy of Donald L. Morton, MD (1934-2014). <i>Clinical and Experimental Metastasis</i> , 2018, 35, 425-429. | 1.7 | 4 |
| 2679 | The Pathology of Melanoma. , 2018, , 193-212. | | 0 |
| 2680 | Surgery for Stage IV Metastatic Melanoma. , 2018, , 467-481. | | 1 |
| 2681 | Adjuvant Therapy of Melanoma. , 2018, , 483-498. | | 0 |
| 2683 | Staging and Classification of Melanoma. , 2018, , 87-103. | | 0 |
| 2684 | In vitro models of melanoma. , 2018, , 57-75. | | 1 |
| 2685 | It is finally time for adjuvant therapy in melanoma. <i>Cancer Treatment Reviews</i> , 2018, 69, 101-111. | 3.4 | 37 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2686 | Molecular classification and subtype-specific characterization of skin cutaneous melanoma by aggregating multiple genomic platform data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1635-1647. | 1.2 | 16 |
| 2687 | MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 916-929. | 5.1 | 131 |
| 2688 | Changing trends in the incidence of invasive melanoma in Victoria, 1985â€“2015. <i>Medical Journal of Australia</i> , 2018, 208, 265-269. | 0.8 | 25 |
| 2689 | <i>In situ</i> and invasive melanoma in a highâ€“risk, New Zealand, population: A populationâ€“based study. <i>Australasian Journal of Dermatology</i> , 2019, 60, 38-44. | 0.4 | 11 |
| 2690 | Dense Deconvolutional Network for Skin Lesion Segmentation. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2019, 23, 527-537. | 3.9 | 114 |
| 2691 | Melanoma Clinical Staging (Historical and Current). , 2019, , 485-500. | | 0 |
| 2692 | Targeted Therapy in Advanced Melanoma. , 2019, , 667-686. | | 0 |
| 2693 | Adjuvant Therapy. , 2019, , 717-741. | | 0 |
| 2694 | Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes. , 2019, , 181-224. | | 0 |
| 2695 | Spitz Tumors. , 2019, , 395-410. | | 0 |
| 2696 | Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink?. <i>Transplant International</i> , 2019, 32, 1223-1240. | 0.8 | 11 |
| 2697 | Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10. | 1.3 | 132 |
| 2698 | Dense-Residual Network With Adversarial Learning for Skin Lesion Segmentation. <i>IEEE Access</i> , 2019, 7, 77037-77051. | 2.6 | 28 |
| 2699 | Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. <i>European Journal of Cancer</i> , 2019, 119, 18-29. | 1.3 | 44 |
| 2700 | Mycobacterium bovis BCG in metastatic melanoma therapy. <i>Applied Microbiology and Biotechnology</i> , 2019, 103, 7903-7916. | 1.7 | 15 |
| 2701 | Neuroblastoma rat sarcoma mutated melanoma: Thatâ€™s what we got so far. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 744-752. | 1.5 | 4 |
| 2702 | Impact of depth of response on survival in patients treated with cobimetinibâ€“vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. <i>British Journal of Cancer</i> , 2019, 121, 522-528. | 2.9 | 20 |
| 2703 | Assessment of Nonradioactive Multispectral Optoacoustic Tomographic Imaging With Conventional Lymphoscintigraphic Imaging for Sentinel Lymph Node Biopsy in Melanoma. <i>JAMA Network Open</i> , 2019, 2, e199020. | 2.8 | 24 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2704 | Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1). <i>Melanoma Management</i> , 2019, 6, MMT19. | 0.1 | 21 |
| 2705 | Image-Guided and Radioguided Surgery. , 2019, , 351-388. | | 1 |
| 2706 | Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. <i>Annals of Surgical Oncology</i> , 2019, 26, 4633-4641. | 0.7 | 24 |
| 2707 | Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. <i>PLoS ONE</i> , 2019, 14, e0221301. | 1.1 | 16 |
| 2708 | Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. <i>EBioMedicine</i> , 2019, 47, 89-97. | 2.7 | 39 |
| 2709 | Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma – A combined IHC score for melanoma risk stratification. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 800-808. | 0.4 | 12 |
| 2710 | A tumor-targeted immune checkpoint blocker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15889-15894. | 3.3 | 21 |
| 2711 | Sentinel lymph node biopsy in patients with malignant melanoma: analysis of post-operative complications. <i>ANZ Journal of Surgery</i> , 2019, 89, 1041-1044. | 0.3 | 7 |
| 2712 | Multi-Size Computer-Aided Diagnosis Of Positron Emission Tomography Images Using Graph Convolutional Networks. , 2019, , . | | 0 |
| 2713 | Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma. <i>Scientific Reports</i> , 2019, 9, 12150. | 1.6 | 54 |
| 2714 | A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma. <i>ELife</i> , 2019, 8, . | 2.8 | 69 |
| 2715 | A flow-through microfluidic system for the detection of circulating melanoma cells. <i>Biosensors and Bioelectronics</i> , 2019, 142, 111522. | 5.3 | 18 |
| 2716 | Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR). <i>PLoS ONE</i> , 2019, 14, e0219622. | 1.1 | 27 |
| 2717 | Intra-nodal nevi in sentinel node-negative patients with cutaneous melanoma does not influence survival. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2291-2295. | 1.3 | 7 |
| 2718 | Region Extraction and Classification of Skin Cancer: A Heterogeneous framework of Deep CNN Features Fusion and Reduction. <i>Journal of Medical Systems</i> , 2019, 43, 289. | 2.2 | 167 |
| 2719 | Surgical cost implications of the AJCC v8 staging system for melanoma and the melanoma in focus consensus statement. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2019, 72, 1700-1738. | 0.5 | 0 |
| 2720 | Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma. <i>Experimental Hematology and Oncology</i> , 2019, 8, 14. | 2.0 | 10 |
| 2721 | Incidence and significance of psammoma bodies in Xp11.2 translocation renal cell carcinoma and papillary renal cell carcinoma. <i>Oncology Letters</i> , 2019, 18, 472-478. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2722 | External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. <i>British Journal of Surgery</i> , 2019, 106, 1319-1326. | 0.1 | 5 |
| 2723 | Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma. <i>Pathology</i> , 2019, 51, 487-493. | 0.3 | 19 |
| 2724 | Frugoside Induces Mitochondria-Mediated Apoptotic Cell Death through Inhibition of Sulfiredoxin Expression in Melanoma Cells. <i>Cancers</i> , 2019, 11, 854. | 1.7 | 4 |
| 2725 | Efficient skin lesion segmentation using separable-Unet with stochastic weight averaging. <i>Computer Methods and Programs in Biomedicine</i> , 2019, 178, 289-301. | 2.6 | 107 |
| 2726 | Malignant melanoma of the male urethra with increased 5- <i>S</i> -cysteinyl-dopa: A case report. <i>IJU Case Reports</i> , 2019, 2, 215-217. | 0.1 | 4 |
| 2727 | Pre-treatment Serum Lactate Dehydrogenase Predicts Distant Metastasis and Poor Survival in Nasopharyngeal Carcinoma. <i>Journal of Cancer</i> , 2019, 10, 3657-3664. | 1.2 | 19 |
| 2728 | Melanoma. <i>Journal of Surgical Oncology</i> , 2019, 120, 873-881. | 0.8 | 67 |
| 2729 | Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389. | 5.1 | 155 |
| 2730 | Focused Ultrasound Surveillance of Lymph Nodes Following Lymphoscintigraphy Without Sentinel Node Biopsy: A Useful and Safe Strategy in Elderly or Frail Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 2855-2863. | 0.7 | 11 |
| 2731 | 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial. <i>Lancet</i> , The, 2019, 394, 471-477. | 6.3 | 35 |
| 2732 | Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies. <i>Annals of Surgical Oncology</i> , 2019, 26, 4621-4630. | 0.7 | 10 |
| 2733 | Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153. | 1.3 | 27 |
| 2734 | A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i> -mutated Melanoma to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2019, 25, 6852-6867. | 3.2 | 74 |
| 2735 | Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment. <i>Biomedicines</i> , 2019, 7, 80. | 1.4 | 0 |
| 2736 | Donation to the university of bologna of the original gaspare tagliacozzi, "De curtorum chirurgia per insitionem". <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2019, 72, 1700-1738. | 0.5 | 1 |
| 2737 | Expression of CMV protein pp65 in cutaneous malignant melanoma. <i>PLoS ONE</i> , 2019, 14, e0223854. | 1.1 | 1 |
| 2738 | Skin Lesion Segmentation with C-UNet. , 2019, 2019, 2785-2788. | | 18 |
| 2739 | Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. <i>Melanoma Management</i> , 2019, 6, MMT20. | 0.1 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2740 | Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. <i>Cancers</i> , 2019, 11, 1685. | 1.7 | 23 |
| 2741 | Regulatory T Cells Induce Metastasis by Increasing Tgf- β 2 and Enhancing the Epithelial-Mesenchymal Transition. <i>Cells</i> , 2019, 8, 1387. | 1.8 | 36 |
| 2742 | Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib. <i>European Journal of Cancer</i> , 2019, 123, 155-161. | 1.3 | 5 |
| 2743 | Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. <i>European Journal of Cancer</i> , 2019, 123, 83-91. | 1.3 | 15 |
| 2744 | Acral Lentiginous Melanoma of Foot and Ankle: A Clinicopathological Study of 7 Cases. <i>Anticancer Research</i> , 2019, 39, 6175-6181. | 0.5 | 4 |
| 2745 | 2-Methoxyestradiol and Its Combination with a Natural Compound, Ferulic Acid, Induces Melanoma Cell Death via Downregulation of Hsp60 and Hsp90. <i>Journal of Oncology</i> , 2019, 2019, 1-12. | 0.6 | 10 |
| 2746 | A case series of breast reconstruction for amastia in a family with ectodermic dysplasia. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2019, 72, 1700-1738. | 0.5 | 2 |
| 2747 | Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. <i>The Cochrane Library</i> , 2019, 7, CD012806. | 1.5 | 22 |
| 2748 | Ellagic acid, extracted from <i>Sanguisorba officinalis</i> , induces G1 arrest by modulating PTEN activity in B16F10 melanoma cells. <i>Genes To Cells</i> , 2019, 24, 688-704. | 0.5 | 15 |
| 2749 | Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III / IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study. <i>Journal of Dermatology</i> , 2019, 46, 1197-1201. | 0.6 | 13 |
| 2751 | Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma. <i>International Journal of Biological Markers</i> , 2019, 34, 414-420. | 0.7 | 6 |
| 2752 | Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. <i>Clinical Cancer Research</i> , 2019, 25, 6801-6814. | 3.2 | 27 |
| 2753 | Novel Biomarkers for Personalized Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1223. | 1.7 | 36 |
| 2754 | The adjuvant treatment revolution for high-risk melanoma patients. <i>Seminars in Cancer Biology</i> , 2019, 59, 283-289. | 4.3 | 40 |
| 2756 | Segmentation of Lesion in Dermoscopy Images Using Dense-Residual Network with Adversarial Learning. , 2019, , . | | 4 |
| 2757 | Practice Patterns and Prognostic Value of Sentinel Lymph Node Biopsy for Thick Melanoma: A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 4651-4662. | 0.7 | 9 |
| 2758 | ASO Author Reflections: Sentinel Lymph Node Biopsy Trend in Melanoma: The More the Merrier. <i>Annals of Surgical Oncology</i> , 2019, 26, 723-724. | 0.7 | 0 |
| 2759 | Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. <i>Cancers</i> , 2019, 11, 1243. | 1.7 | 40 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2761 | <p>²</p>EDNRB isoform 3 confers Temozolomide resistance in A375 melanoma cells by modulating membrane potential, reactive oxygen species and mitochondrial Ca²⁺. Cancer Management and Research, 2019, Volume 11, 7353-7367. | 0.9 | 2 |
| 2762 | Postoperative Development of Polymyalgia Rheumatica Due to Nivolumab Administration in a Patient with Recurrent Anorectal Malignant Melanoma. Japanese Journal of Gastroenterological Surgery, 2019, 52, 327-335. | 0.0 | 1 |
| 2763 | Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma. Clinical Cancer Research, 2019, 25, 7424-7435. | 3.2 | 27 |
| 2764 | Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. Annals of Surgical Oncology, 2019, 26, 4663-4672. | 0.7 | 3 |
| 2765 | Sex- and Site-Related Significance in Cutaneous Head and Neck Melanoma. Ear, Nose and Throat Journal, 2021, 100, 343-349. | 0.4 | 4 |
| 2766 | Common Nevus and Skin Cutaneous Melanoma: Prognostic Genes Identified by Gene Co-Expression Network Analysis. Genes, 2019, 10, 747. | 1.0 | 17 |
| 2767 | Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2019, 30, 1884-1901. | 0.6 | 394 |
| 2768 | Transversus abdominis release in the treatment of subcostal incisional hernias. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2019, 72, 1700-1738. | 0.5 | 3 |
| 2769 | Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. Oncoimmunology, 2019, 8, e1660121. | 2.1 | 4 |
| 2770 | Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma. Future Oncology, 2019, 15, 3665-3674. | 1.1 | 14 |
| 2771 | Clinical melanoma characteristics and survival—a single-center retrospective study between 2000 and 2010. Wiener Medizinische Wochenschrift, 2019, 169, 323-330. | 0.5 | 2 |
| 2772 | Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8th Edition American Joint Committee on Cancer Staging System?. Journal of the American College of Surgeons, 2019, 228, 466-472. | 0.2 | 31 |
| 2773 | Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. Head and Neck, 2019, 41, 871-879. | 0.9 | 13 |
| 2774 | Molecular evaluation of BRAF V600 mutation and its association with clinicopathological characteristics: First findings from Indian malignant melanoma patients. Cancer Genetics, 2019, 231-232, 46-53. | 0.2 | 6 |
| 2775 | Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 857-862. | 1.3 | 34 |
| 2776 | Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment. Cell, 2019, 176, 757-774.e23. | 13.5 | 117 |
| 2777 | Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunology, Immunotherapy, 2019, 68, 553-561. | 2.0 | 57 |
| 2778 | Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of Oncology, 2019, 30, 582-588. | 0.6 | 641 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2779 | <p></p>Elevated nuclear auto-antigenic sperm protein promotes melanoma progression by inducing cell proliferation</p>. OncoTargets and Therapy, 2019, Volume 12, 2105-2113. | 1.0 | 1 |
| 2780 | Capsaicin induces apoptosis and autophagy in human melanoma cells. Oncology Letters, 2019, 17, 4827-4834. | 0.8 | 22 |
| 2781 | Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. International Journal of Cancer, 2019, 145, 3462-3477. | 2.3 | 46 |
| 2782 | Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective. Journal of Medical Economics, 2019, 22, 1243-1252. | 1.0 | 10 |
| 2783 | miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A. Journal of Experimental and Clinical Cancer Research, 2019, 38, 272. | 3.5 | 61 |
| 2784 | Active repurposing of drug candidates for melanoma based on GWAS, PheWAS and a wide range of omics data. Molecular Medicine, 2019, 25, 30. | 1.9 | 21 |
| 2785 | Development and Initial Validation of Calculated Tumor Area as a Prognostic Tool in Cutaneous Malignant Melanoma. JAMA Dermatology, 2019, 155, 890. | 2.0 | 14 |
| 2786 | A History of Melanoma: From Hunter to Morton. , 2019, , 1-19. | | 1 |
| 2787 | Artificial intelligence in dermatology: a joint clinical and data science perspective. International Journal of Dermatology, 2019, 58, 989-990. | 0.5 | 4 |
| 2788 | Cold atmospheric plasma and silymarin nanoemulsion synergistically inhibits human melanoma tumorigenesis via targeting HGF/c-MET downstream pathway. Cell Communication and Signaling, 2019, 17, 52. | 2.7 | 58 |
| 2789 | The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. Journal of Cancer Survivorship, 2019, 13, 503-511. | 1.5 | 31 |
| 2790 | The course of stage III melanoma in accordance with the severity of node involvement. Current Medical Research and Opinion, 2019, 35, 1819-1824. | 0.9 | 1 |
| 2791 | Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2019, 116, 148-157. | 1.3 | 64 |
| 2792 | Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies. BMC Research Notes, 2019, 12, 296. | 0.6 | 6 |
| 2793 | Disease-Free Survival for Patients with Thin Melanomas according to the American Joint Committee on Cancer 8th Edition. Dermatology, 2019, 235, 334-339. | 0.9 | 0 |
| 2794 | A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. Annals of Surgical Oncology, 2019, 26, 2839-2845. | 0.7 | 16 |
| 2795 | Cells to Surgery Quiz: May 2019. Journal of Investigative Dermatology, 2019, 139, e53-e58. | 0.3 | 0 |
| 2796 | MALAT1 regulates miR-34a expression in melanoma cells. Cell Death and Disease, 2019, 10, 389. | 2.7 | 42 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2797 | Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and Akt pathways. <i>International Journal of Oncology</i> , 2019, 54, 2069-2079. | 1.4 | 27 |
| 2798 | Surveillance imaging for metastasis in high-risk melanoma: importance in individualized patient care and survivorship. <i>Melanoma Management</i> , 2019, 6, MMT12. | 0.1 | 27 |
| 2799 | BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 521-526. | 1.1 | 3 |
| 2800 | Cutaneous melanoma in patients from western Mexico: Clinical pathology characteristics and their relationship to prognosis. <i>Australasian Journal of Dermatology</i> , 2019, 60, e298-e303. | 0.4 | 0 |
| 2801 | Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival. <i>Annals of Surgical Oncology</i> , 2019, 26, 2254-2262. | 0.7 | 26 |
| 2802 | Disparities in the management of cutaneous malignant melanoma. A population-based high-resolution study. <i>European Journal of Cancer Care</i> , 2019, 28, e13043. | 0.7 | 7 |
| 2804 | <p>Prognostic significance of serum lactate dehydrogenase in patients with breast cancer: a meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3611-3619. | 0.9 | 42 |
| 2805 | Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor. <i>JAMA Dermatology</i> , 2019, 155, 688. | 2.0 | 74 |
| 2806 | BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas. <i>PLoS ONE</i> , 2019, 14, e0216043. | 1.1 | 8 |
| 2807 | Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 679. | 2.0 | 22 |
| 2808 | Oxalomalate suppresses metastatic melanoma through IDH-targeted stress response to ROS. <i>Free Radical Research</i> , 2019, 53, 418-429. | 1.5 | 7 |
| 2809 | Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. <i>British Journal of Surgery</i> , 2019, 106, 519-522. | 0.1 | 35 |
| 2810 | Does sentinel lymph node status have prognostic significance in patients with acral lentiginous melanoma?. <i>Journal of Surgical Oncology</i> , 2019, 119, 1060-1069. | 0.8 | 12 |
| 2811 | Molecular Diagnostics in Melanoma: An Update. , 2019, , 73-88. | | 0 |
| 2812 | Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. <i>European Journal of Cancer</i> , 2019, 112, 9-11. | 1.3 | 6 |
| 2813 | Eruptive cherry angiomas and skin melanoma: a fortuitous association?. <i>Melanoma Research</i> , 2019, 29, 313-317. | 0.6 | 7 |
| 2814 | A 10-year retrospective study of melanoma stage at diagnosis in the academic emergency hospital of Sibiu county. <i>Oncology Letters</i> , 2019, 17, 4145-4148. | 0.8 | 7 |
| 2815 | Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1349-1361. | 0.3 | 23 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2816 | Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3945-3952. | 0.7 | 24 |
| 2817 | Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. <i>Clinical and Experimental Immunology</i> , 2019, 197, 74-82. | 1.1 | 32 |
| 2818 | Long-term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 2486-2494. | 0.7 | 35 |
| 2819 | Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual. <i>JAMA Dermatology</i> , 2019, 155, 572. | 2.0 | 2 |
| 2820 | The clinical significance of indeterminate pulmonary nodules in melanoma patients at baseline and during follow-up chest CT. <i>European Journal of Radiology Open</i> , 2019, 6, 85-90. | 0.7 | 9 |
| 2821 | Occupational differences in standardized mortality ratios for non-melanotic skin cancer and melanoma in exposed areas among individuals with Fitzpatrick skin types III and IV. <i>Journal of Occupational Health</i> , 2019, 61, 235-241. | 1.0 | 5 |
| 2822 | Clinicopathologic, misdiagnosis, and survival differences between clinically amelanotic melanomas and pigmented melanomas. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1292-1298. | 0.6 | 16 |
| 2823 | Re: "Time to reconsider the role of sentinel lymph node biopsy in melanoma". <i>Journal of the American Academy of Dermatology</i> , 2023, 88, e25-e26. | 0.6 | 3 |
| 2824 | Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. <i>Cancer Medicine</i> , 2019, 8, 2146-2156. | 1.3 | 74 |
| 2825 | NKG2D Polymorphism in Melanoma Patients from Southeastern Spain. <i>Cancers</i> , 2019, 11, 438. | 1.7 | 6 |
| 2826 | Proton radiotherapy in advanced malignant melanoma of the conjunctiva. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 1309-1318. | 1.0 | 17 |
| 2827 | Melanoma risk stratification of individuals with a high-risk naevus phenotype - A pilot study. <i>Australasian Journal of Dermatology</i> , 2019, 60, e292-e297. | 0.4 | 3 |
| 2828 | Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. <i>Cancer Medicine</i> , 2019, 8, 2205-2212. | 1.3 | 58 |
| 2829 | Tumor Heterogeneity on FDG PET/CT and Immunotherapy: An Imaging Biomarker for Predicting Treatment Response in Patients With Metastatic Melanoma. <i>American Journal of Roentgenology</i> , 2019, 212, 1318-1326. | 1.0 | 27 |
| 2830 | Development and initial validation of the Self-Efficacy for Skin Self-Examination Scale in a Canadian sample of patients with melanoma. <i>European Journal of Oncology Nursing</i> , 2019, 40, 78-84. | 0.9 | 7 |
| 2832 | Serum S100B Levels in Melanoma. <i>Methods in Molecular Biology</i> , 2019, 1929, 691-700. | 0.4 | 8 |
| 2833 | Cutaneous Pathology of the Head and Neck. , 2019, , 763-817. | | 1 |
| 2834 | Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1494-1502. | 0.7 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2835 | Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 773-785. | 2.0 | 94 |
| 2836 | Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1127-1134. | 1.2 | 20 |
| 2837 | Genetic variants in <i>ELOVL2</i> and <i>HSD17B12</i> predict melanoma-specific survival. <i>International Journal of Cancer</i> , 2019, 145, 2619-2628. | 2.3 | 11 |
| 2838 | A systematic review and meta-analysis of locoregional treatments for in-transit melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 887-896. | 0.8 | 24 |
| 2839 | Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 774-780. | 1.2 | 7 |
| 2840 | Prognostic value of the Breslow:diameter ratio in cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 806-808. | 0.6 | 5 |
| 2841 | Vulvar cancer association with groin hidradenitis suppurativa: A large, urban, midwestern US patient population study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 808-810. | 0.6 | 9 |
| 2842 | Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma. <i>British Journal of Surgery</i> , 2019, 106, 729-734. | 0.1 | 6 |
| 2843 | First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 765-772. | 2.0 | 35 |
| 2844 | Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 832-837. | 0.5 | 4 |
| 2845 | Evaluation of the efficacy of 3D total-body photography with sequential digital dermoscopy in a high-risk melanoma cohort: protocol for a randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e032969. | 0.8 | 27 |
| 2846 | Decreased expression of nemo-like kinase in melanoma is correlated with increased vascularity and metastasis. <i>Melanoma Research</i> , 2019, 29, 376-381. | 0.6 | 4 |
| 2847 | Routine retrieval of pelvic sentinel lymph nodes for melanoma rarely adds prognostic information or alters management. <i>Melanoma Research</i> , 2019, 29, 38-46. | 0.6 | 3 |
| 2848 | Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome. <i>Melanoma Research</i> , 2019, 29, 590-595. | 0.6 | 2 |
| 2849 | Classifying Melanoma and Seborrheic Keratosis Automatically with Polarization Speckle Imaging. , 2019, , . | | 2 |
| 2850 | Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?. <i>Oncologist</i> , 2019, 24, e1190-e1196. | 1.9 | 24 |
| 2851 | Does 3D printing really guide surgeons in having a more satisfying rhinoplasty result?. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2019, 72, 1700-1738. | 0.5 | 2 |
| 2852 | Letter to the editor—Zygomatico-orbital artery: The largest artery in the temporal area. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2019, 72, 1700-1738. | 0.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2853 | Reossification of the skull base after fronto-orbital advancement for craniosynostosis. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2019, 72, 1700-1738. | 0.5 | 0 |
| 2854 | Acral malignant melanoma; emphasis on the primary metastasis and the usefulness of preoperative ultrasound for sentinel lymph node metastasis. <i>Scientific Reports</i> , 2019, 9, 15894. | 1.6 | 2 |
| 2855 | Targeting L-Lactate Metabolism to Overcome Resistance to Immune Therapy of Melanoma and Other Tumor Entities. <i>Journal of Oncology</i> , 2019, 2019, 1-12. | 0.6 | 47 |
| 2856 | Serum IgG Is Associated With Risk of Melanoma in the Swedish AMORIS Study. <i>Frontiers in Oncology</i> , 2019, 9, 1095. | 1.3 | 5 |
| 2857 | Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. <i>Melanoma Management</i> , 2019, 6, MMT33. | 0.1 | 6 |
| 2858 | 23 Carcinoma of the Skin of the Head, Face, and Neck. , 2019, , . | | 0 |
| 2859 | Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma. <i>Melanoma Research</i> , 2019, 29, 483-490. | 0.6 | 13 |
| 2860 | A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. <i>Scientific Reports</i> , 2019, 9, 17050. | 1.6 | 42 |
| 2861 | A complete lower lip and chin unit resurfacing with expanded cheek flaps: A modified approach with minimal influence on facial cosmetic units. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2019, 72, 1700-1738. | 0.5 | 1 |
| 2862 | Fluvastatin exerts an antitumor effect in vemurafenib-resistant melanoma cells. <i>Anti-Cancer Drugs</i> , 2019, 30, 451-457. | 0.7 | 5 |
| 2863 | Increasing melanoma incidence in the elderly in North-East Hungary: is this a more serious problem than we thought?. <i>European Journal of Cancer Prevention</i> , 2019, 28, 544-550. | 0.6 | 5 |
| 2864 | Enhancing the prognostic role of melanoma sentinel lymph nodes through microscopic tumour burden characterization: clinical usefulness in patients who do not undergo complete lymph node dissection. <i>Melanoma Research</i> , 2019, 29, 163-171. | 0.6 | 13 |
| 2865 | Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients. <i>Melanoma Research</i> , 2019, 29, 70-76. | 0.6 | 9 |
| 2866 | MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2. <i>Melanoma Research</i> , 2019, 29, 119-125. | 0.6 | 19 |
| 2867 | Integration of protein interaction and gene co-expression information for identification of melanoma candidate genes. <i>Melanoma Research</i> , 2019, 29, 126-133. | 0.6 | 4 |
| 2868 | Nuclear morphometric analysis in tissue as an objective tool with potential use to improve melanoma staging. <i>Melanoma Research</i> , 2019, 29, 474-482. | 0.6 | 8 |
| 2869 | Acral Lentiginous Melanomas Harbour Intratumor Heterogeneity in BRAF Exon 15, With Mutations Distinct From V600E/V600K. <i>American Journal of Dermatopathology</i> , 2019, 41, 733-740. | 0.3 | 4 |
| 2870 | “Personalized Excision” of Malignant Melanoma: Need for a Paradigm Shift in the Beginning Era of Personalized Medicine. <i>American Journal of Dermatopathology</i> , 2019, 41, 884-896. | 0.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2871 | Satellite and In-Transit Metastatic Disease in Melanoma Skin Cancer: A Retrospective Review of Disease Presentation, Treatment, and Outcomes. <i>Dermatologic Surgery</i> , 2019, 45, 371-380. | 0.4 | 8 |
| 2872 | An update on adjuvant systemic therapies in melanoma. <i>Melanoma Management</i> , 2019, 6, MMT28. | 0.1 | 10 |
| 2873 | Systemic therapies for unresectable locoregional melanoma: a significant area of need. <i>Melanoma Management</i> , 2019, 6, MMT25. | 0.1 | 6 |
| 2874 | The Translational Status of Cancer Liquid Biopsies. <i>Regenerative Engineering and Translational Medicine</i> , 2021, 7, 312-352. | 1.6 | 39 |
| 2875 | Prognosis and Management of Thick and Ultrathick Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 824-829. | 0.6 | 11 |
| 2876 | Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. <i>Melanoma Research</i> , 2019, 29, 453-464. | 0.6 | 26 |
| 2877 | Impact of initial stage on metastatic melanoma survival. <i>Melanoma Research</i> , 2019, 29, 281-288. | 0.6 | 12 |
| 2878 | Diagnostic and prognostic value of glucose transporters in melanocytic lesions. <i>Melanoma Research</i> , 2019, 29, 603-611. | 0.6 | 9 |
| 2879 | Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1349-1363. | 0.6 | 5 |
| 2880 | Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma. <i>Melanoma Research</i> , 2019, 29, 510-515. | 0.6 | 12 |
| 2881 | Number of Excised Lymph Nodes Has No Impact on Relapse and Survival in Patients With Stage III Melanoma. <i>Annals of Plastic Surgery</i> , 2019, 83, 455-458. | 0.5 | 1 |
| 2883 | Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. <i>American Journal of Dermatopathology</i> , 2019, 41, 264-272. | 0.3 | 29 |
| 2884 | Acral Lentiginous Melanoma: Survival Analysis of 715 Cases. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 38-43. | 0.6 | 18 |
| 2885 | Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology. <i>Survey of Ophthalmology</i> , 2019, 64, 272-288. | 1.7 | 25 |
| 2886 | Clinical implications of the eighth edition of the American Joint Committee on Cancer melanoma staging. <i>Journal of Surgical Oncology</i> , 2019, 119, 168-174. | 0.8 | 15 |
| 2887 | Indications for the surgical resection of stage IV disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 249-261. | 0.8 | 14 |
| 2888 | 1 α , 25 -(OH)_2 Dihydroxyvitamin D3 alters ectonucleotidase expression and activity in human cutaneous melanoma cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 9992-10000. | 1.2 | 9 |
| 2889 | Melanoma-related changes in skin microbiome. <i>Folia Microbiologica</i> , 2019, 64, 435-442. | 1.1 | 54 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2890 | Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples. <i>International Journal of Cancer</i> , 2019, 145, 232-241. | 2.3 | 4 |
| 2891 | Prognosis, Staging, and Reporting of Melanomas. , 2019, , 386-396. | | 4 |
| 2892 | Sentinel node for malignant melanoma: An observational study of a consecutive single centre experience. <i>European Journal of Surgical Oncology</i> , 2019, 45, 225-230. | 0.5 | 4 |
| 2893 | Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome. <i>Cancer Immunology Research</i> , 2019, 7, 12-28. | 1.6 | 21 |
| 2894 | Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 297-303. | 2.0 | 45 |
| 2895 | Advanced stage melanoma therapies: Detailing the present and exploring the future. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 99-111. | 2.0 | 48 |
| 2896 | Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1658-1664. | 0.5 | 7 |
| 2897 | Molecular Pathways in Melanomagenesis. , 2019, , 623-642. | | 0 |
| 2898 | Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 77-85. | 1.6 | 114 |
| 2899 | Adjuvant and Neoadjuvant Treatment of Skin Cancer. <i>Facial Plastic Surgery Clinics of North America</i> , 2019, 27, 139-150. | 0.9 | 8 |
| 2900 | Optimal resection margin for head and neck cutaneous melanoma. <i>Laryngoscope</i> , 2019, 129, 1386-1394. | 1.1 | 5 |
| 2901 | Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilianâ€Dutch Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 395-405. | 0.7 | 16 |
| 2902 | Gene expression profiling in melanoma: past results and future potential. <i>Future Oncology</i> , 2019, 15, 791-800. | 1.1 | 5 |
| 2903 | 5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide and Interleukin-2 Adjuvant Therapy in Resected High-Risk Primary and Regionally Metastatic Melanoma. <i>American Journal of the Medical Sciences</i> , 2019, 357, 43-48. | 0.4 | 1 |
| 2904 | Expression of Neural Crest Markers GLDC and ERRFI1 is Correlated with Melanoma Prognosis. <i>Cancers</i> , 2019, 11, 76. | 1.7 | 11 |
| 2905 | Patients with inâ€transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PVâ€10â€A propensity score matched, single center study. <i>Journal of Surgical Oncology</i> , 2019, 119, 717-727. | 0.8 | 1 |
| 2906 | Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage IIâ€III Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 2494-2502. | 3.2 | 18 |
| 2907 | Increased tumour cell <scp>PD</scp>â€L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 667-675. | 1.3 | 21 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2908 | Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. <i>Oncolmmunology</i> , 2019, 8, e1537581. | 2.1 | 61 |
| 2909 | Fusing fine-tuned deep features for skin lesion classification. <i>Computerized Medical Imaging and Graphics</i> , 2019, 71, 19-29. | 3.5 | 152 |
| 2910 | Inter-observer variation in the histopathology reports of head and neck melanoma; a comparison between the seventh and eighth edition of the AJCC staging system. <i>European Journal of Surgical Oncology</i> , 2019, 45, 235-241. | 0.5 | 5 |
| 2911 | Guidelines of care for the management of primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 208-250. | 0.6 | 400 |
| 2912 | Contrast-enhanced Ultrasound With Perflubutane for Sentinel Lymph Node Mapping in Cutaneous Melanoma: A Pilot Study. <i>Laryngoscope</i> , 2019, 129, 1117-1122. | 1.1 | 9 |
| 2914 | Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies. <i>Methods in Molecular Biology</i> , 2019, 1904, 83-108. | 0.4 | 47 |
| 2915 | Methods of melanoma detection and of skin monitoring for individuals at high risk of melanoma: new Australian clinical practice. <i>Medical Journal of Australia</i> , 2019, 210, 41-47. | 0.8 | 26 |
| 2916 | Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. <i>Journal of Surgical Oncology</i> , 2019, 119, 175-186. | 0.8 | 32 |
| 2917 | Can sentinel node biopsy be safely omitted in thin melanoma? Risk factor analysis of 1272 multicenter prospective cases. <i>European Journal of Surgical Oncology</i> , 2019, 45, 820-824. | 0.5 | 17 |
| 2919 | Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 149-157.e4. | 0.6 | 72 |
| 2920 | Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes. <i>British Journal of Surgery</i> , 2019, 106, 217-225. | 0.1 | 34 |
| 2921 | CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1263-1271. | 0.6 | 16 |
| 2922 | Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters. <i>Journal of Clinical Pathology</i> , 2019, 72, 265-270. | 1.0 | 21 |
| 2923 | The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1028-1034. | 0.7 | 13 |
| 2924 | Sentinel Lymph Node Status is a Main Prognostic Parameter Needful for the Correct Staging of Patients with Melanoma Thicker than 4 mm: Single-Institution Experience and Literature Meta-Analysis. <i>Journal of Investigative Surgery</i> , 2019, 32, 151-161. | 0.6 | 2 |
| 2925 | Invited Brief Commentary: Sentinel Lymph Node Status is a Main Prognostic Parameter Needful for the Correct Staging of Patients with Melanoma Thicker than 4 mm: Single Institutional Experience and Literature Meta-analysis. <i>Journal of Investigative Surgery</i> , 2019, 32, 162-163. | 0.6 | 0 |
| 2926 | Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. <i>Wiener Medizinische Wochenschrift</i> , 2019, 169, 314-322. | 0.5 | 5 |
| 2927 | An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 561-570. | 1.0 | 43 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2928 | Survival prediction in patients with cutaneous melanoma by tumour lymphangiogenesis. <i>Acta Clinica Belgica</i> , 2020, 75, 379-387. | 0.5 | 6 |
| 2929 | Development and Assessment of a Brief Tool to Measure Melanoma-Related Health Literacy and Attitude Among Adolescents. <i>Journal of Cancer Education</i> , 2020, 35, 905-911. | 0.6 | 9 |
| 2930 | Inherited MC 1R variants in patients with melanoma are associated with better survival in women. <i>British Journal of Dermatology</i> , 2020, 182, 138-146. | 1.4 | 10 |
| 2931 | Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1 α /VEGF pathway. <i>Investigational New Drugs</i> , 2020, 38, 20-28. | 1.2 | 28 |
| 2932 | The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). <i>Annals of Surgical Oncology</i> , 2020, 27, 15-21. | 0.7 | 56 |
| 2933 | Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection. <i>Pharmacoeconomics - Open</i> , 2020, 4, 343-351. | 0.9 | 4 |
| 2934 | Male sex and Breslow thickness are important risk factors for recurrence of localized melanoma in Korean populations. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1071-1079. | 0.6 | 10 |
| 2935 | Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 1-11. | 3.3 | 13 |
| 2936 | Evidence and impact of neutrophil extracellular traps in malignant melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 63-73. | 1.5 | 62 |
| 2937 | Mohs micrographic surgery versus wide local excision for head and neck melanoma-in-situ. <i>Journal of Dermatological Treatment</i> , 2020, 31, 559-562. | 1.1 | 10 |
| 2938 | Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review. <i>Value in Health</i> , 2020, 23, 52-60. | 0.1 | 23 |
| 2939 | Cranial nerve outcomes in regionally recurrent head & neck melanoma after sentinel lymph node biopsy. <i>Laryngoscope</i> , 2020, 130, 1707-1714. | 1.1 | 4 |
| 2940 | Staging Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 29-41. | 0.5 | 4 |
| 2941 | Histopathology-guided mass spectrometry differentiates benign nevi from malignant melanoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 226-240. | 0.7 | 16 |
| 2942 | From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years. <i>Human Pathology</i> , 2020, 95, 149-160. | 1.1 | 6 |
| 2943 | Reconstructive burden and financial implications of wider excision margins for invasive primary cutaneous melanoma. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2020, 73, 313-318. | 0.5 | 2 |
| 2944 | The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 910-919. | 0.6 | 10 |
| 2945 | Efficacy and safety of dabrafenib+trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF ^{V600} mutation: A systematic review and network meta-analysis. <i>Dermatologic Therapy</i> , 2020, 33, e13145. | 0.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2947 | Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 956-966. | 1.3 | 19 |
| 2948 | Role of Surgery for Metastatic Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 127-139. | 0.5 | 19 |
| 2949 | The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study. <i>OncolImmunology</i> , 2020, 9, 1682383. | 2.1 | 34 |
| 2950 | The role of mechanical stress in the formation of plantar melanoma: a retrospective analysis of 72 chinese patients with plantar melanomas and a meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 90-96. | 1.3 | 6 |
| 2951 | Quality-of-life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , 2020, 126, 611-618. | 2.0 | 12 |
| 2952 | The Evolution of Melanoma – Moving beyond Binary Models of Genetic Progression. <i>Journal of Investigative Dermatology</i> , 2020, 140, 291-297. | 0.3 | 7 |
| 2953 | Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2020, 31, 144-152. | 0.6 | 69 |
| 2954 | Patterns of failure in patients with cutaneous head and neck melanoma. <i>European Journal of Surgical Oncology</i> , 2020, 46, 914-917. | 0.5 | 6 |
| 2955 | Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib. <i>Annals of Oncology</i> , 2020, 31, 153-159. | 0.6 | 25 |
| 2956 | Time-varying pattern of recurrence risk for localized melanoma in China. <i>World Journal of Surgical Oncology</i> , 2020, 18, 6. | 0.8 | 6 |
| 2957 | Is the survival rate for acral melanoma actually worse than other cutaneous melanomas?. <i>Journal of Dermatology</i> , 2020, 47, 251-256. | 0.6 | 10 |
| 2958 | European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177. | 1.3 | 154 |
| 2959 | Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance. <i>Cancer Medicine</i> , 2020, 9, 1374-1382. | 1.3 | 52 |
| 2960 | Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States. <i>Cancer</i> , 2020, 126, 775-781. | 2.0 | 12 |
| 2961 | Cost-effectiveness of a melanoma screening programme using whole disease modelling. <i>Journal of Medical Screening</i> , 2020, 27, 157-167. | 1.1 | 2 |
| 2964 | Is it Necessary to Perform Sentinel Lymph Node Biopsy in Thin Melanoma? A Retrospective Single Center Analysis. <i>Pathology and Oncology Research</i> , 2020, 26, 1861-1868. | 0.9 | 16 |
| 2965 | Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. <i>European Journal of Cancer</i> , 2020, 125, 38-45. | 1.3 | 36 |
| 2966 | Diagnostic accuracy and safety of short-term teledermoscopic monitoring of atypical melanocytic lesions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1233-1239. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2967 | MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma. <i>Journal of Dermatological Science</i> , 2020, 97, 77-79. | 1.0 | 13 |
| 2968 | External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?. <i>Melanoma Research</i> , 2020, 30, 185-192. | 0.6 | 17 |
| 2969 | Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines. <i>Melanoma Research</i> , 2020, 30, 26-38. | 0.6 | 11 |
| 2970 | Strategies for Reducing Final Surgical Defect Sizes in the Treatment of Lentigo Maligna. <i>Dermatologic Surgery</i> , 2020, 46, 537-545. | 0.4 | 6 |
| 2971 | Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. <i>World Journal of Urology</i> , 2020, 38, 2227-2236. | 1.2 | 12 |
| 2972 | Tumourâ€infiltrating lymphocytes in canine melanocytic tumours: An investigation on the prognostic role of CD3⁺ and CD20⁺ lymphocytic populations. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 370-380. | 0.8 | 19 |
| 2973 | Late recurrence of melanoma after 10Âyears â€“ Is the course of the disease different from early recurrences?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 977-983. | 1.3 | 4 |
| 2974 | Mohs Micrographic Surgery for the Treatment of External Ear Melanoma: an Outcome Study. <i>Dermatologic Surgery</i> , 2020, 46, 995-1003. | 0.4 | 4 |
| 2975 | Global and mitosisâ€specific interobserver variation in mitotic count scoring and implications for malignant melanoma staging. <i>Histopathology</i> , 2020, 76, 803-813. | 1.6 | 6 |
| 2976 | KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020, 16, 4429-4438. | 1.1 | 59 |
| 2977 | Operationalization of skin self-examination in randomized controlled trials with individuals at increased risk for melanoma: A systematic review. <i>Patient Education and Counseling</i> , 2020, 103, 1013-1026. | 1.0 | 8 |
| 2978 | Millimeter-Wave Substrate Integrated Waveguide Probe for Skin Cancer Detection. <i>IEEE Transactions on Biomedical Engineering</i> , 2020, 67, 2462-2472. | 2.5 | 18 |
| 2979 | Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2969. | 1.0 | 24 |
| 2980 | Amiodaroneâ€™s major metabolite, desethylamiodarone inhibits proliferation of B16-F10 melanoma cells and limits lung metastasis formation in an in vivo experimental model. <i>PLoS ONE</i> , 2020, 15, e0239088. | 1.1 | 4 |
| 2981 | Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan. <i>Journal of Medical Economics</i> , 2020, 23, 1542-1552. | 1.0 | 9 |
| 2982 | Inhibition of Melanoma Cell Migration and Invasion Targeting the Hypoxic Tumor Associated CAXII. <i>Cancers</i> , 2020, 12, 3018. | 1.7 | 13 |
| 2983 | How does the mitotic index impact patients with T1 melanoma? Comparison between the 7th and 8th edition of the American Joint Committee on Cancer melanoma staging system. <i>Anais Brasileiros De Dermatologia</i> , 2020, 95, 691-695. | 0.5 | 3 |
| 2984 | Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2020, 31, 1569-1579. | 0.6 | 18 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2985 | Aberrant RNA Splicing Events Driven by Mutations of RNA-Binding Proteins as Indicators for Skin Cutaneous Melanoma Prognosis. <i>Frontiers in Oncology</i> , 2020, 10, 568469. | 1.3 | 4 |
| 2986 | Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020, 9, 8650-8661. | 1.3 | 11 |
| 2987 | An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma. <i>International Immunopharmacology</i> , 2020, 88, 106921. | 1.7 | 5 |
| 2988 | Relevance of sentinel lymph node biopsy for thick melanoma in the era of immunotherapy. <i>Surgical Oncology</i> , 2020, 35, 309-314. | 0.8 | 0 |
| 2989 | An Unsupervised Strategy for Identifying Epithelial-Mesenchymal Transition State Metrics in Breast Cancer and Melanoma. <i>IScience</i> , 2020, 23, 101080. | 1.9 | 8 |
| 2990 | User satisfaction with a smartphone-compatible, artificial intelligence-based cutaneous pigmented lesion evaluator. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 195, 105649. | 2.6 | 4 |
| 2991 | Analysing and Distinguishing Images of Failed Skin Cancer using Modern Swarm Intelligent Techniques(MSITs). <i>IOP Conference Series: Materials Science and Engineering</i> , 2020, 745, 012090. | 0.3 | 0 |
| 2992 | Genetic variants in TKT and DERA in the nicotinamide adenine dinucleotide phosphate pathway predict melanoma survival. <i>European Journal of Cancer</i> , 2020, 136, 84-94. | 1.3 | 3 |
| 2993 | Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2140-2146. | 0.5 | 8 |
| 2994 | Histological regression in primary melanoma and drug-related immune reaction towards metastatic melanoma: Are they associated??. <i>Medical Hypotheses</i> , 2020, 143, 110019. | 0.8 | 3 |
| 2995 | Real-world evidence use in assessments of cancer drugs by NICE. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 388-394. | 0.2 | 23 |
| 2996 | Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1256. | 3.4 | 38 |
| 2997 | Tele dermatology: idea, benefits and risks of modern age – a systematic review based on melanoma. <i>Postepy Dermatologii i Alergologii</i> , 2020, 37, 159-167. | 0.4 | 37 |
| 2998 | The Value of Laboratory Parameters for Anemia, Renal Function, Systemic Inflammation and Nutritional Status as Predictors for Outcome in Elderly Patients with Head-and-Neck Cancers. <i>Cancers</i> , 2020, 12, 1698. | 1.7 | 14 |
| 2999 | Anxiety and depression after diagnosis of high-risk primary cutaneous melanoma: a 4-year longitudinal study. <i>Journal of Cancer Survivorship</i> , 2020, 14, 712-719. | 1.5 | 12 |
| 3000 | Immune Microenvironment Related Competitive Endogenous RNA Network as Powerful Predictors for Melanoma Prognosis Based on WGCNA Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 577072. | 1.3 | 21 |
| 3001 | Locoregional Management of in-Transit Metastasis in Melanoma: An Ontario Health (Cancer Care) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 0.9 | 10 |
| 3002 | Risk prediction in cutaneous melanoma patients from their clinico-pathological features: superiority of clinical data over gene expression data. <i>Heliyon</i> , 2020, 6, e04811. | 1.4 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3003 | Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database. <i>European Journal of Dermatology</i> , 2020, 30, 389-396. | 0.3 | 1 |
| 3004 | Head and neck cutaneous melanoma: 5-year survival analysis in a Serbian university center. <i>World Journal of Surgical Oncology</i> , 2020, 18, 312. | 0.8 | 5 |
| 3005 | Lack of distinct molecular profile of Primary Dermal Melanoma. <i>Human Pathology</i> , 2020, 106, 32-38. | 1.1 | 4 |
| 3006 | Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 596493. | 1.3 | 24 |
| 3007 | Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib±cobimetinib: a pooled analysis of four clinical trials. <i>Journal of Translational Medicine</i> , 2020, 18, 294. | 1.8 | 8 |
| 3008 | 3D in vitro cutaneous melanoma models. , 2020, , 287-303. | | 0 |
| 3009 | Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands â€“ A nationwide population-based study. <i>European Journal of Cancer</i> , 2020, 137, 127-135. | 1.3 | 14 |
| 3010 | Efficacy and safety of dabrafenib±trametinib in the treatment of unresectable or metastatic melanoma with BRAF V600 mutation: A systematic review and network meta-analysis. <i>Dermatologic Therapy</i> , 2020, 33, e14135. | 0.8 | 1 |
| 3011 | Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. <i>Cancer</i> , 2020, 126, 4717-4725. | 2.0 | 14 |
| 3012 | Inherited variations in human pigmentation-related genes modulate cutaneous melanoma risk and clinicopathological features in Brazilian population. <i>Scientific Reports</i> , 2020, 10, 12129. | 1.6 | 6 |
| 3013 | Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. <i>Cancers</i> , 2020, 12, 1994. | 1.7 | 26 |
| 3014 | Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. <i>British Journal of Cancer</i> , 2020, 123, 885-897. | 2.9 | 22 |
| 3015 | A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients. <i>Scientific Reports</i> , 2020, 10, 12462. | 1.6 | 16 |
| 3016 | Clinicoprognostic characteristics of cutaneous metastatic melanoma: a retrospective comparative study between acral and nonacral melanoma. <i>International Journal of Dermatology</i> , 2020, 59, 1249-1257. | 0.5 | 0 |
| 3017 | Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI). <i>European Journal of Cancer</i> , 2020, 137, 30-39. | 1.3 | 4 |
| 3018 | Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer â€“ examining the utility of classifying Ta bladder cancer based on size. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 851.e19-851.e25. | 0.8 | 6 |
| 3019 | Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. <i>Melanoma Research</i> , 2020, 30, 358-363. | 0.6 | 14 |
| 3020 | A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma. <i>International Immunopharmacology</i> , 2020, 87, 106821. | 1.7 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3021 | Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. <i>Immunotherapy</i> , 2020, 12, 1213-1219. | 1.0 | 6 |
| 3022 | Ion mobility mass spectrometry of human melanoma gangliosides. <i>Biochimie</i> , 2020, 177, 226-237. | 1.3 | 15 |
| 3023 | Black Acral Nodule. <i>Journal of the Dermatology Nurses' Association</i> , 2020, 12, 91-93. | 0.1 | 0 |
| 3024 | Postmenopausal exogenous hormone therapy and Melanoma risk in women: A systematic review and time-response meta-analysis. <i>Pharmacological Research</i> , 2020, 160, 105182. | 3.1 | 8 |
| 3025 | Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 561390. | 2.2 | 12 |
| 3026 | Novel application of adipose-derived mesenchymal stem cells via producing antiangiogenic factor TSP-1 in lung metastatic melanoma animal model. <i>Biologicals</i> , 2020, 68, 9-18. | 0.5 | 14 |
| 3027 | sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. <i>Clinical Cancer Research</i> , 2020, 26, 5709-5719. | 3.2 | 17 |
| 3028 | Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US. <i>JAMA Network Open</i> , 2020, 3, e2015656. | 2.8 | 28 |
| 3029 | ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461. | 0.6 | 69 |
| 3030 | Intratumor Heterogeneity of KIT Gene Mutations in Acral Lentiginous Melanoma. <i>American Journal of Dermatopathology</i> , 2020, 42, 265-271. | 0.3 | 4 |
| 3031 | Decoding the Role of CD271 in Melanoma. <i>Cancers</i> , 2020, 12, 2460. | 1.7 | 15 |
| 3032 | The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2147-2153. | 0.5 | 13 |
| 3033 | Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1465-1477. | 5.1 | 330 |
| 3034 | Updates in the evidence-based management of cutaneous melanoma. <i>Head and Neck</i> , 2020, 42, 3396-3404. | 0.9 | 3 |
| 3035 | Anti-Cancer Effects of Lactobacillus plantarum L-14 Cell-Free Extract on Human Malignant Melanoma A375 Cells. <i>Molecules</i> , 2020, 25, 3895. | 1.7 | 9 |
| 3036 | Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications. <i>Journal of Dermatological Treatment</i> , 2020, , 1-8. | 1.1 | 2 |
| 3037 | Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936. | 0.8 | 192 |
| 3038 | Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma. <i>Current Oncology</i> , 2020, 27, 204-214. | 0.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3039 | Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. <i>Journal of Immunotherapy</i> , 2020, 43, 256-264. | 1.2 | 17 |
| 3040 | Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. <i>Annals of Surgical Oncology</i> , 2020, 27, 5107-5118. | 0.7 | 8 |
| 3041 | The Expression of CD74-Regulated Inflammatory Markers in Stage IV Melanoma: Risk of CNS Metastasis and Patient Survival. <i>Cancers</i> , 2020, 12, 3754. | 1.7 | 3 |
| 3042 | Melanoma Biomarkers and Their Potential Application for In Vivo Diagnostic Imaging Modalities. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9583. | 1.8 | 31 |
| 3043 | Skin melanoma survival is not superior in females in the new stage IIID of the 8th edition of the staging system: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database. <i>Annals of Translational Medicine</i> , 2020, 8, 1381-1381. | 0.7 | 7 |
| 3044 | The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma. <i>Surgical Oncology</i> , 2020, 35, 533-539. | 0.8 | 4 |
| 3045 | Prognostic Role of Non-Identification of Sentinel Lymph Node in Cutaneous Melanoma Patients: An Observational Retrospective Study. <i>Cancers</i> , 2020, 12, 3151. | 1.7 | 3 |
| 3047 | Primary dermal melanoma: clinical behaviour, prognosis and treatment. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2131-2139. | 0.5 | 5 |
| 3048 | Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence. <i>Annals of Surgical Oncology</i> , 2020, 27, 3683-3691. | 0.7 | 13 |
| 3049 | An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. <i>Clinical Drug Investigation</i> , 2020, 40, 629-643. | 1.1 | 13 |
| 3050 | Does very early timing of lymph node surgery after resection of the primary tumour improve the clinical outcome of patients with melanoma?. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 1011-1018. | 0.6 | 3 |
| 3051 | Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain. <i>Translational Oncology</i> , 2020, 13, 100750. | 1.7 | 5 |
| 3052 | Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176. | 1.7 | 11 |
| 3053 | Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma. <i>European Journal of Cancer</i> , 2020, 132, 176-186. | 1.3 | 15 |
| 3054 | Prognostic significance of tumor size for primary invasive cutaneous melanoma: A population-based study, 2004-2016. <i>Cancer Medicine</i> , 2020, 9, 4561-4571. | 1.3 | 13 |
| 3055 | MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. , 2020, 8, e000262. | | 44 |
| 3056 | The role of cyclin D1 and Ki67 in the development and prognostication of thin melanoma. <i>Histopathology</i> , 2020, 77, 460-470. | 1.6 | 13 |
| 3057 | â€œPrimum non nocereâ€™: how harmless is routine wide local excision for AJCC stage IA melanoma?. <i>Annals of the Royal College of Surgeons of England</i> , 2020, 102, 483-487. | 0.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3058 | Tumor growth rate as a prognostic factor of acral melanoma in a Korean population. <i>Medicine (United States)</i> , 2020, 99, e19936. | 0.4 | 1 |
| 3059 | Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. <i>BMC Medical Research Methodology</i> , 2020, 20, 103. | 1.4 | 10 |
| 3060 | Increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement. <i>Melanoma Management</i> , 2020, 7, MMT38. | 0.1 | 6 |
| 3061 | Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020, 395, 1558-1568. | 6.3 | 188 |
| 3062 | Speed rate (SR) as a new dynamic index of melanoma behavior. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 709-718. | 1.5 | 11 |
| 3063 | 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. <i>Cancer Imaging</i> , 2020, 20, 36. | 1.2 | 46 |
| 3064 | The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel nodeâ€‘positive melanoma without the need for completion lymph node dissection. <i>European Journal of Cancer</i> , 2020, 134, 9-18. | 1.3 | 11 |
| 3065 | Melanoma Screening Days During the Coronavirus Disease 2019 (COVID-19) Pandemic: Strategies to Adopt. <i>Dermatology and Therapy</i> , 2020, 10, 525-527. | 1.4 | 27 |
| 3066 | Management of Regional Nodal Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 415-431. | 0.6 | 1 |
| 3067 | Role of Surgery in Stage IV Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 485-495. | 0.6 | 8 |
| 3068 | Isorhamnetin Induces Melanoma Cell Apoptosis via the PI3K/Akt and NF- κ B Pathways. <i>BioMed Research International</i> , 2020, 2020, 1-11. | 0.9 | 19 |
| 3069 | Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. <i>Journal of Clinical Oncology</i> , 2020, 38, 2719-2727. | 0.8 | 84 |
| 3070 | Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , 2020, 38, 2543-2551. | 0.8 | 40 |
| 3071 | Sentinel Lymph Node Biopsy for Melanoma: Buggy Whip or Roller Bearing?. <i>Annals of Surgical Oncology</i> , 2020, 27, 2586-2588. | 0.7 | 1 |
| 3072 | Patterns of Omega-3 and Omega-6 Fatty Acid Dietary Intake and Melanoma Thickness at Diagnosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1647-1653. | 1.1 | 4 |
| 3073 | Malignant Melanoma of the Nipple With Axillary Metastasis. <i>JCO Oncology Practice</i> , 2020, 16, 516-518. | 1.4 | 3 |
| 3074 | Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma. <i>Dermatology and Therapy</i> , 2020, 10, 985-999. | 1.4 | 6 |
| 3075 | A comparative study of long interspersed element-1 protein immunoreactivity in cutaneous malignancies. <i>BMC Cancer</i> , 2020, 20, 567. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3077 | International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1420-1429. | 0.7 | 10 |
| 3078 | An update on the implications of cyclin D1 in melanomas. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 788-805. | 1.5 | 34 |
| 3079 | Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. <i>Journal of Translational Medicine</i> , 2020, 18, 121. | 1.8 | 29 |
| 3080 | New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986â€“2016. <i>American Journal of Public Health</i> , 2020, 110, 731-733. | 1.5 | 91 |
| 3081 | Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. <i>Frontiers in Oncology</i> , 2020, 10, 202. | 1.3 | 6 |
| 3082 | Efficacy of positron emission tomography and computed tomography in clinical staging of cutaneous malignant melanoma. <i>Dermatologic Therapy</i> , 2020, 33, e13304. | 0.8 | 0 |
| 3083 | Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study. <i>Journal of Dermatology</i> , 2020, 47, 622-628. | 0.6 | 10 |
| 3084 | A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2589-2598. | 2.0 | 44 |
| 3085 | Challenges in sentinel node pathology in the era of adjuvant treatment. <i>Journal of Surgical Oncology</i> , 2020, 122, 964-972. | 0.8 | 7 |
| 3086 | Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing 18F-FDG-PET/CT: a comparison with serologic markers of tumor burden and inflammation. <i>Cancer Imaging</i> , 2020, 20, 44. | 1.2 | 13 |
| 3087 | The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma. <i>Biochimie</i> , 2020, 176, 21-30. | 1.3 | 18 |
| 3088 | 20/20 in 2020: seeking clarity on the management of stage III melanoma in a rapidly changing treatment environment. <i>Annals of Translational Medicine</i> , 2020, 8, 776-776. | 0.7 | 0 |
| 3089 | Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521. | 1.4 | 31 |
| 3090 | GP-CNN-DTEL: Global-Part CNN Model With Data-Transformed Ensemble Learning for Skin Lesion Classification. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 2870-2882. | 3.9 | 81 |
| 3091 | iMSCGnet: Iterative Multi-Scale Context-Guided Segmentation of Skin Lesion in Dermoscopic Images. <i>IEEE Access</i> , 2020, 8, 39700-39712. | 2.6 | 22 |
| 3092 | The prognostic significance of microsatellites in cutaneous melanoma. <i>Modern Pathology</i> , 2020, 33, 1369-1379. | 2.9 | 13 |
| 3093 | Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 875-885. | 3.0 | 20 |
| 3094 | Association between tumor characteristics and second primary cancers with cutaneous melanoma survival: A nationwide cohort study. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 625-632. | 1.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3095 | Short and long-term barriers and facilitators of skin self-examination among individuals diagnosed with melanoma. <i>BMC Cancer</i> , 2020, 20, 123. | 1.1 | 15 |
| 3096 | A Mutual Bootstrapping Model for Automated Skin Lesion Segmentation and Classification. <i>IEEE Transactions on Medical Imaging</i> , 2020, 39, 2482-2493. | 5.4 | 206 |
| 3097 | Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2021-2025. | 1.3 | 16 |
| 3098 | Differences in direct costs of patients with stage I cutaneous melanoma: A real-world data analysis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 976-981. | 0.5 | 3 |
| 3099 | Melanoma incidence, stage, and survival after solid organ transplant: A population-based cohort study in Ontario, Canada. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 754-761. | 0.6 | 8 |
| 3100 | Prognostic Significance of Tumor-Infiltrating Lymphocyte Grade in Melanoma: A Meta-Analysis. <i>Dermatology</i> , 2020, 236, 481-492. | 0.9 | 8 |
| 3101 | Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas, and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls. <i>Molecular Oncology</i> , 2020, 14, 742-762. | 2.1 | 14 |
| 3102 | Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients. <i>Journal of Translational Medicine</i> , 2020, 18, 78. | 1.8 | 17 |
| 3103 | miRNAs as Key Players in the Management of Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 415. | 1.8 | 23 |
| 3105 | Worse survival of invasive melanoma patients in men and <i>de novo</i> lesions. <i>Anais Brasileiros De Dermatologia</i> , 2020, 95, 158-164. | 0.5 | 5 |
| 3106 | Internal Pathology Review of Invasive Melanoma: An Academic Institution Experience. <i>Journal of Surgical Research</i> , 2020, 250, 97-101. | 0.8 | 1 |
| 3107 | European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics <i>Update</i> 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158. | 1.3 | 133 |
| 3108 | Biomarkers for Melanoma. , 2020, , 73-104. | | 0 |
| 3109 | Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488. | 2.0 | 42 |
| 3110 | Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma. <i>Journal of Dermatological Science</i> , 2020, 97, 172-178. | 1.0 | 4 |
| 3111 | SERINE-910 Phosphorylated Focal Adhesion Kinase Expression Predicts Better Overall and Disease-free Survival in Melanoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 130-138. | 0.6 | 3 |
| 3112 | Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. <i>Cancer Cell</i> , 2020, 37, 85-103.e9. | 7.7 | 91 |
| 3113 | <i>Gynecological Pathology</i> . , 2020, , 1049-1521. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3114 | Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics. <i>Frontiers in Genetics</i> , 2020, 11, 221. | 1.1 | 33 |
| 3115 | Gender Differences and Outcomes in Melanoma Patients. <i>Oncology and Therapy</i> , 2020, 8, 103-114. | 1.0 | 28 |
| 3116 | Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 403-413. | 1.1 | 2 |
| 3117 | Sequencing in management of in-transit melanoma metastasis: Diphencyprone versus isolate limb infusion. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2020, 73, 1263-1267. | 0.5 | 4 |
| 3118 | Demographic, Clinical, and Pathologic Features of Patients With Cutaneous Melanoma: Final Analysis of the Brazilian Melanoma Group Database. <i>JCO Global Oncology</i> , 2020, 6, 575-582. | 0.8 | 5 |
| 3120 | Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e651-e659. | 0.9 | 7 |
| 3121 | BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 833-844. | 0.8 | 48 |
| 3122 | Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies. <i>BMJ, The</i> , 2020, 368, m127. | 3.0 | 140 |
| 3123 | The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. <i>Journal of Translational Medicine</i> , 2020, 18, 171. | 1.8 | 2 |
| 3124 | Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab. <i>Anticancer Research</i> , 2020, 40, 2157-2163. | 0.5 | 5 |
| 3125 | A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients. <i>Cancer Cell International</i> , 2020, 20, 96. | 1.8 | 21 |
| 3126 | ROCK1 and ROCK2 Are Down-regulated in Aggressive and Advanced Skin Melanomas – A Clinicopathological Perspective. <i>Anticancer Research</i> , 2020, 40, 1931-1942. | 0.5 | 8 |
| 3127 | A Novel Hybrid Nanosystem Integrating Cytotoxic and Magnetic Properties as a Tool to Potentiate Melanoma Therapy. <i>Nanomaterials</i> , 2020, 10, 693. | 1.9 | 13 |
| 3128 | Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 59-71. | 1.5 | 65 |
| 3129 | The prognostic impact of the extent of ulceration in patients with clinical stage II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI). <i>British Journal of Dermatology</i> , 2021, 184, 281-288. | 1.4 | 10 |
| 3130 | Survival in 31670 patients with thin melanomas: a Swedish population-based study*. <i>British Journal of Dermatology</i> , 2021, 184, 60-67. | 1.4 | 15 |
| 3131 | Survival Differences Between Pediatric Head and Neck Versus Body Melanoma in the Surveillance, Epidemiology, and End Results Program. <i>Laryngoscope</i> , 2021, 131, E635-E641. | 1.1 | 5 |
| 3132 | The role of technology in melanoma screening and diagnosis. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 288-300. | 1.5 | 22 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3133 | Immune metabolism in PD-1 blockade-based cancer immunotherapy. <i>International Immunology</i> , 2021, 33, 17-26. | 1.8 | 26 |
| 3134 | Comprehensive Investigation into the Role of Ubiquitin-Conjugating Enzyme E2S in Melanoma Development. <i>Journal of Investigative Dermatology</i> , 2021, 141, 374-384. | 0.3 | 10 |
| 3135 | Deep learning techniques for skin lesion analysis and melanoma cancer detection: a survey of state-of-the-art. <i>Artificial Intelligence Review</i> , 2021, 54, 811-841. | 9.7 | 142 |
| 3136 | A mixed methods analysis of access barriers to dermatology care in a rural state. <i>Journal of Advanced Nursing</i> , 2021, 77, 355-366. | 1.5 | 4 |
| 3137 | Survival Outcomes Following Lymph Node Biopsy in Thin Melanoma—A Propensity-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 1634-1641. | 0.7 | 4 |
| 3138 | Lymphoscintigraphy for Sentinel Node Mapping in Head and Neck Cancer. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 39-49. | 2.5 | 21 |
| 3139 | Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010–2017. <i>Journal of Investigative Dermatology</i> , 2021, 141, 830-839.e3. | 0.3 | 10 |
| 3140 | Flow Cytometry for Detection and Quantification of Micrometastases in Sentinel Lymph Nodes from Patients with Primary Melanoma. <i>Journal of Surgical Research</i> , 2021, 257, 477-485. | 0.8 | 3 |
| 3141 | Cholecystectomy as treatment for isolated melanoma metastasis to the gallbladder. <i>ANZ Journal of Surgery</i> , 2021, 91, E310-E311. | 0.3 | 1 |
| 3142 | Primary Dermal Melanoma (PDM): Histological and Clinical Interdependence to Guide Therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 53-58. | 0.6 | 3 |
| 3143 | Current Management of Melanoma. <i>Updates in Surgery Series</i> , 2021, , . | 0.0 | 0 |
| 3144 | Sleep disorders and cancer: State of the art and future perspectives. <i>Sleep Medicine Reviews</i> , 2021, 56, 101409. | 3.8 | 96 |
| 3145 | Five-year survival in patients with nodular and superficial spreading melanomas in the US population. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1015-1022. | 0.6 | 23 |
| 3146 | Risk factors for positive sentinel lymph nodes in head and neck melanoma — a survival analysis. <i>Brazilian Journal of Otorhinolaryngology</i> , 2021, 87, 103-109. | 0.4 | 2 |
| 3147 | Automated skin lesion segmentation using attention-based deep convolutional neural network. <i>Biomedical Signal Processing and Control</i> , 2021, 65, 102358. | 3.5 | 42 |
| 3148 | Downregulation of dihydrolipoyl dehydrogenase by UVA suppresses melanoma progression via triggering oxidative stress and altering energy metabolism. <i>Free Radical Biology and Medicine</i> , 2021, 162, 77-87. | 1.3 | 36 |
| 3149 | State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1-27. | 0.9 | 4 |
| 3150 | Stage IIIa Melanoma and Impact of Multiple Positive Lymph Nodes on Survival. <i>Journal of the American College of Surgeons</i> , 2021, 232, 517-524.e1. | 0.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3151 | Handheld reflectance confocal microscopy: Personalized and accurate presurgical delineation of lentigo maligna (melanoma). <i>Head and Neck</i> , 2021, 43, 895-902. | 0.9 | 5 |
| 3152 | Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1498-1510. | 3.3 | 4 |
| 3153 | Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma*. <i>British Journal of Dermatology</i> , 2021, 184, 944-951. | 1.4 | 26 |
| 3154 | Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23. | 1.3 | 5 |
| 3156 | Identification of IL10RA by Weighted Correlation Network Analysis and in vitro Validation of Its Association With Prognosis of Metastatic Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 630790. | 1.8 | 7 |
| 3157 | Malignant Melanoma: From Molecular Characterization to Targeted Therapies. , 2021, , . | | 0 |
| 3158 | Melanocytic Neoplasms. , 2021, , 289-313. | | 0 |
| 3159 | Percutaneous contrast-enhanced ultrasound for localization and qualitative diagnosis of sentinel lymph nodes in cutaneous malignant melanoma of lower extremities: a preliminary study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 366-375. | 1.1 | 2 |
| 3161 | Disease Progression in Cutaneous Squamous Cell Carcinoma Patients With Satellitosis and In-transit Metastasis. <i>Anticancer Research</i> , 2021, 41, 289-295. | 0.5 | 8 |
| 3163 | Pathology of Melanoma and Skin Carcinomas. , 2021, , 3-30. | | 2 |
| 3165 | Prognostic factors for postoperative survival in melanoma patients with bone metastasis. <i>Medicine (United States)</i> , 2021, 100, e24558. | 0.4 | 2 |
| 3166 | Novel Prognostic Models Predicting the Cancer-Specific Survival in Patients with Cutaneous Melanoma Based on Metastatic Lymph Node Status. <i>Annals of Surgical Oncology</i> , 2021, 28, 4572-4581. | 0.7 | 1 |
| 3167 | Mortality in cutaneous malignant melanoma and its association with Neutrophil-to-Lymphocyte ratio.. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100464. | 0.7 | 4 |
| 3168 | Trends in the characteristics of skin melanoma in accordance with time intervals: A single Turkish tertiary referral center experience. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1119. | 0.3 | 1 |
| 3169 | Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4582-4589. | 0.7 | 13 |
| 3170 | Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 2074-2086. | 3.2 | 12 |
| 3171 | Genomic Landscapes of Acral Melanomas in East Asia. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 83-92. | 1.0 | 6 |
| 3172 | <sc>SegCaps</sc>: An efficient <sc>SegCaps</sc> network-based skin lesion segmentation in dermoscopic images. <i>International Journal of Imaging Systems and Technology</i> , 2021, 31, 874-894. | 2.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 3173 | Aqueous Extract of <i>Adansonia digitata</i> reversed Cotton Seed Extract- Induced Testicular Damage in Wistar rats. <i>Jornal Brasileiro De Reproducao Assistida</i> , 2021, 25, 257-265. | 0.3 | 3 |
| 3174 | Multivariate analysis of prognostic factors in patients with nodular melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2759-2764. | 1.2 | 8 |
| 3175 | The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma. <i>Journal of Immunology Research</i> , 2021, 2021, 1-14. | 0.9 | 8 |
| 3176 | Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy. <i>Cancer Research</i> , 2021, 81, 2545-2555. | 0.4 | 18 |
| 3177 | Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. <i>European Journal of Cancer</i> , 2021, 144, 242-251. | 1.3 | 16 |
| 3178 | Skin melanoma deaths within 1 or 3 years from diagnosis in Europe. <i>International Journal of Cancer</i> , 2021, 148, 2898-2905. | 2.3 | 7 |
| 3179 | Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina. <i>Oncology and Therapy</i> , 2021, 9, 167-185. | 1.0 | 3 |
| 3180 | Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. <i>Cellular Immunology</i> , 2021, 360, 104274. | 1.4 | 8 |
| 3181 | Adjuvant Therapy of High-Risk (Stages II-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 637161. | 1.3 | 15 |
| 3182 | Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309. | 15.2 | 218 |
| 3183 | Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 364-370. | 0.6 | 3 |
| 3184 | UTRN inhibits melanoma growth by suppressing p38 and JNK/c-Jun signaling pathways. <i>Cancer Cell International</i> , 2021, 21, 88. | 1.8 | 15 |
| 3185 | Early detection of melanoma in specialised primary care practice in Australia. <i>Cancer Epidemiology</i> , 2021, 70, 101872. | 0.8 | 5 |
| 3186 | Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. <i>BMC Cancer</i> , 2021, 21, 323. | 1.1 | 22 |
| 3187 | Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study. <i>European Journal of Cancer</i> , 2021, 145, 29-37. | 1.3 | 12 |
| 3188 | Long noncoding RNA LINC00518 induces radioresistance by regulating glycolysis through an miR-33a-3p/HIF-1 β negative feedback loop in melanoma. <i>Cell Death and Disease</i> , 2021, 12, 245. | 2.7 | 30 |
| 3189 | Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e210980. | 2.8 | 16 |
| 3190 | Ultra-high-frequency ultrasound and machine learning approaches for the differential diagnosis of melanocytic lesions. <i>Experimental Dermatology</i> , 2022, 31, 94-98. | 1.4 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3191 | Design, Synthesis, and Evaluation of Small Molecule G1±q/11 Protein Inhibitors for the Treatment of Uveal Melanoma. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3131-3152. | 2.9 | 7 |
| 3192 | A review of the AJCC melanoma staging system in the TNM classification (eighth edition). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 671-674. | 0.6 | 8 |
| 3193 | Sentinel node biopsy for primary cutaneous melanoma. <i>Annals of Oncology</i> , 2021, 32, 290-292. | 0.6 | 8 |
| 3194 | A Four-Gene-Based Prognostic Model Predicts Overall Survival in Patients With Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 639874. | 1.3 | 10 |
| 3195 | Reply to E. HindiÃ©. <i>Journal of Clinical Oncology</i> , 2021, 39, 944-946. | 0.8 | 1 |
| 3196 | Recent advancements in melanoma management. <i>Internal Medicine Journal</i> , 2021, 51, 327-333. | 0.5 | 4 |
| 3197 | Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. <i>Annals of Oncology</i> , 2021, 32, 375-383. | 0.6 | 25 |
| 3198 | Treatment of Cutaneous Melanoma of the Head and Neck With Wide Local Excision Versus Mohs. <i>Laryngoscope</i> , 2021, 131, 2490-2496. | 1.1 | 3 |
| 3199 | Patient-identified early clinical warning signs of nodular melanoma: a qualitative study. <i>BMC Cancer</i> , 2021, 21, 371. | 1.1 | 5 |
| 3200 | Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 497-502. | 1.2 | 5 |
| 3201 | Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. <i>Annals of Surgery</i> , 2021, 274, 383-389. | 2.1 | 28 |
| 3202 | Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021, 13, 419-432. | 1.0 | 9 |
| 3203 | A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanomaã†. <i>ESMO Open</i> , 2021, 6, 100050. | 2.0 | 14 |
| 3204 | Human KIT+ myeloid cells facilitate visceral metastasis by melanoma. <i>Journal of Experimental Medicine</i> , 2021, 218, . | 4.2 | 5 |
| 3205 | Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17. | 4.3 | 70 |
| 3206 | Pediatric Melanomaã€”Diagnosis, Management, and Anticipated Outcomes. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 373-388. | 0.6 | 2 |
| 3207 | Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. <i>Cancers</i> , 2021, 13, 1819. | 1.7 | 16 |
| 3208 | Risk factors and patterns of recurrence after sentinel lymph node biopsy for thin melanoma. <i>Archives of Dermatological Research</i> , 2022, 314, 285-292. | 1.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3209 | Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: Implications for clinical practice. <i>Gynecologic Oncology</i> , 2021, 161, 202-210. | 0.6 | 8 |
| 3210 | Immunohistochemical expression and prognostic role of CD10, CD271 and Nestin in primary and recurrent cutaneous melanoma. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, . | 0.1 | 2 |
| 3211 | To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma. <i>Cancer</i> , 2021, 127, 2333-2341. | 2.0 | 4 |
| 3212 | The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021, 19, 142. | 1.8 | 1 |
| 3213 | The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden. <i>Cancers</i> , 2021, 13, 2456. | 1.7 | 2 |
| 3214 | Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2021, 2021, 1-15. | 0.6 | 8 |
| 3215 | The role of osteopontin in the development and metastasis of melanoma. <i>Melanoma Research</i> , 2021, 31, 283-289. | 0.6 | 6 |
| 3216 | Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 521-535. | 1.5 | 5 |
| 3217 | Retrospective evaluation of malignant melanoma patients: A single-center experience. <i>Family Practice and Palliative Care</i> , 0, , 98-104. | 0.2 | 0 |
| 3218 | Development and external validation of a nomogram predicting overall survival after curative resection of colon cancer. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110150. | 0.4 | 11 |
| 3219 | Melanoma With an Unknown Primary in an Asymptomatic Elderly Male With Unilateral Lymphadenopathy. <i>Cureus</i> , 2021, 13, e15140. | 0.2 | 0 |
| 3220 | Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-13. | 0.6 | 6 |
| 3221 | Dermoscopic Predictors of Tumor Thickness in Cutaneous Melanoma: A Retrospective Analysis of 245 Melanomas. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021059. | 0.5 | 3 |
| 3222 | Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. <i>European Journal of Cancer</i> , 2021, 149, 222-232. | 1.3 | 26 |
| 3223 | Current management of melanoma patients with nodal metastases. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 181-199. | 1.7 | 8 |
| 3224 | Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators. <i>Frontiers in Oncology</i> , 2021, 11, 659754. | 1.3 | 6 |
| 3225 | Survival models induced by zero-modified power series discrete frailty: Application with a melanoma data set. <i>Statistical Methods in Medical Research</i> , 2021, 30, 1874-1889. | 0.7 | 1 |
| 3226 | Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5034. | 1.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3227 | ETS1 promoted cell growth, metastasis and epithelial-mesenchymal transition process in melanoma by regulating miR-16-mediated SOX4 expression. <i>Melanoma Research</i> , 2021, 31, 298-308. | 0.6 | 6 |
| 3228 | m6A-Related lncRNAs Are Potential Biomarkers for the Prognosis of Metastatic Skin Cutaneous Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 687760. | 1.6 | 16 |
| 3229 | Targeting Solid Tumors Using CD3 Bispecific Antibodies. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1350-1358. | 1.9 | 8 |
| 3230 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654. | 5.1 | 224 |
| 3231 | The Negative Binomial Beta Prime Regression Model with Cure Rate: Application with a Melanoma Dataset. <i>Journal of Statistical Theory and Practice</i> , 2021, 15, 1. | 0.3 | 4 |
| 3232 | Fortuitous discovery of melanomas in the ENT Department – a histopathological and immunohistochemical study. <i>Romanian Journal of Morphology and Embryology</i> , 2021, 61, 1163-1171. | 0.4 | 0 |
| 3233 | Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. <i>Gynecologic Oncology</i> , 2021, 161, 645-652. | 0.6 | 15 |
| 3234 | The significance of imaging examinations during follow-up for malignant melanoma. <i>European Journal of Dermatology</i> , 2021, 31, 357-363. | 0.3 | 4 |
| 3235 | 5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021, 27, 5225-5235. | 3.2 | 82 |
| 3236 | A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma. <i>British Journal of Cancer</i> , 2021, 125, 699-713. | 2.9 | 12 |
| 3237 | Landmark Series on Disparities in Surgical Oncology: Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6986-6993. | 0.7 | 4 |
| 3238 | RTP4 is a novel prognosis-related hub gene in cutaneous melanoma. <i>Hereditas</i> , 2021, 158, 22. | 0.5 | 9 |
| 3239 | Sentinel lymph node biopsy guideline concordance in melanoma: Analysis of the National Cancer Database. <i>Journal of Surgical Oncology</i> , 2021, 124, 669-678. | 0.8 | 12 |
| 3240 | Usefulness of High-Frequency Ultrasonography in the Diagnosis of Melanoma: Mini Review. <i>Frontiers in Oncology</i> , 2021, 11, 673026. | 1.3 | 12 |
| 3241 | Nomogram Incorporating the WNT/ β -Catenin Signaling Pathway for Predicting the Survival of Cutaneous Melanoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 2751-2761. | 0.8 | 4 |
| 3242 | Identification of Potential Prognostic Biomarkers Associated With Cancerometastasis in Skin Cutaneous Melanoma. <i>Frontiers in Genetics</i> , 2021, 12, 687979. | 1.1 | 5 |
| 3243 | Current Landscape and Open Questions on Adjuvant Therapies in Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021165S. | 0.5 | 0 |
| 3244 | Melanoma of vulva in situ, presentation of a case. <i>Obstetrics & Gynecology International Journal</i> , 2021, 12, . | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3245 | W-net and inception residual network for skin lesion segmentation and classification. Applied Intelligence, 2022, 52, 3976-3994. | 3.3 | 41 |
| 3246 | Malignant melanoma without primary, presenting as solitary pulmonary nodule: a case report. Journal of Medical Case Reports, 2021, 15, 347. | 0.4 | 1 |
| 3247 | Reduction in the number of early melanomas diagnosed during the COVID-19 pandemic: a single-centre cohort study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e735-e737. | 1.3 | 13 |
| 3248 | Interferon- β 1b for the treatment of metastatic melanoma: results of a retrospective study. Anti-Cancer Drugs, 2021, 32, 1105-1110. | 0.7 | 6 |
| 3249 | Unraveling the Wide Spectrum of Melanoma Biomarkers. Diagnostics, 2021, 11, 1341. | 1.3 | 55 |
| 3250 | Molecular characterization of fast-growing melanomas. Journal of the American Academy of Dermatology, 2022, 86, 312-321. | 0.6 | 11 |
| 3251 | Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer. , 0, , . | | 4 |
| 3252 | Recognition, Staging, and Management of Melanoma. Medical Clinics of North America, 2021, 105, 643-661. | 1.1 | 4 |
| 3253 | FAC-Net: Feedback Attention Network Based on Context Encoder Network for Skin Lesion Segmentation. Sensors, 2021, 21, 5172. | 2.1 | 23 |
| 3254 | A Multi-path CNN for Automated Skin Lesion Segmentation. , 2021, , . | | 0 |
| 3255 | Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 2021, 91, 3-13. | 0.3 | 7 |
| 3256 | Pulmonary metastatic melanoma: current state of diagnostic imaging and treatments. Melanoma Management, 2021, 8, MMT58. | 0.1 | 7 |
| 3257 | Investigating the depolarization property of skin tissue by degree of polarization uniformity contrast using polarization-sensitive optical coherence tomography. Biomedical Optics Express, 2021, 12, 5073. | 1.5 | 15 |
| 3258 | Characterization and Clinical Utility of BRAFV600 Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma. Cancers, 2021, 13, 3591. | 1.7 | 4 |
| 3259 | Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. Current Problems in Surgery, 2022, 59, 101030. | 0.6 | 4 |
| 3260 | The Role of Glycosylation in Melanoma Progression. Cells, 2021, 10, 2136. | 1.8 | 21 |
| 3261 | Performance Evaluation of Novel Convolution Neural Network Architecture for Melanoma Skin Cancer Diagnosis on Different Hardware Processing Units. Journal of Physics: Conference Series, 2021, 1950, 012039. | 0.3 | 2 |
| 3262 | ANN-based diagnosis method for skin cancers using dermoscopic images. Highlights in BioScience, 0, , bs202108. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3263 | Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma. <i>Melanoma Research</i> , 2021, 31, 439-448. | 0.6 | 4 |
| 3264 | Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3829-3838. | 0.8 | 44 |
| 3265 | Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas. <i>Diagnostic Pathology</i> , 2021, 16, 78. | 0.9 | 5 |
| 3266 | Need to restage Korean melanoma patients following publication of the 8th edition of the American Joint Committee on Cancer staging manual. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, . | 0.2 | 0 |
| 3267 | CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma. <i>Cancers</i> , 2021, 13, 3943. | 1.7 | 8 |
| 3268 | Application of generated mask method based on Mask R-CNN in classification and detection of melanoma. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 207, 106174. | 2.6 | 17 |
| 3269 | Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases). <i>Meditinskiy Sovet</i> , 2021, , 64-74. | 0.1 | 2 |
| 3270 | Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. <i>Immunotherapy</i> , 2021, 13, 1011-1029. | 1.0 | 8 |
| 3271 | Next-Generation Immunotherapy Approaches in Melanoma. <i>Current Oncology Reports</i> , 2021, 23, 116. | 1.8 | 3 |
| 3272 | Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188. | | 12 |
| 3273 | Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. <i>Cancers</i> , 2021, 13, 3913. | 1.7 | 5 |
| 3274 | Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. <i>Dermatology and Therapy</i> , 2021, 11, 1481-1496. | 1.4 | 12 |
| 3275 | A mechanism of cooling hot tumors: Lactate attenuates inflammation in dendritic cells. <i>IScience</i> , 2021, 24, 103067. | 1.9 | 8 |
| 3277 | HLA-DRB1 $\hat{=}$ 16:01 and HLA-DQB1 $\hat{=}$ 05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma. <i>Journal of Oncology</i> , 2021, 2021, 1-7. | 0.6 | 3 |
| 3278 | Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10568. | 1.8 | 0 |
| 3279 | Top Ten Tips Palliative Care Clinicians Should Know About Prognostication in Oncology, Dementia, Frailty, and Pulmonary Diseases. <i>Journal of Palliative Medicine</i> , 2021, 24, 1391-1397. | 0.6 | 6 |
| 3280 | Contemporary update of SPECT tracers and novelties in radioguided surgery: a perspective based on urology. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 215-228. | 0.4 | 3 |
| 3281 | Primary Melanoma Characteristics of Metastatic Disease: A Nationwide Cancer Registry Study. <i>Cancers</i> , 2021, 13, 4431. | 1.7 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3282 | Adjuvant treatment for melanoma in clinical practice – Trial versus reality. <i>European Journal of Cancer</i> , 2021, 158, 234-245. | 1.3 | 12 |
| 3283 | Prognostic factors for in-transit metastasis in patients with malignant melanoma. <i>Medicine and Pharmacy Reports</i> , 0, , . | 0.2 | 1 |
| 3284 | Deep ensemble learning for skin lesions classification with convolutional neural network. <i>IAES International Journal of Artificial Intelligence</i> , 2021, 10, 563. | 0.6 | 4 |
| 3285 | Improving Dermal Delivery of Rose Bengal by Deformable Lipid Nanovesicles for Topical Treatment of Melanoma. <i>Molecular Pharmaceutics</i> , 2021, 18, 4046-4057. | 2.3 | 25 |
| 3286 | Health-related quality of life using the FACT-M questionnaire in patients with malignant melanoma: A systematic review. <i>European Journal of Surgical Oncology</i> , 2022, 48, 312-319. | 0.5 | 4 |
| 3287 | ZnO nanoparticles stimulate oxidative stress to induce apoptosis of B16F10 melanoma cells: In vitro and in vivo studies. <i>Biomedical Physics and Engineering Express</i> , 2021, 7, 065014. | 0.6 | 8 |
| 3288 | On a new piecewise regression model with cure rate: Diagnostics and application to medical data. <i>Statistics in Medicine</i> , 2021, 40, 6723-6742. | 0.8 | 9 |
| 3289 | A novel prognostic biomarker for cutaneous malignant melanoma. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 566-574. | 0.6 | 6 |
| 3290 | Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon β . <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 550-554. | 0.6 | 1 |
| 3291 | Sentinel Lymph Node Biopsy, Lymph Node Dissection, and Lymphedema Management Options in Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 607-616. | 0.7 | 2 |
| 3292 | American Joint Committee on Cancer Staging and Other Platforms to Assess Prognosis and Risk. <i>Clinics in Plastic Surgery</i> , 2021, 48, 599-606. | 0.7 | 6 |
| 3293 | Practical Considerations When Interpreting FDG PET/CT Imaging for Staging and Treatment Response Assessment in Melanoma Patients. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 544-553. | 2.5 | 5 |
| 3294 | The increasing role of pigment epithelium-derived factor in metastasis: from biological importance to a promising target. <i>Biochemical Pharmacology</i> , 2021, 193, 114787. | 2.0 | 11 |
| 3295 | Sex-specific survival benefit in early skin melanoma based on 8th AJCC edition: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database. <i>Annals of Translational Medicine</i> , 2021, 9, 53-53. | 0.7 | 3 |
| 3296 | Development of an immune-related gene pairs index for the prognosis analysis of metastatic melanoma. <i>Scientific Reports</i> , 2021, 11, 1253. | 1.6 | 4 |
| 3297 | ARNT deficiency represses pyruvate dehydrogenase kinase 1 to trigger ROS production and melanoma metastasis. <i>Oncogenesis</i> , 2021, 10, 11. | 2.1 | 8 |
| 3298 | Assessing the Educational and Supportive Care Needs of Canadian Metastatic Melanoma Patients and Survivors Attending an Outpatient Clinic. <i>Journal of Patient Experience</i> , 2021, 8, 237437352110331. | 0.4 | 1 |
| 3299 | Automated Skin Lesion Segmentation Via an Adaptive Dual Attention Module. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 357-370. | 5.4 | 97 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3300 | Anti-metastatic Effects of Cationic KT2 Peptide (a Lysine/Tryptophan-rich Peptide) on Human Melanoma A375.S2 Cells. <i>In Vivo</i> , 2021, 35, 215-227. | 0.6 | 6 |
| 3301 | Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis. <i>Investigational New Drugs</i> , 2021, 39, 928-948. | 1.2 | 3 |
| 3302 | Prognostic Significance of Epidermal Growth Factor Receptor Expression in Distant Metastatic Melanoma from Primary Cutaneous Melanoma. <i>Annals of Dermatology</i> , 2021, 33, 432. | 0.3 | 3 |
| 3305 | Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma. <i>Methods in Molecular Biology</i> , 2020, 2055, 155-180. | 0.4 | 7 |
| 3306 | Melanocytic Neoplasms II: Molecular Staging. , 2011, , 105-130. | | 2 |
| 3307 | Introduction to Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. , 2012, , 1-7. | | 1 |
| 3308 | MicroRNA Biomarkers in Melanoma. , 2012, , 113-126. | | 1 |
| 3309 | Current Status of Diagnostic and Prognostic Markers in Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 177-197. | 0.4 | 10 |
| 3310 | Construction and Analysis of Multiparameter Prognostic Models for Melanoma Outcome. <i>Methods in Molecular Biology</i> , 2014, 1102, 227-258. | 0.4 | 7 |
| 3311 | Pathological Staging of Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 325-351. | 0.4 | 6 |
| 3312 | Circulating Tumor Cells as Prognostic Biomarkers in Cutaneous Melanoma Patients. <i>Methods in Molecular Biology</i> , 2014, 1102, 513-522. | 0.4 | 10 |
| 3313 | Surveillance and Follow-Up of Melanoma Patients. , 2020, , 851-866. | | 1 |
| 3314 | Systemic Therapy for Mucosal, Acral, and Uveal Melanoma. , 2020, , 1301-1335. | | 2 |
| 3315 | Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 767-793. | | 1 |
| 3316 | Skin Cancer for Primary Care. , 2019, , 171-208. | | 1 |
| 3317 | Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 51-68. | 0.8 | 41 |
| 3318 | Comparative Effectiveness in Melanoma. <i>Cancer Treatment and Research</i> , 2015, 164, 31-49. | 0.2 | 2 |
| 3319 | Radioguided Surgery for Malignant Melanoma. , 2016, , 1-33. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3320 | Title is missing!. , 2017, , . | | 82 |
| 3321 | Clinicopathologic Overview of Melanoma. , 2017, , 1-5. | | 2 |
| 3322 | Systemic Therapy for Mucosal, Acral and Uveal Melanoma. , 2019, , 1-37. | | 1 |
| 3323 | MedikamentÄrse Tumorthherapie in der Dermato-Onkologie. , 2014, , . | | 2 |
| 3325 | Melanoma: From Tumor-Specific Mutations to a New Molecular Taxonomy and Innovative Therapeutics. , 2015, , 7-27. | | 2 |
| 3326 | Melanom. , 2018, , 1869-1885. | | 1 |
| 3327 | Melanoma: Perspectives of a Vaccine Based on Peptides. , 2013, , 397-412. | | 4 |
| 3328 | Melanoma and Non-Melanoma Skin Cancers. , 2014, , 435-452. | | 1 |
| 3330 | Sentinel Lymph Node Biopsy. Surgical Oncology Clinics of North America, 2020, 29, 401-414. | 0.6 | 3 |
| 3331 | Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Communications, 2021, 12, 1137. | 5.8 | 33 |
| 3333 | Limited-duration anti-PD-1 therapy for patients with metastatic melanoma. Acta OncolÄgica, 2020, 59, 438-443. | 0.8 | 7 |
| 3334 | The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Review of Anticancer Therapy, 2018, 18, 775-784. | 1.1 | 268 |
| 3335 | Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany. Journal of Market Access & Health Policy, 2021, 9, 1861804. | 0.8 | 5 |
| 3336 | Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Research, 2021, 31, 67-75. | 0.6 | 15 |
| 3337 | Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. Melanoma Research, 2010, 20, 240-246. | 0.6 | 46 |
| 3338 | The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past. Melanoma Research, 2010, 20, 422-426. | 0.6 | 45 |
| 3340 | Absolute and relative differential blood count predicts survival of AJCC stage Iâ€œII melanoma patients scheduled for sentinel lymph node biopsy. Australasian Journal of Dermatology, 2020, 61, e310-e318. | 0.4 | 8 |
| 3341 | Optical coherence tomography for the diagnosis of malignant skin tumors: a meta-analysis. Journal of Biomedical Optics, 2018, 23, 1. | 1.4 | 34 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3342 | Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Reports, 2015, 2015, bcr2014208102. | 0.2 | 38 |
| 3343 | Protocol for the melatools skin self-monitoring trial: a phase II randomised controlled trial of an intervention for primary care patients at higher risk of melanoma. BMJ Open, 2017, 7, e017934. | 0.8 | 9 |
| 3344 | Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689. | | 33 |
| 3345 | 218â€¦A preclinical study of IMC-002, a fully human therapeutic antibody safely targeting CD47 in cancer. , 2020, , . | | 1 |
| 3346 | Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. JCI Insight, 2017, 2, . | 2.3 | 48 |
| 3347 | Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight, 2017, 2, . | 2.3 | 62 |
| 3348 | IgG4 subclass antibodies impair antitumor immunity in melanoma. Journal of Clinical Investigation, 2013, 123, 1457-1474. | 3.9 | 181 |
| 3349 | Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma.. Journal of Clinical Oncology, 2010, 28, e19008-e19008. | 0.8 | 3 |
| 3350 | Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma.. Journal of Clinical Oncology, 2015, 33, 9001-9001. | 0.8 | 5 |
| 3351 | Methylation-Mediated Silencing of MicroRNA-211 Decreases the Sensitivity of Melanoma Cells to Cisplatin. Medical Science Monitor, 2019, 25, 1590-1599. | 0.5 | 17 |
| 3352 | Pigmented lesions of the nail unit. Seminars in Cutaneous Medicine and Surgery, 2015, 34, 101-108. | 1.6 | 12 |
| 3353 | Current options and future directions in the systemic treatment of metastatic melanoma. Journal of Community and Supportive Oncology, 2014, 12, 20-26. | 0.1 | 5 |
| 3354 | Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report. World Journal of Clinical Cases, 2020, 8, 4100-4108. | 0.3 | 4 |
| 3355 | Up-Regulated Dicer Expression in Patients with Cutaneous Melanoma. PLoS ONE, 2011, 6, e20494. | 1.1 | 56 |
| 3356 | Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women. PLoS ONE, 2012, 7, e32955. | 1.1 | 78 |
| 3357 | High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy. PLoS ONE, 2012, 7, e38254. | 1.1 | 115 |
| 3358 | An Attempt at a Molecular Prediction of Metastasis in Patients with Primary Cutaneous Melanoma. PLoS ONE, 2012, 7, e49865. | 1.1 | 13 |
| 3359 | Characterization of Human Î³Î³ T Lymphocytes Infiltrating Primary Malignant Melanomas. PLoS ONE, 2012, 7, e49878. | 1.1 | 137 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3360 | Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAFV600. PLoS ONE, 2013, 8, e59221. | 1.1 | 13 |
| 3361 | Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. PLoS ONE, 2014, 9, e87705. | 1.1 | 261 |
| 3362 | P-Selectin-Mediated Platelet Adhesion Promotes the Metastasis of Murine Melanoma Cells. PLoS ONE, 2014, 9, e91320. | 1.1 | 34 |
| 3363 | Primary Localization and Tumor Thickness as Prognostic Factors of Survival in Patients with Mucosal Melanoma. PLoS ONE, 2014, 9, e112535. | 1.1 | 22 |
| 3364 | Uveal Melanoma Cells Utilize a Novel Route for Transendothelial Migration. PLoS ONE, 2014, 9, e115472. | 1.1 | 23 |
| 3365 | A Novel Therapy for Melanoma Developed in Mice: Transformation of Melanoma into Dendritic Cells with <i>Listeria monocytogenes</i> . PLoS ONE, 2015, 10, e0117923. | 1.1 | 12 |
| 3366 | Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma. PLoS ONE, 2015, 10, e0119716. | 1.1 | 27 |
| 3367 | Mechanisms Contributing to Differential Regulation of PAX3 Downstream Target Genes in Normal Human Epidermal Melanocytes versus Melanoma Cells. PLoS ONE, 2015, 10, e0124154. | 1.1 | 7 |
| 3368 | Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes. PLoS ONE, 2015, 10, e0131934. | 1.1 | 11 |
| 3369 | Investigation of FOXM1 as a Potential New Target for Melanoma. PLoS ONE, 2015, 10, e0144241. | 1.1 | 35 |
| 3370 | Absence of Tumor-Infiltrating Lymphocyte Is a Reproducible Predictive Factor for Sentinel Lymph Node Metastasis: A Multicenter Database Study by the Brazilian Melanoma Group. PLoS ONE, 2016, 11, e0148160. | 1.1 | 15 |
| 3371 | CD10-Equipped Melanoma Cells Acquire Highly Potent Tumorigenic Activity: A Plausible Explanation of Their Significance for a Poor Prognosis. PLoS ONE, 2016, 11, e0149285. | 1.1 | 9 |
| 3372 | No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival. PLoS ONE, 2017, 12, e0174234. | 1.1 | 7 |
| 3373 | Dermoscopic characteristics of melanoma according to the criteria "ulceration" and "mitotic rate" of the AJCC 2009 staging system for melanoma. PLoS ONE, 2017, 12, e0174871. | 1.1 | 20 |
| 3374 | Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision. PLoS ONE, 2017, 12, e0176080. | 1.1 | 8 |
| 3375 | SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma. PLoS ONE, 2017, 12, e0180392. | 1.1 | 2 |
| 3376 | Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 651-660. | 1.8 | 7 |
| 3377 | Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e320-e325. | 1.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3378 | Sentinel Lymph Node Biopsy in Patients With Thick Primary Cutaneous Melanoma. <i>World Journal of Oncology</i> , 2019, 10, 112-117. | 0.6 | 4 |
| 3379 | Malign Melanomlu Çocuklar: Türkiye'den tek bir merkez deneyimi. <i>Türk Pediatri Arsivi</i> , 2019, 55, 39-45. | 0.9 | 2 |
| 3380 | Genome-wide profiling of copy number alterations in cancer: focus on melanoma. <i>Biomedical Reviews</i> , 2014, 24, 11. | 0.6 | 1 |
| 3381 | Primary Anorectal Amelanotic Melanoma: The First Case Report from Saudi Arabia. <i>Middle East Journal of Digestive Diseases</i> , 2019, 11, 166-173. | 0.2 | 4 |
| 3382 | Nanomedicine in Melanoma: Current Trends and Future Perspectives. , 0, , 143-159. | | 5 |
| 3383 | Biomarkers in Malignant Melanoma: Recent Trends and Critical Perspective. , 0, , 39-56. | | 9 |
| 3384 | Ulcerated Melanoma: Aspects and Prognostic Impact. , 0, , 67-75. | | 4 |
| 3385 | Clinical Presentation and Staging of Melanoma. , 0, , 79-89. | | 27 |
| 3387 | Melanoma of Unknown Primary. , 0, , 99-116. | | 22 |
| 3388 | The prognostic significance of BRAF mutation status in stage III-IV melanoma. <i>Expert Review of Dermatology</i> , 2013, 8, 127-129. | 0.3 | 2 |
| 3389 | Prognostic role of sentinel lymph node biopsy for patients with cutaneous melanoma: A retrospective study of surveillance, epidemiology, and end-result population-based data. <i>Oncotarget</i> , 2016, 7, 45671-45677. | 0.8 | 21 |
| 3390 | Different growth and metastatic phenotypes associated with a cell-intrinsic change of Met in metastatic melanoma. <i>Oncotarget</i> , 2016, 7, 70779-70793. | 0.8 | 22 |
| 3391 | PAK4 suppresses PDZ-RhoGEF activity to drive invadopodia maturation in melanoma cells. <i>Oncotarget</i> , 2016, 7, 70881-70897. | 0.8 | 26 |
| 3392 | The prognostic significance of heparanase expression in metastatic melanoma. <i>Oncotarget</i> , 2016, 7, 74678-74685. | 0.8 | 21 |
| 3393 | The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. <i>Oncotarget</i> , 2016, 7, 81493-81511. | 0.8 | 14 |
| 3394 | The neurotrophin Neurtin1 (cpg15) is involved in melanoma migration, attachment independent growth, and vascular mimicry. <i>Oncotarget</i> , 2017, 8, 1117-1131. | 0.8 | 17 |
| 3395 | Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation. <i>Oncotarget</i> , 2017, 8, 26471-26491. | 0.8 | 25 |
| 3396 | Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients. <i>Oncotarget</i> , 2017, 8, 75914-75923. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3397 | Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. <i>Oncotarget</i> , 2017, 8, 67355-67368. | 0.8 | 45 |
| 3398 | Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. <i>Oncotarget</i> , 2017, 8, 67439-67456. | 0.8 | 15 |
| 3399 | Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. <i>Oncotarget</i> , 2017, 8, 79731-79741. | 0.8 | 77 |
| 3400 | Inactivation/deficiency of DHODH induces cell cycle arrest and programmed cell death in melanoma. <i>Oncotarget</i> , 2017, 8, 112354-112370. | 0.8 | 27 |
| 3401 | The clinical significance of <i>c-Kit</i> mutations in metastatic oral mucosal melanoma in China. <i>Oncotarget</i> , 2017, 8, 82661-82673. | 0.8 | 21 |
| 3402 | PAX3d mRNA over 2.76 copies/ÅµL in the bloodstream predicts cutaneous malignant melanoma relapse. <i>Oncotarget</i> , 2017, 8, 85479-85491. | 0.8 | 3 |
| 3403 | Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIc melanoma characterized by a BRAFV600E/K mutation. <i>Oncotarget</i> , 2017, 8, 105000-105010. | 0.8 | 10 |
| 3404 | Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway. <i>Oncotarget</i> , 2014, 5, 6387-6403. | 0.8 | 49 |
| 3405 | Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling. <i>Oncotarget</i> , 2017, 8, 107076-107088. | 0.8 | 19 |
| 3406 | Targeting the <i>PTTG1</i> oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib. <i>Oncotarget</i> , 2017, 8, 113472-113493. | 0.8 | 15 |
| 3407 | CKS1 expression in melanocytic nevi and melanoma. <i>Oncotarget</i> , 2018, 9, 4173-4187. | 0.8 | 1 |
| 3408 | Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAFV600E-mutant melanoma. <i>Oncotarget</i> , 2018, 9, 10905-10919. | 0.8 | 17 |
| 3409 | Genetic alterations in main candidate genes during melanoma progression. <i>Oncotarget</i> , 2018, 9, 8531-8541. | 0.8 | 50 |
| 3410 | Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. <i>Oncotarget</i> , 2014, 5, 9609-9618. | 0.8 | 62 |
| 3411 | Cofilin-1 levels and intracellular localization are associated with melanoma prognosis in a cohort of patients. <i>Oncotarget</i> , 2018, 9, 24097-24108. | 0.8 | 11 |
| 3412 | The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. <i>Oncotarget</i> , 2018, 9, 26217-26225. | 0.8 | 6 |
| 3413 | Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. <i>Oncotarget</i> , 2019, 10, 113-122. | 0.8 | 23 |
| 3414 | Stage-specific prognostic biomarkers in melanoma. <i>Oncotarget</i> , 2015, 6, 4180-4189. | 0.8 | 26 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3415 | A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. <i>Oncotarget</i> , 2015, 6, 7053-7064. | 0.8 | 72 |
| 3416 | Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. <i>Oncotarget</i> , 2015, 6, 11683-11693. | 0.8 | 44 |
| 3417 | Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. <i>Oncotarget</i> , 2015, 6, 12297-12309. | 0.8 | 148 |
| 3418 | Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. <i>Oncotarget</i> , 2015, 6, 19868-19879. | 0.8 | 8 |
| 3419 | Analysis of SDHD promoter mutations in various types of melanoma. <i>Oncotarget</i> , 2015, 6, 25868-25882. | 0.8 | 9 |
| 3420 | High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma. <i>Oncotarget</i> , 2015, 6, 25484-25498. | 0.8 | 39 |
| 3421 | The Expression of p-STAT3 in Stage IV Melanoma: Risk of CNS Metastasis and Survival. <i>Oncotarget</i> , 2012, 3, 336-344. | 0.8 | 24 |
| 3422 | Frequent <i>DPH3</i> promoter mutations in skin cancers. <i>Oncotarget</i> , 2015, 6, 35922-35930. | 0.8 | 60 |
| 3423 | Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner. <i>Oncotarget</i> , 2016, 7, 3171-3185. | 0.8 | 41 |
| 3424 | Validation of a preclinical model for assessment of drug efficacy in melanoma. <i>Oncotarget</i> , 2016, 7, 13069-13081. | 0.8 | 12 |
| 3425 | Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression. <i>Oncotarget</i> , 2016, 7, 15065-15092. | 0.8 | 33 |
| 3426 | Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. <i>Oncotarget</i> , 2016, 7, 19997-20015. | 0.8 | 25 |
| 3427 | Exceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a <i>Listeria</i> peptide proposed against metastatic melanoma. <i>Oncotarget</i> , 2016, 7, 16855-16865. | 0.8 | 10 |
| 3428 | Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. <i>Oncotarget</i> , 2016, 7, 23801-23811. | 0.8 | 13 |
| 3429 | Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations. <i>Oncotarget</i> , 2016, 7, 30365-30378. | 0.8 | 10 |
| 3430 | Reprogramming human A375 amelanotic melanoma cells by catalase overexpression: Upregulation of antioxidant genes correlates with regression of melanoma malignancy and with malignant progression when downregulated. <i>Oncotarget</i> , 0, 7, 41154-41171. | 0.8 | 27 |
| 3431 | The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies. , 2020, 3, 117-139. | | 16 |
| 3432 | Melanoma immunotherapy dominates the field. <i>Annals of Translational Medicine</i> , 2016, 4, 269-269. | 0.7 | 19 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3433 | The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab. <i>Annals of Translational Medicine</i> , 2019, 7, S24-S24. | 0.7 | 8 |
| 3434 | Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). <i>Chinese Clinical Oncology</i> , 2016, 5, 57-57. | 0.4 | 46 |
| 3435 | Treatment of cutaneous melanoma: current approaches and future prospects. <i>Cancer Management and Research</i> , 2010, 2, 197. | 0.9 | 38 |
| 3436 | Nanoparticles in Melanoma. <i>Current Medicinal Chemistry</i> , 2014, 21, 3701-3716. | 1.2 | 7 |
| 3437 | Deep Learning Approaches Towards Skin Lesion Segmentation and Classification from Dermoscopic Images - A Review. <i>Current Medical Imaging</i> , 2020, 16, 513-533. | 0.4 | 33 |
| 3438 | Malignant Cutaneous Melanoma: Updates in PET Imaging. <i>Current Radiopharmaceuticals</i> , 2020, 13, 14-23. | 0.3 | 7 |
| 3439 | Videoscopic Inguinal-iliac-obturator Lymph-node Dissection: New Videoscopic Technique for Regional Lymphadenectomy in Patients with Melanoma. <i>Anticancer Research</i> , 2016, 36, 6579-6584. | 0.5 | 7 |
| 3440 | Selumetinib Inhibits Melanoma Metastasis to Mouse Liver via Suppression of EMT-targeted Genes. <i>Anticancer Research</i> , 2017, 37, 607-614. | 0.5 | 15 |
| 3441 | Pharmacological effects of gallic acid in health and diseases: A mechanistic review. <i>Iranian Journal of Basic Medical Sciences</i> , 2019, 22, 225-237. | 1.0 | 250 |
| 3442 | Locoregional Lymph Node Recurrence of Trunk Melanoma in Non-sentinel Lymph Node Basins: An Observational Retrospective Study. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00284. | 0.6 | 1 |
| 3443 | Prognostic factors in head and neck melanoma according to facial aesthetic units. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 41-45. | 0.8 | 19 |
| 3444 | Management of cutaneous melanoma: comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 126-145. | 0.8 | 5 |
| 3445 | The Role of Osteopontin Expression in the Prognosis of Malignant Melanoma. <i>Novel Approaches in Cancer Study</i> , 2018, 1, . | 0.2 | 1 |
| 3446 | VivaScope® 1500 and 3000 systems for detecting and monitoring skin lesions: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-260. | 1.3 | 22 |
| 3447 | Assessment of the Antitumor Potential of Umbelliprenin, a Naturally Occurring Sesquiterpene Coumarin. <i>Biomedicines</i> , 2020, 8, 126. | 1.4 | 14 |
| 3448 | The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. <i>Cancers</i> , 2015, 7, 1154-1177. | 1.7 | 20 |
| 3449 | Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?. <i>Cancers</i> , 2015, 7, 1900-1924. | 1.7 | 18 |
| 3450 | Grapefruit-Derived Micro and Nanovesicles Show Distinct Metabolome Profiles and Anticancer Activities in the A375 Human Melanoma Cell Line. <i>Cells</i> , 2020, 9, 2722. | 1.8 | 61 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3451 | Activation of PGK1 under hypoxic conditions promotes glycolysis and increases stem cell-like properties and the epithelial-mesenchymal transition in oral squamous cell carcinoma cells via the AKT signalling pathway. <i>International Journal of Oncology</i> , 2020, 57, 743-755. | 1.4 | 36 |
| 3452 | Prognostic genes of melanoma identified by weighted gene co-expression network analysis and drug repositioning using a network-based method. <i>Oncology Letters</i> , 2019, 18, 6066-6078. | 0.8 | 9 |
| 3453 | New Systemic Treatment for Malignant Melanoma. <i>Korean Journal of Medicine</i> , 2013, 85, 357. | 0.1 | 3 |
| 3454 | Somatic DNA mutation analysis in targeted therapy of solid tumours. <i>Translational Pediatrics</i> , 2015, 4, 125-38. | 0.5 | 19 |
| 3455 | Update in genetic susceptibility in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 210. | 0.7 | 100 |
| 3456 | Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). <i>Annals of Translational Medicine</i> , 2015, 3, 322. | 0.7 | 32 |
| 3457 | Malignt melanom - diagnostikk, behandling og oppfølging i Norge. <i>Tidsskrift for Den Norske Lægeforening</i> , 2013, 133, 2154-2158. | 0.2 | 10 |
| 3458 | Predictive factors for loco regional recurrence and distant metastasis following primary surgical treatment of cutaneous melanoma. <i>Indian Journal of Dermatology</i> , 2014, 59, 241. | 0.1 | 4 |
| 3459 | Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1167-1175. | 0.3 | 51 |
| 3460 | Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. <i>Cancer Research and Treatment</i> , 2017, 49, 44-53. | 1.3 | 27 |
| 3461 | Weight Status, Physical Activity and the Associations with Health Related Physical Fitness in Nine to Twelve Year Old Scottish Children. , 2013, 03, . | | 28 |
| 3462 | The Application and Indications for Sentinel Lymph Node Biopsy in Pediatric Solid Tumors: Current Status and Future Directions. <i>International Journal of Clinical Medicine</i> , 2014, 05, 1130-1141. | 0.1 | 1 |
| 3463 | Nuclear Odontogenic Ameloblast-Associated Protein (ODAM) Correlates with Melanoma Sentinel Lymph Node Metastasis. <i>Journal of Cancer Therapy</i> , 2013, 04, 1283-1289. | 0.1 | 2 |
| 3464 | Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab. <i>Journal of Cancer Therapy</i> , 2015, 06, 833-840. | 0.1 | 10 |
| 3465 | Medical Costs by Disease Stage in Medicare Patients with Metastatic Melanoma. <i>Journal of Cancer Therapy</i> , 2017, 08, 913-923. | 0.1 | 1 |
| 3466 | The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. <i>Swiss Medical Weekly</i> , 2016, 146, w14279. | 0.8 | 35 |
| 3467 | Metastatic malignant melanoma of the urinary bladder: Case report and literature review. <i>Central European Journal of Urology</i> , 2012, 65, 232-234. | 0.2 | 11 |
| 3468 | Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. <i>World Journal of Clinical Oncology</i> , 2016, 7, 174. | 0.9 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3469 | Novel anti-melanoma treatment: focus on immunotherapy. Chinese Journal of Cancer, 2014, 33, 458-465. | 4.9 | 11 |
| 3470 | Surgery and the Staging of Melanoma. , 0, , . | | 2 |
| 3471 | Early Skin Cancer Detection Using Deep Convolutional Neural Networks on Mobile Smartphone. International Journal of Information Engineering and Electronic Business, 2020, 12, 21-27. | 1.0 | 8 |
| 3472 | “Mitogenicity” the latest and most hilarious episode in the slapstick comedy of melanoma management.. Dermatology Practical and Conceptual, 2012, 2, 57-64. | 0.5 | 1 |
| 3473 | Systematic review of diagnostic accuracy of reflectance confocal microscopy for melanoma diagnosis in patients with clinically equivocal skin lesions. Dermatology Practical and Conceptual, 2013, 3, 19-27. | 0.5 | 79 |
| 3474 | Evaluation of electrical impedance spectroscopy as an adjunct to dermoscopy in short-term monitoring of atypical melanocytic lesions. Dermatology Practical and Conceptual, 2016, 6, 1-6. | 0.5 | 8 |
| 3475 | Use of and intentions to use dermoscopy among physicians in the United States. Dermatology Practical and Conceptual, 2017, 7, 7-16. | 0.5 | 9 |
| 3476 | Thin Melanoma. Archives of Pathology and Laboratory Medicine, 2011, 135, 342-346. | 1.2 | 20 |
| 3477 | Sentinel Lymph Nodes in Cutaneous Melanoma: Handling, Examination, and Clinical Repercussion. Archives of Pathology and Laboratory Medicine, 2010, 134, 1764-1769. | 1.2 | 34 |
| 3478 | Molecular Diagnostics in Melanoma: Current Status and Perspectives. Archives of Pathology and Laboratory Medicine, 2011, 135, 860-869. | 1.2 | 29 |
| 3479 | Prognostication in Thin Cutaneous Melanomas. Archives of Pathology and Laboratory Medicine, 2010, 134, 1758-1763. | 1.2 | 33 |
| 3480 | Management of Malignant Melanoma. Archives of Plastic Surgery, 2012, 39, 565-574. | 0.4 | 12 |
| 3481 | Pembrolizumab: First in Class for Treatment of Metastatic Melanoma. Journal of the Advanced Practitioner in Oncology, 2015, 6, 234-8. | 0.2 | 3 |
| 3482 | NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 364-376. | 2.3 | 167 |
| 3483 | FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. Clinics, 2013, 68, 1018-1027. | 0.6 | 18 |
| 3484 | A spindle cell squamous cell carcinoma on the cheek presenting with in-transit metastases and a satellite lesion. Archives of Craniofacial Surgery, 2020, 21, 58-63. | 0.4 | 3 |
| 3485 | Clinical Significance of SH2B1 Adaptor Protein Expression in Non-small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2012, 13, 2355-2362. | 0.5 | 11 |
| 3486 | A Retrospective Multicenter Evaluation of Cutaneous Melanomas in Turkey. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10451-10456. | 0.5 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 3487 | Do Not Let to Be Late: Overview of Reasons for Melanoma Delayed Diagnosis. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3873-3877. | 0.5 | 23 |
| 3488 | Metastatic melanoma – a review of current and future drugs. Drugs in Context, 2012, 2012, 1-17. | 1.0 | 25 |
| 3489 | Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation. Drugs in Context, 2018, 7, 1-5. | 1.0 | 8 |
| 3490 | Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, XD06-XD08. | 0.8 | 3 |
| 3491 | The impact of neuropsychological assessment in epileptic focus localization. Praxis Medica, 2021, 50, 45-49. | 0.0 | 0 |
| 3492 | Morbidity and Mortality of Melanoma on the Trunk and Extremities Treated With Mohs Surgery Versus Wide Excision. Dermatologic Surgery, 2021, Publish Ahead of Print, . | 0.4 | 1 |
| 3493 | CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma. Diagnostic and Interventional Imaging, 2022, 103, 97-102. | 1.8 | 12 |
| 3494 | Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage III/IV melanoma: a randomized, open-label, phase 2 trial. Nature Medicine, 2021, 27, 1789-1796. | 15.2 | 59 |
| 3495 | Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors. Melanoma Research, 2022, 32, 35-44. | 0.6 | 2 |
| 3496 | Malignes Melanom ohne Primärtumor, das als solitärer pulmonaler Rundherd imponiert: ein Fallbericht. Karger Kompass Pneumologie, 0, , 1-4. | 0.0 | 0 |
| 3497 | Head and neck melanoma: outcome and predictors in a population-based cohort study. Head & Face Medicine, 2021, 17, 45. | 0.8 | 5 |
| 3498 | Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. European Journal of Cancer, 2021, 158, 225-233. | 1.3 | 8 |
| 3499 | Machine learning for the identification of decision boundaries during the transition from radial to vertical growth phase superficial spreading melanomas. Melanoma Research, 2021, Publish Ahead of Print, 533-540. | 0.6 | 0 |
| 3500 | High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. Genes, 2021, 12, 1629. | 1.0 | 8 |
| 3501 | Risk factors of recurrence and distant metastasis in primary cutaneous melanoma in Taiwan. Scientific Reports, 2021, 11, 21012. | 1.6 | 6 |
| 3502 | Deep attention branch networks for skin lesion classification. Computer Methods and Programs in Biomedicine, 2021, 212, 106447. | 2.6 | 25 |
| 3503 | Melanocytic Tumors. , 2010, , 169-196. | | 0 |
| 3504 | Surgical treatment for metastatic disease. Skin Cancer, 2010, 25, 288-292. | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3505 | More than skin deep?. BMJ: British Medical Journal, 2010, 340, c932-c932. | 2.4 | 0 |
| 3506 | Immunotherapy of Melanoma: A New Era. , 2011, , 359-372. | | 0 |
| 3507 | Common Benign and Malignant Skin Lesions. , 2011, , 1221-1243. | | 0 |
| 3508 | A Case of multiple in-transit metastases from penile malignant melanoma after total lymph node dissection. Skin Cancer, 2011, 26, 342-347. | 0.1 | 0 |
| 3509 | Prognostic Factors and Staging in Melanoma. , 2011, , 282-294. | | 0 |
| 3510 | Regional Lymph Node Surgery in Melanoma Patients. , 2011, , 544-558. | | 0 |
| 3511 | Pathology of Melanoma. , 2011, , 295-317. | | 1 |
| 3512 | Treatment of Disseminated Melanoma. , 2011, , 629-633. | | 0 |
| 3513 | Dermatoonkologie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2011, , 69-102. | 0.0 | 0 |
| 3514 | Management of the Patient with Melanoma. , 2011, , 318-326. | | 2 |
| 3516 | An Update on Reporting Histopathologic Prognostic Factors in Melanoma. Archives of Pathology and Laboratory Medicine, 2011, 135, 825-829. | 1.2 | 22 |
| 3517 | Mitose como fator prognóstico para biópsia de linfonodo sentinela em melanoma fino. Anais Brasileiros De Dermatologia, 2011, 86, 107-109. | 0.5 | 1 |
| 3518 | Current Controversies in the Surgical Management of Melanoma. , 0, , | | 0 |
| 3519 | Role of Angiogenesis and Microenvironment in Melanoma Progression. , 0, , | | 1 |
| 3520 | Rare Tumors of the Skin and Subcutaneous Tissues. Pediatric Oncology, 2012, , 455-482. | 0.5 | 0 |
| 3521 | Serological Biomarkers in Melanoma. , 2012, , 195-208. | | 0 |
| 3522 | Tissue-Based Protein Biomarkers in Melanoma: Immunohistochemistry: (B) Prognostication. , 2012, , 177-188. | | 0 |
| 3523 | Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview. , 2012, , 305-317. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3524 | Mohs Micrographic Surgery for the Treatment of Cutaneous Melanoma. , 2012, , 211-223. | | 0 |
| 3525 | Molecular Markers of Lymph Node Disease in Melanoma. , 2012, , 209-226. | | 0 |
| 3526 | Staging of Melanoma. , 2012, , 39-48. | | 0 |
| 3527 | Diagnostic and Prognostic Biomarkers in Melanoma: Current State of Play. , 2012, , 9-18. | | 2 |
| 3528 | Epigenetic Biomarkers in Melanoma. , 2012, , 89-112. | | 0 |
| 3529 | Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly, 2011, 141, w13320. | 0.8 | 41 |
| 3530 | Inguinal lymph node dissection in patients with skin cancer. Korean Journal of Clinical Oncology, 2011, 7, 114-121. | 0.1 | 2 |
| 3531 | Melanom. , 2012, , 1710-1726. | | 0 |
| 3534 | Treatment of Occupational Skin Cancer. , 2012, , 1079-1085. | | 0 |
| 3536 | A Case of Primary Dermal Melanoma. Nishinohon Journal of Dermatology, 2012, 74, 146-148. | 0.0 | 0 |
| 3537 | Molecular Classification of Patients with Cutaneous Melanoma: A Reality. Journal of Molecular Biomarkers & Diagnosis, 2012, 01, . | 0.4 | 0 |
| 3538 | Melanoma and Other Skin Cancers. , 2012, , 439-468. | | 0 |
| 3543 | Melanoma of the vulva: A retrospective study of 46 cases from Queensland. Open Journal of Obstetrics and Gynecology, 2012, 02, 120-126. | 0.1 | 0 |
| 3545 | Desmoplastic melanoma and metastatic melanoma. , 2012, , 247-253. | | 0 |
| 3547 | Cutaneous Melanoma â Surgical Treatment. , 0, , . | | 0 |
| 3548 | Langerhans Cell Histiocytosis of Temporal Bone. , 2013, , 1418-1421. | | 0 |
| 3549 | Treatment of Distant and Irresectable Metastatic Disease. , 2013, , 79-104. | | 0 |
| 3550 | Utility of PET/CT in the staging and treatment of patients with Merkel Cell Carcinoma and Melanoma. Journal of Nuclear Medicine & Radiation Therapy, 2013, 04, . | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3552 | Locoregional Staging of Melanoma. , 2013, , 293-343. | | 2 |
| 3553 | Elastography as a New Screening Tool for Metastatic Lymph Nodes in Melanoma Patients. Journal of Clinical & Experimental Oncology, 2013, 02, . | 0.1 | 2 |
| 3555 | Treatment of Primary Tumor and Locoregional Disease. , 2013, , 53-77. | | 0 |
| 3556 | 8 Herkenning en behandeling van maligne huidtumoren in het aangezicht. , 2013, , 115-136. | | 0 |
| 3558 | Management of In-Transit Malignant Melanoma. , 0, , . | | 1 |
| 3560 | Hauttumoren. , 2013, , 879-910. | | 0 |
| 3561 | After Surgery: Follow-Up Guidelines of Melanoma Patients. , 0, , . | | 0 |
| 3565 | Melanocytic Neoplasms. , 2014, , 271-293. | | 0 |
| 3566 | Emerging Clinical Issues in Melanoma in the Molecularly Targeted Era. Methods in Molecular Biology, 2014, 1102, 11-26. | 0.4 | 0 |
| 3567 | Nanotechnology Applications in Dermatology. , 2013, , 85-194. | | 0 |
| 3568 | The epidemiology of melanoma in young adults. Expert Review of Dermatology, 0, , 1-10. | 0.3 | 0 |
| 3570 | Melanom. , 2014, , 31-97. | | 0 |
| 3571 | Melanoom: chirurgische behandeling. , 2014, , 179-188. | | 0 |
| 3572 | Primary Versus Metastatic Malignant Melanoma. , 2014, , 283-301. | | 0 |
| 3573 | Another Case of Pulmonary Edema or May Be Not: An Unusual Presentation of Metastatic Melanoma. World Journal of Oncology, 2014, 5, 183-186. | 0.6 | 0 |
| 3574 | Metastatic Melanoma. , 2014, , 529-567. | | 0 |
| 3575 | Vemurafenib in the treatment of brain metastases from melanoma. Onkologiya Zhurnal Imeni P A Gertsena, 2014, 3, 85. | 0.0 | 1 |
| 3577 | Cutaneous Melanoma. , 2014, , 331-487. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3578 | Melanoma. Part I. Risk Assessment, Diagnosis, and Prognosis: Using Molecular Tools to Diagnose Melanoma, Predict Its Behavior, and Evaluate for Inheritable Forms. , 2014, , 63-96. | | 1 |
| 3579 | Approach to Microstaging of Primary Melanoma and Evaluation of Prognostic Variables. , 2014, , 359-377. | | 0 |
| 3580 | Molecular testing in Cutaneous Melanoma. , 2014, , 363-374. | | 1 |
| 3581 | Primary Care for Melanoma: Should We Be Screaming for Screening?. Journal of Patient-centered Research and Reviews, 2014, 1, 33-40. | 0.6 | 1 |
| 3584 | Liver Metastases from Melanoma Cancer. , 2015, , 69-77. | | 0 |
| 3585 | Tumor Staging in Dermatology. , 2015, , 103-118. | | 0 |
| 3588 | Analiza wczesnych wyników leczenia chorych na czerniaka skóry poddanych biopsji w warunkach wartowniczych. Nowotwory, 2014, 64, 391-395. | 0.1 | 0 |
| 3589 | Lungenmetastasen beim Melanom. , 2015, , 139-149. | | 0 |
| 3590 | Clinical report. Acral melanoma in Cambodia: challenges associated with a rare and aggressive disease encountered in a developing country setting. Asian Biomedicine, 2014, 8, 809-814. | 0.2 | 0 |
| 3591 | Melanoma of the Head and Neck. , 2014, , 831-856. | | 0 |
| 3593 | Evaluation of Tumor Growth in Treatment of Murine Melanoma by Transdermal Infusion of Etoposide by Radiofrequency. Journal of Clinical & Experimental Dermatology Research, 2015, 07, . | 0.1 | 0 |
| 3594 | Cancer in the Kidney Transplant Recipient. , 2015, , 319-350. | | 0 |
| 3595 | Universal BRAF State Detection by the Pyrosequencing®-Based U-BRAFV600 Assay. Methods in Molecular Biology, 2015, 1315, 63-82. | 0.4 | 0 |
| 3596 | Recently Changed Skin Lesion. , 2015, , 367-376. | | 0 |
| 3597 | Anal Melanoma: A General Surgical Experience. Journal of Clinical Case Reports, 2015, 05, . | 0.0 | 1 |
| 3598 | Pigmented Pre-malignant and Malignant Lesions of Skin with Special Reference to Atypical Presentations. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, EC10-2. | 0.8 | 0 |
| 3599 | Managing Advanced Melanoma: Targeting the PD-1 Pathway with Pembrolizumab. Cancer Research Frontiers, 2015, 1, 127-137. | 0.2 | 0 |
| 3600 | Melanoma and immunotherapy. , 2015, , 199-212. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3601 | Review of Postoperative and Elective Nodal Irradiation in Head and Neck Cancer. <i>Current Cancer Therapy Reviews</i> , 2015, 10, 291-304. | 0.2 | 0 |
| 3602 | A ECOGRAFIA NO ESTADIAMENTO E SEGUIMENTO DO MELANOMA CUTÂNEO. <i>Journal of the Portuguese Society of Dermatology and Venereology</i> , 2015, 73, 63-70. | 0.0 | 0 |
| 3603 | Sarginio limfmazgio nustatymas sergant melanoma. Pirmoji Klaipėdos universitetinės ligoninės patirtis. <i>Health Sciences</i> , 2015, 25, 24-30. | 0.0 | 0 |
| 3604 | Therapie des malignen Melanoms. , 2016, , 169-178. | | 0 |
| 3605 | Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2016, , 1-39. | | 0 |
| 3606 | Melanoma – Diagnosis, Subtypes and AJCC Stages. , 2016, , 21-47. | | 0 |
| 3607 | Brain Metastases from Cutaneous Melanoma. , 2016, , 237-254. | | 0 |
| 3608 | Melanom. , 2016, , 1-17. | | 0 |
| 3609 | Risk Reductions of Recurrence and Mortality in Melanoma Patients Using IFN- γ . , 2016, , 49-63. | | 0 |
| 3610 | Pathology of Melanoma. , 2016, , 85-113. | | 1 |
| 3611 | Melanozytäre Nävi und Melanom. , 2016, , 609-668. | | 0 |
| 3612 | Onkologie. , 2016, , 177-212. | | 0 |
| 3613 | Sentinel Lymph Node in Melanoma. , 2016, , 367-374. | | 0 |
| 3614 | The Role of Sentinel Lymph Node Biopsy in Thin Melanoma (Breslow Thickness \leq 0.75 mm and 0.76 mm -) <i>Tj ETQq1 1 0.784314 rgB</i> 163-168. | 0.1 | 0 |
| 3615 | Magnetic Advances in Cancer Surgery. , 2016, , 463-470. | | 0 |
| 3616 | Melanoma – Treatment. , 2016, , 79-109. | | 0 |
| 3617 | Melanoma – Introduction, History and Epidemiology. , 2016, , 3-20. | | 0 |
| 3618 | Controversies in the Surgical Management of Melanoma. , 2016, , 159-184. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3619 | Cutaneous Metastasis. , 2016, , 103-115. | | 0 |
| 3620 | Immunohistology of Melanocytic Lesions. , 2016, , 311-334. | | 0 |
| 3621 | Diagnostic and Prognostic Value of the Tracer-Count-Rate in Sentinel-Nodes in Melanoma â€” A Cohort Study. Journal of Clinical & Experimental Dermatology Research, 2016, 07, . | 0.1 | 0 |
| 3622 | Applications of Non-coding RNA in the Molecular Pathology of Cancer. , 2016, , 177-217. | | 1 |
| 3623 | Head and Neck Cutaneous Melanoma. , 2016, , 657-663. | | 0 |
| 3624 | Melanoma with regression and in-transit metastasis. Medicine and Pharmacy Reports, 2016, 89, 165-168. | 0.2 | 0 |
| 3625 | OUR EXPERIENCE WITH DACARBAZINE IN THE TREATMENT OF PATIENTS WITH INOPERABLE SKIN MELANOMA. Journal of IMAB, 2016, 22, 1036-1038. | 0.1 | 0 |
| 3626 | Preventative and Personalized Approach to the Treatment of Malignant Melanoma: A Case Report.. University of Ottawa Journal of Medicine, 2016, 6, 49-52. | 0.0 | 0 |
| 3627 | Radicalization of surgical treatment in pediatric melanoma malignum. Medical and Biological Sciences, 2016, 30, 35. | 0.2 | 0 |
| 3628 | BILLCD8 â€” A Multivariable Survival Model as a Simple and Clinically Useful Prognostic Tool to Identify High-risk Cutaneous Melanoma Patients. Anticancer Research, 2016, 36, 4739-4748. | 0.5 | 0 |
| 3629 | Malignant Melanoma in the Adolescent and Young Adult (AYA) Population. Pediatric Oncology, 2017, , 231-267. | 0.5 | 0 |
| 3630 | Histologic Processing and Evaluation of Surgical Excision Specimens. , 2017, , 89-111. | | 0 |
| 3631 | Common Skin Disorders in the Elderly. , 2017, , 1-12. | | 0 |
| 3632 | Radioguided Surgery for Malignant Melanoma. , 2017, , 1401-1432. | | 0 |
| 3633 | Malignes Melanom beim alten und geriatrischen Patienten. , 2017, , 1-8. | | 0 |
| 3634 | Cancer After Kidney Transplantation. , 2017, , 525-542. | | 0 |
| 3636 | Treatment of Nail Unit Melanoma. , 2017, , 141-150. | | 0 |
| 3638 | The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. , 2017, , 481-506. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3639 | Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2017, , 1065-1102. | | 0 |
| 3641 | A tenebrous tale: malignant melanoma of the oesophagus. BMJ Case Reports, 2017, 2017, bcr-2016-217908. | 0.2 | 0 |
| 3642 | Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma. Anticancer Research, 2017, 37, 3243-3248. | 0.5 | 5 |
| 3643 | Melanoma Masquerading as a Zosteriform Rash. American Journal of Case Reports, 2017, 18, 537-540. | 0.3 | 1 |
| 3644 | Malignant melanoma, incidence, risk factor and early diagnosis. Onkologie (Czech Republic), 2017, 11, 138-143. | 0.0 | 0 |
| 3646 | Factors Influencing Disease Progression in Patients with Head and Neck Melanoma. Anticancer Research, 2017, 37, 3811-3816. | 0.5 | 2 |
| 3647 | Melanoma and Spitz Nevi in Children. , 2018, , 1-15. | | 0 |
| 3648 | Melanoma Clinical Staging (Historical and Current). , 2018, , 1-16. | | 0 |
| 3649 | Spitz Tumors. , 2018, , 1-16. | | 0 |
| 3650 | Adjuvant Therapy. , 2018, , 1-25. | | 0 |
| 3651 | Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions. Oncotarget, 2017, 8, 97727-97735. | 0.8 | 0 |
| 3652 | REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROGRESSION ON BRAF AND MEK INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION. Meditsinskiy Sovet, 2017, , 6-10. | 0.1 | 1 |
| 3654 | Cutaneous Pathology of the Head and Neck. , 2018, , 1-55. | | 0 |
| 3655 | Melanom der Vulva. , 2018, , 155-173. | | 0 |
| 3656 | Malignes Melanom beim alten und geriatrischen Patienten. , 2018, , 527-534. | | 0 |
| 3657 | Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes. , 2018, , 1-44. | | 0 |
| 3658 | Cutaneous Pathology of the Head and Neck. , 2018, , 1-55. | | 0 |
| 3660 | Melanoma of the Ear Canal and Temporal Bone. , 2018, , 109-119. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3662 | Cardiac metastasis of malignant melanoma: where are we standing?. , 2018, 01, . | | 0 |
| 3663 | Different presentations of vulvar malignant melanoma: Report of two cases. Cumhuriyet Medical Journal, 0, , 801-805. | 0.1 | 0 |
| 3664 | Malign Melanomda Cerrahi SonrasÄ± Adjuvan Ä°mmunoterapi ve Kemoterapi Deneyimimiz. Ä±taÄŸdaÄŸ TÄ±p Dergisi, 0, , . | 0.1 | 0 |
| 3666 | Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-27. | | 0 |
| 3667 | Assessing the efficacy of a 10-point referral tool in the triaging of pigmented lesions to a Dermatology clinic. Anais Brasileiros De Dermatologia, 2018, 93, 932-933. | 0.5 | 0 |
| 3668 | Skin Lesions and Pressure Ulcers. , 2019, , 1-41. | | 0 |
| 3669 | Local and Recurrent Regional Metastases of Melanoma. , 2019, , 1-33. | | 1 |
| 3670 | CYTOLOGICAL EVALUATION OF METASTATIC MELANOMA- A SERIES OF 3 CASES. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 88-90. | 0.1 | 0 |
| 3671 | The use of Dermoscopy Following a one-day Workshop Among Family Medicine Residents. Marshall Journal of Medicine, 2019, 5, 70-79. | 0.1 | 0 |
| 3672 | Invasive Melanoma. , 2019, , 1095-1116. | | 0 |
| 3673 | Biomarkers for Melanoma. , 2019, , 1-32. | | 0 |
| 3674 | Diagnosis of Stage IV Melanoma. , 2019, , 1-47. | | 1 |
| 3675 | Melanom. , 2019, , 45-134. | | 0 |
| 3676 | Hybrid Imaging of Melanoma and Other Cutaneous Malignancies. , 2019, , 645-653. | | 0 |
| 3677 | Surveillance and Follow-Up of Melanoma Patients. , 2019, , 1-16. | | 0 |
| 3679 | Melanoma Prognosis and Staging. , 2019, , 1-27. | | 0 |
| 3680 | The large spectrum of Spitzoid tumors: a retrospective survival study. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 315-320. | 0.8 | 3 |
| 3683 | FEATURES OF DEFEATS OF SENTINEL LYMPH NODES AT PRIMARY MELANOMA OF SKIN. UÄenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2019, 26, 54-60. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3684 | Evaluation of Kindlin-1 and Ki-67 immunohistochemical expression in primary cutaneous malignant melanoma: a clinical series. <i>Applied Cancer Research</i> , 2019, 39, . | 1.0 | 0 |
| 3685 | Interleukin 1 receptor antagonist gene variable number of tandem repeats polymorphism and cutaneous melanoma. <i>Oncology Letters</i> , 2019, 18, 5759-5768. | 0.8 | 5 |
| 3686 | Recently Changed Skin Lesion. , 2020, , 63-71. | | 0 |
| 3687 | Primary malignant melanoma without melanosis of the colon. <i>Intestinal Research</i> , 2019, 17, 561-564. | 1.0 | 3 |
| 3688 | Malignant melanoma types and treatment. <i>DemiroÄŸlu Bilim Äœniversitesi Florence Nightingale TÄ±p Derigisi</i> , 2019, 5, 155-165. | 0.0 | 0 |
| 3689 | Determining Missing Key Elements in Oncology Information System to Improve Patient Experience and Clinical Care. <i>Healthcare Delivery in the Information Age</i> , 2020, , 567-586. | 0.3 | 0 |
| 3690 | Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019, 14, 203-225. | 0.8 | 1 |
| 3692 | Isolated Limb Perfusion and Infusion in theÄManagement of In-Transit Melanoma of theÄExtremities: Modern Data Affecting Practice. , 2020, , 379-394. | | 0 |
| 3693 | Thick melanoma in Tuscany. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 638-645. | 0.8 | 2 |
| 3694 | A History of Melanoma: From Hunter to Morton. , 2020, , 1457-1475. | | 0 |
| 3695 | Adequacy of sentinel lymph node biopsy in malignant melanoma of the trunk and extremities: Clinical observations regarding prognosis. <i>Archives of Plastic Surgery</i> , 2020, 47, 42-48. | 0.4 | 5 |
| 3697 | Surgery for Stage IV Melanoma. , 2021, , 171-189. | | 0 |
| 3698 | Melanoma Epidemiology, Staging and Prognostic Factors. , 2021, , 61-81. | | 0 |
| 3699 | Lymphedema secondary to melanoma treatments: diagnosis, evaluation, and treatments. <i>Global Health & Medicine</i> , 2020, 2, 227-234. | 0.6 | 9 |
| 3700 | Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients. <i>Aging</i> , 2020, 12, 16457-16475. | 1.4 | 2 |
| 3701 | Features associated with melanoma metastasis in Latvia. <i>Oncology Letters</i> , 2020, 20, 1-1. | 0.8 | 0 |
| 3702 | PET/CT in restaging, prognosis, and recurrence in patients with malignant melanoma. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2020, 51, . | 0.3 | 7 |
| 3703 | Classification of human skin cancer using Stokes-Mueller decomposition method and artificial intelligence models. <i>Optik</i> , 2022, 249, 168239. | 1.4 | 14 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3704 | Prognostic value of key genes of the JAK-STAT signaling pathway in patients with cutaneous melanoma. <i>Oncology Letters</i> , 2020, 19, 1928-1946. | 0.8 | 3 |
| 3705 | Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 21, 162-186. | 0.9 | 2 |
| 3706 | Multidimensional indicators of scholarly impact in the skin oncology literature: is there a correlation between bibliometric and altmetric profiles?. <i>Journal of Plastic Surgery and Hand Surgery</i> , 2021, 55, 232-241. | 0.4 | 3 |
| 3707 | Prognostic significance of regression and mitotic rate in head and neck cutaneous melanoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2021, 6, 109-115. | 0.6 | 3 |
| 3708 | Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis. <i>European Journal of Dermatology</i> , 2020, 30, 699-709. | 0.3 | 1 |
| 3709 | Complications and outcomes following inguinal lymphadenectomy for malignant melanoma in an Asian population. <i>Korean Journal of Clinical Oncology</i> , 2020, 16, 71-78. | 0.1 | 0 |
| 3710 | DE-Net: A deep edge network with boundary information for automatic skin lesion segmentation. <i>Neurocomputing</i> , 2022, 468, 71-84. | 3.5 | 14 |
| 3711 | Skin Lesions and Pressure Ulcers. , 2020, , 743-782. | | 1 |
| 3713 | Local and Recurrent Regional Metastases of Melanoma. , 2020, , 705-737. | | 5 |
| 3714 | Total Body Photography as an Aid for the Early Detection of Skin Cancer. , 2020, , 253-269. | | 0 |
| 3715 | Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00174. | 0.6 | 0 |
| 3716 | Raman Spectroscopy Techniques for Skin Cancer Detection and Diagnosis. , 2020, , 359-393. | | 2 |
| 3717 | Nose and Ear Reconstruction Following Tumor Extirpation. , 2020, , 295-334. | | 0 |
| 3718 | Diagnosis of Stage IV Melanoma. , 2020, , 997-1043. | | 0 |
| 3719 | PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract. <i>Oncology Letters</i> , 2020, 19, 2481-2488. | 0.8 | 4 |
| 3720 | ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3. | | 0 |
| 3722 | Melanoma Prognosis and Staging. , 2020, , 271-297. | | 2 |
| 3723 | Pathological Diagnosis and Analysis of Four Cases of Melanoma in Yunan Black Pigs. <i>Asian Case Reports in Veterinary Medicine</i> , 2020, 09, 50-55. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3724 | Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68. | | 0 |
| 3725 | Non-melanoma Skin Cancer and Cutaneous Melanoma for the Plastic and Reconstructive Surgeon. , 2020, , 153-239. | | 1 |
| 3726 | The Role of the Sentinel Lymph Node Biopsy in the Treatment of Nonmelanoma Skin Cancer and Cutaneous Melanoma. , 2020, , 647-704. | | 1 |
| 3728 | Association of Gender with Survival in Melanoma In Situ of the Head and Neck: A National Database Study. Cureus, 2020, 12, e6924. | 0.2 | 1 |
| 3729 | Melanoma of nasal cavity. Literature review and clinical case report. Modern Medical Technologies, 2020, , 94-99. | 0.1 | 0 |
| 3730 | Análisis de las modificaciones en la estadificación del T segùn el manual del American Joint Committee on Cancer. ¿Còmo cambia nuestro manejo de los pacientes?. DermatologÃa Argentina, 2020, 26, 23-25. | 0.0 | 0 |
| 3731 | NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. European Journal of Cancer, 2021, 159, 113-124. | 1.3 | 13 |
| 3732 | Approaches to metastatic skin melanoma therapy in 2020: a dynamic way forward. Meditsinskiy Sovet, 2020, , 80-93. | 0.1 | 0 |
| 3734 | Surgical Technique and Indications of Radical Dissection: Groin. Updates in Surgery Series, 2021, , 107-114. | 0.0 | 0 |
| 3736 | The Role of Nuclear Medicine in Mapping Sentinel Lymph Nodes and Staging Metastatic Melanoma. Updates in Surgery Series, 2021, , 55-69. | 0.0 | 0 |
| 3739 | Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. Onkologie (Czech Republic), 2020, 14, 199-204. | 0.0 | 0 |
| 3740 | Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. Human Molecular Genetics, 2021, 29, 3578-3587. | 1.4 | 3 |
| 3741 | Cancer of the Vulva: A Review. Dermatologic Surgery, 2021, 47, 174-183. | 0.4 | 13 |
| 3742 | Clinical Significance of Serum Ykl-40 (Chitinase-3-Like-1 Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients. Asian Pacific Journal of Cancer Prevention, 2017, 18, 1383-1387. | 0.5 | 10 |
| 3743 | Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immunity, 2010, 10, 9. | 3.2 | 89 |
| 3744 | Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. Ochsner Journal, 2010, 10, 108-16. | 0.5 | 2 |
| 3745 | Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P and T, 2012, 37, 503-30. | 1.0 | 76 |
| 3746 | Histologic features of conjunctival melanoma predictive of metastasis and death (an American) Tj ETQq1 1 0.784314.rgBT /Overlock 10 | 1.4 | 29 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3747 | A Global Review of Melanoma Follow-up Guidelines. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2013, 6, 18-26. | 0.1 | 128 |
| 3748 | Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 4, 17-28. | 1.0 | 42 |
| 3749 | (68)Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 4, 60-9. | 1.0 | 28 |
| 3750 | Letter to the editor. <i>Dermatology Practical and Conceptual</i> , 2011, 1, 83-4. | 0.5 | 0 |
| 3751 | Diagnostic and prognostic biomarkers in melanoma. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, 13-24. | 0.1 | 65 |
| 3752 | The era of personalized medicine in oncology: novel biomarkers ushering in new approaches to cancer therapy. <i>American Health and Drug Benefits</i> , 2011, 4, 387-8. | 0.5 | 1 |
| 3753 | Melanoma screening by means of complete skin exams for all patients in a dermatology practice reduces the thickness of primary melanomas at diagnosis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, 18-22. | 0.1 | 18 |
| 3754 | MiR-199a inhibits the ability of proliferation and migration by regulating CD44-Ezrin signaling in cutaneous squamous cell carcinoma cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 7131-41. | 0.5 | 32 |
| 3755 | CD24 expression predicts poor prognosis for patients with cutaneous malignant melanoma. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 4337-41. | 1.3 | 8 |
| 3756 | Survival rates of patients with metastatic malignant melanoma. <i>Journal of Medicine and Life</i> , 2014, 7, 572-6. | 0.4 | 168 |
| 3757 | Controversies in the diagnosis and treatment of early cutaneous melanoma. <i>Journal of Medicine and Life</i> , 2015, 8, 132-41. | 0.4 | 6 |
| 3758 | Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3097-103. | 0.5 | 32 |
| 3759 | Down-regulation of tissue microRNA-126 was associated with poor prognosis in patients with cutaneous melanoma. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 4297-301. | 1.3 | 7 |
| 3761 | Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. <i>Yale Journal of Biology and Medicine</i> , 2015, 88, 389-95. | 0.2 | 3 |
| 3762 | Expression of miR-203 is decreased and associated with the prognosis of melanoma patients. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13249-54. | 0.5 | 16 |
| 3763 | Significantly high lymphatic vessel density in cutaneous metastasizing melanoma. <i>Hippokratia</i> , 2015, 19, 210-5. | 0.3 | 5 |
| 3764 | Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 277-285. | 1.0 | 9 |
| 3765 | Systemic Therapies for Late-stage Melanoma. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 36-40. | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3766 | Improving Melanoma Path Reports: the Importance of Histopathological Parameters in Diagnosis of Cutaneous Melanoma. <i>MÃ dica</i> , 2015, 10, 226-230. | 0.4 | 0 |
| 3767 | Precision Diagnosis Of Melanoma And Other Skin Lesions From Digital Images. <i>AMIA Summits on Translational Science Proceedings</i> , 2017, 2017, 220-226. | 0.4 | 7 |
| 3768 | Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. <i>American Surgeon</i> , 2016, 82, 1009-1013. | 0.4 | 13 |
| 3769 | Demographic and Pathologic Characteristics of Malignant Melanoma in West Part of Romania. <i>Iranian Journal of Public Health</i> , 2018, 47, 606-607. | 0.3 | 2 |
| 3770 | Proteomics and melanoma: a current perspective. <i>Global Dermatology</i> , 2016, 3, 366-370. | 0.1 | 1 |
| 3771 | Melanoma in situ: a case report from the patient's perspective. <i>Journal of the Canadian Chiropractic Association</i> , 2018, 62, 56-61. | 0.2 | 1 |
| 3772 | Promising clinical application of ctDNA in evaluating immunotherapy efficacy. <i>American Journal of Cancer Research</i> , 2018, 8, 1947-1956. | 1.4 | 6 |
| 3773 | A Survey of Licensed Massage Therapists' Perceptions of Skin Cancer Prevention and Detection Activities. <i>International Journal of Therapeutic Massage & Bodywork</i> , 2018, 11, 4-10. | 0.1 | 65 |
| 3774 | Systemic Therapy in Metastatic Melanoma. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2015, 32, 57S-65S. | 0.6 | 1 |
| 3775 | Advanced Presentation of Homeopathically treated Giant Melanoma: A Case Report. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2019, 12, 28-31. | 0.1 | 1 |
| 3776 | Long-Term Survival of Cutaneous Malignant Melanoma with Metastasis to Paranasal Sinuses: A Case Report and Literature Review. <i>Galen</i> , 2018, 7, e860. | 0.6 | 0 |
| 3777 | Cell-SELEX-based selection of ssDNA aptamers for specifically targeting <i>BRAF</i> V600E-mutated melanoma. <i>Analyst, The</i> , 2021, 147, 187-195. | 1.7 | 6 |
| 3778 | FusionM4Net: A multi-stage multi-modal learning algorithm for multi-label skin lesion classification. <i>Medical Image Analysis</i> , 2022, 76, 102307. | 7.0 | 33 |
| 3779 | Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. , 2021, 9, e003675. | | 24 |
| 3780 | Proportion of Thick versus Thin Melanomas as a Benchmarking Tool. <i>Journal of Clinical Medicine</i> , 2021, 10, 5545. | 1.0 | 5 |
| 3781 | Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model. <i>Health Technology Assessment</i> , 2021, 25, 1-178. | 1.3 | 4 |
| 3782 | BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment. <i>Cancer Research</i> , 2022, 82, 264-277. | 0.4 | 8 |
| 3783 | Socioeconomic Determinants of Melanoma-Related Health Literacy and Attitudes Among College Students in China: A Population-Based Cross-Sectional Study. <i>Frontiers in Public Health</i> , 2021, 9, 743368. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3784 | Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21. <i>Cancer Research</i> , 2022, 82, 447-457. | 0.4 | 16 |
| 3785 | Epidemiología del melanoma en España: estimación de los pacientes con melanoma con estadio III candidatos al tratamiento adyuvante. <i>Actas Dermo-sifiliográficas</i> , 2022, 113, 354-362. | 0.2 | 0 |
| 3786 | Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168. | 1.3 | 19 |
| 3787 | Adjuvant Pembrolizumab versus FN1±2b or Ipilimumab in Resected High-Risk Melanoma. <i>Cancer Discovery</i> , 2022, 12, 644-653. | 7.7 | 32 |
| 3788 | Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5345-5352. | 1.0 | 5 |
| 3789 | Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 81-111. | 0.8 | 7 |
| 3791 | Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 810388. | 2.2 | 9 |
| 3793 | Fortgeschrittenes malignes Melanom: Kernpunkte der aktualisierten Leitlinie. , 0, , . | | 0 |
| 3794 | A Quaternary Classifier for the Clinical Evaluation of Pigmented Skin Lesions. , 2020, , . | | 1 |
| 3795 | A Multi-Input CNNs with Attention for Skin Lesion Classification. , 2020, , . | | 0 |
| 3796 | Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors. <i>Health Economics Review</i> , 2022, 12, 8. | 0.8 | 1 |
| 3797 | Application of Nanoemulsion in Cancer Treatment. <i>Advances in Chemical and Materials Engineering Book Series</i> , 2022, , 237-258. | 0.2 | 0 |
| 3798 | Therapeutic Potential of Nitric Oxide-Releasing Selective Estrogen Receptor Modulators in Malignant Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2217-2227. | 0.3 | 7 |
| 3799 | Seasonal variation in high-risk phenotypes of cutaneous malignant melanoma diagnosed in Eastern England: An observational study. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2022, 75, 1923-1930. | 0.5 | 1 |
| 3800 | Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy?. <i>Cancers</i> , 2022, 14, 655. | 1.7 | 8 |
| 3801 | Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study*. <i>British Journal of Dermatology</i> , 2022, 186, 977-987. | 1.4 | 9 |
| 3802 | Single-Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment. <i>Clinical Cancer Research</i> , 2022, 28, 2069-2081. | 3.2 | 9 |
| 3803 | PET Imaging of Melanoma. , 2022, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3804 | The efficacy of 99mTc-rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients. <i>Annals of Translational Medicine</i> , 2022, 10, 95-95. | 0.7 | 1 |
| 3805 | Fully transformer network for skin lesion analysis. <i>Medical Image Analysis</i> , 2022, 77, 102357. | 7.0 | 52 |
| 3806 | Skin melanoma: from systematic biology to the personalized therapy. <i>Vestnik Dermatologii i Venerologii</i> , 2013, 89, 4-8. | 0.2 | 0 |
| 3807 | Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. <i>JAMA Surgery</i> , 2022, 157, 335. | 2.2 | 20 |
| 3808 | Extra-Axial Skeletal Metastasis of Malignant Melanoma: Case Report and Literature Review. <i>Cureus</i> , 2022, 14, e22115. | 0.2 | 0 |
| 3810 | Immunohistochemical expression and prognostic role of CD10, CD271 and Nestin in primary and recurrent cutaneous melanoma. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 68-72. | 0.1 | 3 |
| 3812 | Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 997-1005. | 0.6 | 5 |
| 3813 | Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 847901. | 2.0 | 13 |
| 3814 | EpidemiologĀa del melanoma en EspaĀa: estimaciĀn de los pacientes con melanoma con estadio III candidatos al tratamiento adyuvante. <i>Actas Dermo-sifiliogrĀficas</i> , 2022, , . | 0.2 | 0 |
| 3815 | Skin layer structure characterization via multi-contrast polarization-sensitive optical coherence tomography. , 2022, , . | | 1 |
| 3816 | The Interplay between Tumour Microenvironment Components in Malignant Melanoma. <i>Medicina (Lithuania)</i> , 2022, 58, 365. | 0.8 | 8 |
| 3817 | PatchĀ-based local deep feature extraction for automated skin cancer classification. <i>International Journal of Imaging Systems and Technology</i> , 2022, 32, 1774-1788. | 2.7 | 9 |
| 3818 | American Joint Committee on Cancer Tumor Staging System Predicts the Outcome and Metastasis Pattern in Conjunctival Melanoma. <i>Ophthalmology</i> , 2022, 129, 771-780. | 2.5 | 12 |
| 3819 | Analyzing Prognostic Hub Genes in the Microenvironment of Cutaneous Melanoma by Computer Integrated Bioinformatics. <i>Computational Intelligence and Neuroscience</i> , 2022, 2022, 1-14. | 1.1 | 0 |
| 3820 | Progression of untreated gastric and pulmonary metastasis in a patient with resected acral melanoma. <i>BMJ Case Reports</i> , 2022, 15, e247683. | 0.2 | 0 |
| 3821 | Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma. <i>Cancers</i> , 2022, 14, 1590. | 1.7 | 2 |
| 3822 | Long-term control of melanoma adrenal metastasis treated with radiotherapy. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, . | 0.6 | 2 |
| 3823 | Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing. <i>BioDrugs</i> , 2022, 36, 373-380. | 2.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3824 | Adjuvant therapy of malignant melanoma: general and practical experience. <i>Onkologie (Czech)</i> Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 74 | 0.0 | 0 |
| 3825 | Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma. <i>Cancers</i> , 2022, 14, 110. | 1.7 | 5 |
| 3826 | Immunological responses to adjuvant vaccination with combined CD1c ⁺ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. <i>Oncolimmunology</i> , 2022, 11, . | 2.1 | 14 |
| 3827 | Automated skin lesion segmentation using multi-scale feature extraction scheme and dual-attention mechanism. , 2021, , . | | 2 |
| 3828 | Postoperative assessment of malignant melanoma aggressiveness for further treatment personalization. <i>Malignant Tumours</i> , 2021, 11, 45-51. | 0.1 | 0 |
| 3829 | Histopathological evaluation of cutaneous malignant melanoma: A retrospective study. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, . | 0.8 | 6 |
| 3830 | Frailty and checkpoint inhibitor toxicity in older patients with melanoma. <i>Cancer</i> , 2022, 128, 2746-2752. | 2.0 | 12 |
| 3831 | Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition. <i>Frontiers in Oncology</i> , 2022, 12, 830627. | 1.3 | 2 |
| 3832 | Imaging and Laboratory Workup for Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 235-250. | 0.4 | 2 |
| 3833 | An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. <i>Annals of Surgical Oncology</i> , 2022, 29, 5221-5234. | 0.7 | 15 |
| 3854 | Diet quality is associated with primary melanoma thickness. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1745-1750. | 1.3 | 2 |
| 3855 | Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?. <i>Dermatology</i> , 2022, 238, 517-526. | 0.9 | 5 |
| 3856 | A 41-Year-Old Woman with a Late Cerebral Metastasis 16 Years After an Initial Diagnosis of Cutaneous Melanoma. <i>American Journal of Case Reports</i> , 2022, 23, e935728. | 0.3 | 1 |
| 3857 | Positive margins after surgical excision of locoregional cutaneous melanoma metastasis and their impact on patient outcome. <i>European Journal of Dermatology</i> , 2018, 28, 661-667. | 0.3 | 3 |
| 3858 | Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. <i>European Journal of Dermatology</i> , 2019, 29, 315-321. | 0.3 | 14 |
| 3859 | Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors. <i>Tumori</i> , 2012, 98, 185-90. | 0.6 | 5 |
| 3862 | Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 615-617. | 2.3 | 0 |
| 3864 | A mitochondria-localized iridium(^{III})-chlorin E6 conjugate for synergistic sonodynamic and two-photon photodynamic therapy against melanoma. <i>Inorganic Chemistry Frontiers</i> , 2022, 9, 3034-3046. | 3.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3865 | Texture Analysis in Diagnosing Skin Pigmented Lesions in Normal and Polarized Light—A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2022, 11, 2505. | 1.0 | 1 |
| 3866 | Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 5937-5945. | 0.7 | 4 |
| 3867 | An efficient U-shaped network combined with edge attention module and context pyramid fusion for skin lesion segmentation. <i>Medical and Biological Engineering and Computing</i> , 2022, 60, 1987-2000. | 1.6 | 8 |
| 3868 | Classification and Staging of Melanoma in the Head and Neck. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 221-234. | 0.4 | 7 |
| 3869 | Identification of Transcriptional Heterogeneity and Construction of a Prognostic Model for Melanoma Based on Single-Cell and Bulk Transcriptome Analysis. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, . | 1.8 | 6 |
| 3870 | The management of eyelid tumors. , 2012, , 360-372. | | 1 |
| 3871 | Noncontrast-enhanced 3-Tesla MRI using surface coil as a complementary test for assessment of distribution and depth of locoregional cutaneous metastases of malignant melanoma. <i>Melanoma Research</i> , 2022, 32, 211-217. | 0.6 | 2 |
| 3872 | European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 256-284. | 1.3 | 92 |
| 3873 | Perfil epidemiológico de pacientes com melanoma cutâneo em uma cidade do sul de Santa Catarina. <i>Evidência</i> , 0, , 1-12. | 0.1 | 0 |
| 3874 | Cutaneous melanoma. , 2023, , 370-375. | | 0 |
| 3877 | Graph-Based Intercategory and Intermodality Network for Multilabel Classification and Melanoma Diagnosis of Skin Lesions in Dermoscopy and Clinical Images. <i>IEEE Transactions on Medical Imaging</i> , 2022, 41, 3266-3277. | 5.4 | 5 |
| 3881 | Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749. | 0.8 | 33 |
| 3882 | Dense and shuffle attention U-Net for automatic skin lesion segmentation. <i>International Journal of Imaging Systems and Technology</i> , 2022, 32, 2066-2079. | 2.7 | 3 |
| 3883 | Cutaneous melanoma incidence, mortality, and survival in Manizales, Colombia: a population-based study. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211067. | 0.4 | 2 |
| 3884 | Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 717-723. | 1.1 | 1 |
| 3885 | Sinonasal Mucosal Melanoma: Role of Tumor Proliferative Indices and Pathological Factors in Survival. <i>Laryngoscope</i> , 2022, 132, 2350-2358. | 1.1 | 7 |
| 3886 | miRNA-633 and KAI1 as Potential Biomarkers of Malignant Melanoma with Gastric Cancer. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, 1001-1014. | 0.6 | 3 |
| 3887 | ¹⁸ F-FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3190. | 1.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3888 | The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients. <i>Medicine and Pharmacy Reports</i> , 0, , . | 0.2 | 1 |
| 3889 | Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 4, . | 0.1 | 0 |
| 3890 | Association of Systemic Inflammatory and Immune Indices With Survival in Canine Patients With Oral Melanoma, Treated With Experimental Immunotherapy Alone or Experimental Immunotherapy Plus Metronomic Chemotherapy. <i>Frontiers in Veterinary Science</i> , 0, 9, . | 0.9 | 4 |
| 3891 | A Novel Necroptosis-Related Gene Signature in Skin Cutaneous Melanoma Prognosis and Tumor Microenvironment. <i>Frontiers in Genetics</i> , 0, 13, . | 1.1 | 14 |
| 3892 | Long-term results of wide local excision with concurrent venous free flap reconstruction in subungual melanoma. <i>Archives of Hand and Microsurgery</i> , 2022, 27, 240-246. | 0.1 | 2 |
| 3893 | EPAC Regulates Melanoma Growth by Stimulating mTORC1 Signaling and Loss of EPAC Signaling Dependence Correlates with Melanoma Progression. <i>Molecular Cancer Research</i> , 2022, 20, 1548-1560. | 1.5 | 3 |
| 3894 | Management of cutaneous melanoma: radiologists challenging and risk assessment. <i>Radiologia Medica</i> , 2022, 127, 899-911. | 4.7 | 20 |
| 3895 | Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma Pathogenesis. <i>Cancers</i> , 2022, 14, 3371. | 1.7 | 4 |
| 3896 | Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T _{reg} reduction and effector T cell activation. <i>Science Immunology</i> , 2022, 7, . | 5.6 | 18 |
| 3897 | Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma. <i>Cancers</i> , 2022, 14, 3587. | 1.7 | 6 |
| 3898 | Detection of Skin Abnormalities using a Highly Sensitive Planar Microstrip Probe. , 2022, , . | | 1 |
| 3899 | Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 528-540. | 0.8 | 62 |
| 3900 | Association of JAK/STAT genetic variants with cutaneous melanoma. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 0 |
| 3901 | A shallow deep learning approach to classify skin cancer using down-scaling method to minimize time and space complexity. <i>PLoS ONE</i> , 2022, 17, e0269826. | 1.1 | 12 |
| 3902 | Investigation of CTLA4 ^{hi} T _{regs} Application in Advanced Melanoma with Ipilimumab and Nivolumab. , 0, 8, 481-489. | | 0 |
| 3903 | PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 3 |
| 3904 | Association of Tumor Metabolic Activity on PET/CT Scan with Pathological Characteristics in Patients with Malignant Melanoma. <i>Iranian Journal of Radiology</i> , 2022, 19, . | 0.1 | 0 |
| 3905 | Reporting of melanoma cell densities in the sentinel node refines outcome prediction. <i>European Journal of Cancer</i> , 2022, 174, 121-130. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3907 | Metastatic multifocal melanoma of multiple organ systems: A case report. <i>World Journal of Clinical Cases</i> , 0, 10, 10136-10145. | 0.3 | 5 |
| 3908 | Microneedles-mediated drug delivery system for the diagnosis and treatment of melanoma. <i>Colloids and Surfaces B: Biointerfaces</i> , 2022, 219, 112818. | 2.5 | 5 |
| 3909 | Toward Multicenter Skin Lesion Classification Using Deep Neural Network With Adaptively Weighted Balance Loss. <i>IEEE Transactions on Medical Imaging</i> , 2023, 42, 119-131. | 5.4 | 6 |
| 3910 | Radioguided Surgery for Malignant Melanoma. , 2022, , 1595-1631. | | 0 |
| 3911 | Malignant Melanoma in Cerebellopontine Angle: A Case Report and Literature Review. <i>Advances in Clinical Medicine</i> , 2022, 12, 6812-6818. | 0.0 | 0 |
| 3912 | Reconstructing invisible deviating events: A conformance checking approach for recurring events. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 11782-11799. | 1.0 | 0 |
| 3913 | Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 15, 1743-1757. | 0.8 | 4 |
| 3914 | Hypoxia and Ezrin Expression in Primary Melanoma Have High Prognostic Relevance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10745. | 1.8 | 1 |
| 3915 | Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e29390. | 0.4 | 0 |
| 3916 | Neoadjuvant therapy for melanoma: A critical appraisal. <i>Journal of Surgical Oncology</i> , 0, , . | 0.8 | 0 |
| 3917 | <scp>EIF3B</scp> stabilizes <scp>PTGS2</scp> expression by counteracting <scp>MDM2</scp> -mediated ubiquitination to promote the development and progression of malignant melanoma. <i>Cancer Science</i> , 0, , . | 1.7 | 1 |
| 3918 | Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE). <i>Supportive Care in Cancer</i> , 2022, 30, 9587-9596. | 1.0 | 7 |
| 3919 | Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, , . | 0.6 | 3 |
| 3920 | Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 5 |
| 3921 | Is Melanoma Progression Affected by Thyroid Diseases?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10036. | 1.8 | 3 |
| 3922 | Survival analysis in head and neck melanoma after negative sentinel lymph node biopsy: A seer-based population study. <i>Ear, Nose and Throat Journal</i> , 0, , 014556132211263. | 0.4 | 0 |
| 3923 | The role of tumor-associated macrophages and soluble mediators in pulmonary metastatic melanoma. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 6 |
| 3924 | Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). , 2022, 10, e005424. | | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3925 | NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9985. | 1.8 | 11 |
| 3926 | Ways and methods of closing tissue defects of the middle zone of the facial skull after removal of malignant tumors with intracranial spread (case from practice). <i>Ukraïnska ĩntervencĳna Nejrordologĳ Ta Ĥirurgĳ</i> , 2022, 39, 40-49. | 0.1 | 0 |
| 3927 | Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma. , 2022, 1, . | | 29 |
| 3929 | High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. <i>European Journal of Cancer</i> , 2022, 177, 80-93. | 1.3 | 12 |
| 3930 | Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. <i>Cancer Immunology, Immunotherapy</i> , 0, , . | 2.0 | 1 |
| 3931 | Skin lesion classification using CNNs with grouping of multi-scale attention and class-specific loss weighting. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 226, 107166. | 2.6 | 16 |
| 3932 | The importance of mitosis ĩn selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy. <i>Melanoma Research</i> , 2022, 32, 469-476. | 0.6 | 0 |
| 3934 | Prediction of early-stage melanoma recurrence using clinical and histopathologic features. <i>Npj Precision Oncology</i> , 2022, 6, . | 2.3 | 10 |
| 3935 | Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype. <i>Clinical and Translational Medicine</i> , 2022, 12, . | 1.7 | 7 |
| 3936 | An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability. <i>Archives of Dermatological Research</i> , 2023, 315, 799-806. | 1.1 | 4 |
| 3937 | An In Vivo Model of Human Macrophages in Metastatic Melanoma. <i>Journal of Immunology</i> , 2022, 209, 606-620. | 0.4 | 6 |
| 3938 | Smartphone and microfluidic systems in medical and food analysis. , 2023, , 233-257. | | 1 |
| 3939 | Prognostic significance of age on superficial spreading melanoma after resection: lessons from <sc>SEER</sc> database involving 12ĳ536 patients. <i>ANZ Journal of Surgery</i> , 0, , . | 0.3 | 0 |
| 3940 | Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics. <i>Future Oncology</i> , 2022, 18, 3755-3767. | 1.1 | 1 |
| 3942 | Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with veryĳlow melanoma mortality. <i>Cancer</i> , 2023, 129, 89-97. | 2.0 | 7 |
| 3943 | Melanoma Treatment. <i>JACC: CardioOncology</i> , 2022, 4, 549-551. | 1.7 | 0 |
| 3944 | Sentinel Lymph Node Biopsy in Cutaneous Melanoma, a Clinical Point of View. <i>Medicina (Lithuania)</i> , 2022, 58, 1589. | 0.8 | 1 |
| 3945 | Designing a new deep convolutional neural network for skin lesion recognition. <i>Multimedia Tools and Applications</i> , 2023, 82, 18907-18923. | 2.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3946 | Dieckol Inhibits Autophagic Flux and Induces Apoptotic Cell Death in A375 Human Melanoma Cells via Lysosomal Dysfunction and Mitochondrial Membrane Impairment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14149. | 1.8 | 8 |
| 3947 | Vascular endothelial growth factor in activating vascular endothelial growth factor receptor and chemokine receptor in melanoma adhesion. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 5743-5754. | 1.6 | 9 |
| 3948 | Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients. <i>Annals of Surgical Oncology</i> , 0, , . | 0.7 | 2 |
| 3950 | A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1405-1415. | 2.0 | 4 |
| 3951 | Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysis. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 802-807. | 0.6 | 6 |
| 3952 | Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma. <i>JAMA Oncology</i> , 2023, 9, 251. | 3.4 | 3 |
| 3953 | Current status and novel insights into the role of metastasectomy in the era of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 57-66. | 1.1 | 1 |
| 3954 | Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study. <i>Current Oncology</i> , 2022, 29, 9660-9670. | 0.9 | 3 |
| 3955 | Serum Neu5Gc biomarkers are elevated in primary cutaneous melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2023, 642, 162-166. | 1.0 | 3 |
| 3956 | Neoadjuvant treatment for stage III and IV cutaneous melanoma. <i>The Cochrane Library</i> , 2023, 2023, . | 1.5 | 1 |
| 3957 | First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. <i>BMC Medicine</i> , 2023, 21, . | 2.3 | 7 |
| 3958 | Risk of Melanoma in Patients with Basal Cell Carcinoma: A Population-based Cohort Study. <i>Acta Dermato-Venereologica</i> , 0, 103, adv00841. | 0.6 | 1 |
| 3959 | Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. <i>European Journal of Cancer</i> , 2023, 182, 38-42. | 1.3 | 13 |
| 3960 | Construction, validation and, visualization of a web-based nomogram to identify the best candidates for primary tumor resection in advanced cutaneous melanoma patients. <i>Frontiers in Surgery</i> , 0, 9, . | 0.6 | 0 |
| 3961 | Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 3962 | Prognostic model for predicting overall and cancer-specific survival among patients with superficial spreading melanoma: A SEER based study. <i>Medicine (United States)</i> , 2022, 101, e32521. | 0.4 | 0 |
| 3963 | Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. <i>European Journal of Cancer</i> , 2023, 182, 163-169. | 1.3 | 6 |
| 3965 | Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. <i>Cancers</i> , 2023, 15, 648. | 1.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3966 | Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, . | 0.8 | 1 |
| 3967 | KutanĀız Malign Melanom Nedeniyle Takip EttiĀyimiz HastalarĀn Klinikopatolojik Āzellikleri. <i>Turkish Journal of Clinics and Laboratory</i> , 0, , . | 0.2 | 0 |
| 3968 | Primary malignant melanoma of prostate: a case report. <i>Pan African Medical Journal</i> , 0, 44, . | 0.3 | 0 |
| 3969 | Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 6 |
| 3970 | Oral Mukozal Melanom: Nadir GĀrĀlen Bir Vaka Raporu. <i>BandĀrma Onyedi EylĀl UlĀniversitesi SaėlĀk Bilimleri Ve ArařtĀrmalarĀ Dergisi</i> , 0, , . | 0.6 | 0 |
| 3971 | MALĀGN MELANOMLARDA CD271 VE BRAF EKSPRESYONUNUN KLĀNĀKOPATOLOJĀK PARAMETRELERLE VE PROGNOZ ĀLE ĀLĀĀKĀSĀNĀN ĀMMĀceNOHĀSTOKĀMYASAL YĀNTEMLE ARAĀTIRILMASI. <i>SĀleyman Demirel Āniversitesi FakĀltesi Dergisi</i> , 0, , . | | |
| 3972 | ACCPG-Net: A skin lesion segmentation network with Adaptive Channel-Context-Aware Pyramid Attention and Global Feature Fusion. <i>Computers in Biology and Medicine</i> , 2023, 154, 106580. | 3.9 | 2 |
| 3973 | Melanome der Haut und Schleimhaut. , 2022, , 205-236. | | 0 |
| 3974 | A novel soft attention-based multi-modal deep learning framework for multi-label skin lesion classification. <i>Engineering Applications of Artificial Intelligence</i> , 2023, 120, 105897. | 4.3 | 8 |
| 3975 | A Novel Framework for Melanoma Lesion Segmentation Using Multiparallel Depthwise Separable and Dilated Convolutions with Swish Activations. <i>Journal of Healthcare Engineering</i> , 2023, 2023, 1-15. | 1.1 | 1 |
| 3976 | Skin lesion segmentation using two-phase cross-domain transfer learning framework. <i>Computer Methods and Programs in Biomedicine</i> , 2023, 231, 107408. | 2.6 | 7 |
| 3977 | Self-calibrated magnetic aptamer sensor with dual Lanthanide-assisted Time-resolved luminescence for high-sensitive detection of melanoma exosomal PD-L1. <i>Materials and Design</i> , 2023, 227, 111714. | 3.3 | 3 |
| 3978 | Nanodelivery systems for cutaneous melanoma treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2023, 184, 214-247. | 2.0 | 6 |
| 3979 | FairDisCo: Fairer AI inĀDermatology viaĀDisentanglement Contrastive Learning. <i>Lecture Notes in Computer Science</i> , 2023, , 185-202. | 1.0 | 5 |
| 3980 | Anatomic Region of Cutaneous Melanoma Impacts Survival and Clinical Outcomes: A Population-Based Analysis. <i>Cancers</i> , 2023, 15, 1229. | 1.7 | 7 |
| 3981 | Determining the precise extent of sentinel basins during laparoscopic gastrectomy for early gastric cancer. <i>World Journal of Surgical Oncology</i> , 2023, 21, . | 0.8 | 0 |
| 3982 | PCF-Net: Position and context information fusion attention convolutional neural network for skin lesion segmentation. <i>Heliyon</i> , 2023, 9, e13942. | 1.4 | 1 |
| 3983 | TFormer: A throughout fusion transformer for multi-modal skin lesion diagnosis. <i>Computers in Biology and Medicine</i> , 2023, 157, 106712. | 3.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3984 | In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: Prospective analysis and case-control study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 1293-1301. | 1.3 | 1 |
| 3985 | Updates in management strategies of locally advanced sinonasal malignancy. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2023, 31, 39-44. | 0.8 | 1 |
| 3986 | Peritoneal Carcinomatosis From Malignant Melanoma After Wide Local Excision of a T1a Lesion: A Case Report. <i>Cureus</i> , 2023, , . | 0.2 | 0 |
| 3987 | The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography. <i>Melanoma Research</i> , 2023, 33, 199-207. | 0.6 | 0 |
| 3988 | Optimization Convolutional Neural Network for Automatic Skin Lesion Diagnosis Using a Genetic Algorithm. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 3248. | 1.3 | 7 |
| 3989 | Early inflammatory biomarkers and melanoma survival. <i>International Journal of Dermatology</i> , 0, , . | 0.5 | 3 |
| 3990 | Prognostic Factors and Outcomes of Cutaneous Malignant Melanoma. <i>Annals of Plastic Surgery</i> , 2023, 90, 621-625. | 0.5 | 2 |
| 3991 | Melanoma of unknown primary origin with skeletal muscle metastasis: a case report. <i>Journal of Medical Case Reports</i> , 2023, 17, . | 0.4 | 0 |
| 3992 | Similar local recurrence and survival in patients with <scp>T1</scp> radial growth phase melanoma on head and neck treated with 5 or 10%mm margins: A retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 1318-1326. | 1.3 | 0 |
| 3993 | The Influence of Obesity on Melanoma and Sentinel Lymph Node Diagnosis: A Retrospective Monocentric Study in 1001 Patients. <i>Cancers</i> , 2023, 15, 1806. | 1.7 | 1 |
| 3994 | Does Stage Migration Occur as a Consequence of Omitting Completion Lymph Node Dissection for Melanoma?. <i>Annals of Surgical Oncology</i> , 0, , . | 0.7 | 0 |
| 3995 | Is It Time to Supersede the Diagnostic Term "Melanoma In Situ with Regression"? A Narrative Review. <i>Dermatopathology (Basel, Switzerland)</i> , 2023, 10, 120-127. | 0.7 | 1 |
| 3996 | Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. <i>Archives of Dermatological Research</i> , 2023, 315, 2295-2302. | 1.1 | 2 |
| 3999 | Skin Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1296. | 3.8 | 11 |
| 4000 | The Current Status and Future Direction of Extracellular Nano-vesicles in the Alleviation of Skin Disorders. <i>Current Stem Cell Research and Therapy</i> , 2024, 19, 351-366. | 0.6 | 0 |
| 4012 | Malignant Melanoma Misdiagnosed as Diabetic Foot Ulcer. , 2023, , 427-432. | | 0 |
| 4028 | Case report: a robotic-vaginal approach for total vaginectomy and hysterectomy with pelvic sentinel lymph node dissection in primary vaginal melanoma: a 10-step technique and literature review. <i>Frontiers in Surgery</i> , 0, 10, . | 0.6 | 0 |
| 4032 | Skin Disease Classification Based on Multi-level Feature Fusion and Attention Mechanism. , 2023, , . | | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4037 | New and revisited approaches on the transdermal delivery of polyphenols-loaded nanoparticles for melanoma prevention and treatment. , 2023, , 341-373. | | 0 |
| 4042 | Anticancer effect of terpenes: focus on malignant melanoma. Pharmacological Reports, 2023, 75, 1115-1125. | 1.5 | 3 |
| 4065 | Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy. Methods in Cell Biology, 2023, , . | 0.5 | 0 |
| 4101 | Skin cancer biology and its biomarkers: Recent trends and prospective. , 2024, , 321-337. | | 0 |
| 4102 | Fighting melanoma and resistant phenotypes African medicinal plants and their phytoconstituents. Advances in Botanical Research, 2024, , . | 0.5 | 0 |
| 4104 | Prognostic Factors, Staging, and Reporting of Melanoma. , 2024, , 261-268. | | 0 |
| 4108 | Label-Independent Information Compression for Skin Diseases Recognition. Communications in Computer and Information Science, 2024, , 193-204. | 0.4 | 0 |